

Summary Tables by Region, Health Area, Country and Product

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Market Group
1/2019 - 3/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Acceleration Market Group	8,609	-	-	788	613,810	1,011	274,805	334	104	28	1	5,462
Anglophone Africa Market Group	23,952	10	-	1	909,409	874	370,735	132	22	-	3	8,826
Franco/Lusophone Africa Market Gro	2,170	1	-	-	368,483	509	147,579	908	82	-	-	4,563
Latin America & Asia Market Group	1,268	-	-	541	1,148,676	558	437,949	1	16	-	-	3,969
Foundation Market Group	191	1	-	238	209,344	249	83,652	6,833	74	51	1	9,137
Social Enterprise	6,168	-	-	-	315,673	297	101,401	-	180	-	-	1,012
Total	42,359	12	-	1,567	3,565,395	3,497	1,416,121	8,207	477	80	4	32,969

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 3
Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	1,597,546	5,291,876	4,266,131	(19%)		25,179,270	17%
Acceleration Market Group	274,981	851,221	740,528	(13%)	100%	4,096,068	18%
Modern Contraception	98,803	307,038	298,964	(3)%	40%	1,305,027	23%
HIV & STIs	135,542	481,227	358,138	(26)%	48%	2,388,411	15%
Malaria	15,815	26,256	26,013	(1)%	4%	116,230	22%
Maternal, Newborn, and Child H	2,967	8,899	8,560	(4)%	1%	62,513	14%
Non-communicable diseases	8	11	19	80%	0%	73	27%
Nutrition	-	109	-	(100)%	0%	-	0%
Safe Abortion	12,907	9,079	25,300	179%	3%	119,871	21%
Tuberculosis	7,902	17,876	20,381	14%	3%	94,197	22%
WASH	1,037	726	3,153	334%	0%	9,747	32%
Anglophone Africa Market Group	695,358	1,616,879	1,675,117	4%	100%	6,838,586	24%
Modern Contraception	324,981	551,051	706,525	28%	42%	3,168,819	22%
HIV & STIs	359,636	1,034,753	953,283	(8)%	57%	3,592,960	27%
Malaria	8,363	21,884	9,279	(58)%	1%	35,727	26%
Maternal, Newborn, and Child H	100	779	221	(72)%	0%	4,132	5%
Non-communicable diseases	29	78	69	(12)%	0%	264	26%
Safe Abortion	2,072	5,973	4,406	(26)%	0%	25,618	17%
Tuberculosis	16	112	49	(56)%	0%	626	8%
WASH	162	2,249	1,284	(43)%	0%	10,440	12%
Franco/Lusophone Africa Market Group	171,428	392,672	454,257	16%	100%	2,675,993	17%
Modern Contraception	123,649	216,152	284,692	32%	63%	1,220,946	23%
HIV & STIs	14,065	93,493	88,548	(5)%	19%	543,046	16%
Malaria	29,484	66,435	71,345	7%	16%	844,481	8%
Maternal, Newborn, and Child H	1,857	11,409	3,971	(65)%	1%	37,043	11%
Non-communicable diseases	-	1	-	(92)%	0%	-	0%
Nutrition	-	-	-	0%	0%	-	0%
Safe Abortion	1,136	2,338	3,241	39%	1%	18,447	18%
WASH	1,237	2,845	2,460	(14)%	1%	12,029	20%
Latin America & Asia Market Group	149,675	350,913	360,433	3%	100%	1,133,232	32%
Modern Contraception	114,400	254,951	259,805	2%	72%	873,063	30%
HIV & STIs	20,190	53,764	55,579	3%	15%	214,953	26%
Malaria	13	2,112	63	(97)%	0%	424	15%
Maternal, Newborn, and Child H	354	426	1,399	228%	0%	1,827	77%
Non-communicable diseases	-	-	-	0%	0%	-	0%
Safe Abortion	4,305	14,066	14,622	4%	4%	42,896	34%
Tuberculosis	10,407	25,556	28,941	13%	8%	38	76,245%
WASH	6	37	23	(37)%	0%	30	76%
Foundation Market Group	165,946	1,766,441	719,316	(59%)	100%	9,033,832	8%
Modern Contraception	49,129	146,163	136,160	(7)%	19%	949,254	14%
HIV & STIs	3,322	33,016	8,462	(74)%	1%	146,629	6%
Malaria	101,497	1,480,585	529,319	(64)%	74%	7,691,092	7%
Maternal, Newborn, and Child H	4,342	68,305	15,102	(78)%	2%	92,588	16%
Non-communicable diseases	14	12	16	38%	0%	210	8%
Nutrition	6,718	-	14,338	0%	2%	103,209	14%
Safe Abortion	697	2,112	1,726	(18)%	0%	14,822	12%
Tuberculosis	-	33,362	13,352	(60)%	2%	34,091	39%
WASH	228	2,885	842	(71)%	0%	1,936	43%
Social Enterprise	140,157	311,989	316,480	1%	100%	1,401,560	23%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Market Group
Period: 3
Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Modern Contraception	23,563	65,357	49,824	(24)%	16%	381,162	13%
HIV & STIs	104,396	221,074	238,230	8%	75%	838,464	28%
Maternal, Newborn, and Child H	7,584	8,688	15,570	79%	5%	26,486	59%
Nutrition	22	88	59	(33)%	0%	381	16%
Safe Abortion	4,592	16,783	12,798	(24)%	4%	155,067	8%
Other	-	-	-	0%	0%	-	0%
Inactive	-	1,762	0	(100)%	-%	-	-%
Modern Contraception	-	1,520	-	(100)%	0%	-	0%
HIV & STIs	-	242	-	(100)%	0%	-	0%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 3
Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	1,597,546	5,291,876	4,266,131	(19)%		25,179,270	17%
Modern Contraception	734,525	1,542,231	1,735,971	13%	100%	7,898,271	22 %
Acceleration Market Group	98,803	307,038	298,964	(3)%	17 %	1,305,027	23%
Anglophone Africa Market Group	324,981	551,051	706,525	28%	41 %	3,168,819	22%
Franco/Lusophone Africa Market Group	123,649	216,152	284,692	32%	16 %	1,220,946	23%
Latin America & Asia Market Group	114,400	254,951	259,805	2%	15 %	873,063	30%
Foundation Market Group	49,129	146,163	136,160	(7)%	8 %	949,254	14%
Social Enterprise	23,563	65,357	49,824	(24)%	3 %	381,162	13%
Inactive	-	1,520	-	(100)%	0 %	-	0%
HIV & STIs	637,150	1,917,569	1,702,240	(11)%	100%	7,724,464	22 %
Acceleration Market Group	135,542	481,227	358,138	(26)%	21 %	2,388,411	15%
Anglophone Africa Market Group	359,636	1,034,753	953,283	(8)%	56 %	3,592,960	27%
Franco/Lusophone Africa Market Group	14,065	93,493	88,548	(5)%	5 %	543,046	16%
Latin America & Asia Market Group	20,190	53,764	55,579	3%	3 %	214,953	26%
Foundation Market Group	3,322	33,016	8,462	(74)%	0 %	146,629	6%
Social Enterprise	104,396	221,074	238,230	8%	14 %	838,464	28%
Inactive	-	242	-	(100)%	0 %	-	0%
Malaria	155,172	1,597,273	636,019	(60)%	100%	8,687,953	7 %
Acceleration Market Group	15,815	26,256	26,013	(1)%	4 %	116,230	22%
Anglophone Africa Market Group	8,363	21,884	9,279	(58)%	1 %	35,727	26%
Franco/Lusophone Africa Market Group	29,484	66,435	71,345	7%	11 %	844,481	8%
Latin America & Asia Market Group	13	2,112	63	(97)%	0 %	424	15%
Foundation Market Group	101,497	1,480,585	529,319	(64)%	83 %	7,691,092	7%
Maternal, Newborn, and Child Health	17,204	98,506	44,823	(54)%	100%	224,590	20 %
Acceleration Market Group	2,967	8,899	8,560	(4)%	19 %	62,513	14%
Anglophone Africa Market Group	100	779	221	(72)%	0 %	4,132	5%
Franco/Lusophone Africa Market Group	1,857	11,409	3,971	(65)%	9 %	37,043	11%
Latin America & Asia Market Group	354	426	1,399	228%	3 %	1,827	77%
Foundation Market Group	4,342	68,305	15,102	(78)%	34 %	92,588	16%
Social Enterprise	7,584	8,688	15,570	79%	35 %	26,486	59%
Non-communicable diseases	51	101	104	3%	100%	547	19 %
Acceleration Market Group	8	11	19	80%	19 %	73	27%
Anglophone Africa Market Group	29	78	69	(12)%	66 %	264	26%
Franco/Lusophone Africa Market Group	-	1	-	(92)%	0 %	-	0%
Latin America & Asia Market Group	-	-	-	0%	0 %	-	0%
Foundation Market Group	14	12	16	38%	15 %	210	8%
Nutrition	6,740	197	14,397	7,206%	100%	103,591	14 %
Acceleration Market Group	-	109	-	(100)%	0 %	-	0%
Franco/Lusophone Africa Market Group	-	-	-	0%	0 %	-	0%
Foundation Market Group	6,718	-	14,338	0%	100 %	103,209	14%
Social Enterprise	22	88	59	(33)%	0 %	381	16%
Safe Abortion	25,709	50,351	62,092	23%	100%	376,721	16 %
Acceleration Market Group	12,907	9,079	25,300	179%	41 %	119,871	21%
Anglophone Africa Market Group	2,072	5,973	4,406	(26)%	7 %	25,618	17%
Franco/Lusophone Africa Market Group	1,136	2,338	3,241	39%	5 %	18,447	18%
Latin America & Asia Market Group	4,305	14,066	14,622	4%	24 %	42,896	34%
Foundation Market Group	697	2,112	1,726	(18)%	3 %	14,822	12%
Social Enterprise	4,592	16,783	12,798	(24)%	21 %	155,067	8%
Tuberculosis	18,325	76,907	62,723	(18)%	100%	128,952	49 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Health Area
Period: 3
Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Acceleration Market Group	7,902	17,876	20,381	14%	32 %	94,197	22%
Anglophone Africa Market Group	16	112	49	(56)%	0 %	626	8%
Latin America & Asia Market Group	10,407	25,556	28,941	13%	46 %	38	76,245%
Foundation Market Group	-	33,362	13,352	(60)%	21 %	34,091	39%
WASH	2,670	8,742	7,762	(11)%	100%	34,182	23 %
Acceleration Market Group	1,037	726	3,153	334%	41 %	9,747	32%
Anglophone Africa Market Group	162	2,249	1,284	(43)%	17 %	10,440	12%
Franco/Lusophone Africa Market Group	1,237	2,845	2,460	(14)%	32 %	12,029	20%
Latin America & Asia Market Group	6	37	23	(37)%	0 %	30	76%
Foundation Market Group	228	2,885	842	(71)%	11 %	1,936	43%
Other	-	-	-	0%	0%	-	0 %
Social Enterprise	-	-	-	0%	0 %	-	0%

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 3

Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
GRAND TOTAL	1,597,546	5,291,876	4,266,131	(19)%		25,179,270	17%
Acceleration Market Group	274,981	851,221	740,528	(13)%	100%	4,096,068	18%
India	14,566	74,369	53,626	(28)%	7%	151,017	36%
Modern Contraception	13,830	74,361	51,523	(31)%	7%	142,343	36 %
Tuberculosis	-	-	-	0%	0%	1,677	0 %
WASH	736	8	2,103	24,842%	0%	6,997	30 %
Kenya	120,348	349,182	357,080	2 %	48%	2,352,036	15%
Modern Contraception	40,082	93,403	108,550	16%	15%	579,992	19 %
HIV & STIs	66,616	243,754	224,356	(8)%	30%	1,646,645	14 %
Malaria	10,862	5,186	16,113	211%	2%	75,807	21 %
Maternal, Newborn, and Child Health	2,481	6,124	6,995	14%	1%	46,781	15 %
Non-communicable diseases	7	11	15	36%	0%	63	23 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	301	704	1,051	49%	0%	2,750	38 %
Myanmar	24,364	75,362	62,352	(17)%	8%	317,773	20%
Modern Contraception	4,708	15,068	14,218	(6)%	2%	81,594	17 %
HIV & STIs	6,314	18,450	16,284	(12)%	2%	87,494	19 %
Malaria	4,953	21,070	9,899	(53)%	1%	40,423	24 %
Maternal, Newborn, and Child Health	486	2,775	1,565	(44)%	0%	15,733	10 %
Non-communicable diseases	1	-	5	0%	0%	10	48 %
Nutrition	-	109	-	(100)%	0%	-	0 %
Tuberculosis	7,902	17,876	20,381	14%	3%	92,520	22 %
WASH	-	13	-	(100)%	0%	-	0 %
Nigeria	-	9,460	6,776	(28)%	1%	-	-%
Modern Contraception	-	1,160	6,776	484%	1%	-	0 %
HIV & STIs	-	8,300	-	(100)%	0%	-	0 %
PSI Nigeria	53,090	123,489	143,197	16 %	19%	620,328	23%
Modern Contraception	40,183	114,410	117,897	3%	16%	500,457	24 %
Safe Abortion	12,907	9,079	25,300	179%	3%	119,871	21 %
South Africa	62,612	219,359	117,497	(46)%	16%	654,913	18%
Modern Contraception	-	8,636	-	(100)%	0%	641	0 %
HIV & STIs	62,612	210,724	117,497	(44)%	16%	654,272	18 %
Anglophone Africa Market Group	695,358	1,616,879	1,675,117	4%	100%	6,838,586	24%
Ethiopia	7,372	94,108	45,874	(51)%	3%	144,850	32%
Modern Contraception	2,725	32,021	15,499	(52)%	1%	47,793	32 %
HIV & STIs	4,647	61,558	29,763	(52)%	2%	89,820	33 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	-	529	613	16%	0%	7,237	8 %
Ghana	15,671	20,459	22,638	11 %	1%	97,820	23%
Modern Contraception	15,668	20,391	22,624	11%	1%	95,927	24 %
HIV & STIs	-	64	-	(100)%	0%	1,792	0 %
WASH	3	4	13	198%	0%	101	13 %
Lesotho	1,814	40,800	9,377	(77)%	1%	34,799	27%
Modern Contraception	233	3,374	1,134	(66)%	0%	3,516	32 %
HIV & STIs	1,564	37,345	8,194	(78)%	0%	30,657	27 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 3

Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Tuberculosis	16	81	49	(40)%	0%	626	8 %
Malawi	50,898	309,744	190,483	(39)%	11%	1,170,485	16%
Modern Contraception	21,329	128,541	82,786	(36)%	5%	578,870	14 %
HIV & STIs	27,851	180,455	105,569	(41)%	6%	588,683	18 %
Malaria	1,674	556	2,013	262%	0%	2,818	71 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
WASH	43	193	114	(41)%	0%	113	101 %
PSI Uganda	210,666	58,400	398,059	582 %	24%	1,617,541	25%
Modern Contraception	203,791	51,124	385,389	654%	23%	1,561,294	25 %
HIV & STIs	4,929	2,845	8,638	204%	1%	34,195	25 %
Maternal, Newborn, and Child Health	100	547	221	(59)%	0%	4,132	5 %
Non-communicable diseases	2	-	4	0%	0%	-	0 %
Safe Abortion	1,843	3,885	3,772	(3)%	0%	17,809	21 %
WASH	-	-	35	31,379%	0%	111	31 %
Rwanda	23,465	67,322	83,137	23 %	5%	272,046	31%
Modern Contraception	7,133	18,300	23,774	30%	1%	70,959	34 %
HIV & STIs	16,313	48,809	59,300	21%	4%	200,615	30 %
WASH	19	213	64	(70)%	0%	472	14 %
Swaziland	53,401	216,524	169,639	(22)%	10%	330,572	51%
Modern Contraception	3,360	14,047	10,878	(23)%	1%	18,016	60 %
HIV & STIs	50,041	202,477	158,762	(22)%	9%	312,556	51 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Tanzania	33,542	157,363	86,820	(45)%	5%	506,709	17%
Modern Contraception	26,601	134,117	78,795	(41)%	5%	463,818	17 %
HIV & STIs	-	10	46	367%	0%	1,690	3 %
Malaria	6,689	21,329	7,266	(66)%	0%	32,909	22 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	229	1,768	634	(64)%	0%	7,808	8 %
WASH	23	139	78	(44)%	0%	484	16 %
Uganda	65,994	106,128	71,598	(33)%	4%	285,612	25%
Modern Contraception	16,095	103,152	16,140	(84)%	1%	69,347	23 %
HIV & STIs	49,900	2,395	55,458	2,216%	3%	216,265	26 %
Maternal, Newborn, and Child Health	-	232	-	(100)%	0%	-	0 %
Non-communicable diseases	-	28	-	(100)%	0%	-	0 %
Safe Abortion	-	320	-	(100)%	0%	-	0 %
WASH	-	-	-	(100)%	0%	-	0 %
Zambia	43,520	66,089	131,331	99 %	8%	510,034	26%
Modern Contraception	17,616	31,695	46,022	45%	3%	172,215	27 %
HIV & STIs	25,832	33,224	84,942	156%	5%	335,898	25 %
WASH	72	1,170	367	(69)%	0%	1,922	19 %
Zimbabwe	189,015	479,941	466,160	(3)%	28%	1,868,119	25%
Modern Contraception	10,430	14,288	23,485	64%	1%	87,065	27 %
HIV & STIs	178,559	465,574	442,610	(5)%	26%	1,780,790	25 %
Non-communicable diseases	27	49	65	31%	0%	264	25 %
Tuberculosis	-	30	-	(100)%	0%	-	0 %
Franco/Lusophone Africa Market Group	171,428	392,672	454,257	16%	100%	2,675,993	17%

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 3
Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Angola	32,029	71,987	77,818	8 %	17%	252,945	31%
Modern Contraception	4,317	16,805	16,284	(3)%	4%	120,194	14 %
HIV & STIs	916	3,346	2,879	(14)%	1%	23,605	12 %
Malaria	26,598	51,191	58,072	13%	13%	104,947	55 %
Safe Abortion	-	280	150	(46)%	0%	2,557	6 %
WASH	198	366	433	18%	0%	1,641	26 %
Benin	36,980	31,732	47,974	51 %	11%	306,792	16%
Modern Contraception	34,106	16,843	41,344	145%	9%	245,407	17 %
HIV & STIs	1,664	3,168	3,479	10%	1%	24,948	14 %
Malaria	-	18	-	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	1,026	11,542	2,455	(79)%	1%	33,329	7 %
Non-communicable diseases	-	1	-	(92)%	0%	-	0 %
Safe Abortion	36	-	181	0%	0%	-	0 %
WASH	147	160	515	222%	0%	3,108	17 %
Burundi	4,414	27,067	34,764	28 %	8%	151,589	23%
Modern Contraception	1,035	6,547	10,392	59%	2%	42,894	24 %
HIV & STIs	505	4,762	11,371	139%	3%	37,486	30 %
Malaria	2,850	15,709	12,919	(18)%	3%	70,791	18 %
Safe Abortion	25	48	82	69%	0%	418	20 %
Cameroon	50,200	131,019	143,431	9 %	32%	900,441	16%
Modern Contraception	38,014	93,050	98,029	5%	22%	272,311	36 %
HIV & STIs	10,849	37,328	42,246	13%	9%	152,624	28 %
Malaria	36	(591)	297	(150)%	0%	461,281	0 %
Maternal, Newborn, and Child Health	831	(133)	1,516	(1,239)%	0%	3,715	41 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	458	1,328	1,310	(1)%	0%	10,508	12 %
WASH	12	37	34	(9)%	0%	2	1,645 %
Cote d'Ivoire	21,451	4,973	32,040	544 %	7%	81,095	40%
Modern Contraception	21,364	4,255	31,806	647%	7%	78,028	41 %
HIV & STIs	-	663	-	(100)%	0%	2,387	0 %
WASH	87	55	235	327%	0%	679	35 %
Mozambique	15,873	101,238	87,719	(13)%	19%	588,280	15%
Modern Contraception	15,129	55,330	60,659	10%	13%	317,733	19 %
HIV & STIs	-	43,588	25,968	(40)%	6%	264,540	10 %
Malaria	-	95	-	(100)%	0%	-	0 %
WASH	743	2,224	1,092	(51)%	0%	6,006	18 %
Niger	8,469	15,000	18,579	24 %	4%	270,417	7%
Modern Contraception	8,262	14,921	18,024	21%	4%	65,342	28 %
HIV & STIs	131	36	376	942%	0%	1,328	28 %
Malaria	-	-	-	0%	0%	202,854	0 %
Safe Abortion	76	43	179	312%	0%	893	20 %
PSI Benin	1,816	7,748	5,022	(35)%	1%	50,634	10%
Modern Contraception	1,275	7,110	3,682	(48)%	1%	46,563	8 %
Safe Abortion	542	639	1,339	110%	0%	4,071	33 %
Senegal	196	1,908	6,908	262 %	2%	73,800	9%
Modern Contraception	146	1,291	4,471	246%	1%	32,473	14 %
HIV & STIs	-	602	2,229	270%	0%	36,127	6 %
Malaria	-	13	57	347%	0%	4,608	1 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 3

Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Nutrition	-	-	-	0%	0%	-	0 %
WASH	50	3	151	5,263%	0%	593	25 %
Latin America & Asia Market Group	149,675	350,913	360,433	3%	100%	1,133,232	32%
Cambodia	27,256	58,842	66,675	13 %	18%	250,805	27%
Modern Contraception	16,729	32,677	34,564	6%	10%	142,792	24 %
HIV & STIs	8,148	18,905	23,467	24%	7%	77,713	30 %
Malaria	-	342	3	(99)%	0%	160	2 %
Maternal, Newborn, and Child Health	354	425	1,399	229%	0%	1,752	80 %
Safe Abortion	2,025	6,493	7,243	12%	2%	28,390	26 %
Costa Rica	166	531	543	2 %	-%	2,522	22%
Modern Contraception	21	67	69	2%	0%	320	22 %
HIV & STIs	145	463	474	2%	0%	2,201	22 %
Dominican Republic	1,590	3,671	5,791	58 %	2%	15,540	37%
Modern Contraception	476	1,041	1,732	66%	0%	4,631	37 %
HIV & STIs	1,114	2,630	4,058	54%	1%	10,909	37 %
El Salvador	457	1,472	1,382	(6)%	-%	7,134	19%
Modern Contraception	106	496	334	(33)%	0%	1,794	19 %
HIV & STIs	351	973	1,048	8%	0%	5,340	20 %
Maternal, Newborn, and Child Health	-	2	-	(100)%	0%	-	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Safe Abortion	-	2	-	(100)%	0%	-	0 %
El Salvador SA	205	384	510	33 %	-%	1,910	27%
Modern Contraception	198	368	490	33%	0%	1,851	26 %
HIV & STIs	3	16	11	(28)%	0%	-	0 %
Safe Abortion	5	-	8	5,343%	0%	59	14 %
Guatemala	2,578	18,594	6,810	(63)%	2%	29,609	23%
Modern Contraception	1,145	15,114	2,990	(80)%	1%	13,146	23 %
HIV & STIs	1,433	3,371	3,821	13%	1%	16,463	23 %
Safe Abortion	-	109	-	(100)%	0%	-	0 %
Guatemala SA	2,888	2,826	6,428	127 %	2%	10,527	61%
Modern Contraception	2,861	2,789	6,328	127%	2%	10,203	62 %
HIV & STIs	11	28	18	(38)%	0%	-	0 %
Safe Abortion	16	9	82	847%	0%	324	25 %
Honduras	1,744	4,890	5,844	20 %	2%	19,810	30%
Modern Contraception	351	670	989	48%	0%	2,693	37 %
HIV & STIs	1,393	4,221	4,856	15%	1%	17,117	28 %
Kazakhstan	63	83	173	108 %	-%	562	31%
Modern Contraception	-	3	-	(100)%	0%	4	0 %
HIV & STIs	63	80	173	117%	0%	558	31 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Kyrgyzstan	28	170	119	(30)%	-%	457	26%
Modern Contraception	-	12	-	(100)%	0%	22	0 %
HIV & STIs	28	158	119	(25)%	0%	435	27 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Laos	1,889	7,463	6,924	(7)%	2%	27,508	25%
Modern Contraception	1,612	5,932	5,541	(7)%	2%	22,913	24 %

POPULATION SERVICES INTERNATIONAL
Monthly DALY Report by Country
Period: 3
Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
HIV & STIs	264	1,188	1,057	(11)%	0%	3,564	30 %
Malaria	13	53	60	15%	0%	156	39 %
Safe Abortion	-	271	253	(7)%	0%	837	30 %
Tuberculosis	-	20	13	(34)%	0%	38	35 %
Nepal	1,314	12,351	2,997	(76)%	1%	30,224	10%
Modern Contraception	119	8,021	294	(96)%	0%	17,110	2 %
HIV & STIs	-	2	-	(100)%	0%	-	0 %
Safe Abortion	1,195	4,328	2,703	(38)%	1%	13,114	21 %
Nicaragua	1,344	4,247	3,878	(9)%	1%	-	807,882%
Modern Contraception	641	2,557	2,005	(22)%	1%	-	0 %
HIV & STIs	696	1,683	1,851	10%	1%	-	385,685 %
Safe Abortion	7	7	21	184%	0%	-	0 %
Nicaragua SA	-	-	-	- %	-%	16,895	-%
Modern Contraception	-	-	-	0%	0%	10,574	0 %
HIV & STIs	-	-	-	0%	0%	6,148	0 %
Safe Abortion	-	-	-	0%	0%	173	0 %
Pakistan	95,216	163,324	219,476	34 %	61%	383,003	57%
Modern Contraception	77,996	123,283	175,382	42%	49%	348,668	50 %
HIV & STIs	5,756	11,657	10,854	(7)%	3%	34,336	32 %
Safe Abortion	1,057	2,847	4,312	51%	1%	-	0 %
Tuberculosis	10,407	25,537	28,928	13%	8%	-	0 %
Panama	232	1,840	1,416	(23)%	-%	7,260	20%
Modern Contraception	53	433	331	(24)%	0%	1,719	19 %
HIV & STIs	179	1,407	1,085	(23)%	0%	5,542	20 %
Papua New Guinea	-	2,032	3	(100)%	-%	3,278	-%
Modern Contraception	-	165	-	(100)%	0%	1,889	0 %
HIV & STIs	-	150	-	(100)%	0%	1,309	0 %
Malaria	-	1,714	-	(100)%	0%	-	0 %
Maternal, Newborn, and Child Health	-	-	-	0%	0%	76	0 %
WASH	-	3	2	(26)%	0%	4	64 %
PSI Pakistan	12,246	61,387	29,143	(53)%	8%	304,660	10%
Modern Contraception	12,076	61,165	28,709	(53)%	8%	292,577	10 %
HIV & STIs	170	222	434	95%	0%	12,083	4 %
Tajikistan	111	2,399	354	(85)%	-%	19,404	2%
Modern Contraception	3	115	12	(89)%	0%	80	15 %
HIV & STIs	108	2,285	342	(85)%	0%	19,324	2 %
Tuberculosis	-	-	-	0%	0%	-	0 %
Viet Nam	346	4,405	1,967	(55)%	1%	2,123	93%
Modern Contraception	12	43	34	(21)%	0%	76	44 %
HIV & STIs	328	4,325	1,912	(56)%	1%	1,912	100 %
Malaria	-	3	-	(90)%	0%	108	0 %
Non-communicable diseases	-	-	-	0%	0%	-	0 %
Tuberculosis	-	-	-	0%	0%	-	0 %
WASH	6	33	21	(38)%	0%	26	78 %
Foundation Market Group	165,946	1,766,441	719,316	(59)%	100%	9,033,832	8%
Haiti	9,630	72,494	27,909	(62)%	4%	87,193	32%

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 3

Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
Modern Contraception	1,240	16,085	3,537	(78)%	0%	9,184	39 %
HIV & STIs	1,854	21,496	4,469	(79)%	1%	12,871	35 %
Malaria	5,778	1,550	5,781	273%	1%	23,585	25 %
Maternal, Newborn, and Child Health	758	-	770	0%	0%	7,462	10 %
Non-communicable diseases	-	-	-	(100)%	0%	-	0 %
Tuberculosis	-	33,362	13,352	(60)%	2%	34,091	39 %
Liberia	754	2,165	1,837	(15)%	-%	27,447	7%
Modern Contraception	348	993	841	(15)%	0%	12,602	7 %
HIV & STIs	396	1,133	960	(15)%	0%	14,733	7 %
WASH	10	40	36	(8)%	0%	112	33 %
Madagascar	82,590	217,318	231,490	7 %	32%	1,094,187	21%
Modern Contraception	27,539	61,379	67,357	10%	9%	476,130	14 %
HIV & STIs	1,055	10,388	2,992	(71)%	0%	117,859	3 %
Malaria	53,463	125,420	159,513	27%	22%	459,706	35 %
Maternal, Newborn, and Child Health	19	17,134	46	(100)%	0%	36,677	0 %
Non-communicable diseases	1	2	3	33%	0%	-	0 %
Nutrition	-	-	-	0%	0%	-	0 %
Safe Abortion	297	431	976	127%	0%	3,618	27 %
WASH	216	2,564	604	(76)%	0%	197	306 %
Mali	20,207	1,279,779	339,788	(73)%	47%	4,563,000	7%
Modern Contraception	19,793	67,494	63,777	(6)%	9%	446,445	14 %
HIV & STIs	-	-	-	0%	0%	1,036	0 %
Malaria	-	1,210,594	275,244	(77)%	38%	4,103,046	7 %
Non-communicable diseases	13	9	13	42%	0%	210	6 %
Safe Abortion	399	1,681	750	(55)%	0%	11,204	7 %
WASH	2	-	3	0%	0%	1,059	0 %
Somaliland	10,610	10,698	29,761	178 %	4%	158,117	19%
Modern Contraception	210	211	648	207%	0%	4,893	13 %
HIV & STIs	17	-	42	0%	0%	131	32 %
Malaria	100	-	251	0%	0%	866	29 %
Maternal, Newborn, and Child Health	3,565	10,205	14,285	40%	2%	48,449	29 %
Nutrition	6,718	-	14,338	0%	2%	103,209	14 %
WASH	-	282	198	(30)%	0%	568	35 %
South Sudan	42,156	183,986	88,531	(52)%	12%	3,103,888	3%
Malaria	42,156	143,020	88,531	(38)%	12%	3,103,888	3 %
Maternal, Newborn, and Child Health	-	40,966	-	(100)%	0%	-	0 %
Social Enterprise	140,157	311,989	316,480	1%	100%	1,401,560	23%
India LLC	61,418	115,204	106,184	(8)%	34%	805,943	13%
Modern Contraception	18,477	51,701	35,740	(31)%	11%	312,748	11 %
HIV & STIs	30,765	38,032	42,077	11%	13%	311,642	14 %
Maternal, Newborn, and Child Health	7,584	8,688	15,570	79%	5%	26,486	59 %
Safe Abortion	4,592	16,783	12,798	(24)%	4%	155,067	8 %
Other	-	-	-	0%	0%	-	0 %
Paraguay	1,678	5,076	5,358	6 %	2%	24,784	22%
Modern Contraception	478	1,666	1,658	0%	1%	7,205	23 %
HIV & STIs	1,178	3,322	3,641	10%	1%	17,198	21 %
Nutrition	22	88	59	(33)%	0%	381	16 %

POPULATION SERVICES INTERNATIONAL

Monthly DALY Report by Country

Period: 3

Year: 2019

	DALY 3/2019	YTD DALY 2018	YTD DALY 2019	Percentage Change	Percentage of Category	Annual DALY Target	Percentage of Target Achieved
PSI South Africa	77,061	191,710	204,938	7 %	65%	570,833	36%
Modern Contraception	4,609	11,990	12,425	4%	4%	61,209	20 %
HIV & STIs	72,453	179,720	192,513	7%	61%	509,624	38 %
Inactive	-	1,762	-	(100%)	-%	-	-%
Guinea	-	1,762	-	(100)%	-%	-	-%
Modern Contraception	-	1,520	-	(100)%	0%	-	0 %
HIV & STIs	-	242	-	(100)%	0%	-	0 %

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acute Malnutrition Screening_CU5	-	130	389	312	418	(7)%	619,573	621,339	389	-	-
Franco/Lusophone Africa Market Group	-	-	-	312	418	(100)%	518	1,895	-	-	-
Foundation Market Group	-	130	389	-	-	-%	619,055	619,444	389	-	-
Antiretroviral Treatment	-	-	-	-	-	-%	-	18,119	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	18,119	-	-	-
Antiretroviral Treatment (Currently Enrolled)	29,442	29,436	88,125	313,246	67,260	31%	535,855	1,096,322	7,344	-	16,589
Acceleration Market Group	13,710	13,464	40,889	170,176	35,466	15%	152,003	269,373	3,407	-	8,125
Anglophone Africa Market Group	12,734	13,042	38,395	105,390	29,710	29%	148,026	305,654	3,200	-	6,798
Franco/Lusophone Africa Market Group	2,998	2,929	8,841	7,723	2,004	341%	19,016	34,487	737	-	1,666
Latin America & Asia Market Group	-	-	-	-	80	(100)%	233	233	-	-	-
Foundation Market Group	-	-	-	29,957	-	-%	216,577	486,575	-	-	-
Antiretroviral Treatment (Newly Enrolled)	920	806	2,411	13,389	2,557	(6)%	15,865	45,374	2,411	-	-
Acceleration Market Group	310	295	909	3,981	776	17%	3,434	10,495	909	-	-
Anglophone Africa Market Group	506	383	1,330	4,695	1,555	(14)%	6,634	24,195	1,330	-	-
Franco/Lusophone Africa Market Group	104	41	172	1,396	146	18%	1,807	2,393	172	-	-
Latin America & Asia Market Group	-	-	-	-	80	(100)%	92	92	-	-	-
Foundation Market Group	-	87	-	3,317	-	-%	3,898	8,199	-	-	-
Antiretroviral Treatment (Tablet)	-	-	-	-	-	-%	-	97,980	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	97,980	-	-	-
ARV Prophylaxis 28 wks (Mother and Baby)	-	-	-	-	-	-%	-	382	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	382	-	-	-
ARV Prophylaxis 28 wks (Mother Only)	-	-	-	-	-	-%	-	359	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	359	-	-	-
Basic Care Package	-	-	-	-	-	-%	1	176,452,482	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,064,698	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	1	174,969,459	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	418,325	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
CD4 Tests Provided to HIV+ Clients	-	-	-	-	666	(100)%	666	16,834	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	4,995	-	-	-
Anglophone Africa Market Group	-	-	-	-	544	(100)%	544	9,416	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	122	(100)%	122	1,919	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	504	-	-	-
Cervical Cancer-HPV DNA and Cryotherapy	-	-	-	-	3	(100)%	3	3	-	-	-
Anglophone Africa Market Group	-	-	-	-	3	(100)%	3	3	-	-	-
Cervical Cancer-HPV DNA and Refer to any Treatment	-	-	-	-	-	-%	-	11	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	11	-	-	-
Cervical Cancer-HPV DNA and Refer to Conization	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	-	-%	4	39	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	25	-	-	-
Foundation Market Group	-	-	-	-	-	-%	4	4	-	-	-
Inactive	-	-	-	-	-	-%	-	10	-	-	-
Cervical Cancer-Pap and Refer to any Treatment	-	-	-	-	-	-%	-	2	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2	-	-	-
Cervical Cancer-Pap and Refer to Conization	-	-	-	-	-	-%	-	9	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	9	-	-	-
Cervical Cancer-Pap Smear Screening	19	35	125	-	-	-%	92	7,482	125	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	6,497	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	291	-	-	-
Latin America & Asia Market Group	19	35	125	-	-	-%	92	605	125	-	-
Inactive	-	-	-	-	-	-%	-	89	-	-	-
Cervical Cancer-VIA and Conization	21	19	51	290	17	200%	126	355	51	-	18
Anglophone Africa Market Group	21	19	51	290	17	200%	126	355	51	-	18
Cervical Cancer-VIA and Cryotherapy	135	67	265	1,247	280	(5)%	1,162	21,704	265	-	81

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	34	24	83	240	47	77%	286	11,329	83	-	19
Anglophone Africa Market Group	55	34	129	307	183	(30)%	639	8,578	129	-	45
Franco/Lusophone Africa Market Group	-	1	1	-	12	(92)%	48	375	1	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	8	-	-	-
Foundation Market Group	46	8	52	700	38	37%	189	1,394	52	-	16
Inactive	-	-	-	-	-	-%	-	20	-	-	-
Cervical Cancer-VIA and Refer to any Treatment	13	3	22	-	6	267%	25	460	22	-	4
Acceleration Market Group	-	-	-	-	-	-%	-	127	-	-	-
Anglophone Africa Market Group	13	3	22	-	6	267%	25	333	22	-	4
Cervical Cancer-VIA and Refer to Conization	-	5	6	290	5	20%	102	2,066	6	-	1
Acceleration Market Group	-	1	-	-	-	-%	4	4	-	-	-
Anglophone Africa Market Group	-	4	6	290	5	20%	98	2,062	6	-	1
Cervical Cancer-VIA and Refer to Cryotherapy	-	2	-	150	-	-%	39	2,084	-	-	-
Acceleration Market Group	-	2	-	150	-	-%	29	913	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	10	625	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	536	-	-	-
Cervical Cancer-VIA/VILI Screening	11,337	8,899	26,805	145,293	39,681	(32)%	194,523	1,067,509	26,805	-	-
Acceleration Market Group	3,771	2,817	9,810	21,500	5,035	95%	34,714	474,242	9,810	-	-
Anglophone Africa Market Group	4,324	3,077	11,122	88,793	23,614	(53)%	95,922	352,208	11,122	-	-
Franco/Lusophone Africa Market Group	1,269	2,539	3,797	-	6,897	(45)%	50,592	164,626	3,797	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	387	-	-	-
Foundation Market Group	1,973	465	2,076	35,000	4,135	(50)%	13,295	75,776	2,076	-	-
Inactive	-	-	-	-	-	-%	-	270	-	-	-
Chlorhexidine	1,239	427	2,012	25,755	78,584	(97)%	130,742	619,927	1,811	-	140
Acceleration Market Group	-	-	-	-	-	-%	-	148,406	-	-	-
Anglophone Africa Market Group	1,239	427	2,012	16,755	2,248	(10)%	23,622	38,677	1,811	-	140

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	-	-	9,000	76,336	(100)%	107,120	432,844	-	-	-
Clean Delivery Kit	-	-	-	-	3,511	(100)%	3,449	1,708,471	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	346,994	-	-	-
Anglophone Africa Market Group	-	-	-	-	3,511	(100)%	3,449	470,003	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	710,114	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	180,586	-	-	-
Inactive	-	-	-	-	-	-%	-	774	-	-	-
Condom	53,391,719	45,297,767	115,901,588	553,397,069	111,652,084	4%	504,429,167	21,562,911,656	869,262	869,262	1,010,180
Acceleration Market Group	3,329,742	3,950,207	9,681,499	41,769,999	8,144,717	19%	38,017,548	9,763,479,850	72,611	72,611	221,268
Anglophone Africa Market Group	4,836,518	3,857,836	13,641,870	49,703,561	14,149,507	(4)%	65,266,786	3,160,550,553	102,314	102,314	273,054
Franco/Lusophone Africa Market Group	2,372,580	4,735,216	10,789,126	59,938,298	10,659,693	1%	51,015,576	1,640,057,788	80,918	80,918	128,052
Latin America & Asia Market Group	23,096,712	16,936,987	49,537,856	196,479,173	49,409,058	-%	187,072,729	3,901,660,319	371,534	371,534	112,176
Foundation Market Group	56,436	207,640	319,452	2,920,716	374,412	(15)%	3,347,338	952,816,685	2,396	2,396	2,656
Social Enterprise	19,699,731	15,609,881	31,931,785	202,585,322	28,914,697	10%	159,709,190	744,450,660	239,488	239,488	272,974
USA	-	-	-	-	-	-%	-	289,819	-	-	-
Inactive	-	-	-	-	-	-%	-	1,399,605,982	-	-	-
Condom Provided	-	-	-	-	-	-%	-	18,930,351	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	50,644	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	17,527,104	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	673,774	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	651,148	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	27,681	-	-	-
Counseling & Tx for Moderate Acute MalnutritionCU5	1,597	4,389	3,559	20,946	-	-%	20,332	179,046	3,559	-	11,132
Franco/Lusophone Africa Market Group	-	-	-	4	-	-%	-	8	-	-	-
Foundation Market Group	1,597	4,389	3,559	20,942	-	-%	20,332	179,038	3,559	-	11,132
Deworming Tablets	-	-	-	-	-	-%	-	1,095,308	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,095,308	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Diarrhea Treatment Kit	38,169	45,978	125,646	780,367	151,857	(17)%	666,448	19,863,119	113,081	-	7,901
Acceleration Market Group	-	-	-	-	-	-%	-	6,854,139	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	24,379	-	-	-
Franco/Lusophone Africa Market Group	30,609	19,381	61,906	424,000	68,785	(10)%	431,332	4,195,035	55,715	-	3,502
Latin America & Asia Market Group	6,660	4,980	21,600	91,951	21,580	-%	57,190	970,276	19,440	-	425
Foundation Market Group	900	21,617	42,140	264,416	61,492	(31)%	177,926	5,072,344	37,926	-	3,974
Inactive	-	-	-	-	-	-%	-	2,746,946	-	-	-
Diarrhea Treatment Kit Provided	1,817	1,853	5,670	29,000	5,271	8%	20,038	74,601	5,670	-	188
Acceleration Market Group	1,817	1,853	5,670	29,000	4,651	22%	18,226	59,927	5,670	-	188
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,400	-	-	-
Foundation Market Group	-	-	-	-	620	(100)%	1,812	12,274	-	-	-
Early Infant Male Circumcision	-	-	-	-	-	-%	-	4,886	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,886	-	-	-
Emergency Contraception	260,405	310,349	827,109	2,499,767	725,706	14%	3,049,904	45,416,270	37,220	37,220	6,811
Acceleration Market Group	(2,099)	(462)	(3,486)	-	(125)	-%	(121)	16,362,855	(157)	(157)	(20)
Anglophone Africa Market Group	13,906	7,068	22,211	7,000	15,819	40%	180,947	1,669,968	999	999	309
Franco/Lusophone Africa Market Group	7,252	6,025	21,867	255,200	81,860	(73)%	135,874	698,173	984	984	589
Latin America & Asia Market Group	202,818	247,458	639,344	981,837	515,863	24%	2,139,235	21,701,130	28,770	28,770	4,996
Foundation Market Group	(6)	14,946	44,841	15,700	15,223	195%	40,018	165,372	2,018	2,018	549
Social Enterprise	38,534	35,315	102,332	1,240,030	97,066	5%	553,951	3,168,435	4,605	4,605	388
Inactive	-	-	-	-	-	-%	-	1,650,337	-	-	-
Emergency Contraception Provided	5,121	4,218	13,759	1,199,860	6,725	105%	29,591	78,708	688	688	156
Acceleration Market Group	2,254	898	4,077	19,800	393	937%	4,173	9,678	204	204	34
Anglophone Africa Market Group	176	303	832	30,493	894	(7)%	6,887	8,938	42	42	20
Franco/Lusophone Africa Market Group	322	367	1,061	3,000	398	167%	2,877	5,548	53	53	33
Latin America & Asia Market Group	2,363	2,636	7,750	1,146,567	4,963	56%	15,372	52,523	388	388	68
Foundation Market Group	6	14	39	-	77	(49)%	282	2,020	2	2	1

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	1	-	-	-
Expanded Clean Delivery Kit	-	-	-	-	-	-%	13,160	25,000	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	13,160	25,000	-	-	-
Expanded Clean Delivery Kit (+CHX)	94	317	558	20,285	2,367	(76)%	14,531	15,706	502	-	82
Anglophone Africa Market Group	94	317	558	20,285	2,367	(76)%	14,531	15,706	502	-	82
Family Planning Counseling	-	-	-	-	-	-%	-	42,190	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,882	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	21,833	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	3,787	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	688	-	-	-
Fecal Sludge Management (Households)	83	220	357	400	142	151%	2,071	4,010	1,743	-	-
Acceleration Market Group	48	112	258	400	43	500%	697	2,537	1,238	-	-
Franco/Lusophone Africa Market Group	35	107	99	-	99	-%	1,374	1,473	505	-	-
Fecal Sludge Management (Liters)	965,000	1,182,667	3,247,000	15,559,190	743,000	337%	9,121,000	19,514,200	-	-	292
Acceleration Market Group	240,000	561,667	1,290,000	2,000,000	137,000	842%	4,011,000	12,447,200	-	-	79
Franco/Lusophone Africa Market Group	725,000	621,000	1,957,000	13,559,190	606,000	223%	5,110,000	7,067,000	-	-	212
Female Condom	56,439	289,371	719,065	1,763,132	360,133	100%	1,709,647	86,881,929	5,393	5,393	8,650
Acceleration Market Group	12,643	12,398	36,103	70,000	15,736	129%	79,641	10,431,696	271	271	195
Anglophone Africa Market Group	20,812	16,863	65,188	533,000	175,496	(63)%	469,229	48,635,015	489	489	1,862
Franco/Lusophone Africa Market Group	22,984	260,110	617,774	1,160,132	168,881	266%	1,160,677	12,370,419	4,633	4,633	6,594
Latin America & Asia Market Group	-	-	-	-	20	(100)%	100	660,929	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	9,300,709	-	-	-
Social Enterprise	-	-	-	-	-	-%	-	985,104	-	-	-
Inactive	-	-	-	-	-	-%	-	4,498,057	-	-	-
Female Condom Provided	-	-	-	-	-	-%	-	112,394	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	87,306	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	22,060	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,027	-	-	-
Fever Cases Attended	56,024	63,050	144,157	286,938	159,895	(10)%	916,338	6,290,392	144,157	-	-
Acceleration Market Group	38,711	47,063	93,365	-	83,255	12%	697,782	2,551,512	93,365	-	-
Franco/Lusophone Africa Market Group	-	-	-	8,385	-	-%	14,143	26,907	-	-	-
Latin America & Asia Market Group	4,587	5,233	14,617	75,685	51,611	(72)%	118,263	294,542	14,617	-	-
Foundation Market Group	12,726	10,753	36,175	202,868	25,029	45%	86,150	3,417,431	36,175	-	-
Fever Cases Tested with Microscopy	272	3,454	4,653	30,340	10,234	(55)%	56,797	444,141	4,653	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	7,474	-	-	-
Foundation Market Group	272	3,454	4,653	30,340	10,234	(55)%	56,797	436,667	4,653	-	-
Fever Cases Tested with RDTs	53,243	81,198	163,453	276,374	186,018	(12)%	1,120,815	6,709,349	163,453	-	-
Acceleration Market Group	38,711	47,063	93,365	-	83,255	12%	697,782	2,543,684	93,365	-	-
Franco/Lusophone Africa Market Group	-	-	-	8,385	-	-%	14,143	42,041	-	-	-
Latin America & Asia Market Group	5,795	7,043	19,291	95,551	51,608	(63)%	134,061	314,978	19,291	-	-
Foundation Market Group	8,737	27,092	50,797	172,438	51,155	(1)%	274,829	3,808,646	50,797	-	-
Free Condom	7,071,453	8,648,883	18,272,592	109,721,482	35,472,959	(48)%	180,808,636	2,641,360,430	137,044	137,044	382,992
Acceleration Market Group	187,200	2,145,360	1,236,960	35,500,000	10,839,600	(89)%	68,170,320	1,487,194,858	9,277	9,277	36,739
Anglophone Africa Market Group	5,963,045	4,941,457	14,562,462	44,434,784	15,294,752	(5)%	77,319,731	744,509,113	109,218	109,218	333,899
Franco/Lusophone Africa Market Group	31,000	23,605	62,100	5,193,631	257,016	(76)%	3,201,731	70,052,293	466	466	367
Latin America & Asia Market Group	126,000	431,971	690,000	3,124,160	770,933	(10)%	3,430,359	58,634,165	5,175	5,175	1,374
Foundation Market Group	764,208	1,106,490	1,721,070	21,468,907	7,966,342	(78)%	28,342,179	162,272,322	12,908	12,908	10,612
Inactive	-	-	-	-	344,316	(100)%	344,316	118,697,679	-	-	-
Free Female Condom	67,730	33,334	83,890	333,000	121,665	(31)%	1,803,686	17,736,074	629	629	1,712
Acceleration Market Group	-	-	-	-	57,600	(100)%	1,108,500	6,567,761	-	-	-
Anglophone Africa Market Group	67,730	28,001	83,890	251,000	42,884	96%	623,007	6,172,753	629	629	1,712
Franco/Lusophone Africa Market Group	-	5,333	-	52,000	3,746	(100)%	49,536	1,054,694	-	-	-
Latin America & Asia Market Group	-	-	-	30,000	16,245	(100)%	21,200	353,774	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	-	-	-	-	-%	253	3,329,424	-	-	-
Inactive	-	-	-	-	1,190	(100)%	1,190	257,668	-	-	-
HAART (Mother and Baby)	-	-	-	-	-	-%	-	256	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	256	-	-	-
HAART (Mother Only)	-	-	-	-	-	-%	-	239	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	239	-	-	-
HIV Self-Testing Kit	48,376	617,380	156,956	-	106,811	47%	2,354,376	2,880,879	141,260	-	-
Acceleration Market Group	6,774	460,303	30,260	-	-	-%	1,357,422	1,387,682	27,234	-	-
Anglophone Africa Market Group	41,602	157,077	126,696	-	106,811	19%	996,954	1,493,197	114,026	-	-
HIV Testing Services	73,328	84,495	233,110	1,174,518	890,682	(74)%	2,232,177	23,552,648	233,110	-	10,147
Acceleration Market Group	29,057	32,053	93,566	293,418	732,832	(87)%	1,091,132	7,119,602	93,566	-	3,688
Anglophone Africa Market Group	24,157	23,802	74,126	518,172	93,784	(21)%	541,424	10,522,224	74,126	-	6,029
Franco/Lusophone Africa Market Group	11,782	7,281	27,025	93,415	36,018	(25)%	106,415	3,027,597	27,025	-	292
Latin America & Asia Market Group	4,737	4,865	14,991	78,439	26,707	(44)%	98,169	386,772	14,991	-	32
Foundation Market Group	3,595	16,493	23,402	191,074	1,341	1,645%	395,037	1,722,003	23,402	-	106
Inactive	-	-	-	-	-	-%	-	774,450	-	-	-
Hypertension Diagnosis	3,995	1,614	8,410	34,572	29,575	(72)%	84,148	174,219	8,410	-	-
Acceleration Market Group	2,401	607	3,818	20,000	19,107	(80)%	57,768	114,821	3,818	-	-
Anglophone Africa Market Group	16	27	72	-	83	(13)%	278	2,441	72	-	-
Latin America & Asia Market Group	1,578	981	4,520	14,572	10,385	(56)%	26,102	56,957	4,520	-	-
Hypertension Screening	56,418	52,608	164,084	236,477	211,839	(23)%	737,910	1,676,470	164,084	-	-
Acceleration Market Group	9,860	8,208	26,699	50,000	44,097	(39)%	176,640	424,938	26,699	-	-
Anglophone Africa Market Group	12,056	12,881	38,149	36,477	36,246	5%	147,793	536,602	38,149	-	-
Latin America & Asia Market Group	34,502	31,518	99,236	150,000	131,496	(25)%	413,477	714,930	99,236	-	-
Hypertension_C Controlled Condition	3,655	2,473	8,805	13,009	21,671	(59)%	74,033	144,661	3,522	-	-
Acceleration Market Group	1,627	395	2,510	-	13,966	(82)%	43,499	87,656	1,004	-	-
Anglophone Africa Market Group	3	6	15	-	24	(38)%	91	172	6	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	2,025	2,072	6,280	13,009	7,681	(18)%	30,443	56,833	2,512	-	-
Implant 3	9,353	5,877	25,100	87,804	2,685	835%	24,695	1,032,998	22,590	56,475	53,415
Acceleration Market Group	66	631	1,468	12,600	63	2,230%	1,528	820,014	1,321	3,303	2,461
Anglophone Africa Market Group	8,820	2,531	15,685	73,620	(4,456)	-%	6,088	148,280	14,117	35,291	36,731
Franco/Lusophone Africa Market Group	1,427	1,308	2,508	(4,896)	5,467	(54)%	7,323	26,032	2,257	5,643	5,261
Latin America & Asia Market Group	(66)	314	878	4,920	217	305%	1,681	24,722	790	1,976	297
Foundation Market Group	(894)	1,094	4,561	1,560	1,394	227%	8,075	16,215	4,105	10,262	8,665
Inactive	-	-	-	-	-	-%	-	(2,265)	-	-	-
Implant 3 Insertion	23,595	24,753	74,653	341,797	62,131	20%	334,633	1,018,377	74,653	186,633	160,439
Acceleration Market Group	519	1,930	2,007	38,123	1,063	89%	8,884	14,502	2,007	5,018	2,545
Anglophone Africa Market Group	12,647	15,130	48,043	201,554	51,212	(6)%	240,316	758,550	48,043	120,108	112,404
Franco/Lusophone Africa Market Group	4,355	3,366	11,282	27,532	1,871	503%	24,546	57,985	11,282	28,205	25,860
Latin America & Asia Market Group	1,279	659	3,393	12,195	2,523	34%	12,809	37,645	3,393	8,483	1,981
Foundation Market Group	4,795	3,669	9,928	62,393	5,462	82%	48,078	144,988	9,928	24,820	17,649
Inactive	-	-	-	-	-	-%	-	4,707	-	-	-
Implant 4	(2)	(168)	(30)	-	(4)	-%	(3,897)	20,752	(27)	(86)	(76)
Anglophone Africa Market Group	-	(167)	(28)	-	-	-%	(3,883)	7,720	(25)	(81)	(72)
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,200	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	(700)	-	-	-
Foundation Market Group	(2)	(1)	(2)	-	(4)	-%	(14)	7,532	(2)	(6)	(3)
Implant 4 Insertion	18	402	49	-	293	(83)%	34,188	44,422	49	157	120
Acceleration Market Group	-	-	-	-	288	(100)%	288	288	-	-	-
Anglophone Africa Market Group	-	400	28	-	1	2,700%	33,884	35,512	28	90	80
Franco/Lusophone Africa Market Group	16	1	19	-	-	-%	2	750	19	61	36
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,342	-	-	-
Foundation Market Group	2	1	2	-	4	(50)%	14	2,530	2	6	4
Implant 5	15,222	3,993	18,978	50,794	5,576	240%	73,825	763,702	17,080	64,905	70,257

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	(616)	(704)	(4,101)	(7,600)	(1,430)	-%	2,423	270,897	(3,691)	(14,025)	(10,246)
Anglophone Africa Market Group	10,497	2,684	14,407	26,000	(6,456)	-%	17,510	195,202	12,966	49,272	51,512
Franco/Lusophone Africa Market Group	5,407	689	5,086	29,052	128	3,873%	27,720	126,811	4,577	17,394	12,205
Latin America & Asia Market Group	(47)	(241)	(887)	3,342	13,465	(107)%	20,838	84,666	(798)	(3,034)	(625)
Foundation Market Group	(19)	1,564	4,473	-	(131)	-%	5,334	74,491	4,026	15,298	17,411
Inactive	-	-	-	-	-	-%	-	11,635	-	-	-
Implant 5 Insertion	36,982	25,834	93,450	372,974	66,214	41%	373,214	2,080,411	93,450	355,110	312,524
Acceleration Market Group	8,004	6,475	23,908	62,915	12,410	93%	82,547	458,544	23,908	90,850	78,469
Anglophone Africa Market Group	15,212	11,740	43,006	175,505	31,576	36%	154,215	815,740	43,006	163,423	148,649
Franco/Lusophone Africa Market Group	9,917	4,867	19,023	71,842	12,119	57%	76,301	321,295	19,023	72,287	64,832
Latin America & Asia Market Group	1,368	781	3,345	12,712	3,450	(3)%	21,679	91,125	3,345	12,711	2,655
Foundation Market Group	2,481	1,971	4,168	50,000	6,659	(37)%	38,472	330,109	4,168	15,838	17,919
Inactive	-	-	-	-	-	-%	-	63,598	-	-	-
Infant Fortified Food	-	-	-	-	-	-%	-	91,859	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	91,859	-	-	-
Injectable 1	23,063	13,611	53,493	150,016	21,397	150%	130,168	3,712,951	3,703	3,703	874
Acceleration Market Group	-	-	-	-	-	-%	-	1,546,164	-	-	-
Latin America & Asia Market Group	23,063	13,611	53,493	150,016	21,397	150%	130,168	2,166,778	3,703	3,703	874
Inactive	-	-	-	-	-	-%	-	9	-	-	-
Injectable 1 Provided	8,674	4,666	19,010	44,561	21,735	(13)%	89,057	246,637	1,462	1,462	320
Acceleration Market Group	-	14	5	-	-	-%	37	42	-	-	-
Anglophone Africa Market Group	9	4	19	36	107	(82)%	537	1,786	1	1	1
Latin America & Asia Market Group	8,665	4,648	18,986	44,525	21,628	(12)%	88,483	244,809	1,460	1,460	319
Injectable 2	(915)	16,775	24,072	39,747	83,197	(71)%	188,630	23,312,028	3,611	3,611	816
Acceleration Market Group	-	-	-	-	-	-%	-	15,907,000	-	-	-
Franco/Lusophone Africa Market Group	(470)	3,092	(275)	20,016	7,882	(103)%	54,602	294,069	(41)	(41)	(22)
Latin America & Asia Market Group	(445)	13,684	24,347	19,731	75,315	(68)%	134,028	7,110,955	3,652	3,652	838

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	4	-	-	-
Injectable 2 Provided	4,404	6,523	14,725	211,422	28,253	(48)%	102,606	241,625	2,454	2,454	1,182
Acceleration Market Group	-	2,250	876	-	-	-%	5,875	6,751	146	146	123
Anglophone Africa Market Group	1,471	1,772	5,058	29,000	5,542	(9)%	22,699	39,405	843	843	624
Franco/Lusophone Africa Market Group	705	1,124	3,061	50,000	3,275	(7)%	15,848	41,811	510	510	274
Latin America & Asia Market Group	2,228	1,378	5,730	132,422	19,436	(71)%	58,184	153,657	955	955	160
Inactive	-	-	-	-	-	-%	-	1	-	-	-
Injectable 3-IM	405,750	261,978	770,116	3,760,923	1,142,113	(33)%	5,050,702	92,714,301	173,276	173,276	70,578
Acceleration Market Group	30,985	42,081	80,325	480,600	137,403	(42)%	493,679	32,122,286	18,073	18,073	3,527
Anglophone Africa Market Group	191,893	14,603	238,174	605,251	423,030	(44)%	1,797,775	14,323,172	53,589	53,589	24,987
Franco/Lusophone Africa Market Group	59,078	57,425	66,341	105,000	28,462	133%	272,940	1,310,981	14,927	14,927	10,235
Latin America & Asia Market Group	52,059	36,747	111,688	560,836	262,950	(58)%	687,092	11,860,047	25,130	25,130	4,882
Foundation Market Group	68,266	103,661	262,834	1,988,500	273,649	(4)%	1,669,487	29,409,370	59,138	59,138	26,542
Social Enterprise	3,469	7,462	10,754	20,736	16,619	(35)%	129,729	209,564	2,420	2,420	405
Inactive	-	-	-	-	-	-%	-	3,478,881	-	-	-
Injectable 3-IM Provided	117,718	124,757	356,702	1,613,683	424,316	(16)%	1,573,348	3,495,093	89,176	89,176	43,410
Acceleration Market Group	17,175	18,502	50,618	204,422	40,005	27%	175,770	421,672	12,655	12,655	5,690
Anglophone Africa Market Group	32,036	38,565	100,651	357,197	67,222	50%	342,639	809,399	25,163	25,163	16,642
Franco/Lusophone Africa Market Group	15,778	22,556	67,339	255,395	59,508	13%	272,082	695,573	16,835	16,835	12,928
Latin America & Asia Market Group	47,834	40,417	126,533	761,629	243,739	(48)%	705,711	1,284,540	31,633	31,633	6,437
Foundation Market Group	4,895	4,718	11,561	35,040	13,842	(16)%	77,146	283,909	2,890	2,890	1,714
Injectable 3-SC	42,296	27,826	89,606	737,082	101,555	(12)%	617,820	1,760,170	20,161	20,161	11,065
Acceleration Market Group	2,150	1,111	5,484	32,150	-	-%	-	5,484	1,234	1,234	154
Anglophone Africa Market Group	12,470	6,210	25,100	53,892	-	-%	55,900	81,000	5,648	5,648	4,204
Franco/Lusophone Africa Market Group	7,369	4,768	17,424	31,480	470	3,607%	26,328	46,367	3,920	3,920	2,524
Latin America & Asia Market Group	-	-	-	1,400	-	-%	-	-	-	-	-
Foundation Market Group	20,307	15,737	41,598	618,160	101,085	(59)%	535,592	1,627,319	9,360	9,360	4,183

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Injectable 3-SC Provided	5,818	4,895	14,598	44,763	-	-%	5,904	20,502	3,650	3,650	2,947
Acceleration Market Group	-	296	887	-	-	-%	-	887	222	222	187
Franco/Lusophone Africa Market Group	5,723	4,520	13,553	39,163	-	-%	5,729	19,282	3,388	3,388	2,746
Latin America & Asia Market Group	-	-	-	5,600	-	-%	-	-	-	-	-
Foundation Market Group	95	79	158	-	-	-%	175	333	40	40	14
IPTp2	762	891	2,453	291,388	833	194%	85,804	346,904	2,453	-	175
Acceleration Market Group	401	454	1,339	-	812	65%	3,893	15,636	1,339	-	50
Anglophone Africa Market Group	-	-	-	-	-	-%	-	44,748	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	54	-	-	-
Foundation Market Group	361	437	1,114	291,388	21	5,205%	81,911	286,466	1,114	-	125
Iron Folic Acid Tablet	-	-	-	19,843	-	-%	-	48,283,018	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	48,283,018	-	-	-
Foundation Market Group	-	-	-	19,843	-	-%	-	-	-	-	-
ITN	-	-	-	-	-	-%	-	19,397,605	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	5,306,807	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	12,077,111	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,983,399	-	-	-
Inactive	-	-	-	-	-	-%	-	30,288	-	-	-
IUD 10	61,039	6,184	63,558	227,046	51,713	23%	237,201	2,950,346	57,202	263,130	152,266
Acceleration Market Group	(730)	365	(1,894)	(4,600)	(532)	-%	1,452	1,449,132	(1,705)	(7,841)	(6,472)
Anglophone Africa Market Group	19,099	(534)	18,984	93,709	(14,373)	-%	68,077	347,267	17,086	78,594	77,690
Franco/Lusophone Africa Market Group	6,411	1,626	9,138	28,463	7,330	25%	29,804	216,483	8,224	37,831	31,698
Latin America & Asia Market Group	36,825	(7,275)	36,918	102,474	43,676	(15)%	64,790	675,233	33,226	152,841	45,664
Foundation Market Group	(566)	368	377	7,000	612	(38)%	7,568	80,380	339	1,561	3,657
Social Enterprise	-	11,634	35	-	15,000	(100)%	65,510	65,545	32	145	31
Inactive	-	-	-	-	-	-%	-	116,306	-	-	-
IUD 10 Insertion	34,111	28,161	91,315	539,581	120,380	(24)%	572,847	3,298,553	91,315	420,049	294,096

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	7,539	6,725	21,735	103,790	20,592	6%	90,084	647,106	21,735	99,981	99,726
Anglophone Africa Market Group	7,926	7,027	24,575	188,592	46,626	(47)%	220,262	1,224,213	24,575	113,045	98,138
Franco/Lusophone Africa Market Group	4,405	3,709	11,114	76,812	12,529	(11)%	73,738	270,917	11,114	51,124	44,408
Latin America & Asia Market Group	11,376	8,587	28,263	123,733	32,584	(13)%	148,352	787,417	28,263	130,010	31,821
Foundation Market Group	2,865	2,113	5,628	46,654	8,049	(30)%	40,411	354,651	5,628	25,889	20,004
Inactive	-	-	-	-	-	-%	-	14,249	-	-	-
IUD 3	188	(50)	(62)	-	2,213	(103)%	6,953	6,891	(56)	(140)	(30)
Social Enterprise	188	(50)	(62)	-	2,213	(103)%	6,953	6,891	(56)	(140)	(30)
IUD 5	(15,093)	14,281	21,160	208,394	12,582	68%	101,798	4,406,251	19,044	62,845	19,394
Acceleration Market Group	(13,225)	(1,742)	(18,340)	2,500	(65)	-%	(296)	1,117,413	(16,506)	(54,470)	(12,291)
Anglophone Africa Market Group	-	(9)	(25)	-	(129)	-%	(263)	14,530	(23)	(74)	(75)
Latin America & Asia Market Group	(4,960)	8,708	20,321	94,294	(6,604)	-%	22,736	3,071,043	18,289	60,353	18,830
Social Enterprise	3,092	7,324	19,204	111,600	19,380	(1)%	79,621	199,539	17,284	57,036	12,930
Inactive	-	-	-	-	-	-%	-	3,726	-	-	-
IUD 5 Insertion	21,256	18,447	71,232	131,309	45,997	55%	115,881	1,227,518	71,232	235,066	66,700
Acceleration Market Group	13,225	5,544	24,599	65,000	13,251	86%	51,661	205,449	24,599	81,177	18,340
Anglophone Africa Market Group	19	45	99	-	130	(24)%	345	28,921	99	327	216
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	45	-	-	-
Latin America & Asia Market Group	7,979	12,823	46,445	65,998	32,616	42%	63,576	992,715	46,445	153,268	47,845
Foundation Market Group	33	35	89	311	-	-%	299	388	89	294	299
IUS 3	16	8	40	2,500	2	1,900%	98	138	36	90	51
Foundation Market Group	16	8	40	2,500	2	1,900%	98	138	36	90	51
IUS 3 Insertion	37	26	95	-	-	-%	135	230	95	238	135
Foundation Market Group	37	26	95	-	-	-%	135	230	95	238	135
IUS 5	1,110	89	1,346	5,128	(23)	-%	126	2,426	1,211	3,998	3,430
Anglophone Africa Market Group	1,087	1	1,059	(56)	(23)	-%	126	2,139	953	3,145	3,236
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Social Enterprise	23	88	287	5,184	-	-%	-	287	258	852	193
IUS 5 Insertion	68	156	470	756	256	84%	1,516	2,979	470	1,551	1,561
Acceleration Market Group	-	91	232	-	59	293%	775	1,633	232	766	880
Anglophone Africa Market Group	68	64	235	756	197	19%	739	1,340	235	775	679
Latin America & Asia Market Group	-	1	3	-	-	-%	2	6	3	10	2
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-
LifeStraw	-	-	-	-	-	-%	-	15,965	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,320	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	645	-	-	-
LLIN	575,977	2,294,172	2,156,481	18,656,324	1,760,366	23%	31,104,885	360,791,880	3,493,499	-	374,788
Acceleration Market Group	328,906	127,110	368,671	2,049,898	77,627	375%	2,332,163	64,320,107	597,247	-	12,159
Anglophone Africa Market Group	159,867	28,912	176,779	700,054	433,422	(59)%	4,545,198	56,861,181	286,382	-	9,279
Franco/Lusophone Africa Market Group	29,653	180,973	278,585	3,964,115	163,830	70%	4,602,963	52,755,086	451,308	-	32,831
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5,197,868	-	-	-
Foundation Market Group	57,551	1,957,177	1,332,446	11,942,257	1,085,487	23%	19,624,561	177,596,519	2,158,563	-	320,518
Inactive	-	-	-	-	-	-%	-	4,061,119	-	-	-
LLIN (Hammock net)	300	133	700	1,350	435	61%	1,259	2,004	630	-	-
Latin America & Asia Market Group	300	133	700	1,350	435	61%	1,259	2,004	630	-	-
Lubricant	946,741	784,189	2,821,080	-	1,173,396	140%	5,621,900	80,602,954	-	-	-
Acceleration Market Group	6,879	7,729	22,854	-	8,850	158%	51,861	13,575,143	-	-	-
Anglophone Africa Market Group	217,743	200,739	654,329	-	420,626	56%	2,574,286	9,397,511	-	-	-
Franco/Lusophone Africa Market Group	-	3,611	855	-	11,545	(93)%	45,024	1,522,874	-	-	-
Latin America & Asia Market Group	134,913	127,576	441,384	-	295,960	49%	1,423,274	37,139,874	-	-	-
Foundation Market Group	582,910	441,955	1,693,774	-	166,253	919%	1,223,813	3,939,802	-	-	-
Social Enterprise	4,296	2,580	7,884	-	4,464	77%	37,944	594,140	-	-	-
Inactive	-	-	-	-	265,698	(100)%	265,698	14,433,610	-	-	-
Malaria PPT (ACT)	453,768	266,408	962,584	6,556,212	1,647,874	(42)%	7,543,851	136,095,176	866,326	-	252,978

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	35,222	11,855	70,118	182,270	148,925	(53)%	256,333	63,788,404	63,106	-	9,837
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10,387,257	-	-	-
Franco/Lusophone Africa Market Group	95,239	17,143	138,651	320,000	178,416	(22)%	297,014	1,841,459	124,786	-	38,513
Latin America & Asia Market Group	(6)	(70)	(76)	-	1,852	(104)%	147	2,839,654	(68)	-	(8)
Foundation Market Group	323,313	237,480	753,891	6,053,942	1,318,681	(43)%	6,990,357	57,238,402	678,502	-	204,636
Malaria PPT (Non-ACT)	35,986	(206)	35,791	83,621	(238)	-%	(2,041)	13,930,079	32,212	-	3,870
Acceleration Market Group	(114)	(191)	(309)	3,621	(238)	-%	(1,900)	5,113,205	(278)	-	(43)
Latin America & Asia Market Group	-	(14)	-	-	-	-%	(141)	(141)	-	-	-
Foundation Market Group	36,100	-	36,100	80,000	-	-%	-	8,817,015	32,490	-	3,913
Malaria RDK	75,270	131,076	297,470	4,357,458	529,674	(44)%	12,180,985	59,745,433	267,723	-	-
Acceleration Market Group	-	35,833	70,035	432,337	143,020	(51)%	743,410	12,906,502	63,032	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	263,260	-	-	-
Franco/Lusophone Africa Market Group	3,650	21,328	28,225	250,000	(1,015)	-%	177,919	1,125,784	25,403	-	-
Latin America & Asia Market Group	720	1,790	6,060	25,000	278,594	(98)%	305,189	7,060,956	5,454	-	-
Foundation Market Group	70,900	72,125	193,150	3,650,121	109,075	77%	10,954,467	38,388,931	173,835	-	-
Male Circumcision (HIV-Positive)	-	-	-	-	-	-%	-	10,836	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	6,118	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	4,718	-	-	-
Male Vasodilator	366,400	58,300	541,300	-	-	-%	-	541,300	4,060	-	-
Social Enterprise	366,400	58,300	541,300	-	-	-%	-	541,300	4,060	-	-
Manual Vacuum Aspiration for PAC	6,849	10,181	30,064	20,937	16,161	86%	70,499	189,290	30,064	-	3,901
Acceleration Market Group	720	720	2,296	5,220	-	-%	19,176	26,768	2,296	-	1,839
Anglophone Africa Market Group	537	529	1,641	720	128	1,182%	7,531	12,162	1,641	-	264
Franco/Lusophone Africa Market Group	190	331	600	1,918	278	116%	2,579	4,983	600	-	218
Latin America & Asia Market Group	5,009	8,240	24,720	7,295	14,510	70%	34,966	130,684	24,720	-	1,238
Foundation Market Group	393	361	807	5,784	1,245	(35)%	6,247	14,693	807	-	343
Manual Vacuum Aspiration for SA	115	128	352	743	152	132%	1,224	1,576	352	-	133

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	-	-	-	-
Anglophone Africa Market Group	57	50	200	-	39	413%	411	611	200	-	73
Franco/Lusophone Africa Market Group	58	75	144	507	32	350%	562	706	144	-	59
Latin America & Asia Market Group	-	3	8	236	81	(90)%	251	259	8	-	1
Foundation Market Group	-	-	-	-	-	-%	-	-	-	-	-
Medical Abortion	85,296	132,303	252,064	2,153,877	306,377	(18)%	1,610,639	5,679,604	226,858	-	23,647
Acceleration Market Group	-	-	-	9,000	-	-%	-	1,497,044	-	-	-
Anglophone Africa Market Group	1,499	311	2,353	9,331	12,770	(82)%	13,999	27,363	2,118	-	742
Franco/Lusophone Africa Market Group	360	275	1,035	19,550	(43)	-%	172	1,042	932	-	376
Latin America & Asia Market Group	34,027	38,470	110,985	459,996	113,080	(2)%	457,334	2,362,394	99,887	-	9,732
Social Enterprise	49,410	93,247	137,691	1,656,000	180,570	(24)%	1,139,134	1,791,761	123,922	-	12,798
Medical Abortion (Misoprostol) Provided	201	144	537	1,051	58	826%	840	1,377	537	-	180
Anglophone Africa Market Group	70	84	295	-	53	457%	531	826	295	-	92
Franco/Lusophone Africa Market Group	131	60	242	1,051	5	4,740%	309	551	242	-	88
Medical Abortion Provided	1,206	705	2,570	4,788	3,929	(35)%	12,902	24,253	2,570	-	284
Anglophone Africa Market Group	61	48	201	-	206	(2)%	747	1,569	201	-	70
Franco/Lusophone Africa Market Group	-	-	-	-	51	(100)%	51	241	-	-	-
Latin America & Asia Market Group	1,145	657	2,369	4,788	3,672	(35)%	12,104	22,443	2,369	-	213
Micronutrient Powder	83,240	66,337	161,360	35,000	562,162	(71)%	8,746,552	48,704,392	398	-	-
Acceleration Market Group	-	39,687	-	-	-	-%	2,000,000	9,499,690	-	-	-
Franco/Lusophone Africa Market Group	83,240	26,650	161,360	35,000	550,612	(71)%	948,572	8,131,972	398	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,502,912	-	-	-
Foundation Market Group	-	-	-	-	11,550	(100)%	5,797,980	20,562,598	-	-	-
Inactive	-	-	-	-	-	-%	-	1,007,220	-	-	-
Misoprostol for PAC Provided	2,830	8,590	22,105	26,807	27,233	(19)%	86,914	127,843	22,105	-	4,757
Acceleration Market Group	766	704	2,344	5,220	-	-%	14,855	17,199	2,344	-	2,223
Anglophone Africa Market Group	268	310	969	-	177	447%	3,631	5,805	969	-	210

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	145	280	461	2,222	211	118%	2,304	3,841	461	-	238
Latin America & Asia Market Group	461	6,520	15,931	3,935	24,129	(34)%	53,383	73,038	15,931	-	938
Foundation Market Group	1,190	776	2,400	15,430	2,716	(12)%	12,741	27,960	2,400	-	1,149
Misoprostol for PPH	1,000	2,000	3,500	4,500	7,800	(55)%	30,800	6,320,438	1,050	-	23
Acceleration Market Group	-	-	-	-	-	-%	-	395,225	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	5,442,839	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	100,000	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	184,166	-	-	-
Foundation Market Group	1,000	2,000	3,500	4,500	7,800	(55)%	30,800	198,208	1,050	-	23
Misoprostol for Safe Abortion	602,154	411,398	1,441,595	5,447,828	823,977	75%	6,085,267	18,871,049	75,684	-	29,190
Acceleration Market Group	263,236	131,265	481,794	2,339,690	205,950	134%	2,321,200	4,787,844	25,294	-	21,239
Anglophone Africa Market Group	96,760	55,901	210,316	1,993,550	247,772	(15)%	1,655,420	9,250,292	11,042	-	2,955
Franco/Lusophone Africa Market Group	42,212	50,876	119,155	424,360	107,551	11%	745,045	2,090,049	6,256	-	2,262
Latin America & Asia Market Group	202,950	152,667	617,134	320,448	266,464	132%	1,282,555	2,665,861	32,400	-	2,500
Foundation Market Group	(3,004)	20,688	13,196	119,780	(3,760)	-%	81,047	77,003	693	-	234
Social Enterprise	-	-	-	250,000	-	-%	-	-	-	-	-
Multivitamin	130,560	104,160	346,170	2,256,202	711,470	(51)%	2,424,220	98,701,089	1,731	-	59
Acceleration Market Group	-	-	-	-	197,450	(100)%	450,010	3,531,010	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	12,270,645	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	11,484,305	-	-	-
Foundation Market Group	-	-	-	24,202	-	-%	-	-	-	-	-
Social Enterprise	130,560	104,160	346,170	2,232,000	514,020	(33)%	1,974,210	37,355,730	1,731	-	59
Inactive	-	-	-	-	-	-%	-	34,059,399	-	-	-
Naloxone	-	23	-	3,089	-	-%	2,570	68,251	-	-	-
Latin America & Asia Market Group	-	23	-	3,089	-	-%	2,570	32,457	-	-	-
Inactive	-	-	-	-	-	-%	-	35,794	-	-	-
Needle & Syringe	45,100	325,967	270,100	1,355,860	691,300	(61)%	5,815,215	32,635,858	942	-	1,900

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	2,501,888	-	-	-
Latin America & Asia Market Group	45,100	325,967	270,100	1,355,860	691,300	(61)%	5,815,215	26,050,458	942	-	1,900
Inactive	-	-	-	-	-	-%	-	4,083,512	-	-	-
Neonates Receiving Essential Care	-	-	-	-	-	-%	-	174	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	174	-	-	-
NVP	-	-	-	-	-	-%	-	11,442	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	235	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	11,057	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	150	-	-	-
OCs	2,171,895	2,162,435	5,472,991	29,124,425	5,631,365	(3)%	26,777,114	641,129,528	328,379	328,379	106,592
Acceleration Market Group	717,073	884,498	2,036,573	10,222,400	2,120,717	(4)%	9,492,397	314,549,849	122,194	122,194	40,900
Anglophone Africa Market Group	52,135	178,975	369,932	2,258,175	615,496	(40)%	2,600,283	80,324,985	22,196	22,196	11,008
Franco/Lusophone Africa Market Group	39,953	154,678	390,152	851,499	114,279	241%	1,347,096	25,211,045	23,409	23,409	17,463
Latin America & Asia Market Group	949,335	555,497	2,052,981	6,917,751	1,960,955	5%	6,484,744	101,505,652	123,179	123,179	23,736
Foundation Market Group	362,336	58,207	435,574	1,777,420	275,075	58%	2,094,239	71,174,224	26,134	26,134	12,321
Social Enterprise	51,063	330,579	187,779	7,097,180	544,843	(66)%	4,758,355	16,271,179	11,267	11,267	1,162
Inactive	-	-	-	-	-	-%	-	32,092,594	-	-	-
OCs Provided	244,227	189,456	602,280	2,831,217	419,855	43%	1,778,915	4,971,594	40,152	40,152	16,304
Acceleration Market Group	12,159	13,405	35,232	181,469	24,065	46%	151,894	280,341	2,349	2,349	716
Anglophone Africa Market Group	54,012	32,712	118,939	357,372	61,951	92%	321,499	1,503,685	7,929	7,929	4,670
Franco/Lusophone Africa Market Group	28,389	29,382	88,433	683,520	80,361	10%	367,827	1,046,915	5,896	5,896	5,103
Latin America & Asia Market Group	148,919	113,016	357,493	1,601,361	250,059	43%	921,067	1,989,552	23,833	23,833	5,726
Foundation Market Group	748	942	2,183	7,495	3,419	(36)%	16,628	151,097	146	146	88
Inactive	-	-	-	-	-	-%	-	4	-	-	-
ORS	450,559	366,519	969,770	2,220,000	925,555	5%	3,408,447	441,405,329	436,397	-	18,880
Acceleration Market Group	18,522	31,947	59,667	600,000	105,819	(44)%	514,198	326,023,268	26,850	-	1,565
Anglophone Africa Market Group	-	-	-	-	-	-%	-	21,149,275	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	32,783,783	-	-	-
Latin America & Asia Market Group	23,610	193,159	103,087	-	-	-%	500,000	4,380,068	46,389	-	974
Foundation Market Group	30,480	190	31,050	300,000	386,761	(92)%	1,249,743	16,058,731	13,973	-	771
Social Enterprise	377,947	141,223	775,966	1,320,000	432,975	79%	1,144,506	2,246,900	349,185	-	15,570
Inactive	-	-	-	-	-	-%	-	38,763,304	-	-	-
ORS Provided	2,527	2,654	7,730	13,914	644	1,100%	15,726	88,692	7,730	-	367
Acceleration Market Group	240	317	998	-	644	55%	2,217	8,385	998	-	16
Foundation Market Group	2,287	2,337	6,732	13,914	-	-%	13,509	80,307	6,732	-	351
Pneumonia PPT	-	(28)	-	124,910	69,357	(100)%	768,635	7,124,658	-	-	-
Acceleration Market Group	-	-	-	28,910	-	-%	-	1,414,256	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	987,367	-	-	-
Franco/Lusophone Africa Market Group	-	(28)	-	-	(671)	-%	30,316	474,924	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	119,990	-	-	-
Foundation Market Group	-	-	-	96,000	70,028	(100)%	738,319	4,128,121	-	-	-
Pneumonia PPT Provided	3,171	2,768	8,825	-	5,513	60%	31,754	164,497	8,825	-	6,812
Acceleration Market Group	2,054	1,328	5,019	-	5,513	(9)%	20,179	63,092	5,019	-	2,414
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	2,500	-	-	-
Foundation Market Group	1,117	1,440	3,806	-	-	-%	11,575	98,905	3,806	-	4,397
Positive RDTs	1,236	2,532	5,626	11,333	13,705	(59)%	52,281	2,311,966	5,626	-	-
Acceleration Market Group	214	523	739	-	1,308	(44)%	9,712	39,976	739	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	13,716	40,358	-	-	-
Latin America & Asia Market Group	142	308	753	3,333	7,962	(91)%	11,799	39,326	753	-	-
Foundation Market Group	880	1,701	4,134	8,000	4,435	(7)%	17,054	2,192,306	4,134	-	-
Positive RDTs Given First Line Treatment	304	771	1,327	2,474	8,418	(84)%	32,687	2,146,382	1,327	-	-
Acceleration Market Group	180	504	680	-	1,241	(45)%	8,937	35,282	680	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	13,647	39,926	-	-	-
Latin America & Asia Market Group	124	267	647	2,474	7,177	(91)%	10,103	36,195	647	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Foundation Market Group	-	-	-	-	-	-%	-	2,034,979	-	-	-
Pregnancy Test	14,220	68,449	72,936	1,188,000	-	-%	575,675	1,579,060	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	575,317	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	222,334	-	-	-
Social Enterprise	14,220	68,449	72,936	1,188,000	-	-%	575,675	648,611	-	-	-
Inactive	-	-	-	-	-	-%	-	132,798	-	-	-
PrEP	3,176	3,465	10,273	35,111	5,560	85%	34,437	47,826	856	-	342
Anglophone Africa Market Group	3,176	3,465	10,273	35,111	5,560	85%	34,437	47,826	856	-	342
PUR	3,835,543	4,266,160	13,763,673	47,273,857	12,273,290	12%	62,440,224	645,293,000	113,126	-	313
Acceleration Market Group	1,836,480	2,638,483	7,899,610	19,000,000	8,692,050	(9)%	28,508,349	204,453,707	64,928	-	160
Anglophone Africa Market Group	1,999,063	1,627,677	5,864,063	28,273,857	3,581,240	64%	33,931,875	331,746,605	48,198	-	153
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	239,541	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	62,675,382	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	45,927,973	-	-	-
Inactive	-	-	-	-	-	-%	-	249,792	-	-	-
QAACs Provided after Confirmatory Diagnosis	378	12,088	24,952	99,182	23,713	5%	127,263	2,231,445	24,952	-	4,150
Acceleration Market Group	38	11,637	23,993	95,000	16,527	45%	101,767	144,538	23,993	-	3,952
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	13,647	13,647	-	-	-
Latin America & Asia Market Group	73	186	397	2,254	7,186	(94)%	9,977	35,847	397	-	72
Foundation Market Group	267	265	562	1,928	-	-%	1,872	2,037,413	562	-	126
Referral to Advanced Cervical Cancer Treatment	-	3	10	136	5	100%	17	427	10	-	-
Anglophone Africa Market Group	-	3	10	136	5	100%	17	427	10	-	-
Referral to CD4/Clinical Staging	-	-	-	-	-	-%	-	34,138	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	30,613	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	18	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	143	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to Clinical Staging	-	-	-	-	-	-%	-	18,909	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,364	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	15,545	-	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	26	(100)%	67	67	-	-	-
Anglophone Africa Market Group	-	-	-	-	26	(100)%	67	67	-	-	-
Referral to Diabetes Management (non-gestational)	-	-	-	-	-	-%	-	1	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-
Referral to Early Infant Male Circumcision	-	-	-	-	-	-%	-	94	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	94	-	-	-
Referral to Emergency Contraception	-	-	-	1	-	-%	32	250	-	-	-
Anglophone Africa Market Group	-	-	-	1	-	-%	1	143	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	31	107	-	-	-
Referral to HIV Testing Services	5,749	9,694	11,104	91,736	6	184,967%	24,729	321,564	11,104	-	345
Acceleration Market Group	-	-	-	-	-	-%	-	25,875	-	-	-
Anglophone Africa Market Group	5,749	9,693	11,101	82,130	6	184,917%	24,714	209,362	11,101	-	345
Franco/Lusophone Africa Market Group	-	-	-	9,600	-	-%	-	17,256	-	-	-
Latin America & Asia Market Group	-	1	3	6	-	-%	10	35,554	3	-	-
Foundation Market Group	-	-	-	-	-	-%	5	33,366	-	-	-
Inactive	-	-	-	-	-	-%	-	151	-	-	-
Referral to Hypertension Management	29	27	72	-	55	31%	567	1,202	72	-	-
Anglophone Africa Market Group	29	27	72	-	55	31%	567	1,202	72	-	-
Referral to Implant 3 Insertion	615	589	926	1,915	2	46,200%	1,457	18,497	926	1,158	416
Acceleration Market Group	-	-	-	-	-	-%	-	996	-	-	-
Anglophone Africa Market Group	293	-	293	1,915	2	14,550%	2	8,248	293	366	309
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1	-	-	-
Latin America & Asia Market Group	322	589	633	-	-	-%	1,455	4,400	633	791	107
Foundation Market Group	-	-	-	-	-	-%	-	1,674	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	3,178	-	-	-
Referral to Implant 5 Insertion	45	34	122	187	38	221%	223	19,851	122	232	65
Acceleration Market Group	-	-	-	-	-	-%	-	584	-	-	-
Anglophone Africa Market Group	11	-	11	187	2	450%	2	3,607	11	21	17
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,681	-	-	-
Latin America & Asia Market Group	34	34	111	-	36	208%	221	1,373	111	211	48
Foundation Market Group	-	-	-	-	-	-%	-	9,606	-	-	-
Referral to Implant Insertion (duration unknown)	-	-	-	-	-	-%	-	89	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	89	-	-	-
Referral to Injectable (duration unknown)	-	-	-	-	-	-%	-	773	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	110	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	663	-	-	-
Referral to Injectable 1	2	1	3	-	36	(92)%	47	414	3	-	-
Anglophone Africa Market Group	-	-	-	-	36	(100)%	36	400	-	-	-
Latin America & Asia Market Group	2	1	3	-	-	-%	11	14	3	-	-
Referral to Injectable 2	-	-	-	-	-	-%	-	56	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	56	-	-	-
Referral to Injectable 3	979	47	1,084	6,372	129	740%	471	24,557	1,084	136	73
Anglophone Africa Market Group	887	-	887	6,372	75	1,083%	75	7,834	887	111	69
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	8,596	-	-	-
Latin America & Asia Market Group	92	47	197	-	54	265%	396	8,127	197	25	4
Referral to IUD 10 Insertion	239	122	536	48	180	198%	734	133,799	536	1,233	213
Acceleration Market Group	-	-	-	-	-	-%	-	8,256	-	-	-
Anglophone Africa Market Group	4	-	4	48	5	(20)%	5	24,176	4	9	7
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	6,239	-	-	-
Latin America & Asia Market Group	235	122	532	-	175	204%	729	73,722	532	1,224	206
Foundation Market Group	-	-	-	-	-	-%	-	20,969	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Inactive	-	-	-	-	-	-%	-	437	-	-	-
Referral to IUD 5 Insertion	-	-	-	-	-	-%	-	498	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	440	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	58	-	-	-
Referral to IUD Insertion (duration unknown)	-	-	-	-	-	-%	-	16	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	16	-	-	-
Referral to IUS 3 Insertion	-	-	-	-	-	-%	-	26	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	26	-	-	-
Referral to Linkage to HIV Care	5,161	6,566	14,516	45,296	6,195	134%	26,986	67,581	14,516	-	11,321
Acceleration Market Group	-	-	-	12,150	-	-%	-	-	-	-	-
Anglophone Africa Market Group	4,908	6,347	13,842	29,940	5,493	152%	24,186	60,486	13,842	-	10,769
Franco/Lusophone Africa Market Group	-	-	-	1,279	-	-%	-	281	-	-	-
Latin America & Asia Market Group	253	220	674	1,627	702	(4)%	2,800	6,806	674	-	552
Foundation Market Group	-	-	-	300	-	-%	-	-	-	-	-
Inactive	-	-	-	-	-	-%	-	8	-	-	-
Referral to Manual Vacuum Aspiration - PAC	-	-	-	-	-	-%	-	46	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	46	-	-	-
Referral to Medication Abortion	-	-	-	-	-	-%	-	24	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	24	-	-	-
Referral to OCs	211	49	294	665	134	119%	484	10,394	294	10	3
Anglophone Africa Market Group	84	-	84	665	93	(10)%	93	3,389	84	3	2
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,392	-	-	-
Latin America & Asia Market Group	127	49	210	-	41	412%	391	5,613	210	7	1
Referral to Opioid Treatment	7	7	17	37	52	(67)%	135	489	17	-	-
Latin America & Asia Market Group	7	7	17	37	52	(67)%	135	489	17	-	-
Referral to PAC Service (unknown)	-	-	-	-	-	-%	-	488	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	488	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	-	-	2	(100)%	20	250	-	-	-
Anglophone Africa Market Group	-	-	-	-	2	(100)%	20	250	-	-	-
Referral to STI Diagnosis (lab confirmed)	-	-	-	-	-	-%	-	332	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	332	-	-	-
Referral to STI Screening (syndromic)	-	-	-	112,000	7	(100)%	7	14,419	-	-	-
Anglophone Africa Market Group	-	-	-	112,000	7	(100)%	7	14,419	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	28	(100)%	119	9,012	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,690	-	-	-
Anglophone Africa Market Group	-	-	-	-	28	(100)%	119	4,864	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	128	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,330	-	-	-
Referral to TB Diagnosis	-	-	-	-	11	(100)%	11	30,963	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,898	-	-	-
Anglophone Africa Market Group	-	-	-	-	11	(100)%	11	16,052	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	11,013	-	-	-
Referral to TB DOTS (completion confirmed)	140	101	305	2,459	57	435%	1,364	3,831	305	-	849
Acceleration Market Group	140	90	270	2,349	-	-%	1,214	3,116	270	-	837
Anglophone Africa Market Group	-	-	-	-	-	-%	2	19	-	-	-
Latin America & Asia Market Group	-	12	35	110	57	(39)%	148	691	35	-	12
Inactive	-	-	-	-	-	-%	-	5	-	-	-
Referral to TB DOTS (completion unknown)	202	120	339	2,374	51	565%	1,692	10,027	339	-	936
Acceleration Market Group	202	119	335	2,374	-	-%	1,575	5,391	335	-	935
Anglophone Africa Market Group	-	-	-	-	50	(100)%	74	4,388	-	-	-
Latin America & Asia Market Group	-	1	4	-	1	300%	43	248	4	-	1
Referral to TB Screening	-	-	-	5,497	329	(100)%	329	115,621	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	85,548	-	-	-
Anglophone Africa Market Group	-	-	-	5,497	308	(100)%	308	29,857	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	21	(100)%	21	216	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	45	(100)%	47	119	-	-	-
Anglophone Africa Market Group	-	-	-	-	45	(100)%	47	119	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-	-%	3	12	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	3	12	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-	-%	2	136	-	-	-
Anglophone Africa Market Group	-	-	-	112	-	-%	2	136	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-	-%	1	137	-	-	-
Anglophone Africa Market Group	-	-	-	112	-	-%	1	137	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	1	(100)%	53	2,659	-	-	-
Anglophone Africa Market Group	-	-	-	336	1	(100)%	53	2,659	-	-	-
Referral to Treatment for Vaginitis	-	-	-	-	-	-%	-	7,247	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	7,247	-	-	-
Referral to Tubal Ligation	-	-	-	-	-	-%	2	67	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	2	6	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	61	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	3	(67)%	25	1,100	1	-	-
Anglophone Africa Market Group	-	-	1	-	3	(67)%	25	1,100	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	1	4	560	18	(78)%	48	2,474	4	-	-
Anglophone Africa Market Group	-	1	4	560	18	(78)%	48	2,474	4	-	-
Referral to Vasectomy	-	-	1	-	-	-%	-	3	1	5	1
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2	-	-	-
Latin America & Asia Market Group	-	-	1	-	-	-%	-	1	1	5	1
Referral to Voluntary Medical Male Circumcision	-	-	-	-	84	(100)%	139	20,727	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	3,382	-	-	-
Anglophone Africa Market Group	-	-	-	-	84	(100)%	139	17,345	-	-	-
Retreatment	-	-	-	-	-	-%	-	46,984,114	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	-	-	-	-	-	-%	-	8,050,379	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	35,287,804	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	1,094,479	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	1,275,789	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	1,009,438	-	-	-
Inactive	-	-	-	-	-	-%	-	266,225	-	-	-
Retreatment IconMaxx	-	-	-	-	-	-%	-	4,873,846	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	2,297,300	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,576,546	-	-	-
Retreatment KO123	-	-	-	-	-	-%	-	9,124,110	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	1,106,836	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,013,192	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	4,082	-	-	-
Retreatment KO123 net	-	-	-	-	-	-%	-	10,259,477	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	2,151,532	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,107,945	-	-	-
Safe Injection Kit	-	-	-	-	-	-%	-	5	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	5	-	-	-
Safe Water Solution	400,858	385,179	1,166,368	4,507,380	2,330,207	(50)%	5,579,483	164,508,633	964,082	-	3,351
Acceleration Market Group	129,792	149,160	427,116	1,160,000	264,300	62%	1,114,276	33,416,760	351,054	-	866
Anglophone Africa Market Group	42,867	109,639	330,445	1,915,700	897,640	(63)%	2,248,493	82,682,917	225,003	-	788
Franco/Lusophone Africa Market Group	173,263	77,120	254,623	1,400,000	518,413	(51)%	870,831	12,983,744	209,279	-	1,092
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,259,684	-	-	-
Foundation Market Group	54,936	49,260	154,184	31,680	649,854	(76)%	1,345,883	28,566,535	178,745	-	604
Inactive	-	-	-	-	-	-%	-	4,598,993	-	-	-
SD NVP w/o Baby ARV Prophylaxis	-	-	-	-	-	-%	-	271	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	271	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
SD NVP with Baby ARV Prophylaxis	-	-	-	-	-	-%	-	235	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	235	-	-	-
SDM (Cycle Beads)	(29)	9	(59)	306	533	(111)%	6,654	627,546	(53)	(80)	(50)
Acceleration Market Group	-	-	-	-	-	-%	-	201,447	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	8,591	-	-	-
Franco/Lusophone Africa Market Group	(5)	29	4	306	75	(95)%	1,533	48,033	4	5	4
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2,494	-	-	-
Foundation Market Group	(24)	(21)	(63)	-	458	(114)%	5,121	351,223	(57)	(85)	(54)
Inactive	-	-	-	-	-	-%	-	15,758	-	-	-
SDM (Cycle Beads) Provided	68	41	141	2,550	105	34%	609	12,806	141	212	185
Acceleration Market Group	31	8	51	-	-	-%	3	54	51	77	93
Anglophone Africa Market Group	-	-	-	-	-	-%	-	10	-	-	-
Franco/Lusophone Africa Market Group	11	8	22	2,550	16	38%	96	419	22	33	25
Latin America & Asia Market Group	1	-	2	-	1	100%	7	128	2	3	1
Foundation Market Group	25	25	66	-	88	(25)%	503	12,195	66	99	66
Seasonal Malaria Chemoprevention	-	-	-	6,375,721	1,665,225	(100)%	2,009,973	4,420,982	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	990,000	-	-%	344,748	344,748	-	-	-
Foundation Market Group	-	-	-	5,385,721	1,665,225	(100)%	1,665,225	4,076,234	-	-	-
Skilled Birth Attendance	3,234	3,580	9,269	66,196	9,990	(7)%	45,970	165,035	9,269	-	10,026
Acceleration Market Group	1,719	1,752	5,260	40,000	3,959	33%	20,115	67,429	5,260	-	4,372
Anglophone Africa Market Group	-	-	-	-	-	-%	-	50,567	-	-	-
Franco/Lusophone Africa Market Group	115	107	370	9,000	6,031	(94)%	9,160	26,705	370	-	469
Foundation Market Group	1,400	1,721	3,639	17,196	-	-%	16,695	20,334	3,639	-	5,185
STI Kit	-	-	-	-	-	-%	-	691,263	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	240,890	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	438,695	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	329	-	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group	-	-	-	-	-	-%	-	9,882	-	-	-
Inactive	-	-	-	-	-	-%	-	1,467	-	-	-
STI Kit (Non-Ulcerative)	-	956	2,067	1,869	-	-%	6,655	4,020,235	1,860	-	135
Acceleration Market Group	-	-	-	-	-	-%	-	742,374	-	-	-
Anglophone Africa Market Group	-	956	2,067	1,869	-	-%	6,655	868,068	1,860	-	135
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	7,704	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	-	348,335	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	2,053,754	-	-	-
STI Kit (Ulcerative)	-	372	1,115	231	-	-%	-	1,855,269	1,004	-	214
Acceleration Market Group	-	-	-	-	-	-%	-	60,473	-	-	-
Anglophone Africa Market Group	-	372	1,115	231	-	-%	-	73,807	1,004	-	214
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	480	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	1,720,509	-	-	-
STI Screening	11,463	13,912	45,272	227,782	35,154	29%	254,307	1,331,660	45,272	-	-
Acceleration Market Group	2,086	1,946	6,012	-	7,150	(16)%	27,221	79,928	6,012	-	-
Anglophone Africa Market Group	7,968	9,806	34,745	144,457	22,684	53%	75,388	597,661	34,745	-	-
Franco/Lusophone Africa Market Group	629	760	2,355	-	2,176	8%	8,747	33,341	2,355	-	-
Latin America & Asia Market Group	13	6	32	-	39	(18)%	99	4,022	32	-	-
Foundation Market Group	767	1,395	2,128	83,325	3,105	(31)%	142,852	616,210	2,128	-	-
Inactive	-	-	-	-	-	-%	-	498	-	-	-
TB Diagnosis	3,799	4,156	12,397	28,643	17,721	(30)%	62,691	236,254	12,397	-	-
Acceleration Market Group	1,403	952	2,678	16,181	2,727	(2)%	14,315	90,073	2,678	-	-
Anglophone Africa Market Group	16	15	51	77	70	(27)%	283	1,528	51	-	-
Latin America & Asia Market Group	2,380	2,132	6,496	385	7,521	(14)%	29,853	92,132	6,496	-	-
Foundation Market Group	-	1,057	3,172	12,000	7,403	(57)%	18,240	42,302	3,172	-	-
Inactive	-	-	-	-	-	-%	-	10,219	-	-	-
TB DOTS	3,389	4,295	13,228	23,210	18,221	(27)%	61,338	397,794	13,228	-	60,937

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	1,113	947	3,000	13,173	2,882	4%	12,891	224,861	3,000	-	18,608
Anglophone Africa Market Group	2	2	6	77	12	(50)%	35	107	6	-	49
Latin America & Asia Market Group	2,274	2,046	6,321	-	5,580	13%	26,012	120,128	6,321	-	28,928
Foundation Market Group	-	1,300	3,901	9,960	9,747	(60)%	22,400	46,935	3,901	-	13,352
Inactive	-	-	-	-	-	-%	-	5,763	-	-	-
TB Screening	36,074	41,244	122,332	202,098	128,491	(5)%	478,931	2,302,612	122,332	-	-
Acceleration Market Group	14,149	13,099	35,702	149,616	17,365	106%	103,950	516,101	35,702	-	-
Anglophone Africa Market Group	16,080	18,532	56,503	34,396	60,571	(7)%	225,880	1,507,528	56,503	-	-
Latin America & Asia Market Group	5,845	4,636	15,194	4,086	19,402	(22)%	72,433	156,710	15,194	-	-
Foundation Market Group	-	4,978	14,933	14,000	31,153	(52)%	76,668	115,134	14,933	-	-
Inactive	-	-	-	-	-	-%	-	7,139	-	-	-
Toilets Constructed	-	-	-	-	-	-%	-	16,479	-	-	-
Acceleration Market Group	-	-	-	-	-	-%	-	12,802	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	5	-	-	-
Foundation Market Group	-	-	-	-	-	-%	-	3,672	-	-	-
Toilets Sold	7,242	8,608	21,583	98,457	1,154	1,770%	64,462	290,095	106,685	-	2,611
Acceleration Market Group	6,297	6,818	17,660	60,000	-	-%	50,363	263,904	84,768	-	2,023
Anglophone Africa Market Group	-	765	1,468	25,600	-	-%	5,651	7,118	6,688	-	258
Franco/Lusophone Africa Market Group	759	609	1,854	8,107	206	798%	4,017	5,870	12,677	-	306
Latin America & Asia Market Group	177	414	587	750	948	(38)%	4,405	6,890	2,465	-	21
Foundation Market Group	9	2	15	4,000	-	-%	27	6,313	87	-	3
Treatment for Cervicitis	7	19	49	-	5	880%	101	468	49	-	2
Anglophone Africa Market Group	1	10	17	-	5	240%	73	380	17	-	2
Franco/Lusophone Africa Market Group	-	2	6	-	-	-%	-	19	6	-	-
Latin America & Asia Market Group	6	7	26	-	-	-%	28	69	26	-	-
Treatment for Genital Herpes	4	50	135	17	12	1,025%	70	306	135	-	3
Anglophone Africa Market Group	1	3	7	17	11	(36)%	28	106	7	-	-

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group	3	47	127	-	1	12,600%	42	191	127	-	3
Latin America & Asia Market Group	-	-	1	-	-	-%	-	9	1	-	-
Treatment for Inguinal Bubo	3	10	15	-	15	-%	89	235	15	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	3	17	-	-	-
Franco/Lusophone Africa Market Group	2	4	8	-	6	33%	33	75	8	-	-
Foundation Market Group	1	6	7	-	9	(22)%	53	143	7	-	-
Treatment for Lower Abdominal Pain	115	145	378	54	308	23%	1,571	3,755	378	-	-
Anglophone Africa Market Group	3	8	25	54	25	-%	78	238	25	-	-
Franco/Lusophone Africa Market Group	60	80	234	-	124	89%	693	1,301	234	-	-
Latin America & Asia Market Group	-	-	1	-	-	-%	-	1	1	-	-
Foundation Market Group	52	56	118	-	159	(26)%	800	2,215	118	-	-
Treatment for Nonherpetic Genital Ulcer	270	190	644	94	618	4%	6,745	17,171	644	-	116
Anglophone Africa Market Group	89	41	184	94	122	51%	546	1,330	184	-	65
Franco/Lusophone Africa Market Group	128	87	295	-	206	43%	1,027	2,084	295	-	33
Latin America & Asia Market Group	-	-	-	-	-	-%	-	2	-	-	-
Foundation Market Group	53	62	165	-	290	(43)%	5,172	13,755	165	-	18
Treatment for Pre-Eclampsia (with MgSO4)	27	33	70	413	19	268%	392	583	70	-	230
Acceleration Market Group	-	2	5	60	19	(74)%	49	175	5	-	4
Foundation Market Group	27	31	65	353	-	-%	343	408	65	-	226
Treatment for Severe Acute Malnutrition	452	419	841	9,896	-	-%	12,893	55,384	841	-	3,206
Franco/Lusophone Africa Market Group	-	-	-	8	-	-%	-	4	-	-	-
Foundation Market Group	452	419	841	9,888	-	-%	12,893	55,380	841	-	3,206
Treatment for Urethral Discharge (Men)	480	527	1,553	195	1,804	(14)%	7,519	18,628	3,106	-	28
Anglophone Africa Market Group	52	31	129	195	70	84%	292	1,031	258	-	17
Franco/Lusophone Africa Market Group	133	182	566	-	390	45%	1,631	3,522	1,132	-	7
Foundation Market Group	295	314	858	-	1,344	(36)%	5,596	14,075	1,716	-	5
Treatment for Urethral Discharge (Women)	368	348	1,192	2	595	100%	2,577	6,263	1,192	-	55

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group	81	42	171	2	122	40%	507	1,694	171	-	32
Franco/Lusophone Africa Market Group	287	301	1,021	-	473	116%	2,054	4,546	1,021	-	24
Latin America & Asia Market Group	-	-	-	-	-	-%	1	8	-	-	-
Foundation Market Group	-	5	-	-	-	-%	15	15	-	-	-
Treatment for Vaginitis	295	327	948	380	1,464	(35)%	5,511	15,228	948	-	34
Anglophone Africa Market Group	23	46	154	380	199	(23)%	506	2,366	154	-	28
Franco/Lusophone Africa Market Group	-	-	-	-	1	(100)%	2	7	-	-	-
Latin America & Asia Market Group	7	18	61	-	-	-%	25	89	61	-	-
Foundation Market Group	265	263	733	-	1,264	(42)%	4,978	12,766	733	-	6
Tubal Ligation	4,914	5,768	15,621	42,589	23,158	(33)%	67,507	387,177	15,621	195,255	60,165
Acceleration Market Group	3,671	5,111	13,015	25,000	18,409	(29)%	38,957	95,230	13,015	169,195	45,219
Anglophone Africa Market Group	573	503	1,591	17,589	2,910	(45)%	16,391	37,405	1,591	15,910	12,524
Franco/Lusophone Africa Market Group	-	34	-	-	-	-%	204	204	-	-	-
Latin America & Asia Market Group	670	119	1,014	-	1,833	(45)%	11,913	254,221	1,014	10,140	2,417
Foundation Market Group	-	1	1	-	6	(83)%	42	117	1	10	5
Type 2 Diabetes Diagnosis	-	-	-	-	-	-%	4	1,435	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	3	1,434	-	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	1	1	-	-	-
Type 2 Diabetes Screening	241	365	766	33,797	1,855	(59)%	6,712	17,359	766	-	-
Anglophone Africa Market Group	241	365	766	33,797	1,855	(59)%	6,711	17,356	766	-	-
Latin America & Asia Market Group	-	-	-	-	-	-%	1	3	-	-	-
Type 2 Diabetes Controlled Condition	-	-	1	-	1	-%	6	13	-	-	-
Anglophone Africa Market Group	-	-	-	-	1	(100)%	6	12	-	-	-
Latin America & Asia Market Group	-	-	1	-	-	-%	-	1	-	-	-
Vaginal Wash	6,048	640	7,968	-	-	-%	-	7,968	-	-	-
Social Enterprise	6,048	640	7,968	-	-	-%	-	7,968	-	-	-
Vasectomy	32	38	78	1,029	181	(57)%	709	5,079	78	942	248

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group	18	18	54	1,000	104	(48)%	287	4,010	54	702	190
Anglophone Africa Market Group	-	-	-	29	-	-%	-	40	-	-	-
Franco/Lusophone Africa Market Group	-	17	-	-	-	-%	104	104	-	-	-
Latin America & Asia Market Group	14	3	24	-	77	(69)%	318	925	24	240	58
Vivax Treatment after Confirmatory Diagnosis	114	211	318	248	402	(21)%	3,400	9,689	318	-	58
Acceleration Market Group	114	197	318	-	401	(21)%	3,244	9,524	318	-	58
Latin America & Asia Market Group	-	15	-	248	1	(100)%	156	165	-	-	-
Voluntary Medical Male Circumcision	31,737	20,958	76,800	396,145	86,558	(11)%	424,870	2,569,569	76,800	-	536,750
Acceleration Market Group	8,856	3,257	16,596	90,000	9,595	73%	78,885	324,371	16,596	-	116,862
Anglophone Africa Market Group	22,881	17,701	60,204	306,145	76,963	(22)%	345,985	2,183,933	60,204	-	419,888
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	61,265	-	-	-
Water Treatment Tablets	2,518,960	3,098,757	9,520,840	35,643,920	7,347,632	30%	38,726,042	828,309,156	156,507	-	1,195
Acceleration Market Group	4,320	203,097	598,320	300,000	82,080	629%	501,290	6,538,687	9,835	-	24
Anglophone Africa Market Group	430,740	318,000	1,350,140	8,068,408	2,060,142	(34)%	6,957,142	359,534,650	22,194	-	86
Franco/Lusophone Africa Market Group	1,898,200	1,887,440	6,212,820	20,485,262	3,437,510	81%	20,217,570	170,458,720	102,129	-	849
Latin America & Asia Market Group	500	16,833	51,000	80,000	68,900	(26)%	91,160	10,803,983	838	-	2
Foundation Market Group	185,200	673,387	1,308,560	6,710,250	1,699,000	(23)%	10,958,880	280,973,116	21,511	-	234
Woman Condom	1,320	1,016	1,800	-	16,392	(89)%	97,728	141,360	13	13	37
Anglophone Africa Market Group	1,320	1,016	1,800	-	16,392	(89)%	97,728	141,360	13	13	37
Zika Prevention Kit	-	4	-	-	105	(100)%	725	114,581	-	-	-
Latin America & Asia Market Group	-	4	-	-	105	(100)%	725	114,581	-	-	-
Zinc	80	14	122	-	146,999	(100)%	512,836	7,209,521	110	-	1
Acceleration Market Group	-	-	-	-	-	-%	-	953,402	-	-	-
Anglophone Africa Market Group	-	-	-	-	-	-%	-	1,034,758	-	-	-
Franco/Lusophone Africa Market Group	-	-	-	-	-	-%	-	669,429	-	-	-
Latin America & Asia Market Group	-	1	2	-	-	-%	-	481,251	2	-	-
Foundation Market Group	80	13	120	-	146,999	(100)%	512,836	4,070,681	108	-	1

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Product

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	YTD USERS REACHED 2019 ^(a)	YTD CYP 2019	YTD DALY 2019
Zinc Provided	2,294	2,305	6,670	12,189	-	-%	11,834	51,579	6,670	-	175
Foundation Market Group	2,294	2,305	6,670	12,189	-	-%	11,834	51,579	6,670	-	175

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

Acceleration Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 3/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Acceleration Market Group	8,609	-	-	788	613,810	1,011	274,805	334	104	28	1	5,462
India	-	-	-	-	196,997	52	112,345	-	68	-	-	691
Kenya	5,136	-	-	-	190,812	222	70,666	218	19	28	1	1,667
Myanmar	373	-	-	788	112,245	26	39,810	115	17	-	-	1,097
Nigeria	-	-	-	-	6,120	14	2,820	-	-	-	-	85
PSI Nigeria	-	-	-	-	107,636	697	49,163	-	-	-	-	1,923
South Africa	3,100	-	-	-	-	-	-	-	-	-	-	-

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 3
 Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group										613,810	740,528
Antiretroviral Treatment (Currently Enrolled)	13,710	13,464	40,889	170,176	35,466	15%	152,003	269,373	3,407	-	8,125
Antiretroviral Treatment (Newly Enrolled)	310	295	909	3,981	776	17%	3,434	10,495	909	-	-
Cervical Cancer-VIA and Cryotherapy	34	24	83	240	47	77%	286	4,356	83	-	19
Cervical Cancer-VIA and Refer to Conization	-	1	-	-	-	-%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	2	-	150	-	-%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	3,771	2,817	9,810	21,500	5,035	95%	34,714	297,539	9,810	-	-
Condom	3,329,742	3,950,207	9,681,499	41,769,999	8,144,717	19%	38,017,548	985,185,547	72,611	72,611	221,268
Diarrhea Treatment Kit Provided	1,817	1,853	5,670	29,000	4,651	22%	18,226	59,927	5,670	-	188
Emergency Contraception	(2,099)	(462)	(3,486)	-	1,348,700	%	5	174,383	(157)	(157)	(20)
Emergency Contraception Provided	2,254	898	4,077	19,800	393	937%	4,173	9,678	204	204	34
Fecal Sludge Management (Households)	48	112	258	400	43	500%	697	2,537	1,238	-	-
Fecal Sludge Management (Liters)	240,000	561,667	1,290,000	2,000,000	137,000	842%	4,011,000	12,447,200	-	-	79
Female Condom	12,643	12,398	36,103	70,000	15,736	129%	79,641	1,506,569	271	271	195
Fever Cases Attended	38,711	47,063	93,365	-	83,255	12%	697,782	2,524,533	93,365	-	-
Fever Cases Tested with RDTs	38,711	47,063	93,365	-	83,255	12%	697,782	2,524,533	93,365	-	-
Free Condom	187,200	2,145,360	1,236,960	35,500,000	10,839,600	(89)%	68,170,320	1,176,394,157	9,277	9,277	36,739
Free Female Condom	-	-	-	-	57,600	(100)%	1,108,500	5,030,600	-	-	-
HIV Self-Testing Kit	6,774	460,303	30,260	-	-	-%	1,357,422	1,387,682	27,234	-	-
HIV Testing Services	29,057	32,053	93,566	293,418	732,832	(87)%	1,091,132	6,151,529	93,566	-	3,688
Hypertension Diagnosis	2,401	607	3,818	20,000	19,107	(80)%	57,768	77,627	3,818	-	-
Hypertension Screening	9,860	8,208	26,699	50,000	44,097	(39)%	176,640	237,853	26,699	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Hypertension_Controlled Condition	1,627	395	2,510	-	13,966	(82)%	43,499	58,319	1,004	-	-
Implant 3	66	631	1,468	12,600	63	2,230%	1,528	820,144	1,321	3,303	2,461
Implant 3 Insertion	519	1,930	2,007	38,123	1,063	89%	8,884	14,372	2,007	5,018	2,545
Implant 4 Insertion	-	-	-	-	288	(100)%	288	288	-	-	-
Implant 5	(616)	(704)	(4,101)	(7,600)	(1,430)	-%	2,423	49,889	(3,691)	(14,025)	(10,246)
Implant 5 Insertion	8,004	6,475	23,908	62,915	12,410	93%	82,547	438,609	23,908	90,850	78,469
Injectable 1 Provided	-	14	5	-	-	-%	37	42	-	-	-
Injectable 2 Provided	-	2,250	876	-	-	-%	5,875	6,751	146	146	123
Injectable 3-IM	30,985	42,081	80,325	480,600	137,403	(42)%	493,679	15,532,886	18,073	18,073	3,527
Injectable 3-IM Provided	17,175	18,502	50,618	204,422	40,005	27%	175,770	421,672	12,655	12,655	5,690
Injectable 3-SC	2,150	1,111	5,484	32,150	-	-%	-	5,484	1,234	1,234	154
Injectable 3-SC Provided	-	296	887	-	-	-%	-	887	222	222	187
IPTp2	401	454	1,339	-	812	65%	3,893	15,636	1,339	-	50
IUD 10	(730)	365	(1,894)	(4,600)	(532)	-%	1,452	12,220	(1,705)	(7,841)	(6,472)
IUD 10 Insertion	7,539	6,725	21,735	103,790	20,592	6%	90,084	551,263	21,735	99,981	99,726
IUD 5	(13,225)	(1,742)	(18,340)	2,500	(65)	-%	(296)	118,888	(16,506)	(54,470)	(12,291)
IUD 5 Insertion	13,225	5,544	24,599	65,000	13,251	86%	51,661	202,528	24,599	81,177	18,340
IUS 5 Insertion	-	91	232	-	59	293%	775	1,633	232	766	880
LLIN	328,906	127,110	368,671	2,049,898	77,627	375%	2,332,163	24,051,398	597,247	-	12,159
Lubricant	6,879	7,729	22,854	-	8,850	158%	51,861	5,255,540	-	-	-
Malaria PPT (ACT)	35,222	11,855	70,118	182,270	148,925	(53)%	256,333	3,259,014	63,106	-	9,837

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Malaria PPT (Non-ACT)	(114)	(191)	(309)	3,621	(238)	-%	(1,900)	104,017	(278)	-	(43)
Malaria RDK	-	35,833	70,035	432,337	143,020	(51)%	743,410	4,802,009	63,032	-	-
Manual Vacuum Aspiration for PAC	720	720	2,296	5,220	-	-%	19,176	21,472	2,296	-	1,839
Medical Abortion	-	-	-	9,000	-	-%	-	-	-	-	-
Micronutrient Powder	-	39,687	-	-	-	-%	2,000,000	9,499,690	-	-	-
Misoprostol for PAC Provided	766	704	2,344	5,220	-	-%	14,855	17,199	2,344	-	2,223
Misoprostol for Safe Abortion	263,236	131,265	481,794	2,339,690	205,950	134%	2,321,200	2,802,994	25,294	-	21,239
Multivitamin	-	-	-	-	197,450	(100)%	450,010	883,520	-	-	-
OCs	717,073	884,498	2,036,573	10,222,400	2,120,717	(4)%	9,492,397	67,836,928	122,194	122,194	40,900
OCs Provided	12,159	13,405	35,232	181,469	24,065	46%	151,894	280,341	2,349	2,349	716
ORS	18,522	31,947	59,667	600,000	105,819	(44)%	514,198	1,290,521	26,850	-	1,565
ORS Provided	240	317	998	-	644	55%	2,217	8,385	998	-	16
Pneumonia PPT	-	-	-	28,910	-	-%	-	-	-	-	-
Pneumonia PPT Provided	2,054	1,328	5,019	-	5,513	(9)%	20,179	63,092	5,019	-	2,414
Positive RDTs	214	523	739	-	1,308	(44)%	9,712	36,210	739	-	-
Positive RDTs Given First Line Treatment	180	504	680	-	1,241	(45)%	8,937	31,683	680	-	-
PUR	1,836,480	2,638,483	7,899,610	19,000,000	8,692,050	(9)%	28,508,349	188,679,536	64,928	-	160
QAACs Provided after Confirmatory Diagnosis	38	11,637	23,993	95,000	16,527	45%	101,767	144,538	23,993	-	3,952
Referral to Linkage to HIV Care	-	-	-	12,150	-	-%	-	-	-	-	-
Referral to TB DOTS (completion confirmed)	140	90	270	2,349	-	-%	1,214	1,777	270	-	837
Referral to TB DOTS (completion unknown)	202	119	335	2,374	-	-%	1,575	1,910	335	-	935

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Safe Water Solution	129,792	149,160	427,116	1,160,000	264,300	62%	1,114,276	21,901,016	351,054	-	866
SDM (Cycle Beads) Provided	31	8	51	-	-	-%	3	54	51	77	93
Skilled Birth Attendance	1,719	1,752	5,260	40,000	3,959	33%	20,115	67,429	5,260	-	4,372
STI Screening	2,086	1,946	6,012	-	7,150	(16)%	27,221	66,521	6,012	-	-
TB Diagnosis	1,403	952	2,678	16,181	2,727	(2)%	14,315	62,282	2,678	-	-
TB DOTS	1,113	947	3,000	13,173	2,882	4%	12,891	220,451	3,000	-	18,608
TB Screening	14,149	13,099	35,702	149,616	17,365	106%	103,950	407,909	35,702	-	-
Toilets Sold	6,297	6,818	17,660	60,000	-	-%	50,363	68,023	84,768	-	2,023
Treatment for Pre-Eclampsia (with MgSO4)	-	2	5	60	19	(74)%	49	175	5	-	4
Tubal Ligation	3,671	5,111	13,015	25,000	18,409	(29)%	38,957	95,218	13,015	169,195	45,219
Vasectomy	18	18	54	1,000	104	(48)%	287	4,009	54	702	190
Vivax Treatment after Confirmatory Diagnosis	114	197	318	-	401	(21)%	3,244	9,524	318	-	58
Voluntary Medical Male Circumcision	8,856	3,257	16,596	90,000	9,595	73%	78,885	168,823	16,596	-	116,862
Water Treatment Tablets	4,320	203,097	598,320	300,000	82,080	629%	501,290	6,535,520	9,835	-	24

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Acceleration Market Group											613,810	740,528
India											196,997	53,626
Emergency Contraception	(2,099)	(462)	(3,486)	-	-		0%	-	(3,486)	(157)	(157)	(20)
(b)PSI Emergency Contraception Distributed Provided	(2,099)	(462)	(3,486)	-	-		-%	-	(3,486)	(157)	(157)	(20)
Emergency Contraception Provided	2,099	670	3,486	18,000	65		5263%	2,574	6,060	174	174	22
Non-PSI Emergency Contraception Provided	-	208	-	18,000	65		(100)%	2,574	2,574	-	-	-
PSI Emergency Contraception Provided	2,099	462	3,486	-	-		-%	-	3,486	174	174	22
Fecal Sludge Management (Households)	48	112	258	400	43		500%	697	2,537	1,238	-	-
Fecal Sludge Management (Households)	48	112	258	400	43		500%	697	2,537	1,238	-	-
Fecal Sludge Management (Liters)	240,000	561,667	1,290,000	2,000,000	137,000		842%	4,011,000	12,447,200	-	-	79
Fecal Sludge Management (Liters)	240,000	561,667	1,290,000	2,000,000	137,000		842%	4,011,000	12,447,200	-	-	79
Injectable 3-IM	(4,850)	(2,679)	(12,888)	-	-		0%	-	(12,888)	(2,900)	(2,900)	(485)
(b)PSI Injectable 3 IM Distributed Provided	(4,850)	(2,679)	(12,888)	-	-		-%	-	(12,888)	(2,900)	(2,900)	(485)
Injectable 3-IM Provided	4,850	3,762	12,888	35,000	4,655		177%	16,479	64,317	3,222	3,222	539
Non-PSI Injectable 3 IM Provided	-	1,083	-	35,000	4,655		(100)%	16,479	51,429	-	-	-
PSI Injectable 3 IM Provided	4,850	2,679	12,888	-	-		-%	-	12,888	3,222	3,222	539
IUD 10 Insertion	-	-	-	-	41		(100)%	41	2,526	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	41		(100)%	41	2,526	-	-	-
IUD 5	(13,105)	(1,631)	(17,999)	-	-		0%	-	(21,405)	(16,199)	(53,457)	(12,119)
(b)PSI IUD 5 Distributed Inserted	(13,105)	(1,631)	(17,999)	-	-		-%	-	(21,405)	(16,199)	(53,457)	(12,119)
IUD 5 Insertion	13,105	5,289	24,258	65,000	12,823		89%	49,622	143,451	24,258	80,051	18,148
Non-PSI IUD 5 Inserted	-	3,658	6,259	65,000	12,823		(51)%	49,622	122,046	6,259	20,655	4,683
PSI IUD 5 Inserted	13,105	1,631	17,999	-	-		-%	-	21,405	17,999	59,397	13,466
OCs	(8,956)	(5,312)	(24,893)	-	-		0%	-	(24,893)	(1,494)	(1,494)	(264)
(b)PSI OCs Distributed Provided	(8,956)	(5,312)	(24,893)	-	-		-%	-	(24,893)	(1,494)	(1,494)	(264)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs Provided	8,956	8,191	24,893	150,000	17,621		41%	100,521	189,550	1,660	1,660	293
Non-PSI OCs Provided	-	2,878	-	150,000	17,621		(100)%	100,521	164,657	-	-	-
PSI OCs Provided	8,956	5,312	24,893	-	-		-%	-	24,893	1,660	1,660	293
TB Diagnosis	-	-	-	400	-		0%	-	-	-	-	-
TB Diagnosis	-	-	-	400	-		-%	-	-	-	-	-
TB DOTS	-	-	-	500	-		0%	-	-	-	-	-
TB DOTS	-	-	-	500	-		-%	-	-	-	-	-
TB Screening	-	-	-	100,000	-		0%	-	-	-	-	-
TB Screening	-	-	-	100,000	-		-%	-	-	-	-	-
Toilets Sold	6,297	6,818	17,660	60,000	-		0%	50,363	68,023	84,768	-	2,023
Toilets Sold	6,297	6,818	17,660	60,000	-		-%	50,363	68,023	84,768	-	2,023
Tubal Ligation	3,671	5,111	13,015	25,000	18,409		(29)%	38,957	95,218	13,015	169,195	45,219
Tubal Ligation	3,671	5,111	13,015	25,000	18,409		(29)%	38,957	95,218	13,015	169,195	45,219
Vasectomy	18	18	54	1,000	104		(48)%	287	4,009	54	702	190
Vasectomy	18	18	54	1,000	104		(48)%	287	4,009	54	702	190
Kenya											190,812	357,080
Antiretroviral Treatment (Currently Enrolled)	7,570	7,617	22,899	92,100	20,388		12%	85,622	137,351	1,908	-	4,982
Antiretroviral Treatment (Currently Enrolled)	7,570	7,617	22,899	92,100	20,388		12%	85,622	137,351	1,908	-	4,982
Antiretroviral Treatment (Newly Enrolled)	116	110	331	1,754	269		23%	1,227	3,751	331	-	-
Antiretroviral Treatment (Newly Enrolled)	116	110	331	1,754	269		23%	1,227	3,751	331	-	-
Cervical Cancer-VIA and Cryotherapy	29	16	64	200	47		36%	227	3,380	64	-	15
Cervical Cancer-VIA and Cryotherapy	29	16	64	200	47		36%	227	3,380	64	-	15
Cervical Cancer-VIA and Refer to Conization	-	1	-	-	-		0%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Conization	-	1	-	-	-		-%	4	4	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	2	-	150	-		0%	29	48	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Cervical Cancer-VIA and Refer to Cryotherapy	-	2	-	150	-		-%	29	48	-	-	-
Cervical Cancer-VIA/VILI Screening	3,483	2,507	9,074	18,000	4,981		82%	31,803	289,448	9,074	-	-
Cervical Cancer-VIA/VILI Screening	3,483	2,507	9,074	18,000	4,981		82%	31,803	289,448	9,074	-	-
Condom	2,235,936	2,897,872	6,944,016	26,249,999	4,821,381		44%	25,124,074	569,747,333	52,080	52,080	206,247
Trust	1,713,312	2,289,048	5,490,576	20,922,493	3,301,284		66%	19,627,309	507,718,824	41,179	41,179	163,078
Trust Ribbed	90,912	56,328	120,360	591,117	111,312		8%	701,493	3,813,223	903	903	3,575
Trust Scented	-	72	216	-	55,584	5/14	(100)%	60,552	3,301,903	2	2	6
Trust Studded	431,712	552,424	1,332,864	4,736,389	1,353,201		(2)%	4,734,720	54,913,383	9,996	9,996	39,588
Diarrhea Treatment Kit Provided	1,817	1,853	5,670	29,000	4,651		22%	18,226	59,927	5,670	-	188
Non-PSI Diarrhea Treatment Kit Provided	1,817	1,853	5,670	29,000	4,651		22%	18,226	59,927	5,670	-	188
Emergency Contraception	-	-	-	-	(126)		0%	(126)	(1,554)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(126)		-%	(126)	(1,554)	-	-	-
Emergency Contraception Provided	155	214	586	1,800	304		93%	1,539	3,553	29	29	12
Non-PSI Emergency Contraception Provided	155	214	586	1,800	178		229%	1,413	1,999	29	29	12
PSI Emergency Contraception Provided	-	-	-	-	126		(100)%	126	1,554	-	-	-
Free Condom	187,200	2,145,360	1,236,960	35,000,000	4,154,400		(70)%	28,851,120	91,734,397	9,277	9,277	36,739
Free Male Condom - NASCOP	187,200	2,145,360	1,236,960	35,000,000	4,154,400		(70)%	28,851,120	91,734,397	9,277	9,277	36,739
HIV Self-Testing Kit	6,774	26,736	17,812	-	-		0%	69,171	86,983	16,031	-	-
INSTI HIVST (Blood based)	-	13,333	-	-	-		-%	40,000	40,000	-	-	-
INSTI-ORAQUICK HIVST BUNDLE	-	333	-	-	-		-%	1,000	1,000	-	-	-
ORAQUICK HIV Self-Testing Kit (Saliva based)	6,774	13,070	17,812	-	-		-%	28,171	45,983	16,031	-	-
HIV Testing Services	20,939	24,679	69,366	165,478	46,979		48%	212,997	1,256,928	69,366	-	2,898
VCT Individual (HIV-Negative)	20,584	24,297	68,250	161,373	46,272		47%	209,785	1,221,470	68,250	-	2,851
VCT Individual (HIV-Positive)	355	382	1,116	4,105	707	9/11	58%	3,212	35,458	1,116	-	47

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 3	-	500	1,500	6,000	-		0%	1	808,493	1,350	3,375	2,473
Implanon	-	500	1,500	6,000	-		-%	1	808,493	1,350	3,375	2,473
Implant 3 Insertion	-	-	-	38,123	-		0%	-	-	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	38,123	-		-%	-	-	-	-	-
Implant 5	(696)	(706)	(4,186)	(7,600)	(1,430)		0%	2,423	49,697	(3,767)	(14,316)	(10,295)
Jadelle	1,290	947	1,290	2,400	850	1/09	52%	23,710	186,218	1,161	4,412	3,173
(b)PSI Implant 5 Distributed Inserted	(1,986)	(1,653)	(5,476)	(10,000)	(2,280)		-%	(21,287)	(136,521)	(4,928)	(18,728)	(13,467)
Implant 5 Insertion	5,452	4,783	15,495	35,000	6,346		144%	50,514	307,294	15,495	58,881	42,341
Non-PSI Implant 5 Inserted	3,466	3,130	10,019	25,000	4,066		146%	29,227	170,773	10,019	38,072	27,378
PSI Implant 5 Inserted	1,986	1,653	5,476	10,000	2,280		140%	21,287	136,521	5,476	20,809	14,963
Injectable 3-IM	1,521	12,035	14,893	79,400	71,348		(79)%	117,204	5,732,087	3,351	3,351	1,809
Femiplan Injectable	13,824	24,624	51,840	79,400	106,272		(51)%	267,954	6,080,118	11,664	11,664	6,296
(b)PSI Injectable 3 IM Distributed Provided	(12,303)	(12,589)	(36,947)	-	(34,924)		-%	(150,750)	(348,031)	(8,313)	(8,313)	(4,487)
Injectable 3-IM Provided	12,303	12,589	36,947	169,422	34,924		6%	150,750	348,031	9,237	9,237	4,986
Non-PSI Injectable 3 IM Provided	-	-	-	169,422	-		-%	-	-	-	-	-
PSI Injectable 3 IM Provided	12,303	12,589	36,947	-	34,924		6%	150,750	348,031	9,237	9,237	4,986
IPTp2	401	454	1,339	-	812		65%	3,893	15,636	1,339	-	50
IPTp2	401	454	1,339	-	812		65%	3,893	15,636	1,339	-	50
IUD 10	(873)	114	(2,395)	(4,600)	(532)		0%	605	7,632	(2,156)	(9,915)	(6,804)
CU 380A (Copper T)	-	787	-	2,400	1,080		(100)%	10,551	99,224	-	-	-
(b)PSI IUD 10 Distributed Inserted	(873)	(672)	(2,395)	(7,000)	(1,612)		-%	(9,946)	(91,592)	(2,156)	(9,915)	(6,804)
IUD 10 Insertion	1,686	1,396	4,658	27,350	2,847		64%	17,347	183,912	4,658	21,427	14,702
Non-PSI IUD 10 Inserted	813	724	2,263	20,350	1,235		83%	7,401	92,320	2,263	10,410	7,143
PSI IUD 10 Inserted	873	672	2,395	7,000	1,612		49%	9,946	91,592	2,395	11,017	7,559
LLIN	328,906	127,110	368,671	1,824,672	77,627		375%	2,332,163	24,013,318	597,247	-	12,159

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ANC LLIN	-	-	-	1,800,000	-		-%	-	19,189,925	-	-	-
Supanet Conical	981	1,373	2,771	8,578	4,254		(35)%	8,447	18,399	4,489	-	91
Supanet Rectangular	475	895	2,148	16,094	3,240		(34)%	13,913	20,771	3,480	-	71
Supanet XtraPower BL PNET USAID	327,450	124,842	363,752	-	70,133	3/14	419%	2,309,803	4,784,223	589,278	-	11,997
OCs	415,779	387,451	946,563	3,418,400	856,124		11%	3,635,514	39,593,336	56,794	56,794	32,339
Famipill	864	48,288	8,928	-	-	5/18	-%	140,628	149,556	536	536	305
Femi Girl Oral Pills	-	-	-	15,900	162,192		(100)%	162,192	171,936	-	-	-
Femiplan Pill	417,240	341,760	945,000	3,402,500	700,128		35%	3,376,158	39,351,752	56,700	56,700	32,286
(b)PSI OCs Distributed Provided	(2,325)	(2,597)	(7,365)	-	(6,196)		-%	(43,464)	(79,908)	(442)	(442)	(252)
OCs Provided	2,836	3,072	8,883	31,469	6,196		43%	44,411	82,373	592	592	337
Non-PSI OCs Provided	511	475	1,518	31,469	-		-%	947	2,465	101	101	58
PSI OCs Provided	2,325	2,597	7,365	-	6,196		19%	43,464	79,908	491	491	280
ORS Provided	240	317	998	-	644		55%	2,217	8,385	998	-	16
Non-PSI ORS Provided	240	317	998	-	644		55%	2,217	8,385	998	-	16
Pneumonia PPT	-	-	-	28,910	-		0%	-	-	-	-	-
5 & A Pneumonia Pack-Child	-	-	-	28,910	-		-%	-	-	-	-	-
Pneumonia PPT Provided	2,054	1,328	5,019	-	5,513		(9)%	20,179	63,092	5,019	-	2,414
Non-PSI Pneumonia PPT Provided	2,054	1,328	5,019	-	5,513		(9)%	20,179	63,092	5,019	-	2,414
PUR	1,836,480	2,638,483	7,899,610	19,000,000	8,117,280		(3)%	27,875,040	172,821,746	64,928	-	160
PuR	1,836,480	2,638,483	7,899,610	19,000,000	8,117,280		(3)%	27,875,040	172,821,746	64,928	-	160
QAACTs Provided after Confirmatory Diagnosis	-	11,374	23,733	95,000	15,778		50%	96,981	124,639	23,733	-	3,904
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	11,374	23,733	95,000	15,778		50%	96,981	124,639	23,733	-	3,904
Safe Water Solution	129,792	149,160	427,116	1,160,000	264,300		62%	1,114,276	21,901,016	351,054	-	866
WaterGuard	129,792	149,160	427,116	1,160,000	264,300		62%	1,114,276	21,901,016	351,054	-	866

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Skilled Birth Attendance	1,719	1,752	5,260	40,000	3,959		33%	20,115	67,429	5,260	-	4,372
Skilled Birth Attendance	1,719	1,752	5,260	40,000	3,959		33%	20,115	67,429	5,260	-	4,372
TB Diagnosis	58	55	168	281	-		0%	56	839	168	-	-
TB Diagnosis	58	55	168	281	-		-%	56	839	168	-	-
TB Screening	6,450	6,547	19,753	7,816	-		0%	6,339	100,131	19,753	-	-
TB Screening	6,450	6,547	19,753	7,816	-		-%	6,339	100,131	19,753	-	-
Treatment for Pre-Eclampsia (with MgSO4)	-	2	5	60	19		(74)%	49	175	5	-	4
Treatment for Pre-Eclampsia (with MgSO4)	-	2	5	60	19		(74)%	49	175	5	-	4
Voluntary Medical Male Circumcision	3	7	25	-	-		0%	-	25	25	-	139
Voluntary Medical Male Circumcision	3	7	25	-	-		-%	-	25	25	-	139
Water Treatment Tablets	4,320	203,097	598,320	300,000	82,080		629%	501,290	6,535,520	9,835	-	24
Aquatab	4,320	203,097	598,320	300,000	82,080		629%	501,290	6,535,520	9,835	-	24
Myanmar											112,245	62,352
Antiretroviral Treatment (Currently Enrolled)	6,140	5,847	17,990	78,076	15,078		19%	66,381	132,022	1,499	-	3,143
Antiretroviral Treatment (Currently Enrolled)	6,140	5,847	17,990	78,076	15,078		19%	66,381	132,022	1,499	-	3,143
Antiretroviral Treatment (Newly Enrolled)	194	185	578	2,227	507		14%	2,207	6,744	578	-	-
Antiretroviral Treatment (Newly Enrolled)	194	185	578	2,227	507		14%	2,207	6,744	578	-	-
Cervical Cancer-VIA and Cryotherapy	5	7	19	40	-		0%	59	976	19	-	5
Cervical Cancer-VIA and Cryotherapy	5	7	19	40	-		-%	59	976	19	-	5
Cervical Cancer-VIA/VILI Screening	288	310	736	3,500	54		1263%	2,911	8,091	736	-	-
Cervical Cancer-VIA/VILI Screening	288	310	736	3,500	54		1,263%	2,911	8,091	736	-	-
Condom	1,093,806	1,052,335	2,737,483	15,520,000	3,323,336		(18)%	12,893,474	415,438,214	20,531	20,531	15,021
Aphaw	277,140	211,647	311,840	-	758,700	7/96	(59)%	2,515,280	191,577,519	2,339	2,339	1,711
Aphaw - Natural Touch	1,185	1,102	3,831	1,953,000	478,935		(99)%	1,039,098	14,781,504	29	29	21
Aphaw Deluxe GL (3x1)	-	-	-	3,515,400	-		-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Aphaw Flavors	363,420	353,884	970,500	5,208,000	1,322,939		(27)%	5,926,276	177,791,191	7,279	7,279	5,325
Aphaw Studded	120,717	160,851	482,928	2,343,600	536,250		(10)%	1,050,858	18,931,473	3,622	3,622	2,650
Generic Male Condom	331,000	320,867	966,600	2,500,000	201,000		381%	2,270,400	7,125,529	7,249	7,249	5,304
OK Condom	344	3,984	1,784	-	25,512	5/03	(93)%	91,562	5,230,998	13	13	10
Emergency Contraception	-	-	-	-	1		(100)%	5	177,869	-	-	-
OK EC	-	-	-	-	1	8/07	(100)%	5	177,869	-	-	-
Female Condom	12,643	12,398	36,103	70,000	15,736		129%	79,641	1,506,569	271	271	195
Generic Female Condom	12,643	12,398	36,103	70,000	15,736		129%	79,641	1,506,569	271	271	195
Fever Cases Attended	38,711	47,063	93,365	-	83,255		12%	697,782	2,524,533	93,365	-	-
Fever Cases Attended	38,711	47,063	93,365	-	83,255		12%	697,782	2,524,533	93,365	-	-
Fever Cases Tested with RDTs	38,711	47,063	93,365	-	83,255		12%	697,782	2,524,533	93,365	-	-
Fever Cases Tested with RDTs	38,711	47,063	93,365	-	83,255		12%	697,782	2,524,533	93,365	-	-
HIV Testing Services	4,545	4,297	13,266	64,440	11,932		11%	48,784	408,060	13,266	-	16
VCT Individual (HIV-Negative)	4,315	4,084	12,588	59,647	11,077		14%	45,712	379,545	12,588	-	15
VCT Individual (HIV-Positive)	230	212	678	4,793	855		(21)%	3,072	28,515	678	-	1
Hypertension Diagnosis	2,401	607	3,818	20,000	19,107		(80)%	57,768	77,627	3,818	-	-
Hypertension Diagnosis	2,401	607	3,818	20,000	19,107		(80)%	57,768	77,627	3,818	-	-
Hypertension Screening	9,860	8,208	26,699	50,000	44,097		(39)%	176,640	237,853	26,699	-	-
Hypertension Screening	9,860	8,208	26,699	50,000	44,097		(39)%	176,640	237,853	26,699	-	-
Hypertension_Controlled Condition	1,627	395	2,510	-	13,966		(82)%	43,499	58,319	1,004	-	-
Hypertension_Controlled Condition	1,627	395	2,510	-	13,966		(82)%	43,499	58,319	1,004	-	-
Implant 3	66	131	(32)	6,600	63		(151)%	1,527	11,651	(29)	(72)	(12)
Implanon NXT	585	576	1,283	6,600	1,126		14%	6,278	21,198	1,155	2,887	491
(b)PSI Implant 3 Distributed Inserted	(519)	(445)	(1,315)	-	(1,063)		-%	(4,751)	(9,547)	(1,184)	(2,959)	(503)
Implant 3 Insertion	519	445	1,315	-	1,063		24%	4,751	9,547	1,315	3,288	559

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Implant 3 Inserted	519	445	1,315	-	1,063		24%	4,751	9,547	1,315	3,288	559
Implant 5	80	2	85	-	-		0%	-	192	77	291	49
Jadelle	80	2	85	-	-	5/16	-%	-	192	77	291	49
Injectable 3-IM	34,314	32,725	78,320	401,200	66,055		19%	376,475	9,813,687	17,622	17,622	2,204
OK-3 Injection	34,314	32,725	78,320	401,200	66,055		19%	376,475	9,813,687	17,622	17,622	2,204
Injectable 3-SC	2,150	1,111	5,484	32,150	-		0%	-	5,484	1,234	1,234	154
Sayana Press	2,150	1,111	5,484	32,150	-		-%	-	5,484	1,234	1,234	154
IUD 10	143	250	501	-	-		0%	847	4,588	451	2,074	331
OK IUD (Copper T Cu 380A)	143	250	501	-	-	10/14	-%	847	4,588	451	2,074	331
IUD 5	(120)	(111)	(341)	2,500	(65)		0%	(296)	140,293	(307)	(1,013)	(172)
OK IUD	-	-	-	2,500	360		(100)%	1,206	198,833	-	-	-
(b)PSI IUD 5 Distributed Inserted	(120)	(111)	(341)	-	(425)		-%	(1,502)	(58,540)	(307)	(1,013)	(172)
IUD 5 Insertion	120	111	341	-	425		(20)%	1,502	58,540	341	1,125	191
PSI IUD 5 Inserted	120	111	341	-	425		(20)%	1,502	58,540	341	1,125	191
LLIN	-	-	-	225,226	-		0%	-	38,080	-	-	-
LLIN	-	-	-	225,226	-		-%	-	38,080	-	-	-
Lubricant	6,879	7,729	22,854	-	8,850		158%	51,861	5,255,540	-	-	-
Aphaw Gel - Sachet	1,152	-	1,152	-	-		-%	250	4,429,460	-	-	-
Aphaw Gel - Tube 20 cc	896	5,326	9,661	-	8,850		9%	51,611	691,341	-	-	-
Aphaw Gel - Tube 20 cc - Flavors	4,831	2,403	12,041	-	-	10/14	-%	-	134,739	-	-	-
Malaria PPT (ACT)	35,222	11,855	70,118	182,270	148,925		(53)%	256,333	3,259,014	63,106	-	9,837
AL 1	-	142	402	126	2,304		(83)%	3,413	17,404	362	-	56
AL 2	-	139	389	126	1,873		(79)%	3,390	18,142	350	-	55
AL 3	-	164	433	379	2,429		(82)%	3,470	52,827	390	-	61

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
AL 4	-	633	773	5,689	2,361		(67)%	13,664	277,195	696	-	108
Arte+1	720	1	723	2,500	-		-%	-	23,002	651	-	101
Arte+2	720	1	723	2,500	-		-%	-	23,901	651	-	101
Arte+3	720	1	723	3,000	-		-%	-	27,265	651	-	101
Arte+4	21,600	7,200	43,200	79,975	79,387		(46)%	114,680	624,568	38,880	-	6,060
(b)PSI QAACTs Distributed Provided after Diagnosis	(38)	(263)	(260)	-	(749)		-%	(4,786)	(19,899)	(234)	-	(36)
Supa Arte 1	500	168	1,003	2,500	-		-%	-	121,714	903	-	141
Supa Arte 2	500	168	1,003	2,500	-		-%	-	117,555	903	-	141
Supa Arte 3	500	168	1,003	3,000	-		-%	-	197,462	903	-	141
Supa Arte 4	10,000	3,334	20,003	79,975	61,320		(67)%	122,502	1,777,878	18,003	-	2,806
Malaria PPT (Non-ACT)	(114)	(191)	(309)	3,621	(238)		0%	(1,900)	104,017	(278)	-	(43)
(b)PSI Vivax Tx Distributed Provided after Diagnosis	(114)	(197)	(318)	-	(401)		-%	(3,244)	(9,524)	(286)	-	(45)
Vivax Treatment Kit	-	5	9	3,621	163		(94)%	1,344	113,541	8	-	1
Malaria RDK	-	35,833	70,035	432,337	143,020		(51)%	743,410	4,802,009	63,032	-	-
Malaria RDT (Diagnosis)	-	35,833	70,035	432,337	143,020		(51)%	743,410	4,802,009	63,032	-	-
Micronutrient Powder	-	39,687	-	-	-		0%	2,000,000	9,499,690	-	-	-
Happy Kid (Micronutrient powder)	-	39,687	-	-	-	9/16	-%	2,000,000	9,499,690	-	-	-
Multivitamin	-	-	-	-	197,450		(100)%	450,010	883,520	-	-	-
May May Vita Plus	-	-	-	-	197,450	6/17	(100)%	450,010	883,520	-	-	-
OCs	310,250	502,359	1,114,903	6,804,000	1,264,593		(12)%	5,856,883	28,268,485	66,894	66,894	8,825
OK Pills	308,633	501,070	1,110,893	6,804,000	1,255,853		(12)%	5,831,882	28,227,853	66,654	66,654	8,793
OK Pills (Zinnia F)	1,617	1,289	4,010	-	8,740	11/16	(54)%	25,001	40,632	241	241	32
ORS	18,522	31,947	59,667	600,000	105,819		(44)%	514,198	1,290,521	26,850	-	1,565
ORS	18,522	31,947	59,667	600,000	105,819		(44)%	514,198	1,290,521	26,850	-	1,565

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Positive RDTs	214	523	739	-	1,308		(44)%	9,712	36,210	739	-	-
Positive RDTs	214	523	739	-	1,308		(44)%	9,712	36,210	739	-	-
Positive RDTs Given First Line Treatment	180	504	680	-	1,241		(45)%	8,937	31,683	680	-	-
Positive RDTs Given First Line Treatment	180	504	680	-	1,241		(45)%	8,937	31,683	680	-	-
PUR	-	-	-	-	574,770		(100)%	633,309	15,857,790	-	-	-
Purifier of Water	-	-	-	-	574,770	4/14	(100)%	633,309	15,857,790	-	-	-
QAACTs Provided after Confirmatory Diagnosis	38	263	260	-	749		(65)%	4,786	19,899	260	-	48
PSI QAACTs Provided after Confirmed Diagnosis	38	263	260	-	749		(65)%	4,786	19,899	260	-	48
Referral to TB DOTS (completion confirmed)	140	90	270	2,349	-		0%	1,214	1,777	270	-	837
Referral to TB DOTS (completion confirmed)	140	90	270	2,349	-		-%	1,214	1,777	270	-	837
Referral to TB DOTS (completion unknown)	202	119	335	2,374	-		0%	1,575	1,910	335	-	935
Referral to TB DOTS (completion unknown)	202	119	335	2,374	-		-%	1,575	1,910	335	-	935
STI Screening	2,086	1,946	6,012	-	7,150		(16)%	27,221	66,521	6,012	-	-
STI Screening	2,086	1,946	6,012	-	7,150		(16)%	27,221	66,521	6,012	-	-
TB Diagnosis	1,345	896	2,510	15,500	2,727		(8)%	14,259	61,443	2,510	-	-
TB Diagnosis	1,345	896	2,510	15,500	2,727		(8)%	14,259	61,443	2,510	-	-
TB DOTS	1,113	947	3,000	12,673	2,882		4%	12,891	220,451	3,000	-	18,608
TB DOTS	1,113	947	3,000	12,673	2,882		4%	12,891	220,451	3,000	-	18,608
TB Screening	7,699	6,551	15,949	41,800	17,365		(8)%	97,611	307,778	15,949	-	-
TB Screening	7,699	6,551	15,949	41,800	17,365		(8)%	97,611	307,778	15,949	-	-
Vivax Treatment after Confirmatory Diagnosis	114	197	318	-	401		(21)%	3,244	9,524	318	-	58
PSI Vivax Treatment after Confirmed Diagnosis	114	197	318	-	401		(21)%	3,244	9,524	318	-	58
Nigeria											6,120	6,776
Emergency Contraception Provided	-	14	5	-	24		(79)%	60	65	-	-	-
Non-PSI Emergency Contraception Provided	-	14	5	-	24		(79)%	60	65	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
HIV Testing Services	-	-	-	-	572,004		(100)%	609,489	2,485,606	-	-	-
VCT Individual (HIV-Negative)	-	-	-	-	568,035	12/09	(100)%	604,543	2,342,815	-	-	-
VCT Individual (HIV-Positive)	-	-	-	-	3,969	12/09	(100)%	4,946	142,791	-	-	-
Implant 3 Insertion	-	1,484	692	-	-		0%	4,133	4,825	692	1,730	1,986
Non-PSI Implant 3 Inserted	-	1,484	692	-	-		-%	4,133	4,825	692	1,730	1,986
Implant 4 Insertion	-	-	-	-	288		(100)%	288	288	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	288		(100)%	288	288	-	-	-
Implant 5 Insertion	-	(807)	695	-	-		0%	2,833	94,397	695	2,641	2,985
Non-PSI Implant 5 Inserted	-	(807)	695	-	-	3/16	-%	2,833	94,397	695	2,641	2,985
Injectable 1 Provided	-	14	5	-	-		0%	37	42	-	-	-
Non-PSI Injectable 1 Provided	-	14	5	-	-		-%	37	42	-	-	-
Injectable 2 Provided	-	2,250	876	-	-		0%	5,875	6,751	146	146	123
Non-PSI Injectable 2 Provided	-	2,250	876	-	-		-%	5,875	6,751	146	146	123
Injectable 3-IM Provided	-	2,142	734	-	426		72%	6,118	6,852	184	184	155
Non-PSI Injectable 3 IM Provided	-	2,142	734	-	426		72%	6,118	6,852	184	184	155
Injectable 3-SC Provided	-	296	887	-	-		0%	-	887	222	222	187
Non-PSI Injectable 3 SC Provided	-	296	887	-	-		-%	-	887	222	222	187
IUD 10 Insertion	-	(84)	85	-	-		0%	-	275,137	85	391	423
Non-PSI IUD 10 Inserted	-	(84)	85	-	-	3/16	-%	-	275,137	85	391	423
IUD 5 Insertion	-	144	-	-	3		(100)%	479	479	-	-	-
Non-PSI IUD 5 Inserted	-	144	-	-	3		(100)%	479	479	-	-	-
IUS 5 Insertion	-	91	232	-	-		0%	716	1,574	232	766	880
Non-PSI IUS 5 Inserted	-	91	232	-	-		-%	716	1,574	232	766	880
OCs Provided	-	1,984	614	-	248		148%	5,586	6,200	41	41	36
Non-PSI OCs Provided	-	1,984	614	-	248		148%	5,586	6,200	41	41	36

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
SDM (Cycle Beads) Provided	-	1	-	-	-		0%	3	3	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	1	-	-	-		-%	3	3	-	-	-
PSI Nigeria											107,636	143,197
Implant 5 Insertion	2,552	2,499	7,718	27,915	6,064		27%	29,200	36,918	7,718	29,328	33,143
Non-PSI Implant 5 Inserted	2,552	2,499	7,718	27,915	6,064		27%	29,200	36,918	7,718	29,328	33,143
Injectable 3-IM Provided	22	9	49	-	-		0%	2,423	2,472	12	12	10
Non-PSI Injectable 3 IM Provided	22	9	49	-	-		-%	2,423	2,472	12	12	10
IUD 10 Insertion	5,853	5,413	16,992	76,440	17,704		(4)%	72,696	89,688	16,992	78,163	84,600
Non-PSI IUD 10 Inserted	5,853	5,413	16,992	76,440	17,704		(4)%	72,696	89,688	16,992	78,163	84,600
IUD 5 Insertion	-	-	-	-	-		0%	58	58	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	58	58	-	-	-
IUS 5 Insertion	-	-	-	-	59		(100)%	59	59	-	-	-
Non-PSI IUS 5 Inserted	-	-	-	-	59		(100)%	59	59	-	-	-
Manual Vacuum Aspiration for PAC	720	720	2,296	5,220	-		0%	19,176	21,472	2,296	-	1,839
MVA for PAC	720	720	2,296	5,220	-		-%	19,176	21,472	2,296	-	1,839
Medical Abortion	-	-	-	9,000	-		0%	-	-	-	-	-
Combipack	-	-	-	9,000	-		-%	-	-	-	-	-
Misoprostol for PAC Provided	766	704	2,344	5,220	-		0%	14,855	17,199	2,344	-	2,223
PSI Misoprostol for PAC Provided	766	704	2,344	5,220	-		-%	14,855	17,199	2,344	-	2,223
Misoprostol for Safe Abortion	263,236	131,265	481,794	2,339,690	205,950		134%	2,321,200	2,802,994	25,294	-	21,239
Misoclear	266,300	134,080	491,170	2,360,570	205,950		138%	2,380,620	2,871,790	25,786	-	21,652
(b)PSI Misoprostol for Safe Abortion Dist Provided	(3,064)	(2,815)	(9,376)	(20,880)	-		-%	(59,420)	(68,796)	(492)	-	(413)
OCs Provided	367	158	842	-	-		0%	1,376	2,218	56	56	50
Non-PSI OCs Provided	367	158	842	-	-		-%	1,376	2,218	56	56	50
SDM (Cycle Beads) Provided	31	7	51	-	-		0%	-	51	51	77	93

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI SDM (Cycle Beads) Provided	31	7	51	-	-		-%	-	51	51	77	93
South Africa												117,497
Free Condom	-	-	-	500,000	6,685,200		(100)%	39,319,200	1,084,659,760	-	-	-
(b)Public Distribution	-	-	-	500,000	6,685,200		(100)%	39,319,200	1,084,659,760	-	-	-
Free Female Condom	-	-	-	-	57,600		(100)%	1,108,500	5,030,600	-	-	-
Female Condom GOSA	-	-	-	-	57,600	10/13	(100)%	1,108,500	5,030,600	-	-	-
HIV Self-Testing Kit	-	433,566	12,448	-	-		0%	1,288,251	1,300,699	11,203	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	433,566	12,448	-	-		-%	1,288,251	1,300,699	11,203	-	-
HIV Testing Services	3,573	3,077	10,934	63,500	101,917		(89)%	219,862	2,000,935	10,934	-	775
VCT Individual (HIV-Negative)	2,864	2,669	9,165	50,000	96,324		(90)%	206,993	1,839,345	9,165	-	650
VCT Individual (HIV-Positive)	709	408	1,769	13,500	5,593		(68)%	12,869	161,590	1,769	-	125
Referral to Linkage to HIV Care	-	-	-	12,150	-		0%	-	-	-	-	-
Referral to Linkage to HIV Care	-	-	-	12,150	-		-%	-	-	-	-	-
Voluntary Medical Male Circumcision	8,853	3,250	16,571	90,000	9,595		73%	78,885	168,798	16,571	-	116,723
Voluntary Medical Male Circumcision	8,853	3,250	16,571	90,000	9,595		73%	78,885	168,798	16,571	-	116,723

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Anglophone Africa Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 3/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Anglophone Africa Market Group	23,952	10	-	1	909,409	874	370,735	132	22	-	3	8,826
Ethiopia	753	7	-	-	30,649	13	8,711	-	11	-	-	206
Ghana	-	-	-	-	56,841	43	20,214	-	-	-	-	279
Lesotho	195	-	-	1	2,649	2	879	-	-	-	-	15
Malawi	2,663	-	-	-	117,003	193	43,516	29	2	-	-	1,070
PSI Uganda	206	-	-	-	397,047	387	182,310	-	1	-	-	4,706
Rwanda	1,551	-	-	-	43,896	20	12,927	-	1	-	-	288
Swaziland	3,907	1	-	-	27,525	17	7,749	-	-	-	-	134
Tanzania	1	-	-	-	95,856	92	44,311	103	1	-	-	1,073
Uganda	1,276	-	-	-	26,946	15	7,589	-	-	-	-	195
Zambia	2,045	-	-	-	50,000	28	21,788	-	6	-	-	558
Zimbabwe	11,355	2	-	-	60,998	64	20,742	-	-	-	2	302

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 3
 Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group										909,409	1,675,117
Antiretroviral Treatment (Currently Enrolled)	12,734	13,042	38,395	105,390	29,710	29%	148,026	305,654	3,200	-	6,798
Antiretroviral Treatment (Newly Enrolled)	506	383	1,330	4,695	1,555	(14)%	6,634	24,195	1,330	-	-
Basic Care Package	-	-	-	-	-	-%	1	1	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	544	(100)%	544	9,414	-	-	-
Cervical Cancer-HPV DNA and Cryotherapy	-	-	-	-	3	(100)%	3	3	-	-	-
Cervical Cancer-VIA and Conization	21	19	51	290	17	200%	126	355	51	-	18
Cervical Cancer-VIA and Cryotherapy	55	34	129	307	183	(30)%	639	6,609	129	-	45
Cervical Cancer-VIA and Refer to any Treatment	13	3	22	-	6	267%	25	333	22	-	4
Cervical Cancer-VIA and Refer to Conization	-	4	6	290	5	20%	98	2,040	6	-	1
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	-	-%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	4,324	3,077	11,122	88,793	23,614	(53)%	95,922	352,207	11,122	-	-
Chlorhexidine	1,239	427	2,012	16,755	2,248	(10)%	23,622	38,677	1,811	-	140
Clean Delivery Kit	-	-	-	-	3,511	(100)%	3,449	181,765	-	-	-
Condom	4,836,518	3,857,836	13,641,870	49,703,561	14,149,507	(4)%	65,266,786	1,455,493,685	102,314	102,314	273,054
Emergency Contraception	13,906	7,068	22,211	7,000	15,819	40%	180,947	1,085,381	999	999	309
Emergency Contraception Provided	176	303	832	30,493	894	(7)%	6,887	8,884	42	42	20
Expanded Clean Delivery Kit	-	-	-	-	-	-%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	94	317	558	20,285	2,367	(76)%	14,531	15,706	502	-	82
Female Condom	20,812	16,863	65,188	533,000	175,496	(63)%	469,229	28,449,514	489	489	1,862
Free Condom	5,963,045	4,941,457	14,562,462	44,434,784	15,294,752	(5)%	77,319,731	398,673,845	109,218	109,218	333,899
Free Female Condom	67,730	28,001	83,890	251,000	42,884	96%	623,007	4,455,650	629	629	1,712

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 3
 Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
HIV Self-Testing Kit	41,602	157,077	126,696	-	106,811	19%	996,954	1,493,197	114,026	-	-
HIV Testing Services	24,157	23,802	74,126	518,172	93,784	(21)%	541,424	5,767,419	74,126	-	6,029
Hypertension Diagnosis	16	27	72	-	83	(13)%	278	630	72	-	-
Hypertension Screening	12,056	12,881	38,149	36,477	36,246	5%	147,793	536,602	38,149	-	-
Hypertension_Controlled Condition	3	6	15	-	24	(38)%	91	172	6	-	-
Implant 3	8,820	2,531	15,685	73,620	2,254	596%	12,798	169,211	14,117	35,291	36,731
Implant 3 Insertion	12,647	15,130	48,043	201,554	51,212	(6)%	240,316	758,242	48,043	120,108	112,404
Implant 4	-	(167)	(28)	-	-	-%	(3,883)	(3,911)	(25)	(81)	(72)
Implant 4 Insertion	-	400	28	-	1	2,700%	33,884	34,028	28	90	80
Implant 5	10,497	2,684	14,407	26,000	(1,156)	-%	22,810	218,426	12,966	49,272	51,512
Implant 5 Insertion	15,212	11,740	43,006	175,505	31,576	36%	154,215	637,266	43,006	163,423	148,649
Injectable 1 Provided	9	4	19	36	107	(82)%	537	1,778	1	1	1
Injectable 2 Provided	1,471	1,772	5,058	29,000	5,542	(9)%	22,699	39,401	843	843	624
Injectable 3-IM	191,893	14,603	238,174	605,251	423,030	(44)%	1,798,175	8,415,283	53,589	53,589	24,987
Injectable 3-IM Provided	32,036	38,565	100,651	357,197	67,222	50%	342,639	792,874	25,163	25,163	16,642
Injectable 3-SC	12,470	6,210	25,100	53,892	-	-%	55,900	81,000	5,648	5,648	4,204
IUD 10	19,099	(534)	18,984	93,709	2,824	572%	85,274	258,353	17,086	78,594	77,690
IUD 10 Insertion	7,926	7,027	24,575	188,592	46,626	(47)%	220,262	1,146,016	24,575	113,045	98,138
IUD 5	-	(9)	(25)	-	-	-%	(134)	(159)	(23)	(74)	(75)
IUD 5 Insertion	19	45	99	-	130	(24)%	345	28,664	99	327	216
IUS 5	1,087	1	1,059	(56)	(23)	-%	126	2,139	953	3,145	3,236

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
IUS 5 Insertion	68	64	235	756	197	19%	739	1,340	235	775	679
LLIN	159,867	28,912	176,779	700,054	433,422	(59)%	4,545,198	12,560,693	286,382	-	9,279
Lubricant	217,743	200,739	654,329	-	420,626	56%	2,574,286	6,362,624	-	-	-
Manual Vacuum Aspiration for PAC	537	529	1,641	720	128	1,182%	7,531	12,162	1,641	-	264
Manual Vacuum Aspiration for SA	57	50	200	-	39	413%	411	1,809	200	-	73
Medical Abortion	1,499	311	2,353	9,331	12,323	(81)%	16,535	18,888	2,118	-	742
Medical Abortion (Misoprostol) Provided	70	84	295	-	53	457%	531	826	295	-	92
Medical Abortion Provided	61	48	201	-	206	(2)%	747	1,569	201	-	70
Misoprostol for PAC Provided	268	310	969	-	177	447%	3,631	5,805	969	-	210
Misoprostol for Safe Abortion	96,760	55,901	210,316	1,993,550	249,116	(16)%	1,659,272	6,824,388	11,042	-	2,955
OCs	52,135	178,975	369,932	2,258,175	615,496	(40)%	2,600,349	16,576,450	22,196	22,196	11,008
OCs Provided	54,012	32,712	118,939	357,372	61,951	92%	321,499	1,463,173	7,929	7,929	4,670
PrEP	3,176	3,465	10,273	35,111	5,560	85%	34,437	47,826	856	-	342
PUR	1,999,063	1,627,677	5,864,063	28,273,857	3,581,240	64%	33,931,875	210,523,062	48,198	-	153
Referral to Advanced Cervical Cancer Treatment	-	3	10	136	5	100%	17	427	10	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	26	(100)%	67	67	-	-	-
Referral to Emergency Contraception	-	-	-	1	-	-%	1	134	-	-	-
Referral to HIV Testing Services	5,749	9,693	11,101	82,130	6	184,917%	24,714	180,909	11,101	-	345
Referral to Hypertension Management	29	27	72	-	55	31%	567	1,202	72	-	-
Referral to Implant 3 Insertion	293	-	293	1,915	2	14,550%	2	1,441	293	366	309
Referral to Implant 5 Insertion	11	-	11	187	2	450%	2	1,307	11	21	17

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 3
 Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Referral to Injectable 1	-	-	-	-	36	(100)%	36	384	-	-	-
Referral to Injectable 3	887	-	887	6,372	75	1,083%	75	4,717	887	111	69
Referral to IUD 10 Insertion	4	-	4	48	5	(20)%	5	352	4	9	7
Referral to Linkage to HIV Care	4,908	6,347	13,842	29,940	5,493	152%	24,186	60,486	13,842	-	10,769
Referral to OCs	84	-	84	665	93	(10)%	93	2,389	84	3	2
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	-	-	2	(100)%	20	250	-	-	-
Referral to STI Screening (syndromic)	-	-	-	112,000	7	(100)%	7	14,416	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	28	(100)%	119	2,584	-	-	-
Referral to TB Diagnosis	-	-	-	-	11	(100)%	11	255	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	-	-%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	50	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	5,497	308	(100)%	308	29,857	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	45	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-	-%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-	-%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-	-%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Mer	-	-	-	336	1	(100)%	53	113	-	-	-
Referral to Tubal Ligation	-	-	-	-	-	-%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	3	(67)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	1	4	560	18	(78)%	48	551	4	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	84	(100)%	139	15,552	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Safe Water Solution	42,867	109,639	330,445	1,915,700	897,640	(63)%	2,248,493	74,041,568	225,003	-	788
STI Kit (Non-Ulcerative)	-	956	2,067	1,869	-	-%	6,655	833,598	1,860	-	135
STI Kit (Ulcerative)	-	372	1,115	231	-	-%	-	73,343	1,004	-	214
STI Screening	7,968	9,806	34,745	144,457	22,684	53%	75,388	597,661	34,745	-	-
TB Diagnosis	16	15	51	77	70	(27)%	283	1,528	51	-	-
TB DOTS	2	2	6	77	12	(50)%	35	107	6	-	49
TB Screening	16,080	18,532	56,503	34,396	60,571	(7)%	225,880	1,507,528	56,503	-	-
Toilets Sold	-	765	1,468	25,600	-	-%	5,651	7,118	6,688	-	258
Treatment for Cervicitis	1	10	17	-	5	240%	73	380	17	-	2
Treatment for Genital Herpes	1	3	7	17	11	(36)%	28	87	7	-	-
Treatment for Inguinal Bubo	-	-	-	-	-	-%	3	17	-	-	-
Treatment for Lower Abdominal Pain	3	8	25	54	25	-%	78	238	25	-	-
Treatment for Nonherpetic Genital Ulcer	89	41	184	94	122	51%	546	1,330	184	-	65
Treatment for Urethral Discharge (Men)	52	31	129	195	70	84%	292	1,031	258	-	17
Treatment for Urethral Discharge (Women)	81	42	171	2	122	40%	507	1,694	171	-	32
Treatment for Vaginitis	23	46	154	380	199	(23)%	506	2,366	154	-	28
Tubal Ligation	573	503	1,591	17,589	2,910	(45)%	16,391	37,405	1,591	15,910	12,524
Type 2 Diabetes Diagnosis	-	-	-	-	-	-%	3	8	-	-	-
Type 2 Diabetes Screening	241	365	766	33,797	1,855	(59)%	6,711	17,356	766	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	1	(100)%	6	12	-	-	-
Vasectomy	-	-	-	29	-	-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Voluntary Medical Male Circumcision	22,881	17,701	60,204	306,145	76,963	(22)%	345,985	774,226	60,204	-	419,888
Water Treatment Tablets	430,740	318,000	1,350,140	8,068,408	2,060,142	(34)%	6,957,142	53,940,642	22,194	-	86
Woman Condom	1,320	1,016	1,800	-	16,392	(89)%	97,728	141,360	13	13	37

^(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Anglophone Africa Market Group											909,409	1,675,117
Ethiopia											30,649	45,874
Antiretroviral Treatment (Currently Enrolled)	1,122	1,120	3,349	18,804	2,545		32%	16,938	30,599	279	-	536
Antiretroviral Treatment (Currently Enrolled)	1,122	1,120	3,349	18,804	2,545		32%	16,938	30,599	279	-	536
Antiretroviral Treatment (Newly Enrolled)	33	26	86	1,155	151		(43)%	1,115	2,656	86	-	-
Antiretroviral Treatment (Newly Enrolled)	33	26	86	1,155	151		(43)%	1,115	2,656	86	-	-
Free Condom	600,000	1,332,833	3,998,500	11,820,960	8,519,313		(53)%	23,871,707	168,561,945	29,989	29,989	43,705
No Logo Condom	600,000	766,000	2,898,000	11,820,960	-		-%	5,869,000	12,883,000	21,735	21,735	31,676
Protector Plus	-	566,833	1,100,500	-	8,519,313	12/12	(87)%	18,002,707	155,678,945	8,254	8,254	12,029
Free Female Condom	20,000	-	20,000	138,000	-		0%	138,000	919,089	150	150	209
Free Female Condoms	20,000	-	20,000	138,000	-		-%	138,000	919,089	150	150	209
HIV Self-Testing Kit	-	3	-	-	-		0%	14,958	14,958	-	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	3	-	-	-		-%	14,958	14,958	-	-	-
HIV Testing Services	3,866	3,292	10,625	31,606	6,488		64%	219,864	1,199,839	10,625	-	57
VCT Individual (HIV-Negative)	3,739	3,201	10,321	30,390	6,227		66%	213,839	1,171,407	10,321	-	55
VCT Individual (HIV-Positive)	127	91	304	1,216	261		16%	6,025	28,432	304	-	2
Lubricant	-	100	-	-	-		0%	62,647	62,647	-	-	-
Lubricant gel 4.5 g	-	100	-	-	-		-%	62,647	62,647	-	-	-
PUR	-	339,343	-	19,333,057	1,962,240		(100)%	20,446,684	84,712,405	-	-	-
P&G Purifier of Water	-	339,343	-	19,333,057	1,962,240		(100)%	20,446,684	84,712,405	-	-	-
Referral to Emergency Contraception	-	-	-	1	-		0%	1	134	-	-	-
Referral to Emergency Contraception	-	-	-	1	-		-%	1	134	-	-	-
Referral to HIV Testing Services	-	-	-	30,390	6		(100)%	9	119,940	-	-	-
Referral to HIV Testing Services	-	-	-	30,390	6		(100)%	9	119,940	-	-	-
Referral to Implant 3 Insertion	293	-	293	1,915	-		0%	-	1,430	293	366	309

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Implant 3 Insertion	293	-	293	1,915	-	12/14	-%	-	1,430	293	366	309
Referral to Implant 5 Insertion	11	-	11	187	-		0%	-	315	11	21	17
Referral to Implant 5 Insertion	11	-	11	187	-		-%	-	315	11	21	17
Referral to Injectable 3	887	-	887	6,372	-		0%	-	3,301	887	111	69
Referral to Injectable 3	887	-	887	6,372	-		-%	-	3,301	887	111	69
Referral to IUD 10 Insertion	4	-	4	48	-		0%	-	143	4	9	7
Referral to IUD 10 Insertion	4	-	4	48	-		-%	-	143	4	9	7
Referral to Linkage to HIV Care	-	-	-	1,216	28		(100)%	33	2,833	-	-	-
Referral to Linkage to HIV Care	-	-	-	1,216	28		(100)%	33	2,833	-	-	-
Referral to OCs	84	-	84	665	-		0%	-	974	84	3	2
Referral to OCs	84	-	84	665	-		-%	-	974	84	3	2
Referral to STI Screening (syndromic)	-	-	-	112,000	4		(100)%	4	14,311	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	112,000	4		(100)%	4	14,311	-	-	-
Referral to TB Screening	-	-	-	319	4		(100)%	4	13,488	-	-	-
Referrals to TB Screening	-	-	-	319	4		(100)%	4	13,488	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-		0%	-	-	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	112	-		-%	-	-	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-		0%	-	-	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	112	-		-%	-	-	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	-		0%	-	-	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	336	-		-%	-	-	-	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	-	560	-		0%	-	-	-	-	-
Referral to Tx for Urethral Discharge (Women)	-	-	-	560	-		-%	-	-	-	-	-
Safe Water Solution	-	42,451	122,314	740,700	159,704		(23)%	791,708	24,696,205	100,532	-	361
Wuha Agar	-	42,451	122,314	740,700	159,704		(23)%	791,708	24,696,205	100,532	-	361

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
STI Kit (Non-Ulcerative)	-	956	2,067	1,869	-		0%	6,655	833,598	1,860	-	135
STI kit for Urethral Discharge	-	538	1,015	882	-		-%	2,397	451,114	914	-	56
STI Kit for Vaginal Discharge	-	417	1,052	987	-		-%	4,258	382,484	947	-	79
STI Kit (Ulcerative)	-	372	1,115	231	-		0%	-	73,343	1,004	-	214
STI Kit for Genital Ulcer	-	372	1,115	231	-		-%	-	73,343	1,004	-	214
STI Screening	-	2,135	6,405	112,000	7,362		(13)%	33,336	446,455	6,405	-	-
STI Screening	-	2,135	6,405	112,000	7,362		(13)%	33,336	446,455	6,405	-	-
TB Screening	-	2,246	6,738	31,910	7,491		(10)%	31,664	425,480	6,738	-	-
TB Screening	-	2,246	6,738	31,910	7,491		(10)%	31,664	425,480	6,738	-	-
Toilets Sold	-	725	1,405	25,000	-		0%	5,471	6,876	6,463	-	252
Toilets Sold	-	725	1,405	25,000	-		-%	5,471	6,876	6,463	-	252
Treatment for Lower Abdominal Pain	-	-	-	-	3		(100)%	4	67	-	-	-
Treatment for Lower Abdominal Pain	-	-	-	-	3		(100)%	4	67	-	-	-
Treatment for Nonherpetic Genital Ulcer	-	2	7	-	11		(36)%	16	78	7	-	1
Treatment for Nonherpetic Genital Ulcer	-	2	7	-	11		(36)%	16	78	7	-	1
Treatment for Urethral Discharge (Men)	-	3	9	-	5		80%	5	154	18	-	-
Treatment for Urethral Discharge (Men)	-	3	9	-	5		80%	5	154	18	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	12		(100)%	12	76	-	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	12		(100)%	12	76	-	-	-
Treatment for Vaginitis	-	18	53	-	94		(44)%	116	1,288	53	-	1
Treatment for Vaginitis	-	18	53	-	94		(44)%	116	1,288	53	-	1
Ghana											56,841	22,638
Condom	-	-	-	412,211	14,700		(100)%	14,700	799,268	-	-	-
Protector	-	-	-	412,211	14,700		(100)%	14,700	799,268	-	-	-
Injectable 3-IM	176,550	1,742	178,675	495,534	156,707		14%	1,376,081	3,319,318	40,202	40,202	15,748

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Famplan	176,550	1,742	178,675	495,534	156,707		14%	1,376,481	3,319,718	40,202	40,202	15,748
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	-		-%	(400)	(400)	-	-	-
Injectable 3-IM Provided	-	-	-	-	-		0%	400	400	-	-	-
PSI Injectable 3 IM Provided	-	-	-	-	-		-%	400	400	-	-	-
OCs	4,320	155,100	277,320	2,068,038	263,940		5%	1,969,134	4,669,679	16,639	16,639	6,876
(b)PSI OCs Distributed Provided	-	-	-	-	-		-%	(66)	(66)	-	-	-
Secure	4,320	155,100	277,320	2,068,038	263,940		5%	1,969,200	4,669,745	16,639	16,639	6,876
OCs Provided	-	-	-	-	-		0%	66	66	-	-	-
PSI OCs Provided	-	-	-	-	-		-%	66	66	-	-	-
Toilets Sold	-	40	63	600	-		0%	180	242	225	-	6
Toilets Sold	-	40	63	600	-		-%	180	242	225	-	6
Water Treatment Tablets	83,100	45,000	183,500	1,066,668	112,900		63%	844,900	1,121,800	3,016	-	7
Aquatabs 67 mg (20 L)	83,100	45,000	183,500	1,066,668	112,900		63%	844,900	1,121,800	3,016	-	7
Lesotho											2,649	9,377
Antiretroviral Treatment (Currently Enrolled)	1,312	1,464	3,947	1,443	3,372		17%	18,922	42,426	329	-	747
Antiretroviral Treatment (Currently Enrolled)	1,312	1,464	3,947	1,443	3,372		17%	18,922	42,426	329	-	747
Antiretroviral Treatment (Newly Enrolled)	9	5	19	169	33		(42)%	110	247	19	-	-
Antiretroviral Treatment (Newly Enrolled)	9	5	19	169	33		(42)%	110	247	19	-	-
Emergency Contraception Provided	19	2	21	25	3		600%	20	192	1	1	-
Non-PSI Emergency Contraception Provided	19	2	21	25	3		600%	20	192	1	1	-
Female Condom	-	40	120	3,000	34,716		(100)%	96,546	2,511,202	1	1	3
Generic	-	40	120	3,000	34,716		(100)%	96,546	2,511,202	1	1	3
Free Condom	-	90,723	122,570	193,872	1,090,769		(89)%	13,845,256	32,330,952	919	919	3,567
Camouflage Free	-	34,033	24,000	13,872	218,186		(89)%	747,700	2,982,100	180	180	698
Vibe Condom	-	56,690	98,570	180,000	872,583		(89)%	13,097,556	29,348,852	739	739	2,868

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
HIV Self-Testing Kit	7,552	22,015	17,321	-	-		0%	56,275	73,596	15,589	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	7,552	22,015	17,321	-	-		-%	56,275	73,596	15,589	-	-
HIV Testing Services	9,817	11,086	31,488	137,092	44,940		(30)%	158,712	1,134,249	31,488	-	3,299
VCT Individual (HIV-Negative)	9,345	10,574	29,951	129,331	43,519		(31)%	153,406	1,067,133	29,951	-	3,138
VCT Individual (HIV-Positive)	472	512	1,537	7,761	1,421	12/09	8%	5,306	67,116	1,537	-	161
Hypertension Screening	60	68	201	4,020	1,213		(83)%	2,494	13,897	201	-	-
Hypertension Screening	60	68	201	4,020	1,213		(83)%	2,494	13,897	201	-	-
Implant 3 Insertion	-	1	4	10	-		0%	6	844	4	10	6
Non-PSI Implant 3 Inserted	-	1	4	10	-		-%	6	844	4	10	6
Implant 5 Insertion	1	1	2	20	8		(75)%	12	129	2	8	5
Non-PSI Implant 5 Inserted	1	1	2	20	8		(75)%	12	129	2	8	5
Injectable 2 Provided	-	-	1	1,000	290		(100)%	2,864	4,923	-	-	-
Non-PSI Injectable 2 Provided	-	-	1	1,000	290		(100)%	2,864	4,923	-	-	-
Injectable 3-IM Provided	1,183	1,551	4,289	19,508	1,831		134%	12,574	28,998	1,072	1,072	484
Non-PSI Injectable 3 IM Provided	1,183	1,551	4,289	19,508	1,831		134%	12,574	28,998	1,072	1,072	484
OCs Provided	3,054	2,845	9,567	20,147	2,228		329%	17,197	53,822	638	638	304
Non-PSI OCs Provided	3,054	2,845	9,567	20,147	2,228		329%	17,197	53,822	638	638	304
PrEP	49	23	118	84	2		5800%	14	132	10	-	10
PrEP	49	23	118	84	2		5,800%	14	132	10	-	10
Referral to HIV Testing Services	-	107	-	1,740	-		0%	1,299	26,462	-	-	-
Referral to HIV Testing Services	-	107	-	1,740	-		-%	1,299	26,462	-	-	-
Referral to Linkage to HIV Care	363	271	1,176	6,985	1,701		(31)%	3,328	11,924	1,176	-	707
Referral to Linkage to HIV Care	363	271	1,176	6,985	1,701		(31)%	3,328	11,924	1,176	-	707
TB Diagnosis	3	4	12	77	7		71%	41	98	12	-	-
TB Diagnosis	3	4	12	77	7		71%	41	98	12	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
TB DOTS	2	2	6	77	10		(40)%	31	53	6	-	49
TB DOTS	2	2	6	77	10		(40)%	31	53	6	-	49
TB Screening	1,672	1,975	5,438	1,443	3,172		71%	21,329	33,466	5,438	-	-
TB Screening	1,672	1,975	5,438	1,443	3,172		71%	21,329	33,466	5,438	-	-
Type 2 Diabetes Screening	-	-	-	1,340	332		(100)%	395	3,939	-	-	-
Type 2 Diabetes Screening	-	-	-	1,340	332		(100)%	395	3,939	-	-	-
Voluntary Medical Male Circumcision	5	49	15	500	99		(85)%	2,962	3,646	15	-	196
Voluntary Medical Male Circumcision	5	49	15	500	99		(85)%	2,962	3,646	15	-	196
Malawi											117,003	190,483
Cervical Cancer-VIA/VILI Screening	798	676	2,177	10,000	-		0%	19,630	21,807	2,177	-	-
Cervical Cancer-VIA/VILI Screening	798	676	2,177	10,000	-		-%	19,630	21,807	2,177	-	-
Condom	1,007,856	1,024,857	3,110,860	12,000,000	3,548,480		(12)%	17,252,824	228,575,786	23,331	23,331	63,945
Chishango	1,007,856	1,024,857	3,110,860	12,000,000	3,548,480		(12)%	17,252,824	228,575,786	23,331	23,331	63,945
Emergency Contraception	(38)	427	1,028	7,000	2,613		(61)%	11,120	109,368	46	46	23
Levonorgestrel Tablet 0.75 mg x 2's	-	563	1,410	-	-		-%	1,545	2,955	63	63	32
NORLEVO (Norlevo 1.5mg)	-	-	-	35,000	3,333	2/14	(100)%	13,994	111,455	-	-	-
(b)PSI Emergency Contraception Distributed Provided	(38)	(137)	(382)	(28,000)	(720)		-%	(4,419)	(5,042)	(17)	(17)	(9)
Emergency Contraception Provided	38	137	382	28,000	720		(47)%	4,419	5,042	19	19	10
PSI Emergency Contraception Provided	38	137	382	28,000	720		(47)%	4,419	5,042	19	19	10
Female Condom	12,612	11,156	39,868	90,000	10,740		271%	86,203	832,351	299	299	799
Care	12,612	11,156	39,868	90,000	10,740		271%	86,203	832,351	299	299	799
Free Condom	655,325	1,154,861	3,206,592	11,069,952	4,369,560		(27)%	10,466,262	31,126,699	24,049	24,049	65,912
Blue Gold Condoms	-	-	-	-	551,724	8/17	(100)%	590,724	1,856,634	-	-	-
Generic Male Condom	-	-	-	395,000	-		-%	-	-	-	-	-
Key Population Male Condom	655,325	1,154,861	3,206,592	10,000,000	3,636,396		(12)%	9,131,741	23,475,465	24,049	24,049	65,912

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
One Community Male Condom	-	-	-	-	181,440	7/16	(100)%	743,797	5,247,751	-	-	-
VMMC Male Condom	-	-	-	674,952	-		-%	-	546,849	-	-	-
Free Female Condom	-	597	-	-	42,884		(100)%	151,992	407,841	-	-	-
Free Female Condoms	-	597	-	-	17,277	2/14	(100)%	68,719	307,906	-	-	-
Key Population Female Condom	-	-	-	-	25,607	12/17	(100)%	83,273	99,935	-	-	-
HIV Self-Testing Kit	20,675	18,192	56,000	-	60,511		(7)%	258,868	403,865	50,400	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	20,675	18,075	55,650	-	60,511		(8)%	258,868	403,515	50,085	-	-
Sure Check HIV Self-Test	-	117	350	-	-		-%	-	350	315	-	-
HIV Testing Services	3,262	2,353	10,322	35,408	13,939		(26)%	76,101	252,271	10,322	-	439
VCT Individual (HIV-Negative)	3,120	2,231	9,812	34,571	13,306		(26)%	72,736	245,352	9,812	-	417
VCT Individual (HIV-Positive)	142	123	510	837	633		(19)%	3,365	6,919	510	-	22
Implant 3	(2,078)	101	(1,836)	1,000	(2,344)		0%	(11,432)	4,846	(1,652)	(4,131)	(3,753)
Implanon	-	-	-	1,000	7,748		(100)%	18,883	84,144	-	-	-
Implanon NXT	1,072	2,768	8,161	-	-		-%	2,901	11,062	7,345	18,362	16,681
(b)PSI Implant 3 Distributed Inserted	(3,150)	(2,667)	(9,997)	-	(10,092)		-%	(33,216)	(90,360)	(8,997)	(22,493)	(20,434)
Implant 3 Insertion	3,392	2,677	10,269	49,000	10,092		2%	33,272	90,688	10,269	25,673	23,322
Non-PSI Implant 3 Inserted	242	10	272	49,000	-		-%	56	328	272	680	618
PSI Implant 3 Inserted	3,150	2,667	9,997	-	10,092		(1)%	33,216	90,360	9,997	24,993	22,704
Implant 4	-	(167)	(28)	-	-		0%	(3,883)	(3,911)	(25)	(81)	(72)
Levoplant	-	233	-	-	-		-%	30,000	30,000	-	-	-
(b)PSI Implant 4 Distributed Inserted	-	(400)	(28)	-	-		-%	(33,883)	(33,911)	(25)	(81)	(72)
Implant 4 Insertion	-	400	28	-	-		0%	33,883	33,911	28	90	80
PSI Implant 4 Inserted	-	400	28	-	-		-%	33,883	33,911	28	90	80
Implant 5	(1,203)	(880)	(3,914)	1,000	(64)		0%	(9,003)	6,657	(3,523)	(13,386)	(11,985)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Jadelle	93	1,058	1,894	1,000	11,714		(84)%	27,995	123,284	1,705	6,477	5,800
(b)PSI Implant 5 Distributed Inserted	(1,296)	(1,938)	(5,808)	-	(11,778)	3/16	-%	(36,998)	(116,627)	(5,227)	(19,863)	(17,785)
Implant 5 Insertion	1,723	2,005	6,435	55,000	11,778		(45)%	37,102	117,358	6,435	24,453	21,894
Non-PSI Implant 5 Inserted	427	67	627	55,000	-		-%	104	731	627	2,383	2,133
PSI Implant 5 Inserted	1,296	1,938	5,808	-	11,778	3/16	(51)%	36,998	116,627	5,808	22,070	19,761
Injectable 3-IM	4,608	9,651	25,635	35,000	34,131		(25)%	60,576	1,854,472	5,768	5,768	3,841
Depo-Provera	10,145	14,665	44,420	-	-		-%	9,721	54,141	9,995	9,995	6,655
(b)PSI Injectable 3 IM Distributed Provided	(5,537)	(5,015)	(18,785)	-	(15,029)		-%	(66,440)	(92,565)	(4,227)	(4,227)	(2,814)
SafePlan Inj3	-	-	-	35,000	49,160		(100)%	117,295	1,892,896	-	-	-
Injectable 3-IM Provided	5,562	5,025	18,840	84,000	15,029		25%	67,465	93,645	4,710	4,710	3,136
Non-PSI Injectable 3 IM Provided	25	10	55	84,000	-		-%	1,025	1,080	14	14	9
PSI Injectable 3 IM Provided	5,537	5,015	18,785	-	15,029		25%	66,440	92,565	4,696	4,696	3,127
IUD 10	158	(12)	204	500	459		(56)%	(818)	5,456	184	845	726
IUD Copper T 380A	450	436	1,530	500	1,423		8%	5,154	18,679	1,377	6,334	5,442
(b)PSI IUD 10 Distributed Inserted	(292)	(449)	(1,326)	-	(964)	3/16	-%	(5,972)	(13,223)	(1,193)	(5,490)	(4,716)
IUD 10 Insertion	292	449	1,326	5,136	964		38%	5,972	13,223	1,326	6,100	5,240
Non-PSI IUD 10 Inserted	-	-	-	5,136	-		-%	-	-	-	-	-
PSI IUD 10 Inserted	292	449	1,326	-	964	3/16	38%	5,972	13,223	1,326	6,100	5,240
LLIN	26,731	2,841	32,149	45,000	8,870		262%	34,209	464,192	52,081	-	2,013
Super Chitetezo Net	26,731	2,841	32,149	45,000	8,870		262%	34,209	464,192	52,081	-	2,013
Lubricant	34,693	108,789	283,479	-	224,876		26%	1,071,889	3,361,827	-	-	-
Personal Lubricant Water 4.5 g	34,693	108,789	283,479	-	224,876		26%	1,071,889	3,361,827	-	-	-
OCs	3,757	20,092	22,471	65,000	46,772		(52)%	164,930	839,429	1,348	1,348	947
Microgynon	2,079	2,705	8,865	-	64,263	11/11	(86)%	150,604	814,605	532	532	374

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Microgynon combination 3	23,800	9,670	43,450	65,000	-		-%	13,640	57,090	2,607	2,607	1,831
Microlut	-	10,301	-	-	780	8/17	(100)%	47,803	58,879	-	-	-
(b)PSI OCs Distributed Provided	(22,122)	(2,584)	(29,844)	-	(18,271)		-%	(47,117)	(91,145)	(1,791)	(1,791)	(1,258)
OCs Provided	22,821	3,890	34,041	35,000	20,824		63%	58,051	106,276	2,269	2,269	1,594
Non-PSI OCs Provided	699	1,306	4,197	35,000	2,553		64%	10,934	15,131	280	280	197
PSI OCs Provided	22,122	2,584	29,844	-	18,271		63%	47,117	91,145	1,990	1,990	1,398
PUR	1,740,800	933,333	4,540,800	4,540,800	1,240,348		266%	5,781,185	64,649,240	37,322	-	113
PuR WaterGuard Waufa	1,740,800	933,333	4,540,800	4,540,800	1,240,348		266%	5,781,185	64,649,240	37,322	-	113
Safe Water Solution	-	144	432	-	64,936		(99)%	143,085	8,495,987	355	-	1
WaterGuard	-	144	432	-	64,936	12/02	(99)%	143,085	8,495,987	355	-	1
STI Screening	69	75	223	-	82		172%	2,620	2,843	223	-	-
STI Screening	69	75	223	-	82		172%	2,620	2,843	223	-	-
Tubal Ligation	561	496	1,560	17,281	2,857		(45)%	16,027	36,726	1,560	15,600	12,257
Tubal Ligation	561	496	1,560	17,281	2,857		(45)%	16,027	36,726	1,560	15,600	12,257
Voluntary Medical Male Circumcision	-	-	-	56,645	13,326		(100)%	53,033	93,460	-	-	-
Voluntary Medical Male Circumcision	-	-	-	56,645	13,326		(100)%	53,033	93,460	-	-	-
PSI Uganda											397,047	398,059
Basic Care Package	-	-	-	-	-		0%	1	1	-	-	-
PLP Kit - NFB (with WaterGuard Tab)	-	-	-	-	-		-%	1	1	-	-	-
Cervical Cancer-VIA and Cryotherapy	6	2	10	-	-		0%	150	160	10	-	4
Cervical Cancer-VIA and Cryotherapy	6	2	10	-	-		-%	150	160	10	-	4
Cervical Cancer-VIA/VILI Screening	1,401	900	3,846	60,000	-		0%	38,866	42,712	3,846	-	-
Cervical Cancer-VIA/VILI Screening	1,401	900	3,846	60,000	-		-%	38,866	42,712	3,846	-	-
Chlorhexidine	1,239	427	2,012	16,755	1,817		11%	23,211	25,223	1,811	-	140
Chlorhexidine Gel, 5 g tube	1,239	427	2,012	16,755	1,817		11%	23,211	25,223	1,811	-	140

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Clean Delivery Kit	-	-	-	-	2,234		(100)%	2,840	2,840	-	-	-
Maama Kit	-	-	-	-	632		(100)%	572	572	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	1,602		(100)%	2,268	2,268	-	-	-
Condom	379,656	107,664	665,352	2,633,850	219,096		204%	1,604,736	2,270,088	4,990	4,990	11,627
Trust	162,432	31,440	246,816	675,000	60,048		311%	630,504	877,320	1,851	1,851	4,313
Trust Ribbed	72,576	24,216	144,936	665,550	39,384		268%	87,408	232,344	1,087	1,087	2,533
Trust Scented	76,896	29,568	151,344	652,050	57,672		162%	349,272	500,616	1,135	1,135	2,645
Trust Studded	67,752	22,440	122,256	641,250	61,992		97%	537,552	659,808	917	917	2,136
Emergency Contraception	(5)	(41)	(22)	-	-		0%	(107)	(129)	(1)	(1)	(1)
(b)PSI Emergency Contraception Distributed Provided	(5)	(41)	(22)	-	-		-%	(107)	(129)	(1)	(1)	(1)
Emergency Contraception Provided	5	42	22	-	-		0%	109	131	1	1	1
Non-PSI Emergency Contraception Provided	-	1	-	-	-		-%	2	2	-	-	-
PSI Emergency Contraception Provided	5	41	22	-	-		-%	107	129	1	1	1
Expanded Clean Delivery Kit	-	-	-	-	-		0%	13,160	13,160	-	-	-
Mama Kit Expanded(Chlorhexidine 400gm&Misoprostol)	-	-	-	-	-		-%	13,160	13,160	-	-	-
Expanded Clean Delivery Kit (+CHX)	94	317	558	20,285	1,673		(67)%	13,837	14,395	502	-	82
Mama Kit with Chlorhexidine	94	317	558	20,285	1,673		(67)%	13,837	14,395	502	-	82
Free Condom	-	-	-	-	-		0%	576,000	576,000	-	-	-
Generic Male Condom	-	-	-	-	-		-%	576,000	576,000	-	-	-
Implant 3	11,105	2,747	18,437	72,620	6,442		186%	34,268	52,705	16,593	41,483	42,004
Implanon	12,714	4,073	23,492	92,900	6,442		265%	55,110	78,602	21,143	52,857	53,520
(b)PSI Implant 3 Distributed Inserted	(1,609)	(1,325)	(5,055)	(20,280)	-		-%	(20,842)	(25,897)	(4,550)	(11,374)	(11,516)
Implant 3 Insertion	4,033	8,234	22,141	100,280	-		0%	99,913	122,054	22,141	55,353	56,047
Non-PSI Implant 3 Inserted	2,424	6,909	17,086	80,000	-		-%	79,071	96,157	17,086	42,715	43,251

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Implant 3 Inserted	1,609	1,325	5,055	20,280	-		-%	20,842	25,897	5,055	12,638	12,796
Implant 5	11,744	2,888	19,631	25,000	1,270		1446%	41,363	60,994	17,668	67,138	66,818
Jadelle	12,480	3,457	21,840	40,000	1,270		1,620%	53,160	75,000	19,656	74,693	74,336
(b)PSI Implant 5 Distributed Inserted	(736)	(568)	(2,209)	(15,000)	-		-%	(11,797)	(14,006)	(1,988)	(7,555)	(7,519)
Implant 5 Insertion	6,955	4,901	18,445	45,160	-		0%	33,335	51,780	18,445	70,091	69,757
Non-PSI Implant 5 Inserted	6,219	4,333	16,236	30,160	-		-%	21,538	37,774	16,236	61,697	61,402
PSI Implant 5 Inserted	736	568	2,209	15,000	-		-%	11,797	14,006	2,209	8,394	8,354
Injectable 3-IM	6,327	(913)	16,115	48,097	7,025		129%	59,649	75,764	3,626	3,626	2,699
Depo-Provera	8,075	7,992	22,050	68,097	7,025		214%	82,175	104,225	4,961	4,961	3,693
(b)PSI Injectable 3 IM Distributed Provided	(1,748)	(8,904)	(5,935)	(20,000)	-		-%	(22,526)	(28,461)	(1,335)	(1,335)	(994)
Injectable 3-IM Provided	1,823	9,548	6,170	21,700	-		0%	24,298	30,468	1,543	1,543	1,148
Non-PSI Injectable 3 IM Provided	75	644	235	1,700	-		-%	1,772	2,007	59	59	44
PSI Injectable 3 IM Provided	1,748	8,904	5,935	20,000	-		-%	22,526	28,461	1,484	1,484	1,104
Injectable 3-SC	12,470	6,210	25,100	53,892	-		0%	55,900	81,000	5,648	5,648	4,204
Sayana Press	12,470	6,210	25,100	53,892	-		-%	55,900	81,000	5,648	5,648	4,204
IUD 10	20,293	501	22,308	90,759	7,560		195%	112,806	135,114	20,077	92,355	87,893
Copper T 380	19,399	1,217	23,049	87,000	100		22,949%	110,545	133,594	20,744	95,423	90,813
IUD PACK CU T380A	1,680	557	3,230	60,000	7,460		(57)%	43,587	46,817	2,907	13,372	12,726
PPIUD Cu T380A	736	117	1,086	1,359	-		-%	2,675	3,761	977	4,496	4,279
(b)PSI IUD 10 Distributed Inserted	(1,522)	(1,389)	(5,057)	(57,600)	-		-%	(44,001)	(49,058)	(4,551)	(20,936)	(19,924)
IUD 10 Insertion	3,628	3,217	11,444	112,680	-		0%	89,907	101,351	11,444	52,642	50,099
Non-PSI IUD 10 Inserted	2,106	1,828	6,387	55,080	-		-%	45,906	52,293	6,387	29,380	27,961
PSI IUD 10 Inserted	1,522	1,389	5,057	57,600	-		-%	44,001	49,058	5,057	23,262	22,138
IUD 5	-	(9)	(25)	-	-		0%	(134)	(159)	(23)	(74)	(75)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 5 Distributed Inserted	-	(9)	(25)	-	-		-%	(134)	(159)	(23)	(74)	(75)
IUD 5 Insertion	-	9	25	-	-		0%	135	160	25	82	84
Non-PSI IUD 5 Inserted	-	-	-	-	-		-%	1	1	-	-	-
PSI IUD 5 Inserted	-	9	25	-	-		-%	134	159	25	82	84
Manual Vacuum Aspiration for PAC	91	87	339	720	-		0%	469	808	339	-	100
MVA for PAC	91	87	339	720	-		-%	469	808	339	-	100
Manual Vacuum Aspiration for SA	57	50	200	-	-		0%	261	461	200	-	73
Manual Vacuum Aspiration for SA	57	50	200	-	-		-%	261	461	200	-	73
Medical Abortion	1,499	311	2,353	9,331	12,323		(81)%	16,535	18,888	2,118	-	742
Divabo - Combipack (1+4's)	1,560	359	2,554	9,331	12,323		(79)%	16,804	19,358	2,299	-	805
(b)PSI Medical Abortion Distributed Provided	(61)	(48)	(201)	-	-		-%	(269)	(470)	(181)	-	(63)
Medical Abortion (Misoprostol) Provided	70	84	295	-	-		0%	344	639	295	-	92
PSI Medical Abortion (Misoprostol) Provided	70	84	295	-	-		-%	344	639	295	-	92
Medical Abortion Provided	61	48	201	-	-		0%	269	470	201	-	70
PSI Medical Abortion Provided	61	48	201	-	-		-%	269	470	201	-	70
Misoprostol for PAC Provided	76	91	339	-	-		0%	586	925	339	-	116
PSI Misoprostol for PAC Provided	76	91	339	-	-		-%	586	925	339	-	116
Misoprostol for Safe Abortion	76,456	30,859	157,204	893,550	-		0%	452,048	609,252	8,253	-	2,578
Misoprostol for Safe Abortion	77,600	32,227	162,100	893,550	-		-%	458,520	620,620	8,510	-	2,659
(b)PSI Misoprostol for Safe Abortion Dist Provided	(1,144)	(1,368)	(4,896)	-	-		-%	(6,472)	(11,368)	(257)	-	(80)
OCs	19,062	3,562	31,141	45,277	3,777		724%	43,581	74,722	1,868	1,868	1,467
Combination 3	540	453	1,900	-	-		-%	7,900	9,800	114	114	90
Family Planning Pills	-	-	-	26,280	3,777		(100)%	28,590	28,590	-	-	-
Microlut - Oral Contraceptive	-	720	1,662	2,000	-		-%	699	2,361	100	100	78

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI OCs Distributed Provided	(189)	(1,096)	(588)	(3,003)	-		-%	(2,890)	(3,478)	(35)	(35)	(28)
Zinnia	18,711	3,485	28,167	20,000	-		-%	9,282	37,449	1,690	1,690	1,327
OCs Provided	198	1,164	624	3,103	-		0%	3,066	3,690	42	42	33
Non-PSI OCs Provided	9	68	36	100	-		-%	176	212	2	2	2
PSI OCs Provided	189	1,096	588	3,003	-		-%	2,890	3,478	39	39	31
PUR	240	355,000	1,065,240	3,400,000	3,384		31379%	6,413,745	7,478,985	8,755	-	35
PuR	240	355,000	1,065,240	3,400,000	3,384		31,379%	6,413,745	7,478,985	8,755	-	35
Referral to HIV Testing Services	-	3,901	-	-	-		0%	11,703	11,703	-	-	-
Referral to HIV Testing Services	-	3,901	-	-	-		-%	11,703	11,703	-	-	-
Referral to Linkage to HIV Care	-	1,538	-	-	-		0%	4,614	4,614	-	-	-
Referral to Linkage to HIV Care	-	1,538	-	-	-		-%	4,614	4,614	-	-	-
Tubal Ligation	8	6	26	-	-		0%	46	72	26	260	223
Tubal Ligation	8	6	26	-	-		-%	46	72	26	260	223
Rwanda											43,896	83,137
Condom	1,336,596	1,174,055	4,858,760	16,437,500	3,977,568		22%	13,673,659	205,763,646	36,441	36,441	78,173
Plaisir	229,680	187,160	791,160	2,000,000	408,720	2/13	94%	1,688,521	17,371,180	5,934	5,934	12,729
Prudence Plus	1,106,916	986,895	4,067,600	14,437,500	3,568,848	2/13	14%	11,985,138	188,392,466	30,507	30,507	65,444
Free Condom	-	-	-	-	21,600		(100)%	22,662	2,390,408	-	-	-
Military Condom	-	-	-	-	21,600	4/14	(100)%	22,662	2,390,408	-	-	-
Injectable 3-IM	5,290	5,027	20,372	26,620	8,160		150%	42,020	101,984	4,584	4,584	2,950
Confiance Depo-Provera	5,290	5,027	20,372	26,620	8,160	2/13	150%	42,020	101,984	4,584	4,584	2,950
OCs	28,830	6,342	47,857	79,860	38,880		23%	170,171	414,660	2,871	2,871	1,950
Microgynon	28,830	6,342	47,857	79,860	38,880	6/15	23%	170,171	414,660	2,871	2,871	1,950
PUR	258,023	-	258,023	1,000,000	371,428		(31)%	1,286,421	13,118,652	2,121	-	4
PuR	258,023	-	258,023	1,000,000	371,428	2/13	(31)%	1,286,421	13,118,652	2,121	-	4

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Safe Water Solution	9,123	8,928	35,907	275,000	124,768		(71)%	250,823	4,101,490	29,513	-	60
Sur Eau	9,123	8,928	35,907	275,000	124,768	2/13	(71)%	250,823	4,101,490	29,513	-	60
Swaziland											27,525	169,639
Antiretroviral Treatment (Currently Enrolled)	1,062	1,010	3,043	19,040	1,127		170%	9,037	13,953	254	-	626
Antiretroviral Treatment (Currently Enrolled)	1,062	1,010	3,043	19,040	1,127		170%	9,037	13,953	254	-	626
Antiretroviral Treatment (Newly Enrolled)	63	33	132	359	126		5%	593	1,294	132	-	-
Antiretroviral Treatment (Newly Enrolled)	63	33	132	359	126		5%	593	1,294	132	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	101		(100)%	101	1,499	-	-	-
Condom	-	-	-	-	3,371,543		(100)%	5,072,763	24,040,979	-	-	-
Lovers Plus	-	-	-	-	288	2/01	(100)%	288	1,271,986	-	-	-
Lovers Plus C&F	-	-	-	-	65	1/05	(100)%	253	188,237	-	-	-
Lovers Plus R&S	-	-	-	-	48	5/10	(100)%	80	111,824	-	-	-
Trust Regular BGF	-	-	-	-	234	7/08	(100)%	234	74,421	-	-	-
Trust Studded	-	-	-	-	1,908	1/05	(100)%	1,908	5,550,730	-	-	-
Trust Workplace	-	-	-	-	3,369,000	2/06	(100)%	5,070,000	16,843,781	-	-	-
Emergency Contraception Provided	-	-	-	-	-		0%	2	7	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	-	-		-%	2	7	-	-	-
Female Condom	7,000	5,667	24,000	60,000	43,000		(44)%	116,500	1,056,727	180	180	1,031
Female Condom	7,000	5,667	24,000	60,000	43,000		(44)%	116,500	1,056,727	180	180	1,031
Free Condom	1,125,000	1,200,000	3,642,000	6,000,000	1,293,510		182%	11,994,690	76,883,108	27,315	27,315	157,930
Generic	603,000	695,000	1,803,000	3,750,000	1,293,000		39%	11,283,000	63,941,544	13,522	13,522	78,185
Vanilla & Strawberry	522,000	505,000	1,839,000	2,250,000	-		-%	711,000	2,550,000	13,792	13,792	79,746
Workplace	-	-	-	-	510	10/01	(100)%	690	10,391,564	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
HIV Self-Testing Kit	50	12,192	50	-	-		0%	36,575	36,625	45	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	50	12,192	50	-	-		-%	36,575	36,625	45	-	-
HIV Testing Services	3,648	3,414	11,433	32,457	14,930		(23)%	37,788	631,404	11,433	-	1,554
VCT Individual (HIV-Negative)	3,192	3,079	10,208	27,006	13,361		(24)%	32,716	578,005	10,208	-	1,388
VCT Individual (HIV-Positive)	456	335	1,225	5,451	1,569		(22)%	5,072	53,399	1,225	-	167
Hypertension Screening	465	391	1,382	32,457	689		101%	3,270	9,886	1,382	-	-
Hypertension Screening	465	391	1,382	32,457	689		101%	3,270	9,886	1,382	-	-
Implant 3 Insertion	3	3	6	33	39		(85)%	170	178	6	15	10
Non-PSI Implant 3 Inserted	3	3	6	33	39		(85)%	170	178	6	15	10
Injectable 1 Provided	9	4	19	36	107		(82)%	537	1,778	1	1	1
Non-PSI Injectable 1 Provided	9	4	19	36	107		(82)%	537	1,778	1	1	1
Injectable 3-IM Provided	9	18	48	102	198		(76)%	1,194	2,881	12	12	6
Non-PSI Injectable 3 IM Provided	9	18	48	102	198		(76)%	1,194	2,881	12	12	6
Lubricant	106,000	51,000	219,000	-	161,000		36%	1,342,000	2,234,000	-	-	-
Lifestyles Liquid Personal Lubricant (4.5 g)	106,000	51,000	219,000	-	161,000		36%	1,342,000	2,234,000	-	-	-
OCs Provided	3	9	20	70	154		(87)%	692	2,231	1	1	1
Non-PSI OCs Provided	3	9	20	70	154		(87)%	692	2,231	1	1	1
PrEP	16	9	35	-	-		0%	78	113	3	-	2
PrEP	16	9	35	-	-		-%	78	113	3	-	2
Referral to Hypertension Management	-	-	1	-	3		(67)%	3	46	1	-	-
Referral to Hypertension Management	-	-	1	-	3		(67)%	3	46	1	-	-
Referral to Injectable 1	-	-	-	-	36		(100)%	36	384	-	-	-
Referral to Injectable 1	-	-	-	-	36		(100)%	36	384	-	-	-
Referral to Injectable 3	-	-	-	-	55		(100)%	55	646	-	-	-
Referral to Injectable 3	-	-	-	-	55		(100)%	55	646	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Linkage to HIV Care	243	218	782	5,178	1,113		(30)%	2,541	7,385	782	-	511
Referral to Linkage to HIV Care	243	218	782	5,178	1,113		(30)%	2,541	7,385	782	-	511
Referral to OCs	-	-	-	-	76		(100)%	76	547	-	-	-
Referral to OCs	-	-	-	-	76		(100)%	76	547	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	26		(100)%	26	247	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	26	12/14	(100)%	26	247	-	-	-
Referral to TB Screening	-	-	-	5,178	303		(100)%	303	4,032	-	-	-
Referrals to TB Screening	-	-	-	5,178	303		(100)%	303	4,032	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	-		0%	19	4,737	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	-	12/14	-%	19	4,737	-	-	-
STI Screening	3,693	3,442	11,551	32,457	14,930		(23)%	37,972	120,999	11,551	-	-
STI Screening	3,693	3,442	11,551	32,457	14,930		(23)%	37,972	120,999	11,551	-	-
TB Screening	3,648	3,414	11,433	1,043	14,930		(23)%	37,910	111,730	11,433	-	-
TB Screening	3,648	3,414	11,433	1,043	14,930		(23)%	37,910	111,730	11,433	-	-
Treatment for Genital Herpes	-	2	6	17	7		(14)%	17	50	6	-	-
Treatment for Genital Herpes	-	2	6	17	7		(14)%	17	50	6	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		0%	1	5	-	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		-%	1	5	-	-	-
Treatment for Lower Abdominal Pain	1	7	21	54	14		50%	54	130	21	-	-
Treatment for Lower Abdominal Pain	1	7	21	54	14		50%	54	130	21	-	-
Treatment for Nonherpetic Genital Ulcer	8	8	27	94	27		0%	94	266	27	-	10
Treatment for Nonherpetic Genital Ulcer	8	8	27	94	27		-%	94	266	27	-	10
Treatment for Urethral Discharge (Men)	34	19	85	195	42		102%	195	499	170	-	12
Treatment for Urethral Discharge (Men)	34	19	85	195	42		102%	195	499	170	-	12
Treatment for Urethral Discharge (Women)	-	1	3	2	-		0%	2	7	3	-	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Urethral Discharge (Women)	-	1	3	2	-		-%	2	7	3	-	1
Treatment for Vaginitis	23	27	95	380	102		(7)%	380	1,061	95	-	25
Treatment for Vaginitis	23	27	95	380	102		(7)%	380	1,061	95	-	25
Type 2 Diabetes Screening	203	163	640	32,457	71		801%	658	1,557	640	-	-
Type 2 Diabetes Screening	203	163	640	32,457	71		801%	658	1,557	640	-	-
Voluntary Medical Male Circumcision	245	126	567	4,000	662		(14)%	2,766	7,434	567	-	7,918
Voluntary Medical Male Circumcision	245	126	567	4,000	662		(14)%	2,766	7,434	567	-	7,918
Tanzania											95,856	86,820
Cervical Cancer-VIA/VILI Screening	-	-	-	-	39		(100)%	39	19,810	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	39		(100)%	39	19,810	-	-	-
Condom	-	2,160	6,048	220,000	1,296		367%	9,719,136	614,744,060	45	45	69
Salama Halisi	-	-	-	-	432	2/11	(100)%	4,191,696	345,728,504	-	-	-
Salama Scented	-	144	-	220,000	432		(100)%	4,398,624	136,918,956	-	-	-
Salama Studded	-	2,016	6,048	-	432	6/04	1,300%	1,128,816	132,096,600	45	45	69
Emergency Contraception	(81)	(70)	(249)	-	(75)		0%	(779)	(1,077)	(11)	(11)	(5)
(b)PSI Emergency Contraception Distributed Provided	(81)	(70)	(249)	-	(75)		-%	(779)	(1,077)	(11)	(11)	(5)
Emergency Contraception Provided	104	112	376	2,468	155		143%	2,258	2,774	19	19	9
Non-PSI Emergency Contraception Provided	23	43	127	2,468	80		59%	1,479	1,697	6	6	3
PSI Emergency Contraception Provided	81	70	249	-	75		232%	779	1,077	12	12	6
Implant 3	(95)	(194)	(577)	-	(2,760)		0%	(10,487)	(77,811)	(519)	(1,298)	(1,108)
(b)PSI Implant 3 Distributed Inserted	(95)	(194)	(577)	-	(2,760)		-%	(10,487)	(77,811)	(519)	(1,298)	(1,108)
Implant 3 Insertion	4,332	3,452	13,067	49,779	12,310		6%	73,748	234,227	13,067	32,668	27,871
Non-PSI Implant 3 Inserted	4,237	3,258	12,490	49,779	9,550		31%	63,261	156,416	12,490	31,225	26,641
PSI Implant 3 Inserted	95	194	577	-	2,760		(79)%	10,487	77,811	577	1,443	1,231
Implant 5	(349)	(257)	(897)	-	(3,704)		0%	(12,107)	(108,713)	(807)	(3,068)	(2,568)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Implant 5 Distributed Inserted	(349)	(257)	(897)	-	(3,704)		-%	(12,107)	(108,713)	(807)	(3,068)	(2,568)
Implant 5 Insertion	2,786	1,817	7,534	32,829	7,524		0%	45,509	204,673	7,534	28,629	23,967
Non-PSI Implant 5 Inserted	2,437	1,559	6,637	32,829	3,820		74%	33,402	95,960	6,637	25,221	21,114
PSI Implant 5 Inserted	349	257	897	-	3,704		(76)%	12,107	108,713	897	3,409	2,854
Injectable 3-IM	(79)	(169)	(327)	-	207,302		(100)%	241,911	1,900,511	(74)	(74)	(46)
Familia Injectable 3 Kit	-	-	-	-	208,040	1/10	(100)%	246,600	1,913,951	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	(79)	(169)	(327)	-	(738)		-%	(4,689)	(13,440)	(74)	(74)	(46)
Injectable 3-IM Provided	2,857	2,574	8,642	7,419	8,577		1%	37,606	115,079	2,161	2,161	1,358
Non-PSI Injectable 3 IM Provided	2,778	2,405	8,315	7,419	7,839		6%	32,917	101,639	2,079	2,079	1,306
PSI Injectable 3 IM Provided	79	169	327	-	738		(56)%	4,689	13,440	82	82	51
IUD 10	(1,138)	(930)	(2,908)	2,450	(6,115)		0%	(26,670)	(121,450)	(2,617)	(12,039)	(9,617)
Familia IUD Kit	-	500	1,100	2,450	4,800		(77)%	12,820	254,729	990	4,554	3,638
(b)PSI IUD 10 Distributed Inserted	(1,138)	(1,430)	(4,008)	-	(10,915)		-%	(39,490)	(376,179)	(3,607)	(16,593)	(13,255)
IUD 10 Insertion	3,496	2,975	10,469	66,000	21,329		(51)%	96,804	590,073	10,469	48,157	38,470
Non-PSI IUD 10 Inserted	2,358	1,545	6,461	66,000	10,414		(38)%	57,314	213,894	6,461	29,721	23,742
PSI IUD 10 Inserted	1,138	1,430	4,008	-	10,915		(63)%	39,490	376,179	4,008	18,437	14,728
LLIN	133,136	26,071	144,630	655,054	424,552		(66)%	4,510,989	12,096,501	234,301	-	7,266
"New Brand" (School Net Program)	-	-	-	-	97,352		(100)%	97,352	1,255,210	-	-	-
Olyset Nets Health Facility	59,760	17,267	59,760	-	-		-%	486,680	546,440	96,811	-	3,002
Permanet (180x160x180 CM) SI	-	-	-	-	327,200	2/16	(100)%	978,840	7,261,864	-	-	-
Permanet Health Facility	73,376	8,613	84,496	655,054	-		-%	91,648	176,144	136,884	-	4,245
Permanet Nets School	-	191	374	-	-		-%	2,856,469	2,856,843	606	-	19
Manual Vacuum Aspiration for PAC	446	442	1,302	-	-		0%	6,674	9,050	1,302	-	164
MVA for PAC	446	442	1,302	-	-		-%	6,674	9,050	1,302	-	164

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for PAC Provided	192	219	630	-	-		0%	2,547	3,228	630	-	93
PSI Misoprostol for PAC Provided	192	219	630	-	-		-%	2,547	3,228	630	-	93
Misoprostol for Safe Abortion	20,304	25,043	53,112	1,100,000	249,116		(79)%	1,207,224	6,215,136	2,788	-	377
Misoprostol Cipla 200 mcg	21,072	25,920	55,632	1,100,000	-		-%	776,776	832,408	2,921	-	395
Misoprostol for Safe Abortion	-	-	-	-	249,116	3/18	(100)%	440,636	5,395,640	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	(768)	(877)	(2,520)	-	-		-%	(10,188)	(12,912)	(132)	-	(18)
OCs	(21)	(241)	(651)	-	268,428		(100)%	287,100	10,206,538	(39)	(39)	(26)
Familia [OC]	-	-	-	-	269,424	2/08	(100)%	295,056	10,228,009	-	-	-
(b)PSI OCs Distributed Provided	(21)	(241)	(651)	-	(996)		-%	(7,956)	(21,471)	(39)	(39)	(26)
OCs Provided	3,612	2,855	10,587	11,708	7,575		40%	75,344	130,852	706	706	468
Non-PSI OCs Provided	3,591	2,614	9,936	11,708	6,579		51%	67,388	109,381	662	662	439
PSI OCs Provided	21	241	651	-	996		(35)%	7,956	21,471	43	43	29
Water Treatment Tablets	347,640	273,000	1,166,640	7,001,740	1,947,242		(40)%	6,112,242	52,818,842	19,178	-	78
Aquatab Tubs 8.68g	-	-	-	1,740	960		(100)%	960	446,520	-	-	-
WaterGuard Tablet ENF	347,640	273,000	1,166,640	7,000,000	1,946,282		(40)%	6,111,282	52,372,322	19,178	-	78
Uganda											26,946	71,598
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	74		(100)%	74	2,360	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	74	11/13	(100)%	74	2,360	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	18,884		(100)%	18,884	176,960	-	-	-
Cervical Cancer-VIA/VILI Screening	-	-	-	-	18,884		(100)%	18,884	176,960	-	-	-
Chlorhexidine	-	-	-	-	431		(100)%	411	13,454	-	-	-
Chlorhexidine Gel, 5 g tube	-	-	-	-	431	11/16	(100)%	411	13,454	-	-	-
Clean Delivery Kit	-	-	-	-	1,277		(100)%	609	178,925	-	-	-
Maama Kit Extra Clean Delivery	-	-	-	-	1,277	8/10	(100)%	609	178,925	-	-	-
Condom	-	-	-	-	184,464		(100)%	180,648	46,911,638	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Trust	-	-	-	-	50,688	6/06	(100)%	49,392	44,987,870	-	-	-
Trust Ribbed	-	-	-	-	39,528	11/15	(100)%	39,528	610,632	-	-	-
Trust Scented	-	-	-	-	43,632	11/15	(100)%	42,408	649,224	-	-	-
Trust Studded	-	-	-	-	50,616	11/15	(100)%	49,320	663,912	-	-	-
Expanded Clean Delivery Kit (+CHX)	-	-	-	-	694		(100)%	694	1,311	-	-	-
Mama Kit with Chlorhexidine	-	-	-	-	694	11/17	(100)%	694	1,311	-	-	-
Free Condom	3,582,720	1,163,039	3,592,800	15,350,000	-		0%	16,543,154	86,804,733	26,946	26,946	62,785
Generic	2,744,640	736,800	2,744,640	10,350,000	-		-%	13,304,596	82,718,015	20,585	20,585	47,963
Ulinzi Condoms	838,080	426,239	848,160	5,000,000	-		-%	3,238,558	4,086,718	6,361	6,361	14,822
Free Female Condom	-	13,332	-	100,000	-		0%	105,995	2,310,630	-	-	-
Female Condom Free	-	13,332	-	100,000	-		-%	105,995	2,310,630	-	-	-
Implant 3	-	-	-	-	(5,778)		0%	(5,778)	105,174	-	-	-
Implanon	-	-	-	-	932	12/08	(100)%	932	192,634	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	-	(6,710)		-%	(6,710)	(87,460)	-	-	-
Implant 3 Insertion	-	-	-	-	27,489		(100)%	27,489	292,024	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	20,779		(100)%	20,779	204,564	-	-	-
PSI Implant 3 Inserted	-	-	-	-	6,710		(100)%	6,710	87,460	-	-	-
Implant 5	-	-	-	-	(4,540)		0%	(4,540)	95,981	-	-	-
Jadelle	-	-	-	-	760	12/08	(100)%	760	181,319	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(5,300)		-%	(5,300)	(85,338)	-	-	-
Implant 5 Insertion	-	-	-	-	5,464		(100)%	5,464	114,325	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	164		(100)%	164	28,987	-	-	-
PSI Implant 5 Inserted	-	-	-	-	5,300		(100)%	5,300	85,338	-	-	-
Injectable 3-IM	-	-	-	-	4,200		(100)%	3,950	263,573	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Depo-Provera	-	-	-	-	4,200	11/11	(100)%	3,950	263,573	-	-	-
IUD 10	-	-	-	-	(16,067)		0%	(16,307)	1,791	-	-	-
IUD PACK CU T380A	-	-	-	-	1,130	4/11	(100)%	890	238,341	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(17,197)		-%	(17,197)	(236,550)	-	-	-
IUD 10 Insertion	-	-	-	-	23,549		(100)%	23,549	426,314	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	6,352		(100)%	6,352	189,765	-	-	-
PSI IUD 10 Inserted	-	-	-	-	17,197		(100)%	17,197	236,550	-	-	-
IUD 5	-	-	-	-	(129)		0%	(129)	(17,342)	-	-	-
(b)PSI IUD 5 Distributed Inserted	-	-	-	-	(129)		-%	(129)	(17,342)	-	-	-
IUD 5 Insertion	-	-	-	-	130		(100)%	130	28,350	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	-	1		(100)%	1	11,007	-	-	-
PSI IUD 5 Inserted	-	-	-	-	129		(100)%	129	17,342	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	128		(100)%	388	2,304	-	-	-
MVA for PAC	-	-	-	-	128	3/16	(100)%	388	2,304	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	39		(100)%	150	1,348	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	39		(100)%	150	1,348	-	-	-
Medical Abortion	-	-	-	-	447		(100)%	(2,536)	8,475	-	-	-
Divabo - Combipack (1+4's)	-	-	-	-	653	5/17	(100)%	(2,058)	9,574	-	-	-
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(206)		-%	(478)	(1,099)	-	-	-
Medical Abortion (Misoprostol) Provided	-	-	-	-	53		(100)%	187	187	-	-	-
Non-PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	-		-%	26	26	-	-	-
PSI Medical Abortion (Misoprostol) Provided	-	-	-	-	53		(100)%	161	161	-	-	-
Medical Abortion Provided	-	-	-	-	206		(100)%	478	1,099	-	-	-
PSI Medical Abortion Provided	-	-	-	-	206		(100)%	478	1,099	-	-	-
Misoprostol for PAC Provided	-	-	-	-	177		(100)%	498	1,652	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Misoprostol for PAC Provided	-	-	-	-	-		-%	18	36	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	177		(100)%	480	1,616	-	-	-
Misoprostol for Safe Abortion	-	-	-	-	(1,344)		0%	(3,852)	(8,396)	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(1,344)		-%	(3,852)	(8,396)	-	-	-
OCs	-	-	-	-	1,425		(100)%	1,425	394,086	-	-	-
Family Planning Pills	-	-	-	-	1,425	11/11	(100)%	1,425	394,086	-	-	-
PUR	-	-	-	-	3,840		(100)%	3,840	40,563,780	-	-	-
PuR	-	-	-	-	3,840	10/04	(100)%	3,840	40,563,780	-	-	-
Referral to HIV Testing Services	5,749	5,685	11,101	50,000	-		0%	11,703	22,804	11,101	-	345
Referral to HIV Testing Services	5,749	5,685	11,101	50,000	-		-%	11,703	22,804	11,101	-	345
Referral to Linkage to HIV Care	3,760	3,594	9,928	16,561	-		0%	4,614	14,542	9,928	-	8,468
Referral to Linkage to HIV Care	3,760	3,594	9,928	16,561	-		-%	4,614	14,542	9,928	-	8,468
Tubal Ligation	-	-	-	-	10		(100)%	10	123	-	-	-
Tubal Ligation	-	-	-	-	10		(100)%	10	123	-	-	-
Zambia											50,000	131,331
Emergency Contraception Provided	-	-	-	-	-		0%	1	1	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	-	-		-%	1	1	-	-	-
Free Female Condom	-	-	-	13,000	-		0%	3,020	192,200	-	-	-
Free Female Condoms	-	-	-	13,000	-		-%	3,020	192,200	-	-	-
HIV Self-Testing Kit	13,325	26,000	53,325	-	46,300		15%	394,250	728,125	47,993	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	13,325	26,000	53,325	-	46,300		15%	394,250	728,125	47,993	-	-
Implant 3 Insertion	421	430	1,445	-	1,252		15%	4,567	6,909	1,445	3,613	3,646
Non-PSI Implant 3 Inserted	421	430	1,445	-	1,252		15%	4,567	6,909	1,445	3,613	3,646
Implant 4 Insertion	-	-	-	-	1		(100)%	1	117	-	-	-
Non-PSI Implant 4 Inserted	-	-	-	-	1		(100)%	1	117	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 5 Insertion	2,260	1,868	6,619	30,000	4,924		34%	24,703	54,462	6,619	25,152	24,987
Non-PSI Implant 5 Inserted	2,260	1,868	6,619	30,000	4,924		34%	24,703	54,462	6,619	25,152	24,987
Injectable 2 Provided	1,471	1,771	5,057	28,000	5,252		(4)%	19,835	34,478	843	843	624
Non-PSI Injectable 2 Provided	1,471	1,771	5,057	28,000	5,252		(4)%	19,835	34,478	843	843	624
Injectable 3-IM Provided	16,121	15,645	49,938	172,000	32,323		54%	157,477	290,849	12,485	12,485	9,249
Non-PSI Injectable 3 IM Provided	16,121	15,645	49,938	172,000	32,323		54%	157,477	290,849	12,485	12,485	9,249
IUD 10 Insertion	227	153	586	3,000	374		57%	2,175	4,704	586	2,696	2,565
Non-PSI IUD 10 Inserted	227	153	586	3,000	374		57%	2,175	4,704	586	2,696	2,565
IUS 5	1,100	-	1,100	-	-		0%	-	1,900	990	3,267	3,302
LNG-IUS	1,100	-	1,100	-	-		-%	-	1,900	990	3,267	3,302
IUS 5 Insertion	55	43	167	700	174		(4)%	595	940	167	551	557
Non-PSI IUS 5 Inserted	55	43	167	700	174		(4)%	595	940	167	551	557
OCs Provided	6,432	6,468	19,964	100,000	12,585		59%	64,379	117,757	1,331	1,331	1,040
Non-PSI OCs Provided	6,432	6,468	19,964	100,000	12,585		59%	64,379	117,757	1,331	1,331	1,040
Safe Water Solution	33,744	58,116	171,792	900,000	548,232		(69)%	930,072	35,967,227	94,603	-	367
Clorin	33,744	58,116	171,792	900,000	548,232		(69)%	930,072	35,967,227	94,603	-	367
Tubal Ligation	4	1	5	308	43		(88)%	308	484	5	50	43
Tubal Ligation	4	1	5	308	43		(88)%	308	484	5	50	43
Vasectomy	-	-	-	29	-		0%	-	-	-	-	-
Vasectomy	-	-	-	29	-		-%	-	-	-	-	-
Voluntary Medical Male Circumcision	3,460	4,879	11,383	45,000	4,417		158%	43,253	158,782	11,383	-	84,912
Voluntary Medical Male Circumcision	3,460	4,879	11,383	45,000	4,417		158%	43,253	158,782	11,383	-	84,912
Woman Condom	1,320	1,016	1,800	-	16,392		(89)%	97,728	141,360	13	13	37
MAXIMUM DIVA	1,320	1,016	1,800	-	16,392	4/16	(89)%	97,728	141,360	13	13	37
Zimbabwe											60,998	466,160

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Antiretroviral Treatment (Currently Enrolled)	9,238	9,449	28,056	66,103	22,666		24%	103,129	218,676	2,338	-	4,889
Antiretroviral Treatment (Currently Enrolled)	9,238	9,449	28,056	66,103	22,666		24%	103,129	218,676	2,338	-	4,889
Antiretroviral Treatment (Newly Enrolled)	401	319	1,093	3,012	1,245		(12)%	4,816	19,998	1,093	-	-
Antiretroviral Treatment (Newly Enrolled)	401	319	1,093	3,012	1,245		(12)%	4,816	19,998	1,093	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	443		(100)%	443	7,915	-	-	-
Cervical Cancer-HPV DNA and Cryotherapy	-	-	-	-	3		(100)%	3	3	-	-	-
Cervical Cancer-HPV DNA and Cryotherapy	-	-	-	-	3		(100)%	3	3	-	-	-
Cervical Cancer-VIA and Conization	21	19	51	290	17		200%	126	355	51	-	18
Cervical Cancer-VIA and Conization	21	19	51	290	17		200%	126	355	51	-	18
Cervical Cancer-VIA and Cryotherapy	49	33	119	307	109		9%	415	4,089	119	-	42
Cervical Cancer-VIA and Cryotherapy	49	33	119	307	109		9%	415	4,089	119	-	42
Cervical Cancer-VIA and Refer to any Treatment	13	3	22	-	6		267%	25	333	22	-	4
Cervical Cancer-VIA and Refer to any Treatment	13	3	22	-	6	1/15	267%	25	333	22	-	4
Cervical Cancer-VIA and Refer to Conization	-	4	6	290	5		20%	98	2,040	6	-	1
Cervical Cancer-VIA and Refer to Conization	-	4	6	290	5		20%	98	2,040	6	-	1
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	-		0%	10	459	-	-	-
Cervical Cancer-VIA and Refer to Cryotherapy	-	-	-	-	-	12/14	-%	10	459	-	-	-
Cervical Cancer-VIA/VILI Screening	2,125	1,500	5,099	18,793	4,691		9%	18,503	90,918	5,099	-	-
Cervical Cancer-VIA/VILI Screening	2,125	1,500	5,099	18,793	4,691		9%	18,503	90,918	5,099	-	-
Condom	2,112,410	1,549,100	5,000,850	18,000,000	2,832,360		77%	17,748,320	332,388,220	37,506	37,506	119,239
Protector Plus	343,040	348,073	884,040	3,600,000	695,640		27%	3,626,960	277,579,890	6,630	6,630	21,079
Protector Plus Flavors	1,769,370	1,201,027	4,116,810	14,400,000	2,136,720		93%	14,121,360	54,808,330	30,876	30,876	98,160
Emergency Contraception	14,030	6,752	21,454	-	13,281		62%	170,713	977,219	965	965	292
Pregnon	14,040	6,759	21,480	-	-	9/10	-%	160,767	884,442	967	967	292

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Emergency Contraception Distributed Provided	(10)	(7)	(26)	-	(9)		-%	(54)	(523)	(1)	(1)	-
Revoke-72	-	-	-	-	13,290	12/15	(100)%	10,000	93,300	-	-	-
Emergency Contraception Provided	10	10	31	-	16		94%	78	737	2	2	-
Non-PSI Emergency Contraception Provided	-	4	5	-	7		(29)%	24	214	-	-	-
PSI Emergency Contraception Provided	10	7	26	-	9		189%	54	523	1	1	-
Female Condom	1,200	-	1,200	380,000	87,040		(99)%	169,980	24,049,234	9	9	28
Care	1,200	-	1,200	380,000	87,040		(99)%	169,980	24,049,234	9	9	28
Free Female Condom	47,730	14,072	63,890	-	-		0%	224,000	625,890	479	479	1,503
(b)Care (Free Distribution)	47,730	14,072	63,890	-	-	12/11	-%	224,000	625,890	479	479	1,503
HIV Self-Testing Kit	-	78,676	-	-	-		0%	236,028	236,028	-	-	-
ORAQUICK HIV Self-Testing Kit (Pouch)	-	78,676	-	-	-		-%	236,028	236,028	-	-	-
HIV Testing Services	3,564	3,657	10,258	281,609	13,487		(24)%	48,959	2,549,656	10,258	-	680
VCT Individual (HIV-Negative)	2,514	2,518	7,003	264,340	8,355		(16)%	31,915	2,254,173	7,003	-	464
VCT Individual (HIV-Positive)	1,050	1,139	3,255	17,269	5,132		(37)%	17,044	295,483	3,255	-	216
Hypertension Diagnosis	16	27	72	-	83		(13)%	278	630	72	-	-
Hypertension Diagnosis	16	27	72	-	83		(13)%	278	630	72	-	-
Hypertension Screening	11,531	12,422	36,566	-	34,344		6%	142,029	512,819	36,566	-	-
Hypertension Screening	11,531	12,422	36,566	-	34,344		6%	142,029	512,819	36,566	-	-
Hypertension_Controlled Condition	3	6	15	-	24		(38)%	91	172	6	-	-
Hypertension_Controlled Condition	3	6	15	-	24		(38)%	91	172	6	-	-
Implant 3	(112)	(123)	(339)	-	(16)		0%	(483)	(3,163)	(305)	(763)	(412)
(b)PSI Implant 3 Distributed Inserted	(112)	(123)	(339)	-	(16)		-%	(483)	(3,163)	(305)	(763)	(412)
Implant 3 Insertion	466	332	1,111	2,452	30		3603%	1,151	11,318	1,111	2,778	1,502
Non-PSI Implant 3 Inserted	354	209	772	2,452	14	3/16	5,414%	668	8,155	772	1,930	1,043
PSI Implant 3 Inserted	112	123	339	-	16		2,019%	483	3,163	339	848	458

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 5	305	933	(413)	-	582		(171)%	1,797	78,169	(372)	(1,412)	(753)
Jadelle	1,000	1,500	1,500	-	1,600	9/09	(6)%	6,500	114,208	1,350	5,130	2,733
(b)PSI Implant 5 Distributed Inserted	(695)	(567)	(1,913)	-	(1,018)		-%	(4,703)	(36,039)	(1,722)	(6,542)	(3,486)
Implant 5 Insertion	1,487	1,148	3,971	12,496	1,878		111%	8,090	94,539	3,971	15,090	8,039
Non-PSI Implant 5 Inserted	792	581	2,058	12,496	860		139%	3,387	58,500	2,058	7,820	4,166
PSI Implant 5 Inserted	695	567	1,913	-	1,018		88%	4,703	36,039	1,913	7,269	3,873
Injectable 3-IM	(803)	(735)	(2,296)	-	5,505		(142)%	13,588	899,261	(517)	(517)	(205)
Depo-Provera	-	-	-	-	7,162	9/00	(100)%	26,562	724,283	-	-	-
Petogen	-	-	-	-	700	9/09	(100)%	700	230,835	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	(803)	(735)	(2,296)	-	(2,357)		-%	(13,674)	(55,857)	(517)	(517)	(205)
Injectable 3-IM Provided	4,481	4,203	12,724	52,468	9,264		37%	41,625	230,554	3,181	3,181	1,261
Non-PSI Injectable 3 IM Provided	3,678	3,468	10,428	52,468	6,907		51%	27,951	174,697	2,607	2,607	1,033
PSI Injectable 3 IM Provided	803	735	2,296	-	2,357		(3)%	13,674	55,857	574	574	228
IUD 10	(214)	(92)	(620)	-	(210)		0%	(934)	892	(558)	(2,567)	(1,312)
(b)PSI IUD 10 Distributed Inserted	(214)	(192)	(620)	-	(410)	3/16	-%	(1,684)	(9,849)	(558)	(2,567)	(1,312)
TCU 380A IUCD Copper T	-	100	-	-	200	4/12	(100)%	750	10,741	-	-	-
IUD 10 Insertion	283	233	750	1,776	410		83%	1,855	10,351	750	3,450	1,763
Non-PSI IUD 10 Inserted	69	41	130	1,776	-		-%	171	502	130	598	306
PSI IUD 10 Inserted	214	192	620	-	410	3/16	51%	1,684	9,849	620	2,852	1,458
IUD 5 Insertion	19	36	74	-	-		0%	80	154	74	244	132
Non-PSI IUD 5 Inserted	19	36	74	-	-		-%	80	154	74	244	132
IUS 5	(13)	1	(41)	(56)	(23)		0%	126	239	(37)	(122)	(66)
LNG-IUS	-	20	20	-	-		-%	270	615	18	59	32
(b)PSI IUS 5 Distributed Inserted	(13)	(19)	(61)	(56)	(23)		-%	(144)	(376)	(55)	(181)	(98)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUS 5 Insertion	13	21	68	56	23		196%	144	400	68	224	122
Non-PSI IUS 5 Inserted	-	2	7	-	-		-%	-	24	7	23	13
PSI IUS 5 Inserted	13	19	61	56	23		165%	144	376	61	201	109
Lubricant	77,050	40,850	151,850	-	34,750		337%	97,750	704,150	-	-	-
Personal lubricants water based 4.5 g	77,050	40,850	151,850	-	34,750	2/17	337%	97,750	704,150	-	-	-
OCs	(3,813)	(5,880)	(8,206)	-	(7,726)		0%	(36,058)	(22,730)	(492)	(492)	(206)
(b)PSI OCs Distributed Provided	(3,813)	(5,880)	(8,206)	-	(7,726)		-%	(43,258)	(283,879)	(492)	(492)	(206)
Secure POP	-	-	-	-	-	4/12	-%	7,200	261,149	-	-	-
OCs Provided	17,892	15,481	44,136	187,344	18,585		137%	102,704	1,048,479	2,942	2,942	1,230
Non-PSI OCs Provided	14,079	9,601	35,930	187,344	10,859		231%	59,446	764,600	2,395	2,395	1,002
PSI OCs Provided	3,813	5,880	8,206	-	7,726		6%	43,258	283,879	547	547	229
PrEP	3,111	3,434	10,120	35,027	5,558		82%	34,345	47,581	843	-	330
PrEP	3,111	3,434	10,120	35,027	5,558		82%	34,345	47,581	843	-	330
Referral to Advanced Cervical Cancer Treatment	-	3	10	136	5		100%	17	427	10	-	-
Referral to Advanced Cervical Cancer Treatment	-	3	10	136	5		100%	17	427	10	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	26		(100)%	67	67	-	-	-
Referral to Diabetes Management (gestational)	-	-	-	-	26		(100)%	67	67	-	-	-
Referral to Hypertension Management	29	26	71	-	52		37%	564	1,156	71	-	-
Referral to Hypertension Management	29	26	71	-	52		37%	564	1,156	71	-	-
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 3 Insertion	-	-	-	-	2		(100)%	2	11	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2		(100)%	2	992	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	2	12/13	(100)%	2	992	-	-	-
Referral to Injectable 3	-	-	-	-	20		(100)%	20	770	-	-	-
Referral to Injectable 3	-	-	-	-	20		(100)%	20	770	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to IUD 10 Insertion	-	-	-	-	5		(100)%	5	209	-	-	-
Referral to IUD 10 Insertion	-	-	-	-	5	12/13	(100)%	5	209	-	-	-
Referral to Linkage to HIV Care	542	726	1,956	-	2,651		(26)%	9,056	19,188	1,956	-	1,083
Referral to Linkage to HIV Care	542	726	1,956	-	2,651		(26)%	9,056	19,188	1,956	-	1,083
Referral to OCs	-	-	-	-	17		(100)%	17	868	-	-	-
Referral to OCs	-	-	-	-	17	1/15	(100)%	17	868	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	-	-	2		(100)%	20	250	-	-	-
Referral to Pre-Exposure Prophylaxis (PrEP)	-	-	-	-	2		(100)%	20	250	-	-	-
Referral to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referrals to STI Screening (syndromic)	-	-	-	-	3		(100)%	3	105	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	2		(100)%	93	2,337	-	-	-
Referral to STI Treatment (unknown)	-	-	-	-	2	1/15	(100)%	93	2,337	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-
Referral to TB Diagnosis	-	-	-	-	11		(100)%	11	255	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	-		0%	2	19	-	-	-
Referral to TB DOTS (completion confirmed)	-	-	-	-	-		-%	2	19	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	50		(100)%	74	2,704	-	-	-
Referral to TB DOTS (completion unknown)	-	-	-	-	50	12/13	(100)%	74	2,704	-	-	-
Referral to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-
Referrals to TB Screening	-	-	-	-	1		(100)%	1	12,337	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	45		(100)%	47	116	-	-	-
Referral to Treatment for Cervicitis	-	-	-	-	45	1/15	(100)%	47	116	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-		0%	3	6	-	-	-
Referral to Treatment for Genital Herpes	-	-	-	-	-		-%	3	6	-	-	-
Referral to Treatment for Inguinal Bubo	-	-	-	-	-		0%	2	2	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Treatment for Inguinal Bubo	-	-	-	-	-		-%	2	2	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	-		0%	1	28	-	-	-
Referral to Treatment for Lower Abdominal Pain	-	-	-	-	-		-%	1	28	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	1		(100)%	53	113	-	-	-
Referral to Treatment for Urethral Discharge (Men)	-	-	-	-	1		(100)%	53	113	-	-	-
Referral to Tubal Ligation	-	-	-	-	-		0%	2	3	-	-	-
Referral to Tubal Ligation	-	-	-	-	-		-%	2	3	-	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	3		(67)%	25	73	1	-	-
Referral to Tx for Nonherpetic Genital Ulcer	-	-	1	-	3		(67)%	25	73	1	-	-
Referral to Tx for Urethral Discharge (Women)	-	1	4	-	18		(78)%	48	551	4	-	-
Referral to Tx for Urethral Discharge (Women)	-	1	4	-	18		(78)%	48	551	4	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	84		(100)%	120	10,815	-	-	-
Referral to Voluntary Medical Male Circumcision	-	-	-	-	84	12/14	(100)%	120	10,815	-	-	-
Safe Water Solution	-	-	-	-	-		0%	132,805	780,659	-	-	-
WaterGuard Solution 150mL SI	-	-	-	-	-	4/14	-%	132,805	780,659	-	-	-
STI Screening	4,206	4,154	16,566	-	310		5244%	1,460	27,364	16,566	-	-
STI Screening	4,206	4,154	16,566	-	310		5,244%	1,460	27,364	16,566	-	-
TB Diagnosis	13	10	39	-	63		(38)%	242	1,430	39	-	-
TB Diagnosis	13	10	39	-	63		(38)%	242	1,430	39	-	-
TB DOTS	-	-	-	-	2		(100)%	4	54	-	-	-
TB DOTS	-	-	-	-	2	7/14	(100)%	4	54	-	-	-
TB Screening	10,760	10,896	32,894	-	34,978		(6)%	134,977	936,852	32,894	-	-
TB Screening	10,760	10,896	32,894	-	34,978		(6)%	134,977	936,852	32,894	-	-
Treatment for Cervicitis	1	10	17	-	5		240%	73	380	17	-	2
Treatment for Cervicitis	1	10	17	-	5		240%	73	380	17	-	2

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Genital Herpes	1	-	1	-	4		(75)%	11	37	1	-	-
Treatment for Genital Herpes	1	-	1	-	4		(75)%	11	37	1	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		0%	2	12	-	-	-
Treatment for Inguinal Bubo	-	-	-	-	-		-%	2	12	-	-	-
Treatment for Lower Abdominal Pain	2	1	4	-	8		(50)%	20	41	4	-	-
Treatment for Lower Abdominal Pain	2	1	4	-	8		(50)%	20	41	4	-	-
Treatment for Nonherpetic Genital Ulcer	81	31	150	-	84		79%	436	986	150	-	54
Treatment for Nonherpetic Genital Ulcer	81	31	150	-	84		79%	436	986	150	-	54
Treatment for Urethral Discharge (Men)	18	9	35	-	23		52%	92	378	70	-	4
Treatment for Urethral Discharge (Men)	18	9	35	-	23		52%	92	378	70	-	4
Treatment for Urethral Discharge (Women)	81	41	168	-	110		53%	493	1,611	168	-	31
Treatment for Urethral Discharge (Women)	81	41	168	-	110		53%	493	1,611	168	-	31
Treatment for Vaginitis	-	2	6	-	3		100%	10	17	6	-	1
Treatment for Vaginitis	-	2	6	-	3		100%	10	17	6	-	1
Type 2 Diabetes Diagnosis	-	-	-	-	-		0%	3	8	-	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	-		-%	3	8	-	-	-
Type 2 Diabetes Screening	38	203	126	-	1,452		(91)%	5,658	11,860	126	-	-
Type 2 Diabetes Screening	38	203	126	-	1,452		(91)%	5,658	11,860	126	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	1		(100)%	6	12	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	-	-	1		(100)%	6	12	-	-	-
Voluntary Medical Male Circumcision	19,171	12,647	48,239	200,000	58,459		(17)%	243,971	510,904	48,239	-	326,862
Voluntary Medical Male Circumcision	19,171	12,647	48,239	200,000	58,459		(17)%	243,971	510,904	48,239	-	326,862

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Franco/Lusophone Africa Africa Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 3/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Franco/Lusophone Africa Market Gro	2,170	1	-	-	368,483	509	147,579	908	82	-	-	4,563
Angola	80	-	-	-	19,709	22	7,024	720	6	-	-	927
Benin	86	-	-	-	63,191	70	27,231	-	32	-	-	551
Burundi	281	1	-	-	13,988	21	4,419	183	-	-	-	315
Cameroon	998	-	-	-	133,244	196	50,276	4	18	-	-	1,260
Cote d'Ivoire	-	-	-	-	42,094	75	19,605	-	5	-	-	407
Mozambique	660	-	-	-	63,350	63	25,422	-	17	-	-	752
Niger	6	-	-	-	17,512	26	7,648	-	-	-	-	224
PSI Benin	-	-	-	-	5,382	30	2,430	-	-	-	-	69
Senegal	60	-	-	-	10,012	6	3,524	1	3	-	-	59

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 3
 Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group										368,483	454,257
Acute Malnutrition Screening_CU5	-	-	-	312	418	(100)%	518	1,895	-	-	-
Antiretroviral Treatment (Currently Enrolled)	2,998	2,929	8,841	7,723	2,004	341%	19,016	34,487	737	-	1,666
Antiretroviral Treatment (Newly Enrolled)	104	41	172	1,396	146	18%	1,807	2,393	172	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	122	(100)%	122	1,327	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	1	1	-	12	(92)%	48	375	1	-	-
Cervical Cancer-VIA/VILI Screening	1,269	2,539	3,797	-	6,897	(45)%	50,592	155,272	3,797	-	-
Condom	2,372,580	4,736,692	10,789,126	59,938,298	10,661,097	1%	51,030,685	330,856,443	80,918	80,918	128,052
Counseling & Tx for Moderate Acute Malnutrition	-	-	-	4	-	-%	-	-	-	-	-
Diarrhea Treatment Kit	30,609	19,381	61,906	424,000	68,785	(10)%	431,332	4,197,435	55,715	-	3,502
Emergency Contraception	7,252	6,025	21,867	255,200	81,860	(73)%	135,874	192,810	984	984	589
Emergency Contraception Provided	322	367	1,061	3,000	398	167%	2,877	4,464	53	53	33
Fecal Sludge Management (Households)	35	107	99	-	99	-%	1,374	1,473	505	-	-
Fecal Sludge Management (Liters)	725,000	621,000	1,957,000	13,559,190	606,000	223%	5,110,000	7,067,000	-	-	212
Female Condom	22,984	260,110	617,774	1,160,132	168,881	266%	1,160,677	10,215,266	4,633	4,633	6,594
Fever Cases Attended	-	-	-	8,385	-	-%	14,143	26,907	-	-	-
Fever Cases Tested with RDTs	-	-	-	8,385	-	-%	14,143	42,041	-	-	-
Free Condom	31,000	23,605	62,100	5,193,631	257,016	(76)%	3,201,731	22,387,981	466	466	367
Free Female Condom	-	5,333	-	52,000	3,746	(100)%	49,536	260,329	-	-	-
HIV Testing Services	11,782	7,281	27,025	93,415	36,018	(25)%	106,415	1,008,154	27,025	-	292
Implant 3	1,427	1,308	2,508	(4,896)	5,467	(54)%	7,414	28,952	2,257	5,643	5,261
Implant 3 Insertion	4,355	3,366	11,282	27,532	1,871	503%	24,546	55,156	11,282	28,205	25,860

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Implant 4 Insertion	16	1	19	-	-	-%	2	39	19	61	36
Implant 5	5,407	689	5,086	29,052	128	3,873%	27,721	(611)	4,577	17,394	12,205
Implant 5 Insertion	9,917	4,867	19,023	71,842	12,119	57%	76,301	321,240	19,023	72,287	64,832
Injectable 2	(470)	3,092	(275)	20,016	7,882	(103)%	54,602	294,069	(41)	(41)	(22)
Injectable 2 Provided	705	1,124	3,061	50,000	3,275	(7)%	15,848	41,811	510	510	274
Injectable 3-IM	59,078	57,425	66,341	105,000	28,462	133%	272,940	352,606	14,927	14,927	10,235
Injectable 3-IM Provided	15,778	22,556	67,339	255,395	59,508	13%	272,082	679,341	16,835	16,835	12,928
Injectable 3-SC	7,369	4,768	17,424	31,480	470	3,607%	26,328	46,367	3,920	3,920	2,524
Injectable 3-SC Provided	5,723	4,520	13,553	39,163	-	-%	5,729	19,282	3,388	3,388	2,746
IUD 10	6,411	1,626	9,138	28,463	7,330	25%	29,864	221,545	8,224	37,831	31,698
IUD 10 Insertion	4,405	3,709	11,114	76,812	12,529	(11)%	73,738	265,756	11,114	51,124	44,408
LLIN	29,653	180,973	278,585	3,964,115	163,830	70%	4,602,963	31,138,705	451,308	-	32,831
Lubricant	-	3,611	855	-	11,545	(93)%	45,024	614,212	-	-	-
Malaria PPT (ACT)	95,239	17,168	138,651	320,000	181,549	(24)%	297,174	623,592	124,786	-	38,513
Malaria RDK	3,650	21,328	28,225	250,000	(1,015)	-%	177,919	1,120,846	25,403	-	-
Manual Vacuum Aspiration for PAC	190	331	600	1,918	278	116%	2,579	4,760	600	-	218
Manual Vacuum Aspiration for SA	58	75	144	507	32	350%	562	1,327	144	-	59
Medical Abortion	360	275	1,035	19,550	-	-%	215	1,250	932	-	376
Medical Abortion (Misoprostol) Provided	131	60	242	1,051	5	4,740%	309	551	242	-	88
Medical Abortion Provided	-	-	-	-	51	(100)%	51	136	-	-	-
Micronutrient Powder	83,240	26,650	161,360	35,000	550,612	(71)%	948,572	2,497,952	398	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for PAC Provided	145	280	461	2,222	211	118%	2,304	3,839	461	-	238
Misoprostol for Safe Abortion	42,212	50,876	119,155	424,360	107,551	11%	745,045	1,663,449	6,256	-	2,262
OCs	39,953	154,678	390,152	851,499	114,279	241%	1,347,096	6,060,861	23,409	23,409	17,463
OCs Provided	28,389	29,382	88,433	683,520	80,361	10%	367,827	1,035,454	5,896	5,896	5,103
Pneumonia PPT	-	(28)	-	-	(671)	-%	30,316	477,424	-	-	-
Positive RDTs	-	-	-	-	-	-%	13,716	40,358	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	-	-%	13,647	39,926	-	-	-
QAACTs Provided after Confirmatory Diagnosis	-	-	-	-	-	-%	13,647	13,647	-	-	-
Referral to HIV Testing Services	-	-	-	9,600	-	-%	-	-	-	-	-
Referral to Linkage to HIV Care	-	-	-	1,279	-	-%	-	-	-	-	-
Safe Water Solution	173,263	77,120	254,623	1,400,000	518,413	(51)%	870,831	6,360,353	209,279	-	1,092
SDM (Cycle Beads)	(5)	29	4	306	75	(95)%	1,533	48,033	4	5	4
SDM (Cycle Beads) Provided	11	8	22	2,550	16	38%	96	285	22	33	25
Seasonal Malaria Chemoprevention	-	-	-	990,000	-	-%	344,748	344,748	-	-	-
Skilled Birth Attendance	115	107	370	9,000	6,031	(94)%	9,160	26,705	370	-	469
STI Screening	629	760	2,355	-	2,176	8%	8,747	33,341	2,355	-	-
Toilets Sold	759	609	1,854	8,107	206	798%	4,017	5,870	12,677	-	306
Treatment for Cervicitis	-	2	6	-	-	-%	-	6	6	-	-
Treatment for Genital Herpes	3	47	127	-	1	12,600%	42	191	127	-	3
Treatment for Inguinal Bubo	2	4	8	-	6	33%	33	75	8	-	-
Treatment for Lower Abdominal Pain	60	80	234	-	124	89%	693	1,301	234	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Nonherpetic Genital Ulcer	128	87	295	-	206	43%	1,027	2,084	295	-	33
Treatment for Severe Acute Malnutrition	-	-	-	8	-	-%	-	-	-	-	-
Treatment for Urethral Discharge (Men)	133	182	566	-	390	45%	1,631	3,522	1,132	-	7
Treatment for Urethral Discharge (Women)	287	301	1,021	-	473	116%	2,054	4,546	1,021	-	24
Treatment for Vaginitis	-	-	-	-	1	(100)%	2	7	-	-	-
Tubal Ligation	-	34	-	-	-	-%	204	204	-	-	-
Vasectomy	-	17	-	-	-	-%	104	104	-	-	-
Water Treatment Tablets	1,898,200	1,887,440	6,212,820	20,485,262	3,437,510	81%	20,217,570	160,069,900	102,129	-	849

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Franco/Lusophone Africa Market Group											368,483	454,257
Angola											19,709	77,818
Condom	221,220	250,812	695,304	5,700,000	807,912		(14)%	3,793,904	15,715,815	5,215	5,215	6,290
Sensual Champagne	4,356	6,996	17,244	700,000	102,492		(83)%	314,100	701,964	129	129	156
Sensual Chocolate	92,880	91,776	272,448	1,250,000	168,012	12/12	62%	804,168	3,947,532	2,043	2,043	2,465
Sensual Maracuja	27,072	50,472	98,784	1,250,000	90,180		10%	631,476	1,368,504	741	741	894
Sensual Menta	-	-	-	1,250,000	231,444	12/12	(100)%	1,138,688	4,819,068	-	-	-
Sensual Morango	96,912	101,568	306,828	1,250,000	215,784	12/12	42%	905,472	4,878,747	2,301	2,301	2,776
Emergency Contraception	6,682	3,694	17,011	250,000	-		0%	45,514	62,525	765	765	474
Pronta	6,682	3,694	17,011	250,000	-		-%	45,514	62,525	765	765	474
Implant 5	4	3	9	1,000	1,055		(99)%	1,334	1,843	8	31	33
Jadelle	4	3	9	1,000	1,055	12/17	(99)%	1,334	1,843	8	31	33
IUD 10	674	62	(178)	-	(483)		0%	981	8,092	(160)	(737)	(767)
Copper T 380 A – ENOVA	674	668	720	15,000	1,741		(59)%	20,092	30,497	648	2,981	3,101
(b)PSI IUD 10 Distributed Inserted	-	(606)	(898)	(15,000)	(2,224)		-%	(19,111)	(22,405)	(808)	(3,718)	(3,867)
IUD 10 Insertion	-	606	898	15,000	2,224		(60)%	19,111	22,405	898	4,131	4,297
PSI IUD 10 Inserted	-	606	898	15,000	2,224		(60)%	19,111	22,405	898	4,131	4,297
LLIN	1,068	125,513	146,146	120,000	630		23098%	3,520,905	13,173,740	236,757	-	19,559
Generic LLINs	-	125,066	143,875	-	-	4/11	-%	3,409,889	12,303,308	233,078	-	19,255
Joia	1,068	447	2,271	20,000	630	11/04	260%	11,016	348,230	3,679	-	304
PermaNet	-	-	-	100,000	-	10/12	-%	100,000	522,202	-	-	-
Malaria PPT (ACT)	95,239	17,345	138,651	320,000	183,987		(25)%	281,787	520,584	124,786	-	38,513
ALU 20mg/120mg, 12's, 3-8Yrs (15-24Kg)	25,716	5,946	41,851	96,000	45,530	6/17	(8)%	59,156	130,434	37,666	-	11,625
ALU 20mg/120mg, 18's, 9-14Yrs (25-34Kg)	26,785	3,912	36,565	64,000	31,988	6/17	14%	89,660	141,070	32,909	-	10,157

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ALU 20mg/120mg, 24's, >14Yrs (>34Kg)	15,689	2,791	21,858	64,000	72,247	6/17	(70)%	85,439	134,543	19,672	-	6,072
ALU 20mg/120mg, 6's, >3Yrs (5-14Kg)	27,049	4,697	38,377	96,000	34,222	6/17	12%	47,532	114,537	34,539	-	10,660
Malaria RDK	3,650	21,333	28,225	250,000	-		0%	161,350	904,000	25,403	-	-
Bioline (RDT)	3,650	21,333	28,225	250,000	-	2/14	-%	161,350	904,000	25,403	-	-
Misoprostol for Safe Abortion	-	16,203	5,864	100,000	10,936		(46)%	195,208	448,000	308	-	150
ACE Miso (Misoprostol 200mcg tablet)	-	16,203	5,864	100,000	10,936	3/18	(46)%	195,208	448,000	308	-	150
OCs	2,499	56,989	171,736	190,000	6,942		2374%	123,041	316,428	10,304	10,304	8,836
MEURI	2,499	56,989	171,736	190,000	6,942		2,374%	123,041	316,428	10,304	10,304	8,836
Water Treatment Tablets	1,204,400	516,067	2,636,600	10,000,000	2,230,000		18%	7,883,400	70,751,062	43,341	-	433
Certeza Water Tabs	1,204,400	516,067	2,636,600	10,000,000	2,230,000	4/11	18%	7,883,400	70,751,062	43,341	-	433
Benin											63,191	47,974
Cervical Cancer-VIA and Cryotherapy	-	1	1	-	12		(92)%	48	375	1	-	-
Cervical Cancer-VIA and Cryotherapy	-	1	1	-	12	2/13	(92)%	48	375	1	-	-
Cervical Cancer-VIA/VILI Screening	1,269	2,539	3,797	-	6,897		(45)%	50,592	155,272	3,797	-	-
Cervical Cancer-VIA/VILI Screening	1,269	2,539	3,797	-	6,897		(45)%	50,592	155,272	3,797	-	-
Condom	656,022	328,151	1,364,910	7,300,000	1,282,320		6%	4,658,955	78,088,847	10,237	10,237	7,671
Kool	-	-	-	-	143,772	2/10	(100)%	176,099	16,803,302	-	-	-
Kool Banane	54,360	40,183	140,100	600,000	-		-%	360,744	500,844	1,051	1,051	787
Kool Fraise	56,190	39,903	141,090	750,000	-	4/18	-%	352,122	493,212	1,058	1,058	793
Kool Menthe	65,280	43,693	161,520	950,000	-		-%	407,334	568,854	1,211	1,211	908
Prudence Plus	480,192	204,372	922,200	5,000,000	1,138,548		(19)%	3,362,656	59,722,635	6,916	6,916	5,183
Diarrhea Treatment Kit	14,057	12,267	31,707	350,000	62,279		(49)%	399,297	3,387,182	28,536	-	1,986
Orasel Zinc DTK	14,057	12,267	31,707	350,000	62,279		(49)%	399,297	3,387,182	28,536	-	1,986
Fecal Sludge Management (Households)	-	80	-	-	22		(100)%	1,059	1,059	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Fecal Sludge Management (Households)	-	80	-	-	22		(100)%	1,059	1,059	-	-	-
Fecal Sludge Management (Liters)	246,000	200,000	474,000	7,868,190	42,000		1029%	1,743,000	2,217,000	-	-	68
Fecal Sludge Management (Liters)	246,000	200,000	474,000	7,868,190	42,000		1,029%	1,743,000	2,217,000	-	-	68
Female Condom	-	-	-	5,202	888		(100)%	9,985	33,646	-	-	-
Cupid	-	-	-	5,202	888		(100)%	9,985	33,646	-	-	-
Free Condom	31,000	22,139	58,800	3,000,000	-		0%	683,616	2,995,895	441	441	330
No Logo	31,000	22,139	58,800	3,000,000	-		-%	683,616	2,995,895	441	441	330
HIV Testing Services	2,513	2,884	10,469	40,171	16,559		(37)%	47,885	635,220	10,469	-	55
VCT Individual (HIV-Negative)	2,494	2,877	10,438	40,171	16,192		(36)%	47,316	628,077	10,438	-	55
VCT Individual (HIV-Positive)	19	7	31	-	367	1/10	(92)%	569	7,143	31	-	-
Implant 5	5,592	763	5,406	27,440	(745)		0%	28,303	2,196	4,865	18,489	13,213
Implant 5 (insertion)	6,060	1,307	7,000	35,000	1,360		415%	37,266	136,637	6,300	23,940	17,109
(b)PSI Implant 5 Distributed Inserted	(468)	(544)	(1,594)	(7,560)	(2,105)		-%	(8,963)	(134,441)	(1,435)	(5,451)	(3,896)
Implant 5 Insertion	2,502	1,331	4,006	22,060	3,638		10%	38,442	196,626	4,006	15,223	10,879
Non-PSI Implant 5 Inserted	2,034	787	2,412	14,410	1,533		57%	29,479	62,185	2,412	9,166	6,550
PSI Implant 5 Inserted	468	544	1,594	7,650	2,105		(24)%	8,963	134,441	1,594	6,057	4,329
Injectable 2	(470)	3,092	(275)	20,016	7,882		(103)%	54,602	294,069	(41)	(41)	(22)
Noristerat	-	3,784	1,856	65,016	10,045		(82)%	62,728	320,637	278	278	149
(b)PSI Injectable 2 Distributed Provided	(470)	(692)	(2,131)	(45,000)	(2,163)		-%	(8,126)	(26,568)	(320)	(320)	(171)
Injectable 2 Provided	643	926	2,774	50,000	3,213		(14)%	14,475	40,151	462	462	247
Non-PSI Injectable 2 Provided	173	234	643	5,000	1,050		(39)%	6,349	13,583	107	107	57
PSI Injectable 2 Provided	470	692	2,131	45,000	2,163		(1)%	8,126	26,568	355	355	189
Injectable 3-SC	3,633	50	3,783	10,000	-		0%	-	3,783	851	851	454
(b)PSI Injectable 3 SC Distributed Provided	(146)	-	(146)	-	-		-%	-	(146)	(33)	(33)	(18)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Sayana Press	3,779	50	3,929	10,000	-		-%	-	3,929	884	884	472
Injectable 3-SC Provided	146	-	146	-	-		0%	-	146	37	37	19
PSI Injectable 3 SC Provided	146	-	146	-	-		-%	-	146	37	37	19
IUD 10	1,725	(441)	536	10,487	(3,193)		0%	(6,402)	45,862	482	2,219	1,518
IUD (insertion)	-	-	-	-	100	12/09	(100)%	1,109	13,420	-	-	-
IUD Copper-T TCU 380A	2,350	317	2,470	14,000	50		4,840%	7,435	141,478	2,223	10,226	6,997
(b)PSI IUD 10 Distributed Inserted	(625)	(758)	(1,934)	(3,513)	(3,343)		-%	(14,946)	(109,036)	(1,741)	(8,007)	(5,478)
IUD 10 Insertion	1,925	867	3,308	10,513	3,618		(9)%	20,070	121,643	3,308	15,217	10,412
Non-PSI IUD 10 Inserted	1,300	109	1,374	7,000	275		400%	5,124	12,607	1,374	6,320	4,325
PSI IUD 10 Inserted	625	758	1,934	3,513	3,343		(42)%	14,946	109,036	1,934	8,896	6,087
LLIN	-	-	-	-	129		(100)%	5,018	734,451	-	-	-
Super Moustiquaire Longue Durée	-	-	-	-	42	5/06	(100)%	4,808	730,601	-	-	-
SuperMoustiquaire (blanche 1 place)	-	-	-	-	87	9/15	(100)%	210	3,850	-	-	-
Lubricant	-	3,307	-	-	-		0%	9,920	485,348	-	-	-
Gel Lubricant 5 mL	-	3,307	-	-	-	12/16	-%	9,920	485,348	-	-	-
Manual Vacuum Aspiration for PAC	57	104	283	-	-		0%	803	2,253	283	-	90
MVA for PAC	57	104	283	-	-	10/16	-%	803	2,253	283	-	90
Manual Vacuum Aspiration for SA	17	28	87	-	-		0%	211	919	87	-	34
Manual Vacuum Aspiration for SA	17	28	87	-	-		-%	211	919	87	-	34
Medical Abortion (Misoprostol) Provided	3	16	44	-	-		0%	93	137	44	-	15
PSI Medical Abortion (Misoprostol) Provided	3	16	44	-	-		-%	93	137	44	-	15
Misoprostol for PAC Provided	35	55	165	-	-		0%	459	901	165	-	63
PSI Misoprostol for PAC Provided	35	55	165	-	-		-%	459	901	165	-	63
Misoprostol for Safe Abortion	(176)	(408)	(1,188)	-	-		0%	(2,952)	(5,248)	(62)	-	(21)
(b)PSI Misoprostol for Safe Abortion Dist Provided	(176)	(408)	(1,188)	-	-		-%	(2,952)	(5,248)	(62)	-	(21)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs	(153)	(253)	(790)	70,934	37,473		(102)%	215,192	1,296,335	(47)	(47)	(27)
Laafia Pilule	-	20	-	300,434	38,205		(100)%	218,541	1,325,594	-	-	-
(b)PSI OCs Distributed Provided	(153)	(273)	(790)	(229,500)	(732)		-%	(3,349)	(29,259)	(47)	(47)	(27)
OCs Provided	248	318	988	255,000	874		13%	5,041	32,564	66	66	37
Non-PSI OCs Provided	95	45	198	25,500	142		39%	1,692	3,305	13	13	7
PSI OCs Provided	153	273	790	229,500	732		8%	3,349	29,259	53	53	30
SDM (Cycle Beads)	(5)	29	4	306	75		(95)%	1,520	37,326	4	5	4
CycleBeads	2	37	22	2,601	89		(75)%	1,612	37,592	20	30	23
(b)PSI SDM (Cycle Beads) Distributed Provided	(7)	(8)	(18)	(2,295)	(14)		-%	(92)	(266)	(16)	(24)	(19)
SDM (Cycle Beads) Provided	11	8	22	2,550	16		38%	96	285	22	33	25
Non-PSI SDM (Cycle Beads) Provided	4	-	4	255	2		100%	4	19	4	6	5
PSI SDM (Cycle Beads) Provided	7	8	18	2,295	14		29%	92	266	18	27	21
Skilled Birth Attendance	115	107	370	9,000	6,031		(94)%	9,160	26,705	370	-	469
Skilled Birth Attendance	115	107	370	9,000	6,031		(94)%	9,160	26,705	370	-	469
STI Screening	157	236	775	-	975		(21)%	3,265	19,557	775	-	-
STI Screening	157	236	775	-	975		(21)%	3,265	19,557	775	-	-
Toilets Sold	146	129	343	3,428	206		66%	2,776	3,119	1,713	-	86
Toilets Sold	146	129	343	3,428	206		66%	2,776	3,119	1,713	-	86
Treatment for Cervicitis	-	2	6	-	-		0%	-	6	6	-	-
Treatment for Cervicitis	-	2	6	-	-		-%	-	6	6	-	-
Treatment for Genital Herpes	1	7	22	-	-		0%	-	22	22	-	-
Treatment for Genital Herpes	1	7	22	-	-		-%	-	22	22	-	-
Treatment for Lower Abdominal Pain	7	7	27	-	-		0%	-	27	27	-	-
Treatment for Lower Abdominal Pain	7	7	27	-	-		-%	-	27	27	-	-
Treatment for Nonherpetic Genital Ulcer	28	16	76	-	-		0%	-	76	76	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Nonherpetic Genital Ulcer	28	16	76	-	-		-%	-	76	76	-	-
Treatment for Urethral Discharge (Men)	16	35	121	-	-		0%	-	237	242	-	1
Treatment for Urethral Discharge (Men)	16	35	121	-	-		-%	-	237	242	-	1
Treatment for Urethral Discharge (Women)	89	112	425	-	-		0%	-	563	425	-	5
Treatment for Urethral Discharge (Women)	89	112	425	-	-		-%	-	563	425	-	5
Water Treatment Tablets	580,000	964,867	2,770,300	8,605,083	783,100		254%	8,283,060	76,821,830	45,539	-	361
Aquatab	580,000	964,867	2,770,300	8,605,083	783,100		254%	8,283,060	76,821,830	45,539	-	361
Burundi											13,988	34,764
Antiretroviral Treatment (Currently Enrolled)	2,371	2,304	6,963	2,500	1,466		375%	10,802	24,395	580	-	1,308
Antiretroviral Treatment (Currently Enrolled)	2,371	2,304	6,963	2,500	1,466		375%	10,802	24,395	580	-	1,308
Antiretroviral Treatment (Newly Enrolled)	103	40	169	443	46		267%	1,346	1,929	169	-	-
Antiretroviral Treatment (Newly Enrolled)	103	40	169	443	46		267%	1,346	1,929	169	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	56		(100)%	56	539	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	56		(100)%	56	539	-	-	-
Condom	2,700	683,970	1,361,340	3,500,000	599,940		127%	5,134,060	30,524,053	10,210	10,210	16,731
Prudence Class	2,700	683,970	1,361,340	3,500,000	599,940		127%	5,134,060	30,524,053	10,210	10,210	16,731
Emergency Contraception	134	15	222	1,000	369		(40)%	3,720	4,242	10	10	6
Nowill	400	307	1,071	4,000	590		82%	5,699	7,229	48	48	30
(b)PSI Emergency Contraception Distributed Provided	(266)	(292)	(849)	(3,000)	(221)		-%	(1,979)	(2,987)	(38)	(38)	(24)
Emergency Contraception Provided	266	292	849	3,000	221		284%	1,979	2,987	42	42	27
PSI Emergency Contraception Provided	266	292	849	3,000	221		284%	1,979	2,987	42	42	27
Free Condom	-	-	-	1,500,000	-		0%	1,000,800	10,271,216	-	-	-
Free Male Condoms	-	-	-	1,500,000	-		-%	1,000,800	10,271,216	-	-	-
Free Female Condom	-	-	-	40,000	-		0%	16,000	160,930	-	-	-
Free Female Condoms	-	-	-	40,000	-		-%	16,000	160,930	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
HIV Testing Services	2,555	2,133	6,961	22,923	7,215		(4)%	24,249	137,994	6,961	-	46
VCT Individual (HIV-Negative)	2,452	2,084	6,770	22,449	7,097		(5)%	23,617	135,818	6,770	-	45
VCT Individual (HIV-Positive)	103	50	191	474	118		62%	632	2,176	191	-	1
Implant 5	(38)	-	(21)	500	23		(191)%	88	1,062	(19)	(72)	(79)
Jadelle	65	93	274	2,000	355		(23)%	1,413	6,032	247	937	1,033
(b)PSI Implant 5 Distributed Inserted	(103)	(93)	(295)	(1,500)	(332)		-%	(1,325)	(4,970)	(266)	(1,009)	(1,112)
Implant 5 Insertion	103	93	295	1,500	332		(11)%	1,325	4,970	295	1,121	1,235
PSI Implant 5 Inserted	103	93	295	1,500	332		(11)%	1,325	4,970	295	1,121	1,235
Injectable 3-IM	(921)	555	91	3,000	431		(79)%	2,296	11,757	20	20	17
DMPA 3-month Injectable	1,200	2,580	6,181	20,000	5,120		21%	23,387	72,070	1,391	1,391	1,147
(b)PSI Injectable 3 IM Distributed Provided	(2,121)	(2,025)	(6,090)	(17,000)	(4,689)		-%	(21,091)	(60,313)	(1,370)	(1,370)	(1,130)
Injectable 3-IM Provided	2,121	2,025	6,090	17,000	4,689		30%	21,091	60,313	1,523	1,523	1,255
PSI Injectable 3 IM Provided	2,121	2,025	6,090	17,000	4,689		30%	21,091	60,313	1,523	1,523	1,255
IUD 10	66	21	94	400	33		185%	126	1,374	85	389	410
Copper-T 380-A IUD	100	56	212	1,000	172		23%	670	3,166	191	878	925
(b)PSI IUD 10 Distributed Inserted	(34)	(36)	(118)	(600)	(139)		-%	(544)	(1,792)	(106)	(489)	(515)
IUD 10 Insertion	34	36	118	600	139		(15)%	544	1,792	118	543	572
PSI IUD 10 Inserted	34	36	118	600	139		(15)%	544	1,792	118	543	572
LLIN	28,350	53,144	128,500	704,115	156,250		(18)%	790,442	8,025,687	208,170	-	12,919
MII Permant Free	-	-	-	704,115	-		-%	-	6,624,958	-	-	-
MIILDA - DAWA PLUS 2.0	28,350	53,144	128,500	-	156,250	5/17	(18)%	790,442	1,400,729	208,170	-	12,919
Manual Vacuum Aspiration for PAC	14	15	40	80	18		122%	66	193	40	-	25
MVA for PAC	14	15	40	80	18		122%	66	193	40	-	25
Misoprostol for PAC Provided	22	35	81	500	27		200%	179	423	81	-	60
PSI Misoprostol for PAC Provided	22	35	81	500	27		200%	179	423	81	-	60

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for Safe Abortion	(8)	(77)	(84)	-	487		(117)%	779	1,783	(4)	-	(3)
Misoprostol for Safe Abortion	80	63	240	2,000	595		(60)%	1,495	3,475	13	-	8
(b)PSI Misoprostol for Safe Abortion Dist Provided	(88)	(140)	(324)	(2,000)	(108)		-%	(716)	(1,692)	(17)	-	(11)
OCs	(372)	527	540	5,000	945		(43)%	4,428	19,531	32	32	28
Confiance OC	-	1,600	3,081	15,000	3,612		(15)%	16,422	54,666	185	185	161
(b)PSI OCs Distributed Provided	(372)	(1,073)	(2,541)	(10,000)	(2,667)		-%	(11,994)	(35,135)	(152)	(152)	(133)
OCs Provided	372	1,073	2,541	10,000	2,667		(5)%	11,994	35,135	169	169	147
PSI OCs Provided	372	1,073	2,541	10,000	2,667		(5)%	11,994	35,135	169	169	147
STI Screening	472	524	1,580	-	1,201		32%	5,482	13,784	1,580	-	-
STI Screening	472	524	1,580	-	1,201		32%	5,482	13,784	1,580	-	-
Treatment for Genital Herpes	2	40	105	-	1		10400%	42	169	105	-	3
Treatment for Genital Herpes	2	40	105	-	1		10,400%	42	169	105	-	3
Treatment for Inguinal Bubo	2	4	8	-	6		33%	33	75	8	-	-
Treatment for Inguinal Bubo	2	4	8	-	6		33%	33	75	8	-	-
Treatment for Lower Abdominal Pain	53	74	207	-	124		67%	693	1,274	207	-	-
Treatment for Lower Abdominal Pain	53	74	207	-	124		67%	693	1,274	207	-	-
Treatment for Nonherpetic Genital Ulcer	100	71	219	-	206		6%	1,027	2,008	219	-	33
Treatment for Nonherpetic Genital Ulcer	100	71	219	-	206		6%	1,027	2,008	219	-	33
Treatment for Urethral Discharge (Men)	117	147	445	-	390		14%	1,631	3,285	890	-	5
Treatment for Urethral Discharge (Men)	117	147	445	-	390		14%	1,631	3,285	890	-	5
Treatment for Urethral Discharge (Women)	198	189	596	-	473		26%	2,054	3,983	596	-	19
Treatment for Urethral Discharge (Women)	198	189	596	-	473		26%	2,054	3,983	596	-	19
Treatment for Vaginitis	-	-	-	-	1		(100)%	2	7	-	-	-
Treatment for Vaginitis	-	-	-	-	1		(100)%	2	7	-	-	-

Cameroon 133,244 143,431

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Condom	1,492,638	2,019,904	5,324,060	20,364,000	5,073,861		5%	18,305,203	76,756,767	39,930	39,930	59,699
Lovers Plus	-	(1,476)	-	-	(1,404)	1/15	-%	(15,109)	3,215,171	-	-	-
Préservatif Masculin Aromatisé UNFPA	-	-	-	41,000	-		-%	7,200	9,274	-	-	-
Préservatif Masculin UNFPA	27,168	577,929	1,041,756	323,000	-		-%	932,290	2,094,886	7,813	7,813	11,681
Prudence Plus Nouveau	1,465,470	1,443,451	4,282,304	20,000,000	5,075,265	1/15	(16)%	17,380,822	71,437,436	32,117	32,117	48,017
Diarrhea Treatment Kit	16,552	7,114	30,199	74,000	6,506		364%	32,035	810,253	27,179	-	1,516
Orasel Zinc	16,552	7,114	30,199	74,000	6,506		364%	32,035	810,253	27,179	-	1,516
Emergency Contraception	436	2,316	4,634	4,200	81,491		(94)%	86,640	126,043	209	209	109
Norlevo	438	2,321	4,645	4,200	81,496		(94)%	86,934	126,558	209	209	109
(b)PSI Emergency Contraception Distributed Provided	(2)	(4)	(11)	-	(5)		-%	(294)	(515)	-	-	-
Emergency Contraception Provided	2	4	11	-	9		22%	307	533	1	1	-
Non-PSI Emergency Contraception Provided	-	-	-	-	4		(100)%	13	18	-	-	-
PSI Emergency Contraception Provided	2	4	11	-	5		120%	294	515	1	1	-
Female Condom	22,984	260,110	617,774	1,154,930	167,993		268%	1,150,692	10,181,620	4,633	4,633	6,594
Préservatif Féminin CUPID	-	-	-	-	151,364	7/14	(100)%	160,327	1,125,022	-	-	-
Préservatif Féminins UNFPA	11,130	2,033	15,090	608,930	5,285	3/15	186%	26,300	845,509	113	113	161
Protectiv	-	-	-	546,000	-	11/02	-%	-	4,184,561	-	-	-
Protectiv Plus	11,000	43,067	140,200	-	-	4/14	-%	-	1,098,357	1,051	1,051	1,496
Securite Plus Female Condom	854	215,010	462,484	-	11,344	11/13	3,977%	964,065	2,928,171	3,469	3,469	4,936
Fever Cases Attended	-	-	-	8,385	-		0%	14,143	26,907	-	-	-
Fever Cases Attended	-	-	-	8,385	-		-%	14,143	26,907	-	-	-
Fever Cases Tested with RDTs	-	-	-	8,385	-		0%	14,143	42,041	-	-	-
Fever Cases Tested with RDTs	-	-	-	8,385	-		-%	14,143	42,041	-	-	-
Free Condom	-	1,467	3,300	-	32,780		(90)%	419,155	1,350,160	25	25	37

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Generic MC	-	1,467	3,300	-	32,780	11/16	(90)%	419,155	1,350,160	25	25	37
Free Female Condom	-	5,333	-	-	-		0%	23,300	26,400	-	-	-
Generic FC	-	5,333	-	-	-	1/08	-%	23,300	26,400	-	-	-
HIV Testing Services	5,285	1,890	7,402	9,600	-		0%	5,827	74,445	7,402	-	173
VCT Individual (HIV-Negative)	5,198	1,862	7,247	9,380	-		-%	5,742	70,507	7,247	-	169
VCT Individual (HIV-Positive)	87	28	155	220	-		-%	85	3,938	155	-	4
Implant 3	1,427	1,308	2,508	(4,896)	5,467		(54)%	7,414	28,952	2,257	5,643	5,261
Implanon NXT	1,430	3,199	6,349	11,000	5,470		16%	22,089	60,625	5,714	14,285	13,318
(b)PSI Implant 3 Distributed Inserted	(3)	(1,892)	(3,841)	(15,896)	(3)		-%	(14,675)	(31,673)	(3,457)	(8,642)	(8,057)
Implant 3 Insertion	5	1,893	3,843	15,896	6		63950%	14,684	31,687	3,843	9,608	8,957
Non-PSI Implant 3 Inserted	2	2	2	-	3		(33)%	9	14	2	5	5
PSI Implant 3 Inserted	3	1,892	3,841	15,896	3		127,933%	14,675	31,673	3,841	9,603	8,952
Implant 5	(159)	(75)	(312)	-	(205)		0%	(1,373)	2,673	(281)	(1,067)	(978)
Jadelle UNFPA	-	-	-	-	550	3/15	(100)%	550	34,416	-	-	-
(b)PSI Implant 5 Distributed Inserted	(159)	(75)	(312)	-	(755)		-%	(1,923)	(31,743)	(281)	(1,067)	(978)
Implant 5 Insertion	207	93	378	-	1,416		(73)%	3,201	34,248	378	1,436	1,316
Non-PSI Implant 5 Inserted	48	18	66	-	661		(90)%	1,278	2,505	66	251	230
PSI Implant 5 Inserted	159	75	312	-	755		(59)%	1,923	31,743	312	1,186	1,086
Injectable 3-IM	59,931	4,850	66,182	102,000	31,389		111%	130,960	223,393	14,891	14,891	10,205
Equilibre	59,931	13,021	86,128	132,000	31,782		171%	170,812	310,542	19,379	19,379	13,281
(b)PSI Injectable 3 IM Distributed Provided	-	(8,170)	(19,946)	(30,000)	(393)		-%	(39,852)	(87,149)	(4,488)	(4,488)	(3,076)
Injectable 3-IM Provided	-	8,209	19,977	30,000	665		2904%	40,845	88,648	4,994	4,994	3,423
Non-PSI Injectable 3 IM Provided	-	39	31	-	272		(89)%	993	1,499	8	8	5
PSI Injectable 3 IM Provided	-	8,170	19,946	30,000	393		4,975%	39,852	87,149	4,987	4,987	3,417

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 3-SC	1,400	417	2,450	2,400	-		0%	3,476	5,926	551	551	378
Sayana Press	1,400	417	2,450	2,400	-	3/18	-%	3,476	5,926	551	551	378
IUD 10	3,496	1,459	7,314	16,220	8,463		(14)%	20,481	128,429	6,583	30,280	26,535
DIU UNFPA	-	-	-	11,000	2,077		(100)%	2,077	24,810	-	-	-
IUD	1,701	2,050	6,151	-	5,450	9/09	13%	25,200	159,373	5,536	25,465	22,315
IUD Copper T 380A	2,900	645	4,685	23,220	3,300		42%	12,066	34,661	4,217	19,396	16,997
(b)PSI IUD 10 Distributed Inserted	(1,105)	(1,236)	(3,522)	(18,000)	(2,364)		-%	(18,862)	(90,415)	(3,170)	(14,581)	(12,778)
IUD 10 Insertion	1,173	1,303	3,660	18,000	4,016		(9)%	21,794	94,714	3,660	16,836	14,754
Non-PSI IUD 10 Inserted	68	67	138	-	1,652		(92)%	2,932	4,299	138	635	556
PSI IUD 10 Inserted	1,105	1,236	3,522	18,000	2,364		49%	18,862	90,415	3,522	16,201	14,197
LLIN	235	821	1,914	2,975,000	5,673		(66)%	15,521	8,017,841	3,101	-	297
Super Moustiquaire	235	774	1,914	2,975,000	4,358		(56)%	9,665	8,011,941	3,101	-	297
Super Moustiquaire Interceptor	-	47	-	-	1,315	10/15	(100)%	5,856	5,900	-	-	-
Lubricant	-	304	855	-	4,501		(81)%	16,186	37,415	-	-	-
Lubricant 60 mL bottle	-	296	855	-	901	12/15	(5)%	6,061	16,415	-	-	-
Water-based Lubricant, 4 mL sachet	-	8	-	-	3,600	12/16	(100)%	10,125	21,000	-	-	-
Malaria PPT (ACT)	-	(203)	-	-	(5,571)		0%	15,227	109,448	-	-	-
ACT 1 (ASAQ 25 / 67.5 mg, 3 tablets)_2 -11 months	-	(26)	-	-	(3,133)	2/15	-%	(160)	6,440	-	-	-
ACT 2 (ASAQ 50 / 135.5 mg, 3 tablets)_1 - 5 years	-	(61)	-	-	(2,214)	2/15	-%	11,449	67,905	-	-	-
ACT 3 (ASAQ 100 / 270 mg, 3 tablets)_6 - 13 years	-	(59)	-	-	201	2/15	(100)%	1,685	17,250	-	-	-
ACT 4 (ASAQ 100 / 270 mg, 6 tablets)_14 years & up	-	(57)	-	-	(425)	2/15	-%	2,253	17,853	-	-	-
Malaria RDK	-	(5)	-	-	(1,015)		0%	16,569	216,846	-	-	-
Malaria Ag Pf/Pan_PA	-	(5)	-	-	(1,015)	12/12	-%	16,569	216,846	-	-	-
Manual Vacuum Aspiration for PAC	106	200	251	578	260		(3)%	1,309	1,887	251	-	88

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
MVA for PAC	106	200	251	578	260		(3)%	1,309	1,887	251	-	88
Manual Vacuum Aspiration for SA	41	46	57	426	32		78%	351	408	57	-	25
Manual Vacuum Aspiration for SA	41	46	57	426	32		78%	351	408	57	-	25
Medical Abortion	175	245	760	19,550	(43)		0%	172	872	684	-	283
Mifepack	175	245	760	19,550	-		-%	215	975	684	-	283
(b)PSI Medical Abortion Distributed Provided	-	-	-	-	(43)		-%	(43)	(103)	-	-	-
Medical Abortion (Misoprostol) Provided	128	45	198	868	5		3860%	216	414	198	-	73
Non-PSI Medical Abortion (Misoprostol) Provided	22	5	36	-	-		-%	24	60	36	-	13
PSI Medical Abortion (Misoprostol) Provided	106	40	162	868	5		3,140%	192	354	162	-	60
Medical Abortion Provided	-	-	-	-	51		(100)%	51	136	-	-	-
Non-PSI Medical Abortion Provided	-	-	-	-	8		(100)%	8	33	-	-	-
PSI Medical Abortion Provided	-	-	-	-	43		(100)%	43	103	-	-	-
Micronutrient Powder	83,240	26,650	161,360	35,000	550,612		(71)%	948,572	2,497,952	398	-	-
Super Bebe	83,240	26,650	161,360	35,000	550,612		(71)%	948,572	2,497,952	398	-	-
Misoprostol for PAC Provided	38	164	108	594	184		(41)%	1,105	1,847	108	-	45
Non-PSI Misoprostol for PAC Provided	5	2	12	-	42		(71)%	183	195	12	-	5
PSI Misoprostol for PAC Provided	33	161	96	594	142		(32)%	922	1,652	96	-	40
Misoprostol for Safe Abortion	14,108	14,586	40,919	117,208	58,564		(30)%	243,174	783,454	2,148	-	795
Misoprostol for Safe Abortion	15,512	15,712	43,247	130,000	59,192		(27)%	249,166	794,310	2,270	-	841
(b)PSI Misoprostol for Safe Abortion Dist Provided	(1,404)	(1,125)	(2,328)	(12,792)	(628)		-%	(5,992)	(10,856)	(122)	-	(45)
OCs	38,062	14,830	85,473	85,000	41,126		108%	341,853	1,095,393	5,128	5,128	3,708
Microgynon Ed Fe	-	-	-	-	17,886	7/14	(100)%	19,981	478,173	-	-	-
Microlut	-	-	-	-	4,122	12/17	(100)%	5,001	5,001	-	-	-
Novelle Duo	38,062	16,533	87,660	100,000	19,194		357%	340,259	658,028	5,260	5,260	3,803

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI OCs Distributed Provided	-	(1,703)	(2,187)	(15,000)	(76)		-%	(23,388)	(45,809)	(131)	(131)	(95)
OCs Provided	-	1,706	2,187	15,000	182		1102%	23,718	46,334	146	146	105
Non-PSI OCs Provided	-	3	-	-	106		(100)%	330	525	-	-	-
PSI OCs Provided	-	1,703	2,187	15,000	76		2,778%	23,388	45,809	146	146	105
Pneumonia PPT	-	(28)	-	-	(671)		0%	30,316	477,424	-	-	-
Amoxicillin 500mg x 15's -- Children 1-5 years	-	-	-	-	-	1/13	-%	28,750	326,142	-	-	-
Amoxicillin 500mg x 7's - Children 2-11 months	-	(28)	-	-	(671)	1/13	-%	1,566	151,282	-	-	-
Positive RDTs	-	-	-	-	-		0%	13,716	40,358	-	-	-
Positive RDTs	-	-	-	-	-		-%	13,716	40,358	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	-		0%	13,647	39,926	-	-	-
Positive RDTs Given First Line Treatment	-	-	-	-	-		-%	13,647	39,926	-	-	-
QAACTs Provided after Confirmatory Diagnosis	-	-	-	-	-		0%	13,647	13,647	-	-	-
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	-	-	-		-%	13,647	13,647	-	-	-
Referral to HIV Testing Services	-	-	-	9,600	-		0%	-	-	-	-	-
Referral to HIV Testing Services	-	-	-	9,600	-		-%	-	-	-	-	-
Tubal Ligation	-	34	-	-	-		0%	204	204	-	-	-
Tubal Ligation	-	34	-	-	-		-%	204	204	-	-	-
Vasectomy	-	17	-	-	-		0%	104	104	-	-	-
Vasectomy	-	17	-	-	-		-%	104	104	-	-	-
Water Treatment Tablets	113,800	187,107	329,020	20,000	360,410		(9)%	2,071,710	2,554,442	5,409	-	34
Aquatabs 67 mg (20 L)	113,800	187,107	329,020	20,000	360,410		(9)%	2,071,710	2,554,442	5,409	-	34
Cote d'Ivoire											42,094	32,040
Antiretroviral Treatment (Currently Enrolled)	-	-	-	5,223	538		(100)%	7,589	7,589	-	-	-
Antiretroviral Treatment (Currently Enrolled)	-	-	-	5,223	538		(100)%	7,589	7,589	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	953	100		(100)%	460	460	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Antiretroviral Treatment (Newly Enrolled)	-	-	-	953	100		(100)%	460	460	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	66		(100)%	66	788	-	-	-
CD4 Tests Provided to HIV+ Clients	-	-	-	-	66		(100)%	66	788	-	-	-
Emergency Contraception Provided	-	1	-	-	-		0%	16	16	-	-	-
Non-PSI Emergency Contraception Provided	-	1	-	-	-		-%	16	16	-	-	-
Fecal Sludge Management (Households)	35	28	99	-	77		29%	315	414	505	-	-
Fecal Sludge Management (Households)	35	28	99	-	77		29%	315	414	505	-	-
Fecal Sludge Management (Liters)	479,000	421,000	1,483,000	5,691,000	564,000		163%	3,367,000	4,850,000	-	-	145
Fecal Sludge Management (Liters)	479,000	421,000	1,483,000	5,691,000	564,000		163%	3,367,000	4,850,000	-	-	145
Free Condom	-	-	-	393,631	217,612		(100)%	1,091,536	6,318,813	-	-	-
(b)Free Distribution	-	-	-	393,631	217,612	1/08	(100)%	1,091,536	6,318,813	-	-	-
Free Female Condom	-	-	-	12,000	3,746		(100)%	10,236	72,999	-	-	-
Female Condom Free	-	-	-	12,000	3,746	8/12	(100)%	10,236	72,999	-	-	-
HIV Testing Services	-	-	-	17,622	7,447		(100)%	13,282	126,485	-	-	-
VCT Individual (HIV-Negative)	-	-	-	16,343	6,981		(100)%	12,419	120,213	-	-	-
VCT Individual (HIV-Positive)	-	-	-	1,279	466		(100)%	863	6,272	-	-	-
Implant 3 Insertion	2,931	803	4,491	3,308	8		56038%	2,070	6,561	4,491	11,228	8,716
Non-PSI Implant 3 Inserted	2,931	803	4,491	3,308	8		56,038%	2,070	6,561	4,491	11,228	8,716
Implant 5 Insertion	4,759	892	6,883	17,956	1,090		531%	2,823	9,706	6,883	26,155	19,955
Non-PSI Implant 5 Inserted	4,759	892	6,883	17,956	1,090		531%	2,823	9,706	6,883	26,155	19,955
Injectable 2 Provided	62	198	287	-	62		363%	1,373	1,660	48	48	27
Non-PSI Injectable 2 Provided	62	198	287	-	62		363%	1,373	1,660	48	48	27
Injectable 3-IM Provided	3,020	800	5,590	7,144	1,174		376%	7,836	13,426	1,398	1,398	798
Non-PSI Injectable 3 IM Provided	3,020	800	5,590	7,144	1,174		376%	7,836	13,426	1,398	1,398	798
Injectable 3-SC Provided	896	562	1,324	9,808	-		0%	1,258	2,582	331	331	189

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 3 SC Provided	896	562	1,324	9,808	-		-%	1,258	2,582	331	331	189
IUD 10 Insertion	374	121	603	4,576	39		1446%	390	993	603	2,774	2,023
Non-PSI IUD 10 Inserted	374	121	603	4,576	39		1,446%	390	993	603	2,774	2,023
Lubricant	-	-	-	-	7,044		(100)%	18,918	91,449	-	-	-
Gel Lubricant 4.5 g	-	-	-	-	7,044	9/12	(100)%	18,918	91,449	-	-	-
OCs Provided	1,458	570	2,415	9,584	362		567%	4,743	7,158	161	161	97
Non-PSI OCs Provided	1,458	570	2,415	9,584	362		567%	4,743	7,158	161	161	97
Referral to Linkage to HIV Care	-	-	-	1,279	-		0%	-	-	-	-	-
Referral to Linkage to HIV Care	-	-	-	1,279	-		-%	-	-	-	-	-
Toilets Sold	221	171	493	679	-		0%	282	775	2,514	-	90
Toilets Sold	221	171	493	679	-		-%	282	775	2,514	-	90
Mozambique											63,350	87,719
Condom	-	1,129,488	1,668,744	17,000,000	2,794,476		(40)%	13,175,544	101,667,204	12,516	12,516	34,428
J0.1	-	284,640	853,920	1,700,000	144	10/17	592,900%	144	2,582,064	6,404	6,404	17,617
J1	-	559,608	814,824	5,100,000	922,080	10/12	(12)%	4,752,480	48,572,136	6,111	6,111	16,811
J14	-	-	-	1,700,000	-	4/14	-%	-	141,840	-	-	-
J18	-	-	-	1,700,000	-	4/18	-%	1,728,000	1,728,000	-	-	-
J2	-	-	-	1,700,000	95,688	10/12	(100)%	1,469,880	17,399,520	-	-	-
J24	-	-	-	-	1,727,928	10/17	(100)%	1,728,000	3,456,000	-	-	-
J3	-	285,240	-	5,100,000	1,368	10/12	(100)%	3,449,088	22,948,560	-	-	-
Jeito 4	-	-	-	-	44,136	11/13	(100)%	44,568	3,487,464	-	-	-
Jeito 5	-	-	-	-	3,132	1/14	(100)%	3,384	1,351,620	-	-	-
Emergency Contraception Provided	54	70	201	-	168		20%	575	928	10	10	6
Non-PSI Emergency Contraception Provided	54	70	201	-	168		20%	575	928	10	10	6

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Free Condom	-	-	-	-	6,624		(100)%	6,624	697,377	-	-	-
No Logo Condom Lubricant Combo	-	-	-	-	6,624	5/15	(100)%	6,624	697,377	-	-	-
Implant 3 Insertion	-	-	-	-	9		(100)%	40	40	-	-	-
Non-PSI Implant 3 Inserted	-	-	-	-	9		(100)%	40	40	-	-	-
Implant 5	8	(1)	4	-	-		0%	(631)	(8,385)	4	14	15
Jadelle	161	294	750	-	695	12/15	8%	3,427	11,884	675	2,565	2,874
(b)PSI Implant 5 Distributed Inserted	(153)	(295)	(746)	-	(695)		-%	(4,058)	(20,269)	(671)	(2,551)	(2,859)
Implant 5 Insertion	2,064	2,296	6,787	24,990	5,261		29%	28,867	71,657	6,787	25,791	28,897
Non-PSI Implant 5 Inserted	1,911	2,001	6,041	24,990	4,566		32%	24,809	51,388	6,041	22,956	25,721
PSI Implant 5 Inserted	153	295	746	-	695		7%	4,058	20,269	746	2,835	3,176
Injectable 3-IM	68	52,019	68	-	(3,358)		0%	139,684	117,456	15	15	13
Enaf Injectable	556	52,522	1,467	-	1,303	6/13	13%	162,512	239,660	330	330	277
(b)PSI Injectable 3 IM Distributed Provided	(488)	(502)	(1,399)	-	(4,661)		-%	(22,828)	(122,204)	(315)	(315)	(264)
Injectable 3-IM Provided	6,642	8,203	23,780	156,870	44,235		(46)%	161,823	443,690	5,945	5,945	4,994
Non-PSI Injectable 3 IM Provided	6,154	7,701	22,381	156,870	39,574		(43)%	138,995	321,486	5,595	5,595	4,700
PSI Injectable 3 IM Provided	488	502	1,399	-	4,661		(70)%	22,828	122,204	350	350	294
Injectable 3-SC	2,336	1,421	6,439	-	-		0%	8,364	14,803	1,449	1,449	1,217
(b)PSI Injectable 3 SC Distributed Provided	(1,258)	(1,187)	(3,781)	-	-		-%	(1,038)	(4,819)	(851)	(851)	(715)
Sayana Press	3,594	2,608	10,220	-	-		-%	9,402	19,622	2,300	2,300	1,932
Injectable 3-SC Provided	4,574	3,958	11,976	29,355	-		0%	4,471	16,447	2,994	2,994	2,515
Non-PSI Injectable 3 SC Provided	3,316	2,771	8,195	29,355	-		-%	3,433	11,628	2,049	2,049	1,721
PSI Injectable 3 SC Provided	1,258	1,187	3,781	-	-		-%	1,038	4,819	945	945	794
IUD 10	-	24	72	-	-		0%	-	21,810	65	298	319
DIU Copper T 380A	-	24	72	-	-	1/15	-%	-	21,810	65	298	319
IUD 10 Insertion	531	635	1,814	14,055	1,361		33%	8,354	18,408	1,814	8,344	8,927

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 10 Inserted	531	635	1,814	14,055	1,361		33%	8,354	18,408	1,814	8,344	8,927
LLIN	-	-	-	-	695		(100)%	695	199,832	-	-	-
Serena	-	-	-	-	695	4/14	(100)%	695	199,832	-	-	-
OCs	(83)	15,625	46,793	-	1,007		4547%	(1,935)	44,506	2,808	2,808	2,488
Microginon Mobiz	-	-	-	-	1,666	5/15	(100)%	1,682	7,430	-	-	-
Microleenyn 30 Combined OC	1,563	3,735	9,773	-	7,786	6/13	26%	38,163	212,039	586	586	520
Progestyn OC	452	16,267	48,421	-	2,224	6/13	2,077%	10,218	138,127	2,905	2,905	2,575
(b)PSI OCs Distributed Provided	(2,098)	(4,377)	(11,401)	-	(10,669)		-%	(51,998)	(313,090)	(684)	(684)	(606)
OCs Provided	15,070	15,389	47,501	285,460	55,701		(15)%	223,704	711,201	3,167	3,167	2,806
Non-PSI OCs Provided	12,972	11,011	36,100	285,460	45,032		(20)%	171,706	398,111	2,407	2,407	2,133
PSI OCs Provided	2,098	4,377	11,401	-	10,669		7%	51,998	313,090	760	760	674
Safe Water Solution	173,263	77,120	254,623	1,400,000	518,413		(51)%	870,831	6,360,353	209,279	-	1,092
Certeza Commercial ISM	74,175	5,120	89,535	700,000	219,828		(59)%	323,748	3,077,550	73,590	-	384
Certeza Free ISM	99,088	72,000	165,088	700,000	298,585		(45)%	547,083	3,282,803	135,689	-	708
SDM (Cycle Beads)	-	-	-	-	-		0%	13	10,707	-	-	-
Missangas Ciclo	-	-	-	-	-	2/11	-%	13	10,707	-	-	-
Niger											17,512	18,579
Antiretroviral Treatment (Currently Enrolled)	627	625	1,878	-	-		0%	625	2,503	156	-	359
Antiretroviral Treatment (Currently Enrolled)	627	625	1,878	-	-		-%	625	2,503	156	-	359
Antiretroviral Treatment (Newly Enrolled)	1	1	3	-	-		0%	1	4	3	-	-
Antiretroviral Treatment (Newly Enrolled)	1	1	3	-	-		-%	1	4	3	-	-
Free Condom	-	-	-	300,000	-		0%	-	754,520	-	-	-
Generic Condom	-	-	-	300,000	-	6/16	-%	-	754,520	-	-	-
HIV Testing Services	1,429	374	2,193	3,008	4,501		(51)%	14,858	33,107	2,193	-	18

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
VCT Individual (HIV-Negative)	1,428	366	2,173	3,000	4,493		(52)%	14,820	32,439	2,173	-	17
VCT Individual (HIV-Positive)	1	8	20	8	8		150%	38	668	20	-	-
Implant 3	-	-	-	-	-		0%	(91)	(91)	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	-	-		-%	(91)	(91)	-	-	-
Implant 3 Insertion	1,404	642	2,861	8,287	1,822		57%	7,625	16,587	2,861	7,153	8,055
Non-PSI Implant 3 Inserted	1,404	642	2,861	8,287	1,822		57%	7,534	16,496	2,861	7,153	8,055
PSI Implant 3 Inserted	-	-	-	-	-		-%	91	91	-	-	-
Implant 5	-	-	-	-	-		0%	(1)	(1)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	-		-%	(1)	(1)	-	-	-
Implant 5 Insertion	247	117	527	1,634	313		68%	1,486	3,650	527	2,003	2,217
Non-PSI Implant 5 Inserted	247	117	527	1,634	313		68%	1,485	3,649	527	2,003	2,217
PSI Implant 5 Inserted	-	-	-	-	-		-%	1	1	-	-	-
Injectable 3-IM Provided	3,968	3,303	11,843	44,336	8,696		36%	40,305	72,922	2,961	2,961	2,452
Non-PSI Injectable 3 IM Provided	3,968	3,303	11,843	44,336	8,696		36%	40,305	72,922	2,961	2,961	2,452
Injectable 3-SC Provided	107	-	107	-	-		0%	-	107	27	27	22
Non-PSI Injectable 3 SC Provided	107	-	107	-	-		-%	-	107	27	27	22
IUD 10	-	-	-	-	-		0%	(60)	(60)	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	-		-%	(60)	(60)	-	-	-
IUD 10 Insertion	364	135	692	3,727	1,125		(38)%	3,448	5,734	692	3,183	3,369
Non-PSI IUD 10 Inserted	364	135	692	3,727	1,125		(38)%	3,388	5,674	692	3,183	3,369
PSI IUD 10 Inserted	-	-	-	-	-		-%	60	60	-	-	-
Manual Vacuum Aspiration for PAC	13	12	26	450	-		0%	401	427	26	-	15
MVA for PAC	13	12	26	450	-		-%	401	427	26	-	15
Misoprostol for PAC Provided	50	26	107	600	-		0%	561	668	107	-	70
Non-PSI Misoprostol for PAC Provided	50	26	107	600	-		-%	561	668	107	-	70

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for Safe Abortion	1,168	832	3,084	8,000	1,424		117%	99,856	155,920	162	-	94
Misoprostol for Safe Abortion	1,168	832	3,084	8,000	1,424		117%	99,856	155,920	162	-	94
OCs Provided	11,239	10,326	32,798	108,471	20,567		59%	98,610	203,036	2,187	2,187	1,910
Non-PSI OCs Provided	11,239	10,326	32,798	108,471	20,567		59%	98,610	203,036	2,187	2,187	1,910
Seasonal Malaria Chemoprevention	-	-	-	990,000	-		0%	344,748	344,748	-	-	-
SMC for Children ages 12-59 months	-	-	-	825,000	-		-%	291,064	291,064	-	-	-
SMC for Infants ages 3-11 months	-	-	-	165,000	-		-%	53,684	53,684	-	-	-
PSI Benin											5,382	5,022
Implant 5	-	-	-	112	-		0%	-	-	-	-	-
Jadelle	-	-	-	3,766	-		-%	-	-	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	(3,654)	-		-%	-	-	-	-	-
Implant 5 Insertion	-	-	-	3,654	-		0%	-	-	-	-	-
PSI Implant 5 Inserted	-	-	-	3,654	-		-%	-	-	-	-	-
IUD 10	450	500	1,300	1,356	2,510		(48)%	14,678	15,978	1,170	5,382	3,682
IUD Copper T 380A	450	500	1,300	11,690	2,510		(48)%	14,678	15,978	1,170	5,382	3,682
(b)PSI IUD 10 Distributed Inserted	-	-	-	(10,334)	-		-%	-	-	-	-	-
IUD 10 Insertion	-	-	-	10,334	-		0%	-	-	-	-	-
PSI IUD 10 Inserted	-	-	-	10,334	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	810	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	810	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	81	-		0%	-	-	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	81	-		-%	-	-	-	-	-
Medical Abortion	185	30	275	-	-		0%	-	275	248	-	93
Mifeso	185	30	275	-	-		-%	-	275	248	-	93
Medical Abortion (Misoprostol) Provided	-	-	-	183	-		0%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Medical Abortion (Misoprostol) Provided	-	-	-	183	-		-%	-	-	-	-	-
Misoprostol for PAC Provided	-	-	-	528	-		0%	-	-	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	528	-		-%	-	-	-	-	-
Misoprostol for Safe Abortion	27,120	19,740	70,560	199,152	36,140		95%	208,980	279,540	3,704	-	1,247
Misoprostol for Safe Abortion	27,120	19,740	70,560	203,460	36,140		95%	208,980	279,540	3,704	-	1,247
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	(4,308)	-		-%	-	-	-	-	-
Senegal											10,012	6,908
Acute Malnutrition Screening_CU5	-	-	-	312	418		(100)%	518	1,895	-	-	-
Acute Malnutrition Screening_CU5	-	-	-	312	418		(100)%	518	1,895	-	-	-
Condom	-	322,891	374,768	6,074,298	101,184		270%	5,947,910	31,318,928	2,811	2,811	3,234
Fagaru	-	63,947	79,040	2,100,223	5,760	11/12	1,272%	2,751,835	11,898,225	593	593	682
Protec Fraise	-	65,152	88,512	710,207	85,920	1/13	3%	822,288	4,244,116	664	664	764
Protec Naturel	-	193,792	207,216	3,263,868	9,504	1/13	2,080%	2,373,787	15,176,587	1,554	1,554	1,788
Counseling & Tx for Moderate Acute MalnutritionCU!	-	-	-	4	-		0%	-	-	-	-	-
Counseling & Tx for Moderate Acute MalnutritionCU5	-	-	-	4	-		-%	-	-	-	-	-
HIV Testing Services	-	-	-	91	296		(100)%	314	903	-	-	-
VCT Individual (HIV-Negative)	-	-	-	90	295		(100)%	313	888	-	-	-
VCT Individual (HIV-Positive)	-	-	-	1	1		(100)%	1	15	-	-	-
Implant 3 Insertion	15	28	87	41	26		235%	127	281	87	218	131
Non-PSI Implant 3 Inserted	15	28	87	41	26		235%	127	281	87	218	131
Implant 4 Insertion	16	1	19	-	-		0%	2	39	19	61	36
Non-PSI Implant 4 Inserted	16	1	19	-	-		-%	2	39	19	61	36
Implant 5 Insertion	35	45	147	48	69		113%	157	383	147	559	332
Non-PSI Implant 5 Inserted	35	45	147	48	69		113%	157	383	147	559	332
Injectable 3-IM Provided	27	15	59	45	49		20%	182	342	15	15	7

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 3 IM Provided	27	15	59	45	49		20%	182	342	15	15	7
Injectable 3-SC	-	2,880	4,752	19,080	470		911%	14,488	21,855	1,069	1,069	475
Securil Press	-	2,880	4,752	19,080	470		911%	14,488	21,855	1,069	1,069	475
IUD 10 Insertion	4	6	21	7	7		200%	27	67	21	97	55
Non-PSI IUD 10 Inserted	4	6	21	7	7		200%	27	67	21	97	55
LLIN	-	1,495	2,025	165,000	453		347%	270,382	987,154	3,281	-	57
MILDA	-	1,495	2,025	165,000	453		347%	270,382	987,154	3,281	-	57
OCs	-	66,960	86,400	500,565	26,786		223%	664,517	3,288,668	5,184	5,184	2,430
Securil	-	66,960	86,400	500,565	26,786		223%	664,517	3,288,668	5,184	5,184	2,430
OCs Provided	2	1	3	5	8		(63)%	17	26	-	-	-
Non-PSI OCs Provided	2	1	3	5	8		(63)%	17	26	-	-	-
Toilets Sold	392	309	1,018	4,000	-		0%	958	1,976	8,449	-	130
Toilets Sold	392	309	1,018	4,000	-		-%	958	1,976	8,449	-	130
Treatment for Severe Acute Malnutrition	-	-	-	8	-		0%	-	-	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	8	-		-%	-	-	-	-	-
Water Treatment Tablets	-	219,400	476,900	1,860,179	64,000		645%	1,979,400	9,942,566	7,839	-	21
Aquatabs 67 mg (20 L)	-	219,400	476,900	1,860,179	64,000		645%	1,979,400	9,942,566	7,839	-	21

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Latin America & Asia Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 3/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Latin America & Asia Market Group	1,268	-	-	541	1,148,676	558	437,949	1	16	-	-	3,969
Cambodia	589	-	-	-	187,178	165	69,844	-	16	-	-	565
Costa Rica	13	-	-	-	3,331	-	938	-	-	-	-	1
Dominican Republic	105	-	-	-	23,095	3	6,504	-	-	-	-	21
El Salvador	29	-	-	-	5,757	-	1,673	-	-	-	-	4
El Salvador SA	-	-	-	-	5,449	1	2,468	-	-	-	-	6
Guatemala	92	-	-	-	23,548	3	6,781	-	-	-	-	36
Guatemala SA	-	-	-	-	32,119	6	14,496	-	-	-	-	77
Honduras	115	-	-	-	11,204	2	3,482	-	-	-	-	12
Kazakhstan	3	-	-	-	-	-	-	-	-	-	-	-
Kyrgyzstan	2	-	-	-	-	-	-	-	-	-	-	-
Laos	28	-	-	6	26,335	9	10,583	1	-	-	-	78
Nepal	-	-	-	-	1,660	47	752	-	-	-	-	50
Nicaragua	42	-	-	-	16,097	4	5,716	-	-	-	-	25
Pakistan	207	-	-	535	698,221	284	268,661	-	-	-	-	2,739
Panama	27	-	-	-	5,338	1	1,503	-	-	-	-	4
Papua New Guinea	-	-	-	-	-	-	-	-	-	-	-	-
PSI Pakistan	8	-	-	-	108,121	34	44,054	-	-	-	-	348
Tajikistan	6	-	-	-	247	-	70	-	-	-	-	-
Viet Nam	-	-	-	-	975	-	424	-	1	-	-	1

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group										1,148,676	360,433
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	80	(100)%	233	233	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	80	(100)%	92	92	-	-	-
Cervical Cancer-Pap Smear Screening	19	35	125	-	-	-%	92	453	125	-	-
Condom	23,096,712	16,936,987	49,537,856	196,479,173	49,409,490	-%	187,077,716	3,533,480,832	371,534	371,534	112,176
Diarrhea Treatment Kit	6,660	4,980	21,600	91,951	21,580	-%	57,190	970,276	19,440	-	425
Emergency Contraception	202,818	247,458	639,344	981,837	515,916	24%	2,139,292	9,847,363	28,770	28,770	4,996
Emergency Contraception Provided	2,363	2,636	7,750	1,146,567	4,963	56%	15,372	51,600	388	388	68
Female Condom	-	-	-	-	20	(100)%	100	338,539	-	-	-
Fever Cases Attended	4,587	5,233	14,617	75,685	51,611	(72)%	118,263	294,542	14,617	-	-
Fever Cases Tested with RDTs	5,795	7,043	19,291	95,551	51,608	(63)%	134,061	314,978	19,291	-	-
Free Condom	126,000	431,971	690,000	3,124,160	770,933	(10)%	3,430,359	11,284,733	5,175	5,175	1,374
Free Female Condom	-	-	-	30,000	16,245	(100)%	21,200	45,770	-	-	-
HIV Testing Services	4,737	4,865	14,991	78,439	26,707	(44)%	98,169	368,791	14,991	-	32
Hypertension Diagnosis	1,578	981	4,520	14,572	10,385	(56)%	26,102	56,955	4,520	-	-
Hypertension Screening	34,502	31,518	99,236	150,000	131,496	(25)%	413,477	714,930	99,236	-	-
Hypertension_Controlled Condition	2,025	2,072	6,280	13,009	7,681	(18)%	30,443	56,831	2,512	-	-
Implant 3	(66)	314	878	4,920	217	305%	1,681	3,421	790	1,976	297
Implant 3 Insertion	1,279	659	3,393	12,195	2,523	34%	12,809	30,153	3,393	8,483	1,981
Implant 5	(47)	(241)	(887)	3,342	14,332	(106)%	21,739	55,369	(798)	(3,034)	(625)
Implant 5 Insertion	1,368	781	3,345	12,712	3,450	(3)%	21,679	91,077	3,345	12,711	2,655
Injectable 1	23,063	13,611	53,493	150,016	22,410	139%	131,181	2,022,007	3,703	3,703	874

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1 Provided	8,665	4,648	18,986	44,525	21,628	(12)%	88,483	243,942	1,460	1,460	319
Injectable 2	(445)	13,684	24,347	19,731	75,315	(68)%	134,028	7,108,430	3,652	3,652	838
Injectable 2 Provided	2,228	1,378	5,730	132,422	19,436	(71)%	58,184	152,306	955	955	160
Injectable 3-IM	52,059	36,747	111,688	560,836	153,081	(27)%	688,678	8,548,911	25,130	25,130	4,882
Injectable 3-IM Provided	47,834	40,417	126,533	761,629	243,739	(48)%	705,711	1,282,083	31,633	31,633	6,437
Injectable 3-SC	-	-	-	1,400	-	-%	-	-	-	-	-
Injectable 3-SC Provided	-	-	-	5,600	-	-%	-	-	-	-	-
IUD 10	36,825	(7,275)	36,918	102,474	27,589	34%	67,041	165,866	33,226	152,841	45,664
IUD 10 Insertion	11,376	8,587	28,263	123,733	32,584	(13)%	148,352	786,700	28,263	130,010	31,821
IUD 5	(4,960)	8,708	20,321	94,294	(9,509)	-%	22,736	3,039,494	18,289	60,353	18,830
IUD 5 Insertion	7,979	12,823	46,445	65,998	32,616	42%	63,576	985,730	46,445	153,268	47,845
IUS 5 Insertion	-	1	3	-	-	-%	2	6	3	10	2
LLIN (Hammock net)	300	133	700	1,350	435	61%	1,259	2,004	630	-	-
Lubricant	134,913	127,576	441,384	-	295,960	49%	1,423,274	16,954,199	-	-	-
Malaria PPT (ACT)	(6)	(52)	(76)	-	1,852	(104)%	357	860,619	(68)	-	(8)
Malaria RDK	720	1,790	6,060	25,000	278,594	(98)%	305,189	3,288,536	5,454	-	-
Manual Vacuum Aspiration for PAC	5,009	8,240	24,720	7,295	14,510	70%	34,966	130,684	24,720	-	1,238
Manual Vacuum Aspiration for SA	-	3	8	236	81	(90)%	251	259	8	-	1
Medical Abortion	34,027	38,471	110,985	459,996	113,080	(2)%	457,337	2,222,145	99,887	-	9,732
Medical Abortion Provided	1,145	657	2,369	4,788	3,672	(35)%	12,104	22,443	2,369	-	213
Misoprostol for PAC Provided	461	6,520	15,931	3,935	24,129	(34)%	53,383	72,964	15,931	-	938

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Misoprostol for Safe Abortion	202,950	152,667	617,134	320,448	269,852	129%	1,285,943	2,603,271	32,400	-	2,500
Naloxone	-	23	-	3,089	-	-%	2,570	16,713	-	-	-
Needle & Syringe	45,100	325,967	270,100	1,355,860	691,300	(61)%	5,815,215	25,779,168	942	-	1,900
OCs	949,335	555,497	2,052,981	6,917,751	1,747,101	18%	6,487,754	66,607,117	123,179	123,179	23,736
OCs Provided	148,919	113,016	357,493	1,601,361	250,059	43%	921,067	1,980,847	23,833	23,833	5,726
ORS	23,610	193,159	103,087	-	-	-%	500,000	632,321	46,389	-	974
Positive RDTs	142	308	753	3,333	7,962	(91)%	11,799	39,326	753	-	-
Positive RDTs Given First Line Treatment	124	267	647	2,474	7,177	(91)%	10,103	36,195	647	-	-
QAACTs Provided after Confirmatory Diagnosis	73	186	397	2,254	7,186	(94)%	9,977	35,847	397	-	72
Referral to Emergency Contraception	-	-	-	-	-	-%	31	107	-	-	-
Referral to HIV Testing Services	-	1	3	6	-	-%	10	20,731	3	-	-
Referral to Implant 3 Insertion	322	589	633	-	-	-%	1,455	2,088	633	791	107
Referral to Implant 5 Insertion	34	34	111	-	36	208%	221	1,138	111	211	48
Referral to Injectable 1	2	1	3	-	-	-%	11	14	3	-	-
Referral to Injectable 3	92	47	197	-	54	265%	396	1,832	197	25	4
Referral to IUD 10 Insertion	235	122	532	-	175	204%	729	58,776	532	1,224	206
Referral to Linkage to HIV Care	253	220	674	1,627	702	(4)%	2,800	6,806	674	-	552
Referral to OCs	127	49	210	-	41	412%	391	1,152	210	7	1
Referral to Opioid Treatment	7	7	17	37	52	(67)%	135	489	17	-	-
Referral to TB DOTS (completion confirmed)	-	12	35	110	57	(39)%	148	426	35	-	12
Referral to TB DOTS (completion unknown)	-	1	4	-	1	300%	43	248	4	-	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Referral to TB Screening	-	-	-	-	21	(100)%	21	50	-	-	-
Referral to Vasectomy	-	-	1	-	-	-%	-	1	1	5	1
SDM (Cycle Beads) Provided	1	-	2	-	1	100%	7	124	2	3	1
STI Screening	13	6	32	-	39	(18)%	99	3,925	32	-	-
TB Diagnosis	2,380	2,132	6,496	385	7,521	(14)%	29,853	92,114	6,496	-	-
TB DOTS	2,274	2,046	6,321	-	5,580	13%	26,012	119,796	6,321	-	28,928
TB Screening	5,845	4,636	15,194	4,086	19,402	(22)%	72,433	156,710	15,194	-	-
Toilets Sold	177	414	587	750	948	(38)%	4,405	6,890	2,465	-	21
Treatment for Cervicitis	6	7	26	-	-	-%	28	69	26	-	-
Treatment for Genital Herpes	-	-	1	-	-	-%	-	9	1	-	-
Treatment for Lower Abdominal Pain	-	-	1	-	-	-%	-	1	1	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	-	-%	1	8	-	-	-
Treatment for Vaginitis	7	18	61	-	-	-%	25	89	61	-	-
Tubal Ligation	670	119	1,014	-	1,833	(45)%	11,913	28,435	1,014	10,140	2,417
Type 2 Diabetes Diagnosis	-	-	-	-	-	-%	1	1	-	-	-
Type 2 Diabetes Screening	-	-	-	-	-	-%	1	3	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	1	-	-	-%	-	1	-	-	-
Vasectomy	14	3	24	-	77	(69)%	318	925	24	240	58
Vivax Treatment after Confirmatory Diagnosis	-	15	-	248	1	(100)%	156	165	-	-	-
Water Treatment Tablets	500	16,833	51,000	80,000	68,900	(26)%	91,160	1,029,783	838	-	2
Zika Prevention Kit	-	4	-	-	105	(100)%	725	2,621	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Zinc	-	1	2	-	-	-%	-	32,846	2	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Latin America & Asia Market Group											1,148,676	360,433
Cambodia											187,178	66,675
Condom	1,280,622	1,102,092	3,688,476	12,214,854	2,971,542		24%	10,667,766	389,753,027	27,664	27,664	27,334
Number One	395,136	224,952	731,160	4,448,814	1,269,072	12/94	(42)%	4,440,816	270,003,229	5,484	5,484	5,418
OK Condom	885,486	877,140	2,957,316	7,766,040	1,702,470	2/04	74%	6,226,950	119,749,798	22,180	22,180	21,915
Diarrhea Treatment Kit	6,660	4,980	21,600	89,037	21,580		0%	57,190	952,040	19,440	-	425
Orasel Kit	6,660	4,980	21,600	89,037	21,580		-%	57,190	952,040	19,440	-	425
Emergency Contraception	2,108	7,684	18,391	94,412	20,407		(10)%	73,948	320,926	828	828	110
NEXT 72 EC	2,120	7,686	18,410	90,602	20,420		(10)%	73,979	321,009	828	828	110
Pronta1	-	-	-	3,810	-		-%	-	-	-	-	-
(b)PSI Emergency Contraception Distributed Provided	(12)	(3)	(19)	-	(13)		-%	(31)	(83)	(1)	(1)	-
Emergency Contraception Provided	12	3	19	-	13		46%	31	83	1	1	-
PSI Emergency Contraception Provided	12	3	19	-	13		46%	31	83	1	1	-
Fever Cases Attended	784	1,180	2,473	15,685	45,403		(95)%	75,172	228,246	2,473	-	-
Fever Cases Attended	784	1,180	2,473	15,685	45,403		(95)%	75,172	228,246	2,473	-	-
Fever Cases Tested with RDTs	740	1,079	2,124	15,551	45,401		(95)%	75,088	227,791	2,124	-	-
Fever Cases Tested with RDTs	740	1,079	2,124	15,551	45,401		(95)%	75,088	227,791	2,124	-	-
Implant 3 Insertion	36	10	51	-	-		0%	112	163	51	128	30
Non-PSI Implant 3 Inserted	36	10	51	-	-		-%	112	163	51	128	30
Implant 5	586	(70)	340	8,643	2,302		(85)%	8,131	22,368	306	1,163	270
Implant 5	800	99	854	11,184	2,970		(71)%	10,570	54,180	769	2,921	678
(b)PSI Implant 5 Distributed Inserted	(214)	(169)	(514)	(2,541)	(668)		-%	(2,439)	(31,812)	(463)	(1,758)	(408)
Implant 5 Insertion	214	169	514	2,541	668		(23)%	2,439	31,812	514	1,953	453
PSI Implant 5 Inserted	214	169	514	2,541	668		(23)%	2,439	31,812	514	1,953	453
Injectable 3-IM	33,007	18,826	66,788	334,044	76,372		(13)%	290,704	5,621,017	15,027	15,027	2,610

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OK Injection-3	33,550	19,117	67,900	334,044	76,975		(12)%	294,200	5,636,459	15,278	15,278	2,654
(b)PSI Injectable 3 IM Distributed Provided	(543)	(291)	(1,112)	-	(603)		-%	(3,496)	(15,442)	(250)	(250)	(43)
Injectable 3-IM Provided	543	291	1,112	-	603		84%	3,496	15,442	278	278	48
PSI Injectable 3 IM Provided	543	291	1,112	-	603		84%	3,496	15,442	278	278	48
IUD 10	4,465	250	4,076	25,008	3,714		10%	20,787	96,610	3,668	16,875	3,740
IUD Copper T	6,705	1,573	8,710	40,488	8,995		(3)%	40,515	245,035	7,839	36,059	7,993
(b)PSI IUD 10 Distributed Inserted	(2,240)	(1,323)	(4,634)	(15,480)	(5,281)		-%	(19,728)	(148,425)	(4,171)	(19,185)	(4,252)
IUD 10 Insertion	2,240	1,323	4,634	15,480	5,281		(12)%	19,728	148,425	4,634	21,316	4,725
PSI IUD 10 Inserted	2,240	1,323	4,634	15,480	5,281		(12)%	19,728	148,425	4,634	21,316	4,725
Lubricant	67,260	52,860	200,760	-	145,020		38%	521,340	9,378,860	-	-	-
OK Plus Lubricant	67,260	52,860	200,760	-	145,020	6/09	38%	521,340	9,378,860	-	-	-
Malaria PPT (ACT)	(6)	(52)	(76)	-	(5,930)		0%	(7,425)	15,142	(68)	-	(8)
ASMQ for Adult	-	-	-	-	776	5/16	(100)%	776	46,378	-	-	-
ASMQ for Children	-	-	-	-	175	10/16	(100)%	175	2,033	-	-	-
(b)PSI QAACTs Distributed Provided after Diagnosis	(6)	(52)	(76)	-	(6,881)		-%	(8,376)	(33,269)	(68)	-	(8)
Malaria RDK	-	-	-	-	270,425		(100)%	276,500	1,896,300	-	-	-
Malaria RDT (Diagnosis)	-	-	-	-	270,425	6/15	(100)%	276,500	1,896,300	-	-	-
Medical Abortion	24,427	30,882	89,407	360,280	78,319		14%	334,762	1,835,524	80,466	-	7,045
Medabon	19,699	14,340	57,437	185,650	81,991		(30)%	240,656	1,717,418	51,693	-	4,526
Mifeso	5,873	17,159	34,227	174,630	-		-%	104,939	139,166	30,804	-	2,697
(b)PSI Medical Abortion Distributed Provided	(1,145)	(617)	(2,257)	-	(3,672)		-%	(10,833)	(21,060)	(2,031)	-	(178)
Medical Abortion Provided	1,145	617	2,257	-	3,672		(39)%	10,833	21,060	2,257	-	198
PSI Medical Abortion Provided	1,145	617	2,257	-	3,672		(39)%	10,833	21,060	2,257	-	198
OCs	631,709	535,880	1,686,277	6,233,333	1,373,262		23%	5,456,565	61,877,110	101,177	101,177	18,542

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Marvelon	111,495	91,223	307,806	1,006,355	215,380		43%	908,657	2,672,018	18,468	18,468	3,385
OK Pills	520,608	444,784	1,379,088	5,226,978	1,159,128		19%	4,551,732	59,218,268	82,745	82,745	15,164
(b)PSI OCs Distributed Provided	(394)	(126)	(617)	-	(1,246)		-%	(3,824)	(13,176)	(37)	(37)	(7)
OCs Provided	394	126	617	-	1,246		(50)%	3,825	13,178	41	41	8
Non-PSI OCs Provided	-	-	-	-	-		-%	1	2	-	-	-
PSI OCs Provided	394	126	617	-	1,246		(50)%	3,824	13,176	41	41	8
ORS	23,600	193,158	103,075	-	-		0%	500,000	603,075	46,384	-	974
Orasel ORS Sachet	23,600	193,158	103,075	-	-		-%	500,000	603,075	46,384	-	974
Positive RDTs	6	75	141	1,143	7,575		(98)%	9,841	36,015	141	-	-
Positive RDTs	6	75	141	1,143	7,575		(98)%	9,841	36,015	141	-	-
Positive RDTs Given First Line Treatment	6	52	76	1,099	6,881		(99)%	8,376	33,269	76	-	-
Positive RDTs Given First Line Treatment	6	52	76	1,099	6,881		(99)%	8,376	33,269	76	-	-
QAACTs Provided after Confirmatory Diagnosis	6	52	76	1,099	6,890		(99)%	8,400	33,324	76	-	11
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	-	1,099	9		(100)%	24	55	-	-	-
PSI QAACTs Provided after Confirmed Diagnosis	6	52	76	-	6,881		(99)%	8,376	33,269	76	-	11
Referral to Emergency Contraception	-	-	-	-	-		0%	31	107	-	-	-
Referral to Emergency Contraception	-	-	-	-	-		-%	31	107	-	-	-
Referral to Implant 5 Insertion	28	27	92	-	36		156%	190	1,063	92	175	41
Referral to Implant 5 Insertion	28	27	92	-	36		156%	190	1,063	92	175	41
Referral to Injectable 3	92	47	197	-	54		265%	396	1,832	197	25	4
Referral to Injectable 3	92	47	197	-	54		265%	396	1,832	197	25	4
Referral to IUD 10 Insertion	75	70	227	-	175		30%	677	9,706	227	522	116
Referral to IUD 10 Insertion	75	70	227	-	175	12/11	30%	677	9,706	227	522	116
Referral to OCs	127	49	210	-	41		412%	389	1,150	210	7	1
Referral to OCs	127	49	210	-	41		412%	389	1,150	210	7	1

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Costa Rica											3,331	543
Condom	136,020	148,785	444,110	2,062,125	434,063		2%	1,937,134	19,190,173	3,331	3,331	543
Combo-Pack Lub Fresa	1,392	1,253	3,920	27,338	5,990	10/10	(35)%	29,308	89,751	29	29	5
Vive	81,042	87,879	266,517	243,763	59,970	12/97	344%	504,093	5,430,025	1,999	1,999	326
Vive Amor	-	-	-	999,666	176,832	6/04	(100)%	602,928	8,042,921	-	-	-
Vive Colors/Mas Colors	31,566	36,580	103,095	487,706	116,052	5/03	(11)%	489,846	3,778,812	773	773	126
Vive Mas Fuerte /Retardante	9,390	9,194	28,620	127,286	31,191	6/04	(8)%	133,953	806,208	215	215	35
Vive Mas Natural /Sensitivo	12,630	13,879	41,958	176,366	44,028	6/04	(5)%	177,006	1,042,456	315	315	51
Lubricant	2,406	2,716	8,592	-	7,642		12%	22,294	170,393	-	-	-
Vive Lub Natural (sachet)	200	649	1,800	-	2,254	5/11	(20)%	5,532	56,314	-	-	-
Vive Lub Natural (tube)	778	734	2,306	-	1,605	5/11	44%	5,433	25,661	-	-	-
Vive Lub Sachet Fresa 5 mL	450	617	1,800	-	1,229	5/12	46%	3,809	59,988	-	-	-
Vive Lub Tubo Fresa 120 mL	978	716	2,686	-	2,554	1/12	5%	7,520	28,430	-	-	-
Dominican Republic											23,095	5,791
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	80		(100)%	233	233	-	-	-
Antiretroviral Treatment (Currently Enrolled)	-	-	-	-	80		(100)%	233	233	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	80		(100)%	92	92	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	-	80		(100)%	92	92	-	-	-
Condom	728,552	1,054,351	2,422,296	5,720,648	1,436,092		69%	7,560,134	44,988,874	18,167	18,167	4,555
Pante	728,552	1,038,999	2,376,240	5,433,008	1,436,092	6/14	65%	7,554,566	44,937,250	17,822	17,822	4,468
Vive Colors/Mas Colors	-	7,488	22,464	244,800	-		-%	2,784	25,248	168	168	42
VIVE Mas/Sensitivo	-	4,136	12,408	24,480	-		-%	1,392	13,800	93	93	23
Vive Mas/Texturizado	-	3,728	11,184	18,360	-		-%	1,392	12,576	84	84	21
Free Condom	117,000	208,000	657,000	2,511,000	414,000		59%	2,214,000	8,514,423	4,927	4,927	1,235

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
No Logo	117,000	208,000	657,000	2,511,000	414,000	6/14	59%	2,214,000	8,514,423	4,927	4,927	1,235
HIV Testing Services	-	-	-	25,152	11,061		(100)%	31,033	107,865	-	-	-
VCT Individual (HIV-Negative)	-	-	-	24,237	10,748		(100)%	30,230	105,214	-	-	-
VCT Individual (HIV-Positive)	-	-	-	915	313		(100)%	803	2,651	-	-	-
Lubricant	24,000	17,667	61,000	-	40,000		53%	278,000	1,849,992	-	-	-
No Logo Lubricant (4.5 gram sachet)	24,000	17,667	61,000	-	40,000	6/14	53%	278,000	1,849,992	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	349		(100)%	371	412	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	349		(100)%	371	412	-	-	-
EI Salvador											5,757	1,382
Cervical Cancer-Pap Smear Screening	19	35	125	-	-		0%	92	453	125	-	-
Cervical Cancer-Pap Smear Screening	19	35	125	-	-		-%	92	453	125	-	-
Condom	231,072	299,786	701,523	3,630,855	655,240		7%	3,210,525	40,903,259	5,261	5,261	1,327
Combo-Mix Lub Natural	-	-	-	-	48	10/10	(100)%	48	19,432	-	-	-
Combo-Pack Lub Fresa	-	-	-	4,682	16	5/12	(100)%	4,896	10,224	-	-	-
Vive	49,488	70,416	183,456	960,267	147,696	4/98	24%	739,008	15,388,300	1,376	1,376	347
Vive Amor	97,152	132,048	239,040	1,617,436	331,488	7/04	(28)%	1,534,176	14,697,457	1,793	1,793	452
Vive Colors/Mas Colors	68,568	65,505	208,032	695,657	106,392	10/03	96%	597,348	7,511,646	1,560	1,560	394
Vive Mas Fuerte /Retardante	10,392	20,825	42,531	263,210	43,680	7/04	(3)%	206,016	1,596,959	319	319	80
Vive Mas Natural /Sensitivo	5,472	10,992	28,464	89,603	19,728	7/04	44%	87,849	829,169	213	213	54
Vive Mas/Texturizado	-	-	-	-	6,192	7/04	(100)%	41,184	850,072	-	-	-
HIV Testing Services	351	284	981	2,340	795		23%	2,945	45,785	981	-	1
VCT Individual (HIV-Negative)	334	273	938	2,206	757		24%	2,823	45,090	938	-	1
VCT Individual (HIV-Positive)	17	11	43	134	38		13%	122	695	43	-	-
Hypertension Screening	-	-	1	-	-		0%	2	6	1	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Hypertension Screening	-	-	1	-	-		-%	2	6	1	-	-
Implant 5	(1)	(18)	(1)	(7,072)	27		(104)%	(25)	4,362	(1)	(3)	-
Jadelle	11	6	18	-	51	12/08	(65)%	336	5,634	16	62	6
(b)PSI Implant 5 Distributed Inserted	(12)	(24)	(19)	(7,072)	(24)		-%	(361)	(1,272)	(17)	(65)	(6)
Implant 5 Insertion	12	24	19	7,072	24		(21)%	361	1,272	19	72	7
PSI Implant 5 Inserted	12	24	19	7,072	24		(21)%	361	1,272	19	72	7
Injectable 1	-	(3)	(6)	-	-		0%	(2)	(18)	-	-	-
(b)PSI Injectable 1 Distributed Provided	-	(3)	(6)	-	-		-%	(2)	(18)	-	-	-
Injectable 1 Provided	-	3	6	-	8		(25)%	19	86	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	-	8		(100)%	17	68	-	-	-
PSI Injectable 1 Provided	-	3	6	-	-		-%	2	18	-	-	-
IUD 10	(10)	(30)	(27)	(255)	(549)		0%	(761)	(25,208)	(24)	(112)	(10)
(b)PSI IUD 10 Distributed Inserted	(10)	(30)	(27)	(255)	(549)		-%	(761)	(25,208)	(24)	(112)	(10)
IUD 10 Insertion	10	30	27	255	906		(97)%	1,118	36,443	27	124	11
Non-PSI IUD 10 Inserted	-	-	-	-	357	11/13	(100)%	357	11,235	-	-	-
PSI IUD 10 Inserted	10	30	27	255	549		(95)%	761	25,208	27	124	11
Lubricant	18,748	21,541	65,273	-	17,094		282%	175,111	1,492,852	-	-	-
Vive Lub (sachet)	11,050	9,717	31,950	-	12,650		153%	94,900	834,340	-	-	-
Vive Lub (tube)	3,048	1,392	6,233	-	1,799		246%	8,084	69,292	-	-	-
Vive Lub Natural (sachet)	4,050	9,667	24,750	-	1,250		1,880%	65,700	557,602	-	-	-
Vive Lub Natural (tube)	600	766	2,340	-	1,395		68%	6,427	31,618	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	109		(100)%	109	2,666	-	-	-
MVA for PAC	-	-	-	-	109	8/16	(100)%	109	2,666	-	-	-
OCs	880	2,771	6,794	-	7,252		(6)%	22,861	178,735	408	408	30

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI OCs Distributed Provided	-	(3)	(1)	-	(6)		-%	(17)	(27)	-	-	-
Segura Plus	880	2,775	6,795	-	7,258	2/12	(6)%	22,878	178,762	408	408	30
OCs Provided	-	3	1	-	6		(83)%	51	67	-	-	-
Non-PSI OCs Provided	-	-	-	-	-		-%	34	40	-	-	-
PSI OCs Provided	-	3	1	-	6		(83)%	17	27	-	-	-
Referral to HIV Testing Services	-	-	-	-	-		0%	2	469	-	-	-
Referral to HIV Testing Services	-	-	-	-	-	12/13	-%	2	469	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	-		0%	4	6	-	-	-
Referral to Implant 5 Insertion	-	-	-	-	-	12/11	-%	4	6	-	-	-
Referral to Injectable 1	1	1	2	-	-		0%	6	8	2	-	-
Referral to Injectable 1	1	1	2	-	-		-%	6	8	2	-	-
Referral to IUD 10 Insertion	2	1	3	-	-		0%	4	18,941	3	7	1
Referral to IUD 10 Insertion	2	1	3	-	-	12/11	-%	4	18,941	3	7	1
Referral to Linkage to HIV Care	22	5	32	-	18		78%	41	222	32	-	16
Referral to Linkage to HIV Care	22	5	32	-	18		78%	41	222	32	-	16
STI Screening	13	6	32	-	-		0%	60	2,727	32	-	-
STI Screening	13	6	32	-	-		-%	60	2,727	32	-	-
Treatment for Cervicitis	6	7	26	-	-		0%	28	69	26	-	-
Treatment for Cervicitis	6	7	26	-	-		-%	28	69	26	-	-
Treatment for Genital Herpes	-	-	1	-	-		0%	-	9	1	-	-
Treatment for Genital Herpes	-	-	1	-	-		-%	-	9	1	-	-
Treatment for Lower Abdominal Pain	-	-	1	-	-		0%	-	1	1	-	-
Treatment for Lower Abdominal Pain	-	-	1	-	-		-%	-	1	1	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	-		0%	1	8	-	-	-
Treatment for Urethral Discharge (Women)	-	-	-	-	-		-%	1	8	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Treatment for Vaginitis	7	18	61	-	-		0%	25	89	61	-	-
Treatment for Vaginitis	7	18	61	-	-		-%	25	89	61	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	-		0%	1	1	-	-	-
Type 2 Diabetes Diagnosis	-	-	-	-	-		-%	1	1	-	-	-
Type 2 Diabetes Screening	-	-	-	-	-		0%	1	3	-	-	-
Type 2 Diabetes Screening	-	-	-	-	-		-%	1	3	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	1	-	-		0%	-	1	-	-	-
Type 2 Diabetes_Controlled Condition	-	-	1	-	-		-%	-	1	-	-	-
Zika Prevention Kit	-	4	-	-	105		(100)%	725	2,621	-	-	-
Zika Prevention Kit	-	4	-	-	105	7/16	(100)%	725	2,621	-	-	-
EI Salvador SA											5,449	510
Condom	1,872	2,736	7,632	-	10,656		(28)%	30,048	37,680	57	57	14
Vive Amor	1,872	2,736	7,632	-	10,656	10/17	(28)%	30,048	37,680	57	57	14
Implant 3 Insertion	21	24	93	-	-		0%	-	93	93	233	22
Non-PSI Implant 3 Inserted	21	24	93	-	-		-%	-	93	93	233	22
Implant 5	33	70	122	574	83		47%	911	1,033	110	417	39
Jadelle	38	77	138	1,032	83		66%	976	1,114	124	472	44
(b)PSI Implant 5 Distributed Inserted	(5)	(7)	(16)	(458)	-		-%	(65)	(81)	(14)	(55)	(5)
Implant 5 Insertion	5	7	16	458	-		0%	69	85	16	61	6
Non-PSI Implant 5 Inserted	-	-	-	-	-		-%	4	4	-	-	-
PSI Implant 5 Inserted	5	7	16	458	-		-%	65	81	16	61	6
Injectable 1 Provided	-	-	-	-	-		0%	4	4	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	-	-		-%	4	4	-	-	-
IUD 10	146	110	226	150	906		(75)%	2,576	2,802	203	936	84
Copper T 380	289	260	718	3,660	906		(21)%	4,021	4,739	646	2,973	267

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 10 Distributed Inserted	(143)	(149)	(492)	(3,510)	-		-%	(1,445)	(1,937)	(443)	(2,037)	(183)
IUD 10 Insertion	305	244	812	3,510	-		0%	2,956	3,768	812	3,735	335
Non-PSI IUD 10 Inserted	162	95	320	-	-		-%	1,511	1,831	320	1,472	132
PSI IUD 10 Inserted	143	149	492	3,510	-		-%	1,445	1,937	492	2,263	203
Lubricant	-	-	-	-	12		(100)%	12	12	-	-	-
Vive Lub Natural (tube)	-	-	-	-	12	10/17	(100)%	12	12	-	-	-
Manual Vacuum Aspiration for PAC	71	52	136	1,800	-		0%	965	1,101	136	-	2
MVA for PAC	71	52	136	1,800	-		-%	965	1,101	136	-	2
Medical Abortion	-	(1)	-	-	-		0%	(3)	(3)	-	-	-
(b)PSI Medical Abortion Distributed Provided	-	(1)	-	-	-		-%	(3)	(3)	-	-	-
Medical Abortion Provided	-	3	-	-	-		0%	8	8	-	-	-
Non-PSI Medical Abortion Provided	-	2	-	-	-		-%	5	5	-	-	-
PSI Medical Abortion Provided	-	1	-	-	-		-%	3	3	-	-	-
Misoprostol for PAC Provided	45	15	91	360	-		0%	291	382	91	-	2
Non-PSI Misoprostol for PAC Provided	37	14	78	-	-		-%	250	328	78	-	1
PSI Misoprostol for PAC Provided	8	2	13	360	-		-%	41	54	13	-	-
Misoprostol for Safe Abortion	2,748	775	4,432	23,552	160		2670%	5,928	10,360	233	-	4
Misoprostol for Safe Abortion	2,780	781	4,484	24,992	160		2,703%	6,092	10,576	235	-	4
(b)PSI Misoprostol for Safe Abortion Dist Provided	(32)	(7)	(52)	(1,440)	-		-%	(164)	(216)	(3)	-	-
OCs	-	-	-	-	44		(100)%	100	100	-	-	-
Segura Plus	-	-	-	-	44	10/17	(100)%	100	100	-	-	-
Tubal Ligation	-	-	1	-	-		0%	1	2	1	10	1
Tubal Ligation	-	-	1	-	-		-%	1	2	1	10	1
Guatemala											23,548	6,810
Condom	1,100,594	1,043,949	2,932,890	12,678,434	2,591,656		13%	11,280,624	147,723,431	21,997	21,997	6,538

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Combo Pack	(16)	3,685	8,400	33,486	6,064	4/05	39%	28,752	455,656	63	63	19
Vive	354,960	324,784	989,856	4,031,144	855,984	4/98	16%	3,743,136	58,694,733	7,424	7,424	2,207
Vive Amor	612,720	573,344	1,526,544	7,075,590	1,423,296	7/04	7%	6,293,856	68,654,463	11,449	11,449	3,403
Vive Colors/Mas Colors	73,386	84,792	247,746	938,160	201,576	4/02	23%	725,880	14,553,520	1,858	1,858	552
Vive Mas Fuerte /Retardante	46,920	44,240	119,736	495,025	92,280	7/04	30%	393,648	3,281,912	898	898	267
Vive Mas Natural /Sensitivo	12,768	10,848	36,864	105,029	12,456	7/04	196%	86,712	1,119,733	276	276	82
Vive Mas/Texturizado	(144)	2,256	3,744	-	-	7/04	-%	8,640	963,414	28	28	8
Emergency Contraception	-	-	-	-	(1)		0%	(1)	(1)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(1)		-%	(1)	(1)	-	-	-
Emergency Contraception Provided	-	-	-	-	1		(100)%	1	1	-	-	-
PSI Emergency Contraception Provided	-	-	-	-	1		(100)%	1	1	-	-	-
HIV Testing Services	313	276	899	2,912	552		63%	2,755	52,797	899	-	2
VCT Individual (HIV-Negative)	304	270	878	2,749	532		65%	2,647	51,989	878	-	2
VCT Individual (HIV-Positive)	9	6	21	163	20	12/09	5%	108	808	21	-	-
Implant 5	-	-	-	-	(867)		0%	(867)	(14,210)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	(867)		-%	(867)	(14,210)	-	-	-
Implant 5 Insertion	-	-	-	-	2,308		(100)%	2,308	34,014	-	-	-
Non-PSI Implant 5 Inserted	-	-	-	-	1,441		(100)%	1,441	19,804	-	-	-
PSI Implant 5 Inserted	-	-	-	-	867		(100)%	867	14,210	-	-	-
Injectable 1	3,470	3,265	9,415	40,420	5,437		73%	29,950	267,095	652	652	109
Cyclofem	3,470	3,265	9,415	40,420	6,448		46%	30,961	274,309	652	652	109
(b)PSI Injectable 1 Distributed Provided	-	-	-	-	(1,011)		-%	(1,011)	(7,214)	-	-	-
Injectable 1 Provided	-	-	-	-	14,790		(100)%	14,790	62,320	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	-	13,779		(100)%	13,779	55,106	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Injectable 1 Provided	-	-	-	-	1,011		(100)%	1,011	7,214	-	-	-
Injectable 2 Provided	-	-	-	-	13,271		(100)%	13,271	34,974	-	-	-
Non-PSI Injectable 2 Provided	-	-	-	-	13,271		(100)%	13,271	34,974	-	-	-
Injectable 3-IM Provided	-	-	-	-	130,743		(100)%	130,743	266,096	-	-	-
Non-PSI Injectable 3 IM Provided	-	-	-	-	130,743		(100)%	130,743	266,096	-	-	-
IUD 10	-	-	-	-	(2,251)		0%	(2,251)	(88,649)	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	-	(2,251)		-%	(2,251)	(88,649)	-	-	-
IUD 10 Insertion	-	-	-	-	2,939		(100)%	2,939	111,458	-	-	-
Non-PSI IUD 10 Inserted	-	-	-	-	688		(100)%	688	22,809	-	-	-
PSI IUD 10 Inserted	-	-	-	-	2,251		(100)%	2,251	88,649	-	-	-
Lubricant	6,205	18,463	54,635	-	11,084		393%	115,766	1,605,629	-	-	-
Vive Lub (sachet)	450	11,505	32,916	-	850	4/05	3,772%	54,903	1,032,557	-	-	-
Vive Lub (tube)	1,769	1,915	6,007	-	3,330	4/05	80%	14,996	153,773	-	-	-
Vive Lub Natural (sachet)	1,550	3,150	9,200	-	3,450	1/10	167%	29,200	310,977	-	-	-
Vive Lub Natural (tube)	2,436	1,892	6,512	-	3,454	1/10	89%	16,667	108,322	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	1,431		(100)%	1,431	9,176	-	-	-
MVA for PAC	-	-	-	-	1,431	5/16	(100)%	1,431	9,176	-	-	-
Misoprostol for PAC Provided	-	-	-	-	2,281		(100)%	2,281	5,883	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	1,452		(100)%	1,452	3,049	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	829		(100)%	829	2,834	-	-	-
Misoprostol for Safe Abortion	-	-	-	-	(3,316)		0%	(3,316)	(11,336)	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(3,316)		-%	(3,316)	(11,336)	-	-	-
OCs	7,901	5,046	13,921	89,184	18,220		(24)%	63,764	203,582	835	835	136
(b)PSI OCs Distributed Provided	-	-	-	-	(699)		-%	(699)	(4,667)	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Segura Plus	7,901	5,046	13,921	89,184	18,919		(26)%	64,463	208,249	835	835	136
OCs Provided	-	-	-	-	31,295		(100)%	31,295	85,031	-	-	-
Non-PSI OCs Provided	-	-	-	-	30,596		(100)%	30,596	80,364	-	-	-
PSI OCs Provided	-	-	-	-	699		(100)%	699	4,667	-	-	-
Referral to Implant 5 Insertion	6	7	19	-	-		0%	27	69	19	36	7
Referral to Implant 5 Insertion	6	7	19	-	-	12/11	-%	27	69	19	36	7
Referral to Injectable 1	1	-	1	-	-		0%	5	6	1	-	-
Referral to Injectable 1	1	-	1	-	-		-%	5	6	1	-	-
Referral to IUD 10 Insertion	1	7	10	-	-		0%	48	29,837	10	23	5
Referral to IUD 10 Insertion	1	7	10	-	-	12/11	-%	48	29,837	10	23	5
Referral to Linkage to HIV Care	5	5	17	-	8		113%	55	238	17	-	12
Referral to Linkage to HIV Care	5	5	17	-	8		113%	55	238	17	-	12
Referral to OCs	-	-	-	-	-		0%	2	2	-	-	-
Referral to OCs	-	-	-	-	-		-%	2	2	-	-	-
Referral to Vasectomy	-	-	1	-	-		0%	-	1	1	5	1
Referral to Vasectomy	-	-	1	-	-		-%	-	1	1	5	1
SDM (Cycle Beads) Provided	-	-	-	-	1		(100)%	1	116	-	-	-
Non-PSI SDM (Cycle Beads) Provided	-	-	-	-	1		(100)%	1	116	-	-	-
Tubal Ligation	-	-	-	-	1,807		(100)%	1,807	17,292	-	-	-
Tubal Ligation	-	-	-	-	1,807	7/12	(100)%	1,807	17,292	-	-	-
Vasectomy	-	-	-	-	77		(100)%	77	660	-	-	-
Vasectomy	-	-	-	-	77	7/12	(100)%	77	660	-	-	-
Guatemala SA											32,119	6,428
Condom	8,352	2,448	13,680	-	21,888		(38)%	95,328	109,008	103	103	30
Vive	-	-	-	-	15,408	7/17	(100)%	50,832	50,832	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vive Amor	8,352	2,448	13,680	-	6,480	7/17	111%	44,496	58,176	103	103	30
Emergency Contraception	-	-	-	-	-		0%	(4)	(4)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	-		-%	(4)	(4)	-	-	-
Emergency Contraception Provided	1	1	4	-	-		0%	6	10	-	-	-
Non-PSI Emergency Contraception Provided	1	1	4	-	-		-%	2	6	-	-	-
PSI Emergency Contraception Provided	-	-	-	-	-		-%	4	4	-	-	-
Implant 5	(661)	(239)	(1,395)	1,152	1,006		(239)%	1,602	207	(1,256)	(4,771)	(984)
Jadelle	-	16	10	3,365	1,006		(99)%	3,672	3,682	9	34	7
(b)PSI Implant 5 Distributed Inserted	(661)	(255)	(1,405)	(2,213)	-		-%	(2,070)	(3,475)	(1,265)	(4,805)	(992)
Implant 5 Insertion	1,128	572	2,763	2,213	-		0%	15,706	18,469	2,763	10,499	2,167
Non-PSI Implant 5 Inserted	467	317	1,358	-	-		-%	13,636	14,994	1,358	5,160	1,065
PSI Implant 5 Inserted	661	255	1,405	2,213	-		-%	2,070	3,475	1,405	5,339	1,102
Injectable 1	(1,067)	(46)	(1,060)	-	1,023		(204)%	417	(643)	(73)	(73)	(12)
Cyclofem	73	70	227	-	1,023	7/17	(78)%	2,127	2,354	16	16	3
(b)PSI Injectable 1 Distributed Provided	(1,140)	(116)	(1,287)	-	-		-%	(1,710)	(2,997)	(89)	(89)	(15)
Injectable 1 Provided	3,862	1,151	6,905	-	-		0%	50,852	57,757	531	531	89
Non-PSI Injectable 1 Provided	2,722	1,035	5,618	-	-		-%	49,142	54,760	432	432	72
PSI Injectable 1 Provided	1,140	116	1,287	-	-		-%	1,710	2,997	99	99	17
Injectable 2 Provided	1,783	1,002	4,699	-	-		0%	34,427	39,126	783	783	121
Non-PSI Injectable 2 Provided	1,783	1,002	4,699	-	-		-%	34,427	39,126	783	783	121
Injectable 3-IM Provided	9,488	10,298	39,817	-	-		0%	224,719	264,536	9,954	9,954	1,536
Non-PSI Injectable 3 IM Provided	9,488	10,298	39,817	-	-		-%	224,719	264,536	9,954	9,954	1,536
IUD 10	(875)	(257)	(1,905)	(778)	1,742		(209)%	4,388	2,483	(1,715)	(7,887)	(1,556)
Copper T 380	163	230	487	7,000	1,719		(72)%	11,187	11,674	438	2,016	398

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Copper T 380 Postpartum	-	9	6	-	23	7/17	(74)%	1,084	1,090	5	25	5
(b)PSI IUD 10 Distributed Inserted	(1,038)	(495)	(2,398)	(7,778)	-		-%	(7,883)	(10,281)	(2,158)	(9,928)	(1,959)
IUD 10 Insertion	1,207	562	2,748	9,133	-		0%	11,810	14,558	2,748	12,641	2,495
Non-PSI IUD 10 Inserted	169	67	350	1,355	-		-%	3,927	4,277	350	1,610	318
PSI IUD 10 Inserted	1,038	495	2,398	7,778	-		-%	7,883	10,281	2,398	11,031	2,177
IUD 5	-	-	-	-	1,000		(100)%	1,002	1,002	-	-	-
IUD Slek	-	-	-	-	1,000	7/17	(100)%	1,002	1,002	-	-	-
Lubricant	14	10	22	-	27		(19)%	136	158	-	-	-
Vive Lub (tube)	12	4	12	-	23	7/17	(48)%	74	86	-	-	-
Vive Lub Natural (tube)	2	6	10	-	4	7/17	150%	62	72	-	-	-
Manual Vacuum Aspiration for PAC	215	1,828	798	4,675	-		0%	4,901	5,699	798	-	22
MVA for PAC	215	1,828	798	4,675	-		-%	4,901	5,699	798	-	22
Misoprostol for PAC Provided	383	1,662	1,282	3,275	-		0%	4,088	5,370	1,282	-	42
Non-PSI Misoprostol for PAC Provided	4	748	8	-	-		-%	2,240	2,248	8	-	-
PSI Misoprostol for PAC Provided	379	914	1,274	3,275	-		-%	1,848	3,122	1,274	-	42
Misoprostol for Safe Abortion	(1,436)	2,052	11,752	59,100	5,660		108%	56,728	68,480	617	-	18
Misoprostol for Safe Abortion	80	5,709	16,848	72,200	5,660		198%	64,120	80,968	885	-	26
(b)PSI Misoprostol for Safe Abortion Dist Provided	(1,516)	(3,657)	(5,096)	(13,100)	-		-%	(7,392)	(12,488)	(268)	-	(8)
OCs	(494)	29	(369)	-	-		0%	(1,020)	(1,389)	(22)	(22)	(4)
(b)PSI OCs Distributed Provided	(526)	(24)	(555)	-	-		-%	(2,320)	(2,875)	(33)	(33)	(5)
Segura Plus	32	53	186	-	-	7/17	-%	1,300	1,486	11	11	2
OCs Provided	1,881	603	3,556	-	-		0%	40,905	44,461	237	237	39
Non-PSI OCs Provided	1,355	579	3,001	-	-		-%	38,585	41,586	200	200	33
PSI OCs Provided	526	24	555	-	-		-%	2,320	2,875	37	37	6

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
SDM (Cycle Beads) Provided	1	-	2	-	-		0%	6	8	2	3	1
Non-PSI SDM (Cycle Beads) Provided	1	-	2	-	-		-%	6	8	2	3	1
Tubal Ligation	649	117	988	-	-		0%	9,992	10,980	988	9,880	2,368
Tubal Ligation	649	117	988	-	-		-%	9,992	10,980	988	9,880	2,368
Vasectomy	14	3	24	-	-		0%	241	265	24	240	58
Vasectomy	14	3	24	-	-		-%	241	265	24	240	58
Honduras											11,204	5,844
Condom	359,072	308,952	1,255,192	4,436,599	1,090,376		15%	4,116,704	51,599,960	9,414	9,414	5,596
Combo-Pack Lub Fresa	272	608	1,888	5,355	608	2/16	211%	6,880	17,936	14	14	8
Combo-Pack Lub Natural	-	-	-	-	480	10/10	(100)%	688	27,648	-	-	-
Vive	59,760	63,632	248,256	1,082,225	258,144	9/00	(4)%	1,088,832	15,669,187	1,862	1,862	1,107
Vive Amor	252,720	174,560	764,544	2,593,241	700,944	8/04	9%	2,348,928	24,903,416	5,734	5,734	3,409
Vive Colors/Mas Colors	33,936	52,064	176,136	560,470	80,304	4/02	119%	455,400	8,789,974	1,321	1,321	785
Vive Mas Fuerte /Retardante	10,584	13,584	50,184	154,949	23,304	8/04	115%	145,680	1,171,440	376	376	224
Vive Mas Natural /Sensitivo	1,488	4,312	13,368	40,359	9,720	8/04	38%	45,096	503,186	100	100	60
Vive Mas/Texturizado	312	192	816	-	16,872	8/04	(95)%	25,200	517,173	6	6	4
HIV Testing Services	309	255	911	2,407	741		23%	3,254	16,028	911	-	2
VCT Individual (HIV-Negative)	289	241	856	2,271	718		19%	3,156	15,699	856	-	2
VCT Individual (HIV-Positive)	20	14	55	136	23		139%	98	329	55	-	-
Implant 3 Insertion	18	(469)	20	-	15		33%	22	81	20	50	7
Non-PSI Implant 3 Inserted	18	(469)	20	-	15		33%	22	81	20	50	7
Injectable 1	-	-	-	3,268	-		0%	-	-	-	-	-
Cyclofem	-	-	-	3,268	-		-%	-	-	-	-	-
Injectable 1 Provided	-	1	2	-	6		(67)%	9	60	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Injectable 1 Provided	-	1	2	-	6		(67)%	9	60	-	-	-
Injectable 3-IM Provided	2	1	4	-	15		(73)%	21	82	1	1	-
Non-PSI Injectable 3 IM Provided	2	1	4	-	15		(73)%	21	82	1	1	-
IUD 10	-	(39)	(91)	-	-		0%	(570)	(664)	(82)	(377)	(48)
(b)PSI IUD 10 Distributed Inserted	-	(39)	(91)	-	-		-%	(570)	(664)	(82)	(377)	(48)
IUD 10 Insertion	50	40	142	-	14		914%	977	1,150	142	653	83
Non-PSI IUD 10 Inserted	50	1	51	-	14		264%	407	486	51	235	30
PSI IUD 10 Inserted	-	39	91	-	-		-%	570	664	91	419	53
Lubricant	7,910	5,913	20,370	-	28,265		(28)%	113,476	927,117	-	-	-
Vive Lub (sachet)	3,350	1,600	8,000	-	16,330		(51)%	49,802	587,679	-	-	-
Vive Lub (tube)	384	1,594	5,106	-	3,265		56%	14,051	99,906	-	-	-
Vive Lub Natural (sachet)	4,030	1,683	4,030	-	6,730		(40)%	37,832	178,578	-	-	-
Vive Lub Natural (tube)	146	1,036	3,234	-	1,940		67%	11,791	60,954	-	-	-
OCs Provided	-	-	-	-	2		(100)%	2	15	-	-	-
Non-PSI OCs Provided	-	-	-	-	2		(100)%	2	15	-	-	-
Referral to Implant 3 Insertion	322	589	633	-	-		0%	1,455	2,088	633	791	107
Referral to Implant 3 Insertion	322	589	633	-	-		-%	1,455	2,088	633	791	107
Referral to IUD 10 Insertion	157	45	292	-	-		0%	-	292	292	672	85
Referral to IUD 10 Insertion	157	45	292	-	-		-%	-	292	292	672	85
Referral to Linkage to HIV Care	12	4	20	-	22		(9)%	75	191	20	-	13
Referral to Linkage to HIV Care	12	4	20	-	22		(9)%	75	191	20	-	13
Kazakhstan											-	173
Free Condom	-	-	-	23,000	14,900		(100)%	46,385	673,550	-	-	-
Generic Male Condom	-	-	-	23,000	14,900	8/16	(100)%	46,385	673,550	-	-	-
Free Female Condom	-	-	-	-	3,245		(100)%	8,200	32,770	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Generic Female Condom	-	-	-	-	3,245	8/16	(100)%	8,200	32,770	-	-	-
HIV Testing Services	108	225	600	2,298	575		4%	2,373	6,503	600	-	1
VCT Individual (HIV-Negative)	94	212	562	2,210	552		2%	2,219	6,254	562	-	1
VCT Individual (HIV-Positive)	14	13	38	88	23		65%	154	249	38	-	-
Referral to HIV Testing Services	-	-	-	-	-		0%	4	5,152	-	-	-
Referral to HIV Testing Services	-	-	-	-	-	12/13	-%	4	5,152	-	-	-
Referral to Linkage to HIV Care	70	78	190	590	69		175%	997	1,906	190	-	172
Referral to Linkage to HIV Care	70	78	190	590	69		175%	997	1,906	190	-	172
Referral to Opioid Treatment	1	2	6	-	5		20%	26	99	6	-	-
Referral to Opioid Treatment	1	2	6	-	5		20%	26	99	6	-	-
Referral to TB Screening	-	-	-	-	7		(100)%	7	17	-	-	-
Referrals to TB Screening	-	-	-	-	7		(100)%	7	17	-	-	-
TB Diagnosis	2	-	2	5	3		(33)%	11	46	2	-	-
TB Diagnosis	2	-	2	5	3		(33)%	11	46	2	-	-
TB Screening	168	224	542	1,086	601		(10)%	2,591	6,171	542	-	-
TB Screening	168	224	542	1,086	601		(10)%	2,591	6,171	542	-	-
Kyrgyzstan											-	119
Free Condom	-	-	-	70,000	27,144		(100)%	30,144	30,144	-	-	-
Generic Male Condom	-	-	-	70,000	27,144	11/17	(100)%	30,144	30,144	-	-	-
Free Female Condom	-	-	-	-	13,000		(100)%	13,000	13,000	-	-	-
Generic Female Condom	-	-	-	-	13,000	11/17	(100)%	13,000	13,000	-	-	-
HIV Testing Services	1,388	1,653	4,549	16,165	5,603		(19)%	25,008	43,025	4,549	-	8
VCT Individual (HIV-Negative)	1,360	1,620	4,447	15,831	5,497		(19)%	24,608	42,287	4,447	-	8
VCT Individual (HIV-Positive)	28	33	102	334	106		(4)%	400	738	102	-	-
Referral to Linkage to HIV Care	24	38	105	287	84		25%	456	1,623	105	-	110

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Linkage to HIV Care	24	38	105	287	84		25%	456	1,623	105	-	110
Referral to Opioid Treatment	-	3	3	-	26		(88)%	44	193	3	-	-
Referral to Opioid Treatment	-	3	3	-	26		(88)%	44	193	3	-	-
Referral to TB Screening	-	-	-	-	13		(100)%	13	25	-	-	-
Referrals to TB Screening	-	-	-	-	13		(100)%	13	25	-	-	-
TB Diagnosis	-	1	2	10	2		0%	8	40	2	-	-
TB Diagnosis	-	1	2	10	2		-%	8	40	2	-	-
TB Screening	72	107	263	1,000	384		(32)%	1,418	6,854	263	-	-
TB Screening	72	107	263	1,000	384		(32)%	1,418	6,854	263	-	-
Laos											26,335	6,924
Condom	259,200	404,084	1,038,240	3,500,000	1,166,961		(11)%	3,760,689	32,259,711	7,787	7,787	2,219
No 1 Condom Grp	34,560	69,929	156,960	328,032	200,448	11/10	(22)%	628,416	5,065,828	1,177	1,177	335
No 1 Condom Orange	-	-	-	372,032	-		-%	-	-	-	-	-
No 1 Condom Strw	120,960	172,827	466,560	1,277,856	430,704	8/08	8%	1,901,232	16,533,672	3,499	3,499	997
No 1 Condom Super Thin	-	-	-	148,608	-		-%	-	-	-	-	-
Number One Rose	103,680	161,328	414,720	1,373,472	535,809	4/08	(23)%	1,231,041	10,660,211	3,110	3,110	886
Fever Cases Attended	3,803	4,053	12,144	60,000	6,208		96%	43,091	66,296	12,144	-	-
Fever Cases Attended	3,803	4,053	12,144	60,000	6,208		96%	43,091	66,296	12,144	-	-
Fever Cases Tested with RDTs	3,803	4,053	12,144	60,000	6,207		96%	43,075	66,266	12,144	-	-
Fever Cases Tested with RDTs	3,803	4,053	12,144	60,000	6,207		96%	43,075	66,266	12,144	-	-
HIV Testing Services	491	441	1,385	5,641	1,239		12%	5,345	20,782	1,385	-	1
VCT Individual (HIV-Negative)	485	440	1,377	5,621	1,225		12%	5,309	20,601	1,377	-	1
VCT Individual (HIV-Positive)	6	1	8	20	14		(43)%	36	181	8	-	-
Implant 3 Insertion	877	1,029	2,796	11,031	2,381		17%	11,434	27,093	2,796	6,990	1,755

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Implant 3 Inserted	877	1,029	2,796	11,031	2,381		17%	11,434	27,093	2,796	6,990	1,755
Injectable 3-IM	-	-	-	-	-		0%	(1,586)	(1,586)	-	-	-
(b)PSI Injectable 3 IM Distributed Provided	-	-	-	-	-		-%	(1,586)	(1,586)	-	-	-
Injectable 3-IM Provided	1,452	1,808	5,027	17,304	3,337		51%	19,748	42,484	1,257	1,257	233
Non-PSI Injectable 3 IM Provided	1,452	1,808	5,027	17,304	3,337		51%	18,162	40,898	1,257	1,257	233
PSI Injectable 3 IM Provided	-	-	-	-	-		-%	1,586	1,586	-	-	-
IUD 10	(58)	(59)	(181)	-	-		0%	(260)	(441)	(163)	(749)	(175)
(b)PSI IUD 10 Distributed Inserted	(58)	(59)	(181)	-	-		-%	(260)	(441)	(163)	(749)	(175)
IUD 10 Insertion	680	876	2,296	10,176	2,706		(15)%	11,005	47,985	2,296	10,562	2,469
Non-PSI IUD 10 Inserted	622	817	2,115	10,176	2,706		(22)%	10,745	47,544	2,115	9,729	2,274
PSI IUD 10 Inserted	58	59	181	-	-		-%	260	441	181	833	195
IUD 5	-	-	-	-	-		0%	800	2,610	-	-	-
IUD Cu375	-	-	-	-	-	7/12	-%	800	2,610	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	220	-		0%	-	-	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	220	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	81		(100)%	81	81	-	-	-
Manual Vacuum Aspiration for SA	-	-	-	-	81		(100)%	81	81	-	-	-
Misoprostol for PAC Provided	-	-	-	-	70		(100)%	70	70	-	-	-
Non-PSI Misoprostol for PAC Provided	-	-	-	-	52		(100)%	52	52	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	-	18		(100)%	18	18	-	-	-
Misoprostol for Safe Abortion	-	27,333	53,000	172,876	53,928		(2)%	202,928	649,398	2,782	-	253
Misoprostol for Safe Abortion	-	27,333	53,000	172,876	54,000		(2)%	203,000	649,470	2,782	-	253
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	-	(72)		-%	(72)	(72)	-	-	-
OCs	-	-	-	-	-		0%	(2,241)	(2,241)	-	-	-
(b)PSI OCs Distributed Provided	-	-	-	-	-		-%	(2,241)	(2,241)	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs Provided	2,234	2,624	7,345	24,784	5,000		47%	29,665	61,057	490	490	96
Non-PSI OCs Provided	2,234	2,624	7,345	24,784	5,000		47%	27,424	58,816	490	490	96
PSI OCs Provided	-	-	-	-	-		-%	2,241	2,241	-	-	-
Positive RDTs	67	116	320	1,500	279		15%	1,324	2,207	320	-	-
Positive RDTs	67	116	320	1,500	279		15%	1,324	2,207	320	-	-
Positive RDTs Given First Line Treatment	67	116	320	825	279		15%	1,324	2,207	320	-	-
Positive RDTs Given First Line Treatment	67	116	320	825	279		15%	1,324	2,207	320	-	-
QAACTs Provided after Confirmatory Diagnosis	67	116	320	825	279		15%	1,324	2,207	320	-	60
Non-PSI QAACTs Provided after Confirmed Diagnosis	67	116	320	825	279		15%	1,324	2,207	320	-	60
Referral to TB DOTS (completion confirmed)	-	12	35	110	57		(39)%	148	426	35	-	12
Referral to TB DOTS (completion confirmed)	-	12	35	110	57		(39)%	148	426	35	-	12
Referral to TB DOTS (completion unknown)	-	1	4	-	1		300%	43	248	4	-	1
Referral to TB DOTS (completion unknown)	-	1	4	-	1	12/13	300%	43	248	4	-	1
TB Diagnosis	-	16	47	370	52		(10)%	185	836	47	-	-
TB Diagnosis	-	16	47	370	52		(10)%	185	836	47	-	-
TB Screening	-	70	209	-	176		19%	755	3,226	209	-	-
TB Screening	-	70	209	-	176		19%	755	3,226	209	-	-
Nepal											1,660	2,997
Emergency Contraception	-	-	-	-	80		(100)%	221	221	-	-	-
i-pill	-	-	-	-	80	7/17	(100)%	221	221	-	-	-
Free Condom	-	-	-	-	689		(100)%	2,148	574,282	-	-	-
Generic Condom	-	-	-	-	689	1/16	(100)%	2,148	574,282	-	-	-
Implant 5	-	-	-	-	-		0%	(34)	(1,377)	-	-	-
(b)PSI Implant 5 Distributed Inserted	-	-	-	-	-		-%	(34)	(1,377)	-	-	-
Implant 5 Insertion	5	9	29	428	6		383%	75	1,714	29	110	21

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI Implant 5 Inserted	5	9	29	428	6		383%	41	337	29	110	21
PSI Implant 5 Inserted	-	-	-	-	-		-%	34	1,377	-	-	-
IUD 10	(1,255)	(8,484)	(2,980)	3,959	1,638		(282)%	(9,464)	(183,135)	(2,682)	(12,337)	(2,173)
OK IUD	-	(7,500)	-	21,141	9,650		(100)%	23,060	41,310	-	-	-
Pregna T Cu 380A	-	-	-	-	20	7/17	(100)%	20	40	-	-	-
(b)PSI IUD 10 Distributed Inserted	(1,255)	(984)	(2,980)	(17,182)	(8,032)		-%	(32,544)	(224,485)	(2,682)	(12,337)	(2,173)
IUD 10 Insertion	1,272	1,015	3,019	17,182	8,365		(64)%	33,521	235,944	3,019	13,887	2,446
Non-PSI IUD 10 Inserted	17	31	39	-	333		(88)%	977	11,458	39	179	32
PSI IUD 10 Inserted	1,255	984	2,980	17,182	8,032		(63)%	32,544	224,485	2,980	13,708	2,414
Manual Vacuum Aspiration for PAC	-	-	-	-	-		0%	12	12	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	-	-		-%	12	12	-	-	-
Manual Vacuum Aspiration for SA	-	3	8	236	-		0%	170	178	8	-	1
Manual Vacuum Aspiration for SA	-	3	8	236	-		-%	170	178	8	-	1
Medical Abortion	9,600	7,588	21,578	99,716	34,761		(38)%	122,575	386,621	19,420	-	2,687
Medabon	9,600	7,626	21,690	104,504	34,761		(38)%	123,798	387,956	19,521	-	2,701
(b)PSI Medical Abortion Distributed Provided	-	(37)	(112)	(4,788)	-		-%	(1,223)	(1,335)	(101)	-	(14)
Medical Abortion Provided	-	37	112	4,788	-		0%	1,263	1,375	112	-	15
Non-PSI Medical Abortion Provided	-	-	-	-	-		-%	40	40	-	-	-
PSI Medical Abortion Provided	-	37	112	4,788	-		-%	1,223	1,335	112	-	15
OCs	-	-	-	-	4,961		(100)%	15,134	158,306	-	-	-
Zinnia	-	-	-	-	176	8/15	(100)%	554	143,726	-	-	-
Zinnia - F	-	-	-	-	4,785	7/17	(100)%	14,580	14,580	-	-	-
STI Screening	-	-	-	-	39		(100)%	39	1,198	-	-	-
STI Screening	-	-	-	-	39		(100)%	39	1,198	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Nicaragua											16,097	3,878
Condom	487,848	330,664	1,296,720	-	1,178,376		10%	3,880,941	76,093,949	9,725	9,725	2,815
Bodyguard	-	-	-	-	-	2/04	-%	(1,613)	11,095,477	-	-	-
Combo-Pack Lub Fresa	-	288	864	-	4,320	5/11	(80)%	14,866	70,282	6	6	2
Combo-Pack Lub Natural	-	-	-	-	(432)	10/10	-%	(3,374)	23,618	-	-	-
Vive	366,768	205,952	892,224	-	743,472	4/98	20%	2,580,363	49,003,067	6,692	6,692	1,937
Vive Colors/Mas Colors	85,536	86,592	287,640	-	291,840	4/02	(1)%	864,750	11,892,146	2,157	2,157	625
Vive Mas Fuerte /Retardante	30,456	29,408	97,296	-	109,560	6/04	(11)%	325,560	2,251,910	730	730	211
Vive Mas Natural /Sensitivo	5,184	8,424	18,792	-	26,304	6/04	(29)%	88,989	1,007,552	141	141	41
Vive Mas/Texturizado	(96)	-	(96)	-	3,312	6/04	(103)%	11,400	749,897	(1)	(1)	-
HIV Testing Services	66	70	231	614	93		148%	687	7,949	231	-	-
VCT Individual (HIV-Negative)	61	63	209	578	90		132%	648	7,796	209	-	-
VCT Individual (HIV-Positive)	5	7	22	36	3		633%	39	153	22	-	-
Implant 3	(83)	265	761	-	(6)		0%	789	2,111	685	1,712	287
Implanon	141	294	1,021	-	-	7/15	-%	1,506	4,036	919	2,297	385
(b)PSI Implant 3 Distributed Inserted	(224)	(29)	(260)	-	(6)	3/16	-%	(717)	(1,925)	(234)	(585)	(98)
Implant 3 Insertion	318	51	387	-	27		1333%	974	2,330	387	968	162
Non-PSI Implant 3 Inserted	94	22	127	-	21		505%	257	405	127	318	53
PSI Implant 3 Inserted	224	29	260	-	6	3/16	4,233%	717	1,925	260	650	109
Implant 5	(4)	(1)	(4)	-	702		(101)%	474	2,369	(4)	(14)	(2)
Jadelle	-	-	-	-	1,146	12/08	(100)%	1,195	6,080	-	-	-
(b)PSI Implant 5 Distributed Inserted	(4)	(1)	(4)	-	(444)		-%	(721)	(3,711)	(4)	(14)	(2)
Implant 5 Insertion	4	1	4	-	444		(99)%	721	3,711	4	15	3
PSI Implant 5 Inserted	4	1	4	-	444		(99)%	721	3,711	4	15	3

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Injectable 1 Provided	61	21	115	-	61		89%	312	715	9	9	1
Non-PSI Injectable 1 Provided	61	21	115	-	61		89%	312	715	9	9	1
Injectable 3-IM Provided	13	6	28	-	10		180%	62	139	7	7	1
Non-PSI Injectable 3 IM Provided	13	6	28	-	10		180%	62	139	7	7	1
IUD 10	(209)	162	179	-	701		(74)%	2,979	40,389	161	741	117
Copper T 380	144	254	689	-	1,286	12/08	(46)%	5,325	85,564	620	2,852	449
Copper-T 380-A IUD	5	13	25	-	-	3/16	-%	84	171	23	103	16
(b)PSI IUD 10 Distributed Inserted	(358)	(105)	(535)	-	(585)		-%	(2,430)	(45,346)	(482)	(2,215)	(349)
IUD 10 Insertion	358	105	535	-	585		(9)%	2,430	45,346	535	2,461	388
PSI IUD 10 Inserted	358	105	535	-	585		(9)%	2,430	45,346	535	2,461	388
IUD 5	(6)	14	37	-	120		(69)%	659	1,024	33	110	18
Copper T375 Sleek	19	17	66	-	130	3/16	(49)%	732	1,138	59	196	33
(b)PSI IUD 5 Distributed Inserted	(25)	(2)	(29)	-	(10)		-%	(73)	(114)	(26)	(86)	(14)
IUD 5 Insertion	25	2	29	-	10		190%	73	114	29	96	16
PSI IUD 5 Inserted	25	2	29	-	10		190%	73	114	29	96	16
IUS 5 Insertion	-	1	3	-	-		0%	2	6	3	10	2
Non-PSI IUS 5 Inserted	-	1	3	-	-		-%	2	6	3	10	2
Lubricant	8,370	13,845	40,635	-	28,116		45%	175,397	1,071,903	-	-	-
Vive Lub (sachet)	4,050	5,100	14,850	-	13,233	3/05	12%	74,450	481,243	-	-	-
Vive Lub (tube)	1,782	1,845	6,372	-	3,564	3/05	79%	18,659	133,356	-	-	-
Vive Lub Natural (sachet)	1,350	4,983	13,500	-	6,702	1/10	101%	63,538	365,683	-	-	-
Vive Lub Natural (tube)	1,188	1,917	5,913	-	4,617	1/10	28%	18,750	91,621	-	-	-
Manual Vacuum Aspiration for PAC	129	46	250	-	113		121%	496	1,658	250	-	10
MVA for PAC	129	46	250	-	113	5/16	121%	496	1,658	250	-	10
Misoprostol for PAC Provided	33	10	62	-	10		520%	82	192	62	-	3

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PSI Misoprostol for PAC Provided	33	10	62	-	10		520%	82	192	62	-	3
Misoprostol for Safe Abortion	38	1,068	4,034	-	1,224		230%	37,641	49,599	212	-	8
Misoprostol for Safe Abortion	170	1,109	4,282	-	1,264	3/18	239%	37,969	50,367	225	-	9
(b)PSI Misoprostol for Safe Abortion Dist Provided	(132)	(41)	(248)	-	(40)		-%	(328)	(768)	(13)	-	(1)
OCs Provided	60	23	102	-	33		209%	300	574	7	7	1
Non-PSI OCs Provided	60	23	102	-	33		209%	300	574	7	7	1
Referral to Linkage to HIV Care	-	-	-	-	1		(100)%	2	39	-	-	-
Referral to Linkage to HIV Care	-	-	-	-	1		(100)%	2	39	-	-	-
Tubal Ligation	21	2	25	-	26		(4)%	113	161	25	250	48
Tubal Ligation	21	2	25	-	26		(4)%	113	161	25	250	48
Nicaragua SA												
Condom	-	-	-	4,306,525	-		0%	-	-	-	-	-
Combo-Pack Lub Fresa	-	-	-	15,530	-		-%	-	-	-	-	-
Vive	-	-	-	2,948,290	-		-%	-	-	-	-	-
Vive Colors/Mas Colors	-	-	-	872,758	-		-%	-	-	-	-	-
Vive Mas Fuerte /Retardante	-	-	-	378,032	-		-%	-	-	-	-	-
Vive Mas Natural /Sensitivo	-	-	-	91,915	-		-%	-	-	-	-	-
Implant 3	-	-	-	4,860	-		0%	-	-	-	-	-
Implanon	-	-	-	5,784	-		-%	-	-	-	-	-
(b)PSI Implant 3 Distributed Inserted	-	-	-	(924)	-		-%	-	-	-	-	-
Implant 3 Insertion	-	-	-	924	-		0%	-	-	-	-	-
PSI Implant 3 Inserted	-	-	-	924	-		-%	-	-	-	-	-
Injectable 1	-	-	-	13,832	-		0%	-	-	-	-	-
Cyclofem	-	-	-	13,832	-		-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 10	-	-	-	3,612	-		0%	-	-	-	-	-
Copper T 380	-	-	-	6,000	-		-%	-	-	-	-	-
(b)PSI IUD 10 Distributed Inserted	-	-	-	(2,388)	-		-%	-	-	-	-	-
IUD 10 Insertion	-	-	-	2,388	-		0%	-	-	-	-	-
PSI IUD 10 Inserted	-	-	-	2,388	-		-%	-	-	-	-	-
Manual Vacuum Aspiration for PAC	-	-	-	600	-		0%	-	-	-	-	-
MVA for PAC	-	-	-	600	-		-%	-	-	-	-	-
Misoprostol for PAC Provided	-	-	-	300	-		0%	-	-	-	-	-
PSI Misoprostol for PAC Provided	-	-	-	300	-		-%	-	-	-	-	-
Misoprostol for Safe Abortion	-	-	-	64,920	-		0%	-	-	-	-	-
Misoprostol for Safe Abortion	-	-	-	66,120	-		-%	-	-	-	-	-
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	-	-	(1,200)	-		-%	-	-	-	-	-
OCs	-	-	-	120,000	-		0%	-	-	-	-	-
Segura Plus	-	-	-	120,000	-		-%	-	-	-	-	-
Pakistan											698,221	219,476
Condom	17,861,472	11,606,784	33,679,176	106,540,076	36,171,023		(7)%	133,792,588	2,681,786,955	252,594	252,594	57,509
Do	136,800	168,720	510,120	2,002,578	255,600	8/17	100%	1,581,084	3,260,124	3,826	3,826	871
Sathi	16,248,432	10,053,264	28,688,256	89,986,310	31,444,957	1/87	(9)%	116,349,078	2,417,415,769	215,162	215,162	48,986
Sathi Plus	360,960	356,160	1,226,400	2,550,929	613,440	8/17	100%	2,133,120	4,475,520	9,198	9,198	2,094
Touch	1,030,320	921,240	2,916,000	11,226,177	3,635,986	4/96	(20)%	13,002,106	254,695,502	21,870	21,870	4,979
Touch Delay	84,960	107,400	338,400	774,082	221,040	8/17	53%	727,200	1,940,040	2,538	2,538	578
Emergency Contraception	200,710	239,774	620,953	857,425	495,429		25%	2,065,123	9,526,216	27,943	27,943	4,887
ECP	203,060	242,407	628,680	857,425	500,280		26%	2,080,232	9,576,836	28,291	28,291	4,948
(b)PSI Emergency Contraception Distributed Provided	(2,350)	(2,632)	(7,727)	-	(4,851)		-%	(15,109)	(50,620)	(348)	(348)	(61)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Emergency Contraception Provided	2,350	2,632	7,727	-	4,851		59%	15,109	50,620	386	386	68
PSI Emergency Contraception Provided	2,350	2,632	7,727	-	4,851		59%	15,109	50,620	386	386	68
Implant 5	-	17	51	45	10,212		(100)%	10,646	25,030	46	174	54
Jadelle	-	17	51	45	10,212		(100)%	10,646	25,030	46	174	54
Injectable 1	20,660	10,395	45,144	92,496	14,939		202%	99,805	1,748,359	3,125	3,125	777
Femi-ject	25,400	13,867	57,100	92,496	21,700		163%	122,300	1,871,313	3,953	3,953	983
(b)PSI Injectable 1 Distributed Provided	(4,740)	(3,472)	(11,956)	-	(6,761)		-%	(22,495)	(122,954)	(828)	(828)	(206)
Injectable 1 Provided	4,740	3,472	11,956	-	6,761		77%	22,495	122,954	920	920	229
PSI Injectable 1 Provided	4,740	3,472	11,956	-	6,761		77%	22,495	122,954	920	920	229
Injectable 2	(445)	13,684	24,347	19,731	75,315		(68)%	134,028	7,108,430	3,652	3,652	838
Novaject	-	14,059	25,378	19,731	81,480		(69)%	144,514	7,186,636	3,807	3,807	874
(b)PSI Injectable 2 Distributed Provided	(445)	(376)	(1,031)	-	(6,165)		-%	(10,486)	(78,206)	(155)	(155)	(35)
Injectable 2 Provided	445	376	1,031	-	6,165		(83)%	10,486	78,206	172	172	39
PSI Injectable 2 Provided	445	376	1,031	-	6,165		(83)%	10,486	78,206	172	172	39
Injectable 3-IM	18,013	21,396	54,281	226,792	76,711		(29)%	406,105	2,945,173	12,213	12,213	2,803
Depo-Provera	20,273	27,280	67,714	226,792	88,793		(24)%	451,716	3,063,897	15,236	15,236	3,497
(b)PSI Injectable 3 IM Distributed Provided	(2,260)	(5,884)	(13,433)	-	(12,082)		-%	(45,611)	(118,724)	(3,022)	(3,022)	(694)
Injectable 3-IM Provided	2,260	5,884	13,433	-	12,082		11%	45,611	118,724	3,358	3,358	771
PSI Injectable 3 IM Provided	2,260	5,884	13,433	-	12,082		11%	45,611	118,724	3,358	3,358	771
IUD 10	34,621	1,072	37,621	70,778	19,437		94%	47,316	232,880	33,859	155,751	45,685
Safeload	34,621	1,072	37,621	70,778	19,437		94%	47,316	232,880	33,859	155,751	45,685
IUD 5	(4,954)	8,693	20,284	94,294	(10,629)		0%	20,275	3,034,858	18,256	60,243	18,811
Multiloader	3,000	21,514	66,700	-	20,115	12/95	232%	81,850	4,013,226	60,030	198,099	61,858
Protect 5	-	-	-	94,294	-		-%	-	-	-	-	-
(b)PSI IUD 5 Distributed Inserted	(7,954)	(12,821)	(46,416)	-	(30,744)		-%	(61,575)	(978,368)	(41,774)	(137,856)	(43,046)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IUD 5 Insertion	7,954	12,821	46,416	-	30,744		51%	61,575	978,368	46,416	153,173	47,829
PSI IUD 5 Inserted	7,954	12,821	46,416	-	30,744		51%	61,575	978,368	46,416	153,173	47,829
Manual Vacuum Aspiration for PAC	4,594	6,314	23,536	-	12,857		83%	27,052	110,372	23,536	-	1,205
Manual Vacuum Aspiration for PAC	4,594	6,314	23,536	-	12,857		83%	27,052	110,372	23,536	-	1,205
Misoprostol for PAC Provided	-	4,832	14,496	-	21,768		(33)%	46,571	61,067	14,496	-	891
PSI Misoprostol for PAC Provided	-	4,832	14,496	-	21,768		(33)%	46,571	61,067	14,496	-	891
Misoprostol for Safe Abortion	201,600	121,439	543,916	-	208,808		160%	982,646	1,825,362	28,556	-	2,217
Misoprostol for Safe Abortion	201,600	140,767	601,900	-	295,880	3/18	103%	1,168,930	2,069,630	31,600	-	2,453
(b)PSI Misoprostol for Safe Abortion Dist Provided	-	(19,328)	(57,984)	-	(87,072)		-%	(186,284)	(244,268)	(3,044)	-	(236)
OCs	309,339	31,847	406,587	475,234	342,663		19%	963,276	4,279,860	24,395	24,395	5,907
Novadol	309,759	32,952	408,399	475,234	357,876		14%	1,004,634	4,489,779	24,504	24,504	5,934
(b)PSI OCs Distributed Provided	(420)	(1,105)	(1,812)	-	(15,213)		-%	(41,358)	(209,919)	(109)	(109)	(26)
OCs Provided	420	1,105	1,812	-	15,213		(88)%	41,358	209,919	121	121	29
PSI OCs Provided	420	1,105	1,812	-	15,213		(88)%	41,358	209,919	121	121	29
TB Diagnosis	2,378	2,115	6,445	-	7,268		(11)%	29,215	85,821	6,445	-	-
TB Diagnosis	2,378	2,115	6,445	-	7,268		(11)%	29,215	85,821	6,445	-	-
TB DOTS	2,274	2,046	6,321	-	5,580		13%	26,012	119,796	6,321	-	28,928
TB DOTS	2,274	2,046	6,321	-	5,580	4/05	13%	26,012	119,796	6,321	-	28,928
TB Screening	5,499	4,132	13,894	-	18,008		(23)%	65,777	133,192	13,894	-	-
TB Screening	5,499	4,132	13,894	-	18,008		(23)%	65,777	133,192	13,894	-	-
Panama											5,338	1,416
Condom	114,360	233,320	711,744	3,696,114	931,632		(24)%	3,308,400	43,899,102	5,338	5,338	1,397
Vive	71,472	178,992	572,592	2,951,521	737,520	7/00	(22)%	2,656,128	36,401,921	4,294	4,294	1,124
Vive Colors/Mas Colors	19,944	29,728	66,408	376,881	90,144	3/05	(26)%	263,112	4,103,340	498	498	130
Vive Mas Fuerte /Retardante	20,472	11,608	38,496	259,851	62,208	3/05	(38)%	240,288	1,801,783	289	289	76

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Vive Mas Natural /Sensitivo	2,472	6,720	22,632	107,861	30,696	3/05	(26)%	92,832	882,425	170	170	44
Vive Mas/Texturizado	-	6,272	11,616	-	11,064	3/05	5%	56,040	709,633	87	87	23
HIV Testing Services	211	119	483	1,731	292		65%	1,395	19,260	483	-	1
VCT Individual (HIV-Negative)	189	107	432	1,564	257		68%	1,259	18,532	432	-	1
VCT Individual (HIV-Positive)	22	12	51	167	35		46%	136	728	51	-	-
Lubricant	-	(5,439)	(9,903)	-	18,700		(153)%	21,742	457,283	-	-	-
Vive Lub (sachet)	-	(67)	(200)	-	9,200		(102)%	9,200	268,026	-	-	-
Vive Lub (tube)	-	(4)	-	-	3,050		(100)%	10,843	76,283	-	-	-
Vive Lub Natural (sachet)	-	(5,367)	(9,700)	-	3,900		(349)%	(850)	49,705	-	-	-
Vive Lub Natural (tube)	-	(1)	(3)	-	2,550		(100)%	2,549	63,269	-	-	-
Referral to Linkage to HIV Care	15	11	38	-	22		73%	112	300	38	-	18
Referral to Linkage to HIV Care	15	11	38	-	22		73%	112	300	38	-	18
Papua New Guinea												3
Condom	-	-	-	200,000	60,819		(100)%	62,259	8,050,159	-	-	-
Seif Raida	-	-	-	120,000	59,552	1/08	(100)%	59,552	6,969,005	-	-	-
Seif Raida Orange Plus	-	-	-	80,000	1,267	8/13	(100)%	2,707	1,081,154	-	-	-
Diarrhea Treatment Kit	-	-	-	2,914	-		0%	-	18,236	-	-	-
DTK	-	-	-	2,914	-		-%	-	18,236	-	-	-
Emergency Contraception	-	-	-	30,000	-		0%	-	-	-	-	-
Emergency Contraception	-	-	-	30,000	-		-%	-	-	-	-	-
Female Condom	-	-	-	-	20		(100)%	100	338,539	-	-	-
Stap Seif	-	-	-	-	20	2/09	(100)%	100	338,539	-	-	-
Free Condom	-	-	-	300,800	-		0%	-	-	-	-	-
Generic Male Condom	-	-	-	300,800	-		-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Free Female Condom	-	-	-	30,000	-		0%	-	-	-	-	-
Generic Female Condom	-	-	-	30,000	-		-%	-	-	-	-	-
Malaria PPT (ACT)	-	-	-	-	7,782		(100)%	7,782	845,477	-	-	-
Coartem 1x12's for 1-5 years old	-	-	-	-	95	8/15	(100)%	95	125,793	-	-	-
Coartem 1x18's for 6-13 years old	-	-	-	-	4,535	8/15	(100)%	4,535	275,970	-	-	-
Coartem 1x24's for 14+ years old	-	-	-	-	1,490	8/15	(100)%	1,490	259,952	-	-	-
Coartem 1x6's for 2-11 months	-	-	-	-	1,662	8/15	(100)%	1,662	183,762	-	-	-
Malaria RDK	-	-	-	-	4,469		(100)%	4,469	1,361,956	-	-	-
Carestart Malaria HRP2/pLDH (pf/PAN)	-	-	-	-	4,469	10/13	(100)%	4,469	1,361,956	-	-	-
ORS	10	1	12	-	-		0%	-	29,246	5	-	-
ORS	10	1	12	-	-	12/11	-%	-	29,246	5	-	-
Water Treatment Tablets	500	16,833	51,000	80,000	68,900		(26)%	91,160	1,029,783	838	-	2
Aquatab	500	16,833	51,000	80,000	68,900		(26)%	91,160	1,029,783	838	-	2
Zinc	-	1	2	-	-		0%	-	32,846	2	-	-
Zinc 20 mg	-	1	2	-	-	12/11	-%	-	32,846	2	-	-
PSI Pakistan											108,121	29,143
Condom	527,676	399,036	1,346,177	37,492,943	688,734		95%	3,369,589	8,204,639	10,096	10,096	2,299
Generic Male Condom	527,676	399,036	1,346,177	37,492,943	688,734	4/16	95%	3,369,589	8,204,639	10,096	10,096	2,299
Emergency Contraception Provided	-	-	-	1,146,567	-		0%	-	-	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	1,146,567	-		-%	-	-	-	-	-
Injectable 1 Provided	-	-	-	44,525	-		0%	-	-	-	-	-
Non-PSI Injectable 1 Provided	-	-	-	44,525	-		-%	-	-	-	-	-
Injectable 2 Provided	-	-	-	132,422	-		0%	-	-	-	-	-
Non-PSI Injectable 2 Provided	-	-	-	132,422	-		-%	-	-	-	-	-
Injectable 3-IM	-	(3,479)	(10,437)	-	-		0%	(8,571)	(19,008)	(2,348)	(2,348)	(539)

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Injectable 3 IM Distributed Provided	-	(3,479)	(10,437)	-	-		-%	(8,571)	(19,008)	(2,348)	(2,348)	(539)
Injectable 3-IM Provided	34,055	22,102	67,038	744,325	96,817		(31)%	280,576	572,949	16,760	16,760	3,847
Non-PSI Injectable 3 IM Provided	34,055	18,623	56,601	744,325	96,817		(42)%	272,005	553,941	14,150	14,150	3,248
PSI Injectable 3 IM Provided	-	3,479	10,437	-	-		-%	8,571	19,008	2,609	2,609	599
IUD 10 Insertion	5,238	4,358	13,976	65,609	11,709		19%	61,472	140,958	13,976	64,290	18,857
Non-PSI IUD 10 Inserted	5,238	4,358	13,976	65,609	11,709		19%	61,472	140,958	13,976	64,290	18,857
IUD 5 Insertion	-	-	-	65,998	1,862		(100)%	1,928	7,248	-	-	-
Non-PSI IUD 5 Inserted	-	-	-	65,998	1,862		(100)%	1,928	7,248	-	-	-
OCs	-	(20,076)	(60,229)	-	-		0%	(33,625)	(93,854)	(3,614)	(3,614)	(875)
(b)PSI OCs Distributed Provided	-	(20,076)	(60,229)	-	-		-%	(33,625)	(93,854)	(3,614)	(3,614)	(875)
OCs Provided	143,930	108,531	344,060	1,576,577	197,137		75%	773,098	1,565,027	22,937	22,937	5,554
Non-PSI OCs Provided	143,930	88,455	283,831	1,576,577	197,137		44%	739,473	1,471,173	18,922	18,922	4,582
PSI OCs Provided	-	20,076	60,229	-	-		-%	33,625	93,854	4,015	4,015	972
Tajikistan											247	354
Free Condom	9,000	223,971	33,000	219,360	314,200		(89)%	1,137,682	1,492,334	247	247	138
Generic Male Condom	9,000	223,971	33,000	219,360	314,200	8/16	(89)%	1,137,682	1,492,334	247	247	138
HIV Testing Services	1,462	1,325	4,400	18,627	4,658		(6)%	16,547	36,194	4,400	-	14
VCT Individual (HIV-Negative)	1,420	1,290	4,283	18,094	4,516		(5)%	16,076	35,227	4,283	-	14
VCT Individual (HIV-Positive)	42	35	117	533	142		(18)%	471	967	117	-	-
Naloxone	-	23	-	3,089	-		0%	2,570	16,713	-	-	-
Naloxone	-	23	-	3,089	-		-%	2,570	16,713	-	-	-
Needle & Syringe	-	6,567	-	1,085,760	76,800		(100)%	689,065	2,858,018	-	-	-
Needle/Syringe	-	6,567	-	1,085,760	76,800		(100)%	689,065	2,858,018	-	-	-
Referral to HIV Testing Services	-	1	3	6	-		0%	4	15,110	3	-	-
Referral to HIV Testing Services	-	1	3	6	-		-%	4	15,110	3	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Linkage to HIV Care	86	78	253	731	129		96%	691	1,856	253	-	201
Referral to Linkage to HIV Care	86	78	253	731	129		96%	691	1,856	253	-	201
Referral to Opioid Treatment	6	2	8	37	21		(62)%	65	197	8	-	-
Referral to Opioid Treatment	6	2	8	37	21		(62)%	65	197	8	-	-
Referral to TB Screening	-	-	-	-	1		(100)%	1	8	-	-	-
Referrals to TB Screening	-	-	-	-	1		(100)%	1	8	-	-	-
TB Screening	106	103	286	2,000	233		23%	1,892	7,267	286	-	-
TB Screening	106	103	286	2,000	233		23%	1,892	7,267	286	-	-
Viet Nam											975	1,967
Emergency Contraception	-	-	-	-	(52)		0%	(52)	(104)	-	-	-
(b)PSI Emergency Contraception Distributed Provided	-	-	-	-	(52)		-%	(52)	(104)	-	-	-
Emergency Contraception Provided	-	-	-	-	98		(100)%	225	886	-	-	-
Non-PSI Emergency Contraception Provided	-	-	-	-	46		(100)%	173	782	-	-	-
PSI Emergency Contraception Provided	-	-	-	-	52		(100)%	52	104	-	-	-
Fever Cases Tested with RDTs	1,252	1,912	5,023	20,000	-		0%	15,898	20,921	5,023	-	-
Fever Cases Tested with RDTs	1,252	1,912	5,023	20,000	-		-%	15,898	20,921	5,023	-	-
HIV Testing Services	38	218	552	552	1,098		(50)%	6,827	12,603	552	-	1
VCT Individual (HIV-Negative)	36	209	527	527	1,039		(49)%	6,402	11,753	527	-	1
VCT Individual (HIV-Positive)	2	9	25	25	59		(58)%	425	850	25	-	-
Hypertension Diagnosis	1,578	981	4,520	14,572	10,385		(56)%	26,102	56,955	4,520	-	-
Hypertension Diagnosis	1,578	981	4,520	14,572	10,385		(56)%	26,102	56,955	4,520	-	-
Hypertension Screening	34,502	31,518	99,235	150,000	131,496		(25)%	413,475	714,924	99,235	-	-
Hypertension Screening	34,502	31,518	99,235	150,000	131,496		(25)%	413,475	714,924	99,235	-	-
Hypertension_Controlled Condition	2,025	2,072	6,280	13,009	7,681		(18)%	30,443	56,831	2,512	-	-
Hypertension_Controlled Condition	2,025	2,072	6,280	13,009	7,681		(18)%	30,443	56,831	2,512	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implant 3	17	49	117	60	223		(48)%	892	1,310	105	263	10
Implanon NXT	26	64	163	300	316		(48)%	1,147	1,646	147	367	14
(b)PSI Implant 3 Distributed Inserted	(9)	(15)	(46)	(240)	(93)		-%	(255)	(336)	(41)	(104)	(4)
Implant 3 Insertion	9	15	46	240	100		(54)%	267	393	46	115	4
Non-PSI Implant 3 Inserted	-	-	-	-	7		(100)%	12	57	-	-	-
PSI Implant 3 Inserted	9	15	46	240	93		(51)%	255	336	46	115	4
Injectable 1	-	-	-	-	(2)		0%	(2)	(4)	-	-	-
(b)PSI Injectable 1 Distributed Provided	-	-	-	-	(2)		-%	(2)	(4)	-	-	-
Injectable 1 Provided	2	-	2	-	2		0%	2	46	-	-	-
Non-PSI Injectable 1 Provided	2	-	2	-	-		-%	-	42	-	-	-
PSI Injectable 1 Provided	-	-	-	-	2		(100)%	2	4	-	-	-
Injectable 3-IM	1,039	4	1,056	-	(2)		0%	440	1,729	238	238	7
Depoteron	1,050	17	1,100	-	-	2/17	-%	712	2,283	248	248	7
(b)PSI Injectable 3 IM Distributed Provided	(11)	(13)	(44)	-	(2)		-%	(272)	(554)	(10)	(10)	-
Injectable 3-IM Provided	21	26	74	-	132		(44)%	735	1,631	19	19	1
Non-PSI Injectable 3 IM Provided	10	13	30	-	130		(77)%	463	1,077	8	8	-
PSI Injectable 3 IM Provided	11	13	44	-	2		2,100%	272	554	11	11	-
Injectable 3-SC	-	-	-	1,400	-		0%	-	-	-	-	-
(b)PSI Injectable 3 SC Distributed Provided	-	-	-	(5,600)	-		-%	-	-	-	-	-
Sayana Press	-	-	-	7,000	-		-%	-	-	-	-	-
Injectable 3-SC Provided	-	-	-	5,600	-		0%	-	-	-	-	-
PSI Injectable 3 SC Provided	-	-	-	5,600	-		-%	-	-	-	-	-
IUD 10	-	-	-	-	-		0%	50	150	-	-	-
Copper-T 380-A IUD	-	-	-	-	-	9/16	-%	50	150	-	-	-
IUD 10 Insertion	16	34	74	-	79		(6)%	396	665	74	340	12

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Non-PSI IUD 10 Inserted	16	34	74	-	79		(6)%	396	665	74	340	12
LLIN (Hammock net)	300	133	700	1,350	435		61%	1,259	2,004	630	-	-
Tana Nets	300	133	700	1,350	435		61%	1,259	2,004	630	-	-
Malaria PPT (ACT)	-	(18)	-	-	-		0%	(210)	(210)	-	-	-
(b)PSI QAACTs Distributed Provided after Diagnosis	-	(18)	-	-	-		-%	(210)	(210)	-	-	-
Malaria PPT (Non-ACT)	-	(14)	-	-	-		0%	(141)	(141)	-	-	-
(b)PSI Vivax Tx Distributed Provided after Diagnosis	-	(14)	-	-	-		-%	(141)	(141)	-	-	-
Malaria RDK	720	1,790	6,060	25,000	3,700		64%	24,220	30,280	5,454	-	-
On-site Malaria Pf/Pv Ag Rapid Test	-	40	90	-	3,700	10/17	(98)%	24,220	24,310	81	-	-
SD Bioline Malaria Ag Pf/Pv Rapid Test	720	1,750	5,970	25,000	-		-%	-	5,970	5,373	-	-
Needle & Syringe	45,100	319,400	270,100	270,100	614,500		(56)%	5,126,150	22,921,150	942	-	1,900
B-braun Omnican 40 (U-40 Insulin/40I.U.)	45,100	160,700	270,100	270,100	614,500		(56)%	4,610,150	22,405,150	942	-	1,900
Co-pack LDS	-	158,700	-	-	-		-%	516,000	516,000	-	-	-
OCs	-	-	-	-	(70)		0%	(70)	(187)	-	-	-
(b)PSI OCs Distributed Provided	-	-	-	-	(70)		-%	(70)	(187)	-	-	-
OCs Provided	-	-	-	-	127		(100)%	568	1,518	-	-	-
Non-PSI OCs Provided	-	-	-	-	57		(100)%	498	1,331	-	-	-
PSI OCs Provided	-	-	-	-	70		(100)%	70	187	-	-	-
Positive RDTs	69	118	292	690	108		170%	634	1,104	292	-	-
Positive RDTs	69	118	292	690	108		170%	634	1,104	292	-	-
Positive RDTs Given First Line Treatment	51	99	251	550	17		1376%	403	719	251	-	-
Positive RDTs Given First Line Treatment	51	99	251	550	17		1,376%	403	719	251	-	-
QAACTs Provided after Confirmatory Diagnosis	-	18	1	330	17		(94)%	253	316	1	-	-
Non-PSI QAACTs Provided after Confirmed Diagnosis	-	-	1	330	17		(94)%	43	106	1	-	-
PSI QAACTs Provided after Confirmed Diagnosis	-	18	-	-	-		-%	210	210	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Referral to Linkage to HIV Care	19	-	19	19	-		0%	-	19	19	-	11
Referral to Linkage to HIV Care	19	-	19	19	-		-%	-	19	19	-	11
TB Diagnosis	-	-	-	-	196		(100)%	434	5,371	-	-	-
TB Diagnosis	-	-	-	-	196		(100)%	434	5,371	-	-	-
Toilets Sold	177	414	587	750	948		(38)%	4,405	6,890	2,465	-	21
Toilet Type 1, Direct Sales	-	-	-	-	246		(100)%	246	2,144	-	-	-
Toilets Sold	177	414	587	750	702		(16)%	4,159	4,746	2,465	-	21
Vivax Treatment after Confirmatory Diagnosis	-	15	-	248	1		(100)%	156	165	-	-	-
Non-PSI Vivax Treatment after Confirmed Diagnosis	-	-	-	248	1		(100)%	15	24	-	-	-
PSI Vivax Treatment after Confirmed Diagnosis	-	14	-	-	-		-%	141	141	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Foundation Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 3/2019

	New HIV Infections	STI Deaths	PWID Deaths	TB Deaths	CYP*	Maternal Deaths	Unintended Pregnancies	Malaria Deaths	Diarrhea Deaths	Pneumonia Deaths	Cervical Cancer Death	Sum of All Deaths
Foundation Market Group	191	1	-	238	209,344	249	83,652	6,833	74	51	1	9,137
Haiti	113	-	-	238	12,284	5	3,468	59	9	-	-	349
Liberia	20	-	-	-	1,880	2	530	-	1	-	-	11
Madagascar	57	1	-	-	137,474	120	52,898	1,915	10	-	-	2,770
Mali	-	-	-	-	57,027	109	26,453	3,760	-	-	1	4,558
Somaliland	1	-	-	-	679	12	304	3	55	51	-	353
South Sudan	-	-	-	-	-	-	-	1,096	-	-	-	1,096

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 3
 Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Foundation Market Group										209,344	719,316
Acute Malnutrition Screening_CU5	-	130	389	-	-	-%	619,055	619,444	389	-	-
Antiretroviral Treatment (Currently Enrolled)	-	-	-	29,957	-	-%	216,577	486,575	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	87	-	3,317	-	-%	3,898	8,199	-	-	-
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	-	-%	4	4	-	-	-
Cervical Cancer-VIA and Cryotherapy	46	8	52	700	38	37%	189	1,394	52	-	16
Cervical Cancer-VIA/VILI Screening	1,973	465	2,076	35,000	4,135	(50)%	13,295	75,776	2,076	-	-
Chlorhexidine	-	-	-	9,000	76,336	(100)%	107,120	432,844	-	-	-
Condom	56,436	207,640	319,452	2,920,716	374,412	(15)%	3,347,338	69,617,464	2,396	2,396	2,656
Counseling & Tx for Moderate Acute Malnutrition	1,597	4,389	3,559	20,942	-	-%	20,332	23,891	3,559	-	11,132
Diarrhea Treatment Kit	900	21,617	42,140	264,416	62,112	(32)%	179,738	2,305,564	37,926	-	3,974
Diarrhea Treatment Kit Provided	-	-	-	-	620	(100)%	1,812	12,274	-	-	-
Emergency Contraception	(6)	14,946	44,841	15,700	15,223	195%	40,018	83,802	2,018	2,018	549
Emergency Contraception Provided	6	14	39	-	77	(49)%	282	1,378	2	2	1
Fever Cases Attended	12,726	10,753	36,175	202,868	25,029	45%	86,150	502,334	36,175	-	-
Fever Cases Tested with Microscopy	272	3,454	4,653	30,340	10,234	(55)%	56,797	188,895	4,653	-	-
Fever Cases Tested with RDTs	8,737	27,092	50,797	172,438	51,155	(1)%	274,829	1,187,636	50,797	-	-
Free Condom	764,208	1,106,490	1,721,070	21,468,907	7,966,342	(78)%	28,342,179	37,432,198	12,908	12,908	10,612
Free Female Condom	-	-	-	-	-	-%	253	21,253	-	-	-
HIV Testing Services	3,595	16,493	23,402	191,074	1,341	1,645%	395,037	1,439,088	23,402	-	106
Implant 3	(894)	1,094	4,561	1,560	1,394	227%	8,075	15,042	4,105	10,262	8,665
Implant 3 Insertion	4,795	3,669	9,928	62,393	5,462	82%	48,078	109,266	9,928	24,820	17,649

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Implant 4	(2)	(1)	(2)	-	(4)	-%	(14)	(2,530)	(2)	(6)	(3)
Implant 4 Insertion	2	1	2	-	4	(50)%	14	2,530	2	6	4
Implant 5	(19)	1,564	4,473	-	(131)	-%	5,334	118,732	4,026	15,298	17,411
Implant 5 Insertion	2,481	1,971	4,168	50,000	6,659	(37)%	38,472	110,854	4,168	15,838	17,919
Injectable 3-IM	68,266	103,661	262,834	1,988,500	273,649	(4)%	1,669,487	20,139,090	59,138	59,138	26,542
Injectable 3-IM Provided	4,895	4,718	11,561	35,040	13,842	(16)%	77,146	256,843	2,890	2,890	1,714
Injectable 3-SC	20,307	15,737	41,598	618,160	101,085	(59)%	535,592	1,458,392	9,360	9,360	4,183
Injectable 3-SC Provided	95	79	158	-	-	-%	175	333	40	40	14
IPTp2	361	437	1,114	291,388	21	5,205%	81,911	286,466	1,114	-	125
Iron Folic Acid Tablet	-	-	-	19,843	-	-%	-	-	-	-	-
IUD 10	(566)	368	377	7,000	612	(38)%	7,568	45,590	339	1,561	3,657
IUD 10 Insertion	2,865	2,113	5,628	46,654	8,049	(30)%	40,411	273,672	5,628	25,889	20,004
IUD 5 Insertion	33	35	89	311	-	-%	299	388	89	294	299
IUS 3	16	8	40	2,500	2	1,900%	98	138	36	90	51
IUS 3 Insertion	37	26	95	-	-	-%	135	230	95	238	135
LLIN	57,551	1,957,177	1,332,446	11,942,257	1,085,487	23%	19,624,561	72,305,046	2,158,563	-	320,518
Lubricant	582,910	441,955	1,693,774	-	166,253	919%	1,223,813	3,636,428	-	-	-
Malaria PPT (ACT)	323,313	237,480	753,891	6,053,942	1,318,681	(43)%	6,990,357	26,146,820	678,502	-	204,636
Malaria PPT (Non-ACT)	36,100	-	36,100	80,000	-	-%	-	352,340	32,490	-	3,913
Malaria RDK	70,900	72,125	193,150	3,650,121	109,075	77%	10,954,467	25,784,908	173,835	-	-
Manual Vacuum Aspiration for PAC	393	361	807	5,784	1,245	(35)%	6,247	14,693	807	-	343

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Micronutrient Powder	-	-	-	-	11,550	(100)%	5,797,980	16,505,640	-	-	-
Misoprostol for PAC Provided	1,190	776	2,400	15,430	2,716	(12)%	12,741	27,960	2,400	-	1,149
Misoprostol for PPH	1,000	2,000	3,500	4,500	7,800	(55)%	30,800	198,208	1,050	-	23
Misoprostol for Safe Abortion	(3,004)	20,688	13,196	119,780	(3,760)	-%	81,047	77,003	693	-	234
Multivitamin	-	-	-	24,202	-	-%	-	-	-	-	-
OCs	362,336	58,207	435,574	1,777,420	275,075	58%	2,094,239	41,426,557	26,134	26,134	12,321
OCs Provided	748	942	2,183	7,495	3,419	(36)%	16,628	100,762	146	146	88
ORS	30,480	190	31,050	300,000	386,761	(92)%	1,249,743	15,638,392	13,973	-	771
ORS Provided	2,287	2,337	6,732	13,914	-	-%	13,509	20,241	6,732	-	351
Pneumonia PPT	-	-	-	96,000	70,028	(100)%	738,319	2,839,112	-	-	-
Pneumonia PPT Provided	1,117	1,440	3,806	-	-	-%	11,575	15,381	3,806	-	4,397
Positive RDTs	880	1,701	4,134	8,000	4,435	(7)%	17,054	157,327	4,134	-	-
QAACs Provided after Confirmatory Diagnosis	267	265	562	1,928	-	-%	1,872	2,434	562	-	126
Referral to HIV Testing Services	-	-	-	-	-	-%	5	607	-	-	-
Referral to Linkage to HIV Care	-	-	-	300	-	-%	-	-	-	-	-
Safe Water Solution	54,936	49,260	154,184	31,680	649,854	(76)%	1,345,883	23,712,359	178,745	-	604
SDM (Cycle Beads)	(24)	(21)	(63)	-	458	(114)%	5,121	143,454	(57)	(85)	(54)
SDM (Cycle Beads) Provided	25	25	66	-	88	(25)%	503	5,223	66	99	66
Seasonal Malaria Chemoprevention	-	-	-	5,385,721	1,665,225	(100)%	1,665,225	4,076,234	-	-	-
Skilled Birth Attendance	1,400	1,721	3,639	17,196	-	-%	16,695	20,334	3,639	-	5,185
STI Screening	767	1,395	2,128	83,325	3,105	(31)%	142,852	616,210	2,128	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Market Group and Product
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
TB Diagnosis	-	1,057	3,172	12,000	7,403	(57)%	18,240	42,302	3,172	-	-
TB DOTS	-	1,300	3,901	9,960	9,747	(60)%	22,400	46,935	3,901	-	13,352
TB Screening	-	4,978	14,933	14,000	31,153	(52)%	76,668	115,134	14,933	-	-
Toilets Sold	9	2	15	4,000	-	-%	27	6,313	87	-	3
Treatment for Inguinal Bubo	1	6	7	-	9	(22)%	53	143	7	-	-
Treatment for Lower Abdominal Pain	52	56	118	-	159	(26)%	800	2,215	118	-	-
Treatment for Nonherpetic Genital Ulcer	53	62	165	-	290	(43)%	5,172	13,755	165	-	18
Treatment for Pre-Eclampsia (with MgSO4)	27	31	65	353	-	-%	343	408	65	-	226
Treatment for Severe Acute Malnutrition	452	419	841	9,888	-	-%	12,893	55,380	841	-	3,206
Treatment for Urethral Discharge (Men)	295	314	858	-	1,344	(36)%	5,596	14,075	1,716	-	5
Treatment for Urethral Discharge (Women)	-	5	-	-	-	-%	15	15	-	-	-
Treatment for Vaginitis	265	263	733	-	1,264	(42)%	4,978	12,766	733	-	6
Tubal Ligation	-	1	1	-	6	(83)%	42	117	1	10	5
Water Treatment Tablets	185,200	673,387	1,308,560	6,710,250	1,699,000	(23)%	10,958,880	147,833,602	21,511	-	234
Zinc	80	13	120	-	146,999	(100)%	512,836	1,906,356	108	-	1
Zinc Provided	2,294	2,305	6,670	12,189	-	-%	11,834	18,504	6,670	-	175

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Foundation Market Group											209,344	719,316
Haiti											12,284	27,909
Antiretroviral Treatment (Currently Enrolled)	-	-	-	29,957	-		0%	216,577	486,575	-	-	-
Antiretroviral Treatment (Currently Enrolled)	-	-	-	29,957	-		-%	216,577	486,575	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	3,317	-		0%	3,561	7,862	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	-	-	3,317	-		-%	3,561	7,862	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	1		(100)%	5	123	-	-	-
Cervical Cancer-VIA and Cryotherapy	-	-	-	-	1		(100)%	5	123	-	-	-
Cervical Cancer-VIA/VILI Screening	2	1	3	-	14		(79)%	31	816	3	-	-
Cervical Cancer-VIA/VILI Screening	2	1	3	-	14		(79)%	31	816	3	-	-
Emergency Contraception	-	14,960	44,880	15,700	15,300		193%	40,300	85,180	2,020	2,020	549
Levonorgestrel 1.5 mg Tablet	-	14,960	44,880	-	15,300	9/17	193%	40,300	85,180	2,020	2,020	549
Pronta1	-	-	-	15,700	-		-%	-	-	-	-	-
Fever Cases Attended	-	677	795	202,868	2,925		(73)%	9,014	47,364	795	-	-
Fever Cases Attended	-	677	795	202,868	2,925		(73)%	9,014	47,364	795	-	-
Fever Cases Tested with Microscopy	-	3,373	4,252	30,340	9,697		(56)%	54,725	179,487	4,252	-	-
Fever Cases Tested with Microscopy	-	3,373	4,252	30,340	9,697		(56)%	54,725	179,487	4,252	-	-
Fever Cases Tested with RDTs	-	19,833	25,901	172,438	36,949		(30)%	221,408	793,741	25,901	-	-
Fever Cases Tested with RDTs	-	19,833	25,901	172,438	36,949		(30)%	221,408	793,741	25,901	-	-
Free Condom	554,400	870,234	1,336,302	2,000,000	6,427,738		(79)%	8,256,538	9,592,840	10,022	10,022	7,348
Generic Condom	554,400	870,234	1,336,302	2,000,000	6,427,738		(79)%	8,256,538	9,592,840	10,022	10,022	7,348
HIV Testing Services	-	-	-	136,153	-		0%	127,117	666,958	-	-	-
VCT Individual (HIV-Negative)	-	-	-	133,702	-		-%	122,702	633,641	-	-	-
VCT Individual (HIV-Positive)	-	-	-	2,451	-		-%	4,415	33,317	-	-	-
Implant 3	-	-	-	1,200	-		0%	2,016	4,032	-	-	-

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Implanon NXT	-	-	-	1,200	-		-%	2,016	4,032	-	-	-
Implant 3 Insertion	18	13	39	120	149		(74)%	465	726	39	98	47
Non-PSI Implant 3 Inserted	18	13	39	120	149		(74)%	465	726	39	98	47
Injectable 3-IM Provided	-	-	-	-	296		(100)%	949	1,137	-	-	-
Non-PSI Injectable 3 IM Provided	-	-	-	-	296		(100)%	949	1,137	-	-	-
Injectable 3-SC	-	-	-	10,560	-		0%	12,500	12,500	-	-	-
Sayana Press	-	-	-	10,560	-		-%	12,500	12,500	-	-	-
Injectable 3-SC Provided	95	79	158	-	-		0%	175	333	40	40	14
Non-PSI Injectable 3 SC Provided	95	79	158	-	-		-%	175	333	40	40	14
IUD 10	-	-	-	-	-		0%	50	2,297	-	-	-
Confiance Plus IUD	-	-	-	-	-	12/13	-%	50	2,297	-	-	-
IUD 10 Insertion	7	7	20	900	50		(60)%	125	344	20	92	42
Non-PSI IUD 10 Inserted	7	7	20	900	50		(60)%	125	344	20	92	42
LLIN	34,102	1,000	34,152	272,770	28,360		20%	36,486	3,739,478	55,326	-	1,867
LLIN Free	34,102	1,000	34,152	272,770	28,360		20%	36,486	3,739,478	55,326	-	1,867
Lubricant	468,500	430,667	1,545,500	-	8,000		19219%	223,000	1,768,500	-	-	-
Lube Sachet Free	468,500	430,667	1,545,500	-	8,000		19,219%	223,000	1,768,500	-	-	-
Malaria PPT (Non-ACT)	36,100	-	36,100	80,000	-		0%	-	352,340	32,490	-	3,913
Chloroquine	36,100	-	36,100	80,000	-		-%	-	352,340	32,490	-	3,913
OCs	-	-	-	21,120	76,322		(100)%	76,322	76,322	-	-	-
MEURI	-	-	-	21,120	76,322		(100)%	76,322	76,322	-	-	-
OCs Provided	3	152	192	-	510		(62)%	1,413	1,947	13	13	5
Non-PSI OCs Provided	3	152	192	-	510		(62)%	1,413	1,947	13	13	5
ORS	30,480	163	30,970	300,000	-		0%	-	10,078,308	13,937	-	770
Sel Lavi	30,480	163	30,970	300,000	-		-%	-	10,078,308	13,937	-	770

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Positive RDTs	-	751	1,099	8,000	2,710		(59)%	8,354	40,783	1,099	-	-
Positive RDTs	-	751	1,099	8,000	2,710		(59)%	8,354	40,783	1,099	-	-
STI Screening	-	-	-	80,737	-		0%	127,773	535,770	-	-	-
STI Screening	-	-	-	80,737	-		-%	127,773	535,770	-	-	-
TB Diagnosis	-	1,057	3,172	12,000	7,403		(57)%	18,240	42,302	3,172	-	-
TB Diagnosis	-	1,057	3,172	12,000	7,403		(57)%	18,240	42,302	3,172	-	-
TB DOTS	-	1,300	3,901	9,960	9,747		(60)%	22,400	46,935	3,901	-	13,352
TB DOTS	-	1,300	3,901	9,960	9,747		(60)%	22,400	46,935	3,901	-	13,352
TB Screening	-	4,978	14,933	14,000	31,153		(52)%	76,668	115,134	14,933	-	-
TB Screening	-	4,978	14,933	14,000	31,153		(52)%	76,668	115,134	14,933	-	-
Treatment for Nonherpetic Genital Ulcer	-	-	-	-	-		0%	4,007	10,724	-	-	-
Treatment for Nonherpetic Genital Ulcer	-	-	-	-	-		-%	4,007	10,724	-	-	-
Liberia											1,880	1,837
Antiretroviral Treatment (Newly Enrolled)	-	87	-	-	-		0%	337	337	-	-	-
Antiretroviral Treatment (Newly Enrolled)	-	87	-	-	-		-%	337	337	-	-	-
Condom	-	61,468	129,024	-	267,264		(52)%	1,042,072	6,625,082	968	968	926
STAR	-	61,468	129,024	-	267,264	7/09	(52)%	1,042,072	6,625,082	968	968	926
Free Condom	103,680	78,000	121,680	3,758,480	28,944		320%	606,240	877,061	913	913	873
Generic Condom	103,680	78,000	121,680	3,758,480	28,944		320%	606,240	877,061	913	913	873
Free Female Condom	-	-	-	-	-		0%	253	21,253	-	-	-
Generic Female Condom	-	-	-	-	-	5/17	-%	253	21,253	-	-	-
HIV Testing Services	-	403	159	17,084	-		0%	12,049	14,464	159	-	1
VCT Individual (HIV-Negative)	-	383	154	17,084	-		-%	11,479	13,812	154	-	1
VCT Individual (HIV-Positive)	-	20	5	-	-	5/14	-%	570	652	5	-	-
Lubricant	108,000	11,000	141,000	-	30,750		359%	431,750	742,891	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Lube Sachet Free	108,000	11,000	141,000	-	30,750		359%	431,750	742,891	-	-	-
Referral to HIV Testing Services	-	-	-	-	-		0%	5	607	-	-	-
Referral to HIV Testing Services	-	-	-	-	-	12/13	-%	5	607	-	-	-
Referral to Linkage to HIV Care	-	-	-	300	-		0%	-	-	-	-	-
Referral to Linkage to HIV Care	-	-	-	300	-		-%	-	-	-	-	-
Safe Water Solution	2,736	3,976	10,344	31,680	11,208		(8)%	37,800	783,033	8,502	-	36
WaterGuard	2,736	3,976	10,344	31,680	11,208		(8)%	37,800	783,033	8,502	-	36
STI Screening	-	21	-	-	-		0%	63	64	-	-	-
STI Screening	-	21	-	-	-		-%	63	64	-	-	-
Treatment for Lower Abdominal Pain	-	16	-	-	-		0%	48	48	-	-	-
Treatment for Lower Abdominal Pain	-	16	-	-	-		-%	48	48	-	-	-
Treatment for Urethral Discharge (Women)	-	5	-	-	-		0%	15	15	-	-	-
Treatment for Urethral Discharge (Women)	-	5	-	-	-		-%	15	15	-	-	-
Madagascar											137,474	231,490
Cervical Cancer-Pap and Cryotherapy	-	-	-	-	-		0%	4	4	-	-	-
Cervical Cancer-PAP and Cryotherapy	-	-	-	-	-		-%	4	4	-	-	-
Cervical Cancer-VIA and Cryotherapy	2	4	8	-	6		33%	63	188	8	-	3
Cervical Cancer-VIA and Cryotherapy	2	4	8	-	6		33%	63	188	8	-	3
Cervical Cancer-VIA/VILI Screening	73	50	158	-	183		(14)%	899	2,590	158	-	-
Cervical Cancer-VIA/VILI Screening	73	50	158	-	183		(14)%	899	2,590	158	-	-
Chlorhexidine	-	-	-	9,000	76,336		(100)%	107,120	432,844	-	-	-
Arofoitra	-	-	-	9,000	76,336		(100)%	107,120	432,844	-	-	-
Condom	56,436	146,172	190,428	2,920,716	107,148		78%	2,305,266	62,992,382	1,428	1,428	1,730
Protector Plus	23,136	40,272	86,928	2,680,416	107,088		(19)%	573,456	58,454,162	652	652	790
YES	33,300	105,900	103,500	240,300	60		172,400%	1,731,810	4,538,220	776	776	941

(a) The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Diarrhea Treatment Kit	900	1,617	2,140	44,000	13,134		(84)%	49,568	1,157,334	1,926	-	45
Hydrazinc	-	-	-	-	13,754	1/10	(100)%	13,754	701,539	-	-	-
ORS-Zinc	900	1,617	2,140	44,000	-		-%	37,626	468,069	1,926	-	45
(b)PSI Diarrhea Treatment Kit Distributed Provided	-	-	-	-	(620)		-%	(1,812)	(12,274)	-	-	-
Diarrhea Treatment Kit Provided	-	-	-	-	620		(100)%	1,812	12,274	-	-	-
PSI Diarrhea Treatment Kit Provided	-	-	-	-	620		(100)%	1,812	12,274	-	-	-
Emergency Contraception	(6)	(14)	(39)	-	(77)		0%	(282)	(1,378)	(2)	(2)	(1)
(b)PSI Emergency Contraception Distributed Provided	(6)	(14)	(39)	-	(77)		-%	(282)	(1,378)	(2)	(2)	(1)
Emergency Contraception Provided	6	14	39	-	77		(49)%	282	1,378	2	2	1
PSI Emergency Contraception Provided	6	14	39	-	77		(49)%	282	1,378	2	2	1
Fever Cases Attended	12,726	10,076	35,380	-	22,104		60%	77,136	454,970	35,380	-	-
Fever Cases Attended	12,726	10,076	35,380	-	22,104		60%	77,136	454,970	35,380	-	-
Fever Cases Tested with Microscopy	272	80	401	-	537		(25)%	2,072	9,408	401	-	-
Fever Cases Tested with Microscopy	272	80	401	-	537		(25)%	2,072	9,408	401	-	-
Fever Cases Tested with RDTs	8,737	7,259	24,896	-	14,206		75%	53,421	393,895	24,896	-	-
Fever Cases Tested with RDTs	8,737	7,259	24,896	-	14,206		75%	53,421	393,895	24,896	-	-
Free Condom	106,128	158,256	263,088	15,510,427	1,509,660		(83)%	19,479,201	26,962,097	1,973	1,973	2,391
Generic Condom	-	-	-	-	11,836	10/16	(100)%	15,700	7,235,508	-	-	-
KPOTY	106,128	158,256	263,088	15,510,427	1,497,824		(82)%	19,463,501	19,726,589	1,973	1,973	2,391
HIV Testing Services	1,842	13,857	18,867	24,117	1,341		1307%	243,365	740,784	18,867	-	64
VCT Individual (HIV-Negative)	1,831	13,779	18,743	23,065	1,326		1,313%	242,688	738,956	18,743	-	63
VCT Individual (HIV-Positive)	11	78	124	1,052	15		727%	677	1,828	124	-	-
Implant 3	(894)	409	2,586	-	1,438		80%	4,681	7,190	2,327	5,819	3,530
Implanon	-	-	-	-	1,478	7/06	(100)%	2,007	35,127	-	-	-
Implanon NXT	2,860	3,215	10,538	44,320	1,589		563%	36,178	50,243	9,484	23,711	14,384

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL
Monthly Distribution by Country
Period: 3
Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI Implant 3 Distributed Inserted	(3,754)	(2,806)	(7,952)	(44,320)	(1,629)		-%	(33,504)	(78,180)	(7,157)	(17,892)	(10,854)
Implant 3 Insertion	3,754	2,806	7,952	44,320	1,629		388%	33,504	78,180	7,952	19,880	12,060
PSI Implant 3 Inserted	3,754	2,806	7,952	44,320	1,629		388%	33,504	78,180	7,952	19,880	12,060
Implant 4	(2)	(1)	(2)	-	(4)		0%	(14)	(2,530)	(2)	(6)	(3)
(b)PSI Implant 4 Distributed Inserted	(2)	(1)	(2)	-	(4)		-%	(14)	(2,530)	(2)	(6)	(3)
Implant 4 Insertion	2	1	2	-	4		(50)%	14	2,530	2	6	4
PSI Implant 4 Inserted	2	1	2	-	4		(50)%	14	2,530	2	6	4
Implant 5	(19)	(3)	(27)	-	(131)		0%	(265)	1,479	(24)	(92)	(55)
Jadelle	-	-	-	-	10	7/14	(100)%	20	3,703	-	-	-
(b)PSI Implant 5 Distributed Inserted	(19)	(3)	(27)	-	(141)		-%	(285)	(2,224)	(24)	(92)	(55)
Implant 5 Insertion	19	3	27	-	141		(81)%	285	2,224	27	103	61
PSI Implant 5 Inserted	19	3	27	-	141		(81)%	285	2,224	27	103	61
Injectable 3-IM	68,266	103,096	261,489	1,985,000	272,599		(4)%	1,664,193	20,109,492	58,835	58,835	26,293
Confiance Injectable	70,610	105,720	268,760	1,985,000	281,075		(4)%	1,702,545	20,320,256	60,471	60,471	27,024
(b)PSI Injectable 3 IM Distributed Provided	(2,344)	(2,624)	(7,271)	-	(8,476)		-%	(38,352)	(210,764)	(1,636)	(1,636)	(731)
Injectable 3-IM Provided	2,344	2,624	7,271	-	8,476		(14)%	38,352	210,764	1,818	1,818	812
PSI Injectable 3 IM Provided	2,344	2,624	7,271	-	8,476		(14)%	38,352	210,764	1,818	1,818	812
Injectable 3-SC	20,307	15,737	41,598	607,600	101,085		(59)%	523,092	1,445,892	9,360	9,360	4,183
Sayana Press	20,307	15,737	41,598	607,600	101,085		(59)%	523,092	1,445,892	9,360	9,360	4,183
IPTp2	-	-	-	287,518	21		(100)%	78,153	281,594	-	-	-
IPTp2	-	-	-	287,518	21		(100)%	78,153	281,594	-	-	-
IUD 10	(566)	(78)	(911)	-	612		(249)%	1,979	17,432	(820)	(3,772)	(2,141)
Copper T	150	129	511	17,754	50		922%	4,320	198,263	460	2,116	1,201
IUD 1 x 5	-	-	-	-	5	8/11	(100)%	25	5,285	-	-	-
Pregna T Cu 380A	987	878	1,962	-	2,998	7/17	(35)%	15,143	22,262	1,766	8,123	4,612

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
(b)PSI IUD 10 Distributed Inserted	(1,703)	(1,085)	(3,384)	(17,754)	(2,441)		-%	(17,509)	(208,378)	(3,046)	(14,010)	(7,954)
IUD 10 Insertion	1,703	1,085	3,384	17,754	2,441		39%	17,509	208,378	3,384	15,566	8,838
PSI IUD 10 Inserted	1,703	1,085	3,384	17,754	2,441		39%	17,509	208,378	3,384	15,566	8,838
IUS 3	16	8	40	2,500	2		1900%	98	138	36	90	51
Avibela (52 mg levonorgestrel)	53	33	135	2,500	2		6,650%	233	368	122	304	173
(b)PSI IUS 3 Distributed Inserted	(37)	(26)	(95)	-	-		-%	(135)	(230)	(86)	(214)	(122)
IUS 3 Insertion	37	26	95	-	-		0%	135	230	95	238	135
PSI IUS 3 Inserted	37	26	95	-	-		-%	135	230	95	238	135
LLIN	4,050	1,528,533	579,300	2,377,984	359,900		61%	13,921,182	33,852,903	938,466	-	22,913
Dawa Plus Blue	-	16,867	-	-	-		-%	1,161,814	1,161,814	-	-	-
Dawa Plus White	-	815,635	131,050	-	-	4/18	-%	6,891,750	7,022,800	212,301	-	5,183
Generic net "PERMANET WHITE"	-	-	-	-	-	5/15	-%	1,760	9,216,036	-	-	-
Interceptor White	-	-	-	1,000,000	-		-%	-	1,099,951	-	-	-
PermaNet	300	331,015	38,300	-	9,600	3/07	299%	2,216,858	4,704,931	62,046	-	1,515
Safe Net Blue	-	149,200	8,650	-	-		-%	1,732,600	1,741,250	14,013	-	342
Safe Net White	-	138,750	363,400	-	-		-%	495,650	859,050	588,708	-	14,373
Super Moustiquaire	3,750	9,783	6,250	450,000	301,800		(98)%	482,572	3,666,854	10,125	-	247
Yorkool Blue (Generic Net)	-	31,533	-	927,984	21,750		(100)%	313,000	1,378,824	-	-	-
Yorkool White (Generic Net)	-	35,750	31,650	-	26,750	9/13	18%	625,178	3,001,393	51,273	-	1,252
Lubricant	6,410	288	7,274	-	127,503		(94)%	569,063	1,125,037	-	-	-
Gel Lubricant 5 mL	6,410	288	7,274	-	127,503	12/16	(94)%	569,063	1,125,037	-	-	-
Malaria PPT (ACT)	209,949	109,365	538,043	1,403,822	437,936		23%	3,507,514	7,216,762	484,239	-	136,600
ACT 100 mg (1x3's)	-	-	-	-	-	7/15	-%	331,575	574,532	-	-	-
ACT 100 mg (1x6's)	-	-	-	-	-	7/15	-%	318,325	560,050	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
ACT 25 mg (1x3's)	-	-	-	-	-	7/15	-%	280,575	520,199	-	-	-
ACT 50 mg (1x3's)	-	-	-	-	-	7/15	-%	773,650	1,454,575	-	-	-
AL for Adolescent, 20/120mg, 18's	-	-	-	-	19,618	7/16	(100)%	20,581	67,103	-	-	-
AL for Adult, 20/120mg, 24's	-	-	-	-	27,591	7/16	(100)%	28,330	98,705	-	-	-
AL for Infant, 20/120mg, 6's	-	-	-	-	8,729	7/16	(100)%	11,097	43,625	-	-	-
AL for Toddler, 20/120mg, 12's	-	-	-	-	29,444	7/16	(100)%	37,176	100,505	-	-	-
ASAQ for Adolescent, 100/270mg, 3's	36,252	36,665	146,247	-	73,596	7/16	99%	503,415	1,034,823	131,622	-	37,130
ASAQ for Adult, 100/270mg, 6's	42,857	51,158	196,332	-	115,882	7/16	69%	542,613	1,196,686	176,699	-	49,845
ASAQ for Infant, 25/67.5mg, 3's	21,219	3,286	31,078	-	36,926	7/16	(16)%	69,596	277,107	27,970	-	7,890
ASAQ for Toddler, 50/135mg, 3's	109,621	18,255	164,386	-	126,150	7/16	30%	590,581	1,288,852	147,947	-	41,735
PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-3	-	-	-	46,149	-	-	-%	-	-	-	-	-
PRIVATE - AS/AQ 100mg+270mg (base) - 3 - Blister-6	-	-	-	127,100	-	-	-%	-	-	-	-	-
PRIVATE - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3	-	-	-	35,331	-	-	-%	-	-	-	-	-
PRIVATE - AS/AQ 50mg+135mg (base) - 3 - Blister-3	-	-	-	145,989	-	-	-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,24's,Indiv)	-	-	-	30,501	-	-	-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,6x1,Indiv)	-	-	-	11,602	-	-	-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,6x2,Indiv)	-	-	-	21,214	-	-	-%	-	-	-	-	-
PRIVATE A/L(20/120mg,FDC,6x3,Indiv)	-	-	-	15,839	-	-	-%	-	-	-	-	-
PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-3	-	-	-	144,112	-	-	-%	-	-	-	-	-
PUBLIC - AS/AQ 100mg+270mg (base) - 3 - Blister-6	-	-	-	138,865	-	-	-%	-	-	-	-	-
PUBLIC - AS/AQ 25mg+67.5mg (base) - 3 - Blister-3	-	-	-	157,923	-	-	-%	-	-	-	-	-
PUBLIC - AS/AQ 50mg+135mg (base) - 3 - Blister-3	-	-	-	407,046	-	-	-%	-	-	-	-	-
PUBLIC A/L(20/120mg,FDC,6x1,Indiv)	-	-	-	12,217	-	-	-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
PUBLIC A/L(20/120mg,FDC,6x2,Indiv)	-	-	-	31,424	-		-%	-	-	-	-	-
PUBLIC A/L(20/120mg,FDC,6x3,Indiv)	-	-	-	19,574	-		-%	-	-	-	-	-
PUBLIC A/L(20/120mg,FDC,6x4,Indiv)	-	-	-	58,936	-		-%	-	-	-	-	-
Malaria RDK	41,250	23,650	112,200	2,374,725	75		149500%	7,698,425	17,212,063	100,980	-	-
RDT Malaria	41,250	23,650	112,200	2,374,725	75		149,500%	7,698,425	17,212,063	100,980	-	-
Manual Vacuum Aspiration for PAC	229	177	498	2,334	472		6%	2,719	6,674	498	-	157
MVA for PAC	229	177	498	2,334	472		6%	2,719	6,674	498	-	157
Micronutrient Powder	-	-	-	-	11,550		(100)%	5,797,980	16,505,640	-	-	-
ZAZATOMADY (ZZT)	-	-	-	-	11,550	2/13	(100)%	5,797,980	16,505,640	-	-	-
Misoprostol for PAC Provided	751	495	1,576	4,430	940		68%	6,438	12,924	1,576	-	584
PSI Misoprostol for PAC Provided	751	495	1,576	4,430	940		68%	6,438	12,924	1,576	-	584
Misoprostol for Safe Abortion	(3,004)	20,688	13,196	69,780	(3,760)		0%	81,047	74,603	693	-	234
Misoprostol 200 mcg Tablet	-	22,667	19,500	87,500	-		-%	106,799	126,299	1,024	-	346
(b)PSI Misoprostol for Safe Abortion Dist Provided	(3,004)	(1,979)	(6,304)	(17,720)	(3,760)		-%	(25,752)	(51,696)	(331)	-	(112)
OCs	362,336	58,207	435,574	1,730,300	198,753		119%	1,994,828	41,200,195	26,134	26,134	12,321
Combination 3	342,757	-	342,757	-	-		-%	-	342,757	20,565	20,565	9,695
Microgynon	1,480	17,497	29,440	-	49,770	2/18	(41)%	1,471,355	1,500,795	1,766	1,766	833
Pilplan	18,500	41,098	64,495	1,730,300	151,092		(57)%	531,113	39,445,822	3,870	3,870	1,824
(b)PSI OCs Distributed Provided	(401)	(388)	(1,118)	-	(2,109)		-%	(7,640)	(89,179)	(67)	(67)	(32)
OCs Provided	401	388	1,118	-	2,109		(47)%	7,640	89,179	75	75	35
PSI OCs Provided	401	388	1,118	-	2,109		(47)%	7,640	89,179	75	75	35
ORS	-	27	80	-	-		0%	39,368	39,448	36	-	1
SRO Generique	-	27	80	-	-	4/18	-%	39,368	39,448	36	-	1
Pneumonia PPT	-	-	-	96,000	33,730		(100)%	157,872	791,414	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Pneumox 250 (10's) for Children under 12 months	-	-	-	96,000	33,730		(100)%	157,872	791,414	-	-	-
Positive RDTs	880	950	3,035	-	1,725		76%	8,700	116,544	3,035	-	-
Positive RDTs	880	950	3,035	-	1,725		76%	8,700	116,544	3,035	-	-
Safe Water Solution	52,200	45,284	143,840	-	638,646		(77)%	1,308,083	22,929,326	170,244	-	568
Sur Eau Vaovao	52,200	45,284	143,840	-	638,646	9/04	(77)%	1,308,083	22,929,326	170,244	-	568
SDM (Cycle Beads)	(24)	(21)	(63)	-	458		(114)%	5,121	143,454	(57)	(85)	(54)
(b)PSI SDM (Cycle Beads) Distributed Provided	(24)	(21)	(63)	-	(87)		-%	(467)	(5,174)	(57)	(85)	(54)
Rojo	-	-	-	-	545	3/12	(100)%	5,588	148,628	-	-	-
SDM (Cycle Beads) Provided	24	21	63	-	87		(28)%	467	5,174	63	95	61
PSI SDM (Cycle Beads) Provided	24	21	63	-	87		(28)%	467	5,174	63	95	61
STI Screening	674	697	1,913	-	3,105		(38)%	12,714	77,859	1,913	-	-
STI Screening	674	697	1,913	-	3,105		(38)%	12,714	77,859	1,913	-	-
Treatment for Inguinal Bubo	1	6	7	-	9		(22)%	53	143	7	-	-
Treatment for Inguinal Bubo	1	6	7	-	9		(22)%	53	143	7	-	-
Treatment for Lower Abdominal Pain	52	40	118	-	159		(26)%	752	2,167	118	-	-
Treatment for Lower Abdominal Pain	52	40	118	-	159		(26)%	752	2,167	118	-	-
Treatment for Nonherpetic Genital Ulcer	53	62	165	-	290		(43)%	1,165	3,031	165	-	18
Treatment for Nonherpetic Genital Ulcer	53	62	165	-	290		(43)%	1,165	3,031	165	-	18
Treatment for Severe Acute Malnutrition	-	-	-	-	-		0%	187	187	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	-	-		-%	187	187	-	-	-
Treatment for Urethral Discharge (Men)	295	314	858	-	1,344		(36)%	5,596	14,075	1,716	-	5
Treatment for Urethral Discharge (Men)	295	314	858	-	1,344		(36)%	5,596	14,075	1,716	-	5
Treatment for Vaginitis	265	263	733	-	1,264		(42)%	4,978	12,766	733	-	6
Treatment for Vaginitis	265	263	733	-	1,264		(42)%	4,978	12,766	733	-	6
Tubal Ligation	-	1	1	-	6		(83)%	42	117	1	10	5

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Tubal Ligation	-	1	1	-	6		(83)%	42	117	1	10	5
Water Treatment Tablets	185,200	337,333	660,400	3,600,000	775,600		(15)%	6,183,000	28,950,030	10,856	-	36
SUR'EAU PILINA (67mg tablet)	185,200	337,333	660,400	3,600,000	775,600		(15)%	6,183,000	28,950,030	10,856	-	36
Zinc	80	13	120	-	-		0%	13,132	13,252	108	-	1
Zinc	80	13	120	-	-	1/08	-%	13,132	13,252	108	-	1
Mali											57,027	339,788
Cervical Cancer-VIA and Cryotherapy	44	4	44	700	31		42%	121	1,083	44	-	13
Cervical Cancer-VIA and Cryotherapy	44	4	44	700	31		42%	121	1,083	44	-	13
Cervical Cancer-VIA/VILI Screening	1,898	414	1,915	35,000	3,938		(51)%	12,365	72,370	1,915	-	-
Cervical Cancer-VIA/VILI Screening	1,898	414	1,915	35,000	3,938		(51)%	12,365	72,370	1,915	-	-
Free Condom	-	-	-	200,000	-		0%	200	200	-	-	-
Generic Condom	-	-	-	200,000	-		-%	200	200	-	-	-
Implant 3	-	672	2,016	-	-		0%	1,336	3,552	1,814	4,536	5,229
Implanon NXT	-	672	2,016	-	-	2/16	-%	1,336	3,552	1,814	4,536	5,229
Implant 3 Insertion	998	787	1,814	17,600	3,631		(50)%	13,564	29,341	1,814	4,535	5,228
Non-PSI Implant 3 Inserted	998	787	1,814	17,600	3,631		(50)%	13,564	29,341	1,814	4,535	5,228
Implant 5	-	1,567	4,500	-	-		0%	5,599	117,253	4,050	15,390	17,466
Jadelle	-	1,567	4,500	-	-	7/09	-%	5,599	117,253	4,050	15,390	17,466
Implant 5 Insertion	2,462	1,968	4,141	50,000	6,518		(36)%	38,187	108,630	4,141	15,736	17,858
Non-PSI Implant 5 Inserted	2,462	1,968	4,141	50,000	6,518		(36)%	38,187	108,630	4,141	15,736	17,858
Injectable 3-IM	-	342	1,025	-	-		0%	927	1,952	231	231	195
Depo-Provera	-	342	1,025	-	-	1/08	-%	927	1,952	231	231	195
Injectable 3-IM Provided	2,419	2,003	4,035	34,000	5,070		(20)%	36,909	43,751	1,009	1,009	853
Non-PSI Injectable 3 IM Provided	2,419	2,003	4,035	34,000	5,070		(20)%	36,909	43,751	1,009	1,009	853
IUD 10	-	446	1,288	7,000	-		0%	5,539	25,861	1,159	5,332	5,798

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Copper-T 380-A with inserter	-	-	-	7,000	-		-%	112	112	-	-	-
IUD Copper T 380A	-	379	1,088	-	-	12/13	-%	5,302	25,424	979	4,504	4,898
PPIUD Cu T380A	-	67	200	-	-		-%	125	325	180	828	900
IUD 10 Insertion	1,155	1,021	2,224	28,000	5,558		(60)%	22,777	64,950	2,224	10,230	11,124
Non-PSI IUD 10 Inserted	1,155	1,021	2,224	28,000	5,558		(60)%	22,777	64,950	2,224	10,230	11,124
LLIN	-	219,032	657,095	4,343,735	665,434		(1)%	4,911,866	20,195,332	1,064,494	-	275,244
MILD - (G)	-	-	-	4,343,735	15,237		(100)%	3,685,706	11,198,152	-	-	-
MILD - (O)	-	-	-	-	-	9/16	-%	45	1,125,683	-	-	-
MILD - (U)	-	219,032	657,095	-	650,197	12/14	1%	1,226,115	7,871,497	1,064,494	-	275,244
Malaria PPT (ACT)	-	-	-	-	460,404		(100)%	460,404	4,646,729	-	-	-
Coartem 12 tabs	-	-	-	-	138,127	5/10	(100)%	138,127	1,694,442	-	-	-
Coartem 6 tabs	-	-	-	-	322,277	5/10	(100)%	322,277	2,952,287	-	-	-
Manual Vacuum Aspiration for PAC	164	184	309	3,450	773		(60)%	3,528	8,019	309	-	185
MVA for PAC	164	184	309	3,450	773	7/15	(60)%	3,528	8,019	309	-	185
Misoprostol for PAC Provided	439	282	824	11,000	1,776		(54)%	6,303	15,036	824	-	565
Non-PSI Misoprostol for PAC Provided	439	282	824	11,000	1,776		(54)%	6,303	15,036	824	-	565
Misoprostol for Safe Abortion	-	-	-	50,000	-		0%	-	2,400	-	-	-
Misoprostol for Safe Abortion	-	-	-	50,000	-		-%	-	2,400	-	-	-
OCs Provided	148	271	352	5,500	800		(56)%	5,695	7,235	23	23	21
Non-PSI OCs Provided	148	271	352	5,500	800		(56)%	5,695	7,235	23	23	21
SDM (Cycle Beads) Provided	1	4	3	-	1		200%	36	49	3	5	5
Non-PSI SDM (Cycle Beads) Provided	1	4	3	-	1		200%	36	49	3	5	5
Seasonal Malaria Chemoprevention	-	-	-	5,385,721	1,665,225		(100)%	1,665,225	4,076,234	-	-	-
SMC for Children ages 12-59 months	-	-	-	5,385,721	1,361,725		(100)%	1,361,725	3,333,317	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
SMC for Infants ages 3-11 months	-	-	-	-	303,500	3/17	(100)%	303,500	742,917	-	-	-
Toilets Sold	9	2	15	4,000	-		0%	27	6,313	87	-	3
Toilet Type 1, Direct Sales	9	2	15	4,000	-		-%	27	6,313	87	-	3
Water Treatment Tablets	-	-	-	1,248,000	-		0%	262,400	43,524,470	-	-	-
Aquatab	-	-	-	1,248,000	-		-%	262,400	43,524,470	-	-	-
Somaliland											679	29,761
Acute Malnutrition Screening_CU5	-	130	389	-	-		0%	-	389	389	-	-
Acute Malnutrition Screening_CU5	-	130	389	-	-		-%	-	389	389	-	-
Counseling & Tx for Moderate Acute MalnutritionCU!	1,597	4,389	3,559	20,942	-		0%	20,332	23,891	3,559	-	11,132
Counseling & Tx for Moderate Acute MalnutritionCU5	1,597	4,389	3,559	20,942	-		-%	20,332	23,891	3,559	-	11,132
Diarrhea Treatment Kit	-	20,000	40,000	220,416	48,358		(17)%	128,358	1,135,956	36,000	-	3,929
SD OFLV-DTK	-	20,000	40,000	-	48,358	9/11	(17)%	128,358	990,435	36,000	-	3,929
Shuban Daweeye_DTK	-	-	-	220,416	-		-%	-	145,521	-	-	-
HIV Testing Services	1,753	2,233	4,376	13,720	-		0%	12,506	16,882	4,376	-	42
VCT Individual (HIV-Negative)	1,753	2,233	4,376	13,720	-		-%	12,506	16,882	4,376	-	42
Implant 3	-	14	(41)	360	(44)		0%	42	268	(37)	(92)	(94)
Nasiye Implant (Implanon)	-	38	5	360	-		-%	236	824	5	11	11
(b)PSI Implant 3 Distributed Inserted	-	(25)	(46)	-	(44)		-%	(194)	(556)	(41)	(104)	(105)
Implant 3 Insertion	25	63	123	353	53		132%	545	1,019	123	308	313
Non-PSI Implant 3 Inserted	25	38	77	353	9		756%	351	463	77	193	196
PSI Implant 3 Inserted	-	25	46	-	44		5%	194	556	46	115	117
Injectable 3-IM	-	223	320	3,500	1,050		(70)%	4,367	27,646	72	72	54
Nasiye - Inj 3	-	223	320	3,500	1,050		(70)%	4,367	27,646	72	72	54
Injectable 3-IM Provided	132	91	255	1,040	-		0%	936	1,191	64	64	48
Non-PSI Injectable 3 IM Provided	132	91	255	1,040	-		-%	936	1,191	64	64	48

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
IPTp2	361	437	1,114	3,870	-		0%	3,758	4,872	1,114	-	125
IPTp2	361	437	1,114	3,870	-		-%	3,758	4,872	1,114	-	125
Iron Folic Acid Tablet	-	-	-	19,843	-		0%	-	-	-	-	-
Iron Folic Acid Tablet	-	-	-	19,843	-		-%	-	-	-	-	-
IUD 5 Insertion	33	35	89	311	-		0%	299	388	89	294	299
Non-PSI IUD 5 Inserted	33	35	89	311	-		-%	299	388	89	294	299
Misoprostol for PPH	1,000	2,000	3,500	4,500	7,800		(55)%	30,800	198,208	1,050	-	23
Ummul-gargaar	1,000	2,000	3,500	4,500	7,800		(55)%	30,800	198,208	1,050	-	23
Multivitamin	-	-	-	24,202	-		0%	-	-	-	-	-
Multivitamin	-	-	-	24,202	-		-%	-	-	-	-	-
OCs	-	-	-	26,000	-		0%	23,089	150,040	-	-	-
Nasiye - OC	-	-	-	26,000	-		-%	23,089	150,040	-	-	-
OCs Provided	196	131	521	1,995	-		0%	1,880	2,401	35	35	27
Non-PSI OCs Provided	196	131	521	1,995	-		-%	1,880	2,401	35	35	27
ORS Provided	2,287	2,337	6,732	13,914	-		0%	13,509	20,241	6,732	-	351
Non-PSI ORS Provided	2,287	2,337	6,732	13,914	-		-%	13,509	20,241	6,732	-	351
Pneumonia PPT	-	-	-	-	5,197		(100)%	14,500	53,213	-	-	-
Pneumox 125mg tablet (Amoxicillin) x 20's	-	-	-	-	1,317	11/14	(100)%	2,900	10,716	-	-	-
Pneumox 250mg tablet (Amoxicillin) x 20's	-	-	-	-	3,880	11/14	(100)%	11,600	42,497	-	-	-
Pneumonia PPT Provided	1,117	1,440	3,806	-	-		0%	11,575	15,381	3,806	-	4,397
Non-PSI Pneumonia PPT Provided	1,117	1,440	3,806	-	-		-%	11,575	15,381	3,806	-	4,397
QAACTs Provided after Confirmatory Diagnosis	267	265	562	1,928	-		0%	1,872	2,434	562	-	126
Non-PSI QAACTs Provided after Confirmed Diagnosis	267	265	562	1,928	-		-%	1,872	2,434	562	-	126
Skilled Birth Attendance	1,400	1,721	3,639	17,196	-		0%	16,695	20,334	3,639	-	5,185
Skilled Birth Attendance	1,400	1,721	3,639	17,196	-		-%	16,695	20,334	3,639	-	5,185

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
STI Screening	93	677	215	2,588	-		0%	2,302	2,517	215	-	-
STI Screening	93	677	215	2,588	-		-%	2,302	2,517	215	-	-
Treatment for Pre-Eclampsia (with MgSO4)	27	31	65	353	-		0%	343	408	65	-	226
Treatment for Pre-Eclampsia (with MgSO4)	27	31	65	353	-		-%	343	408	65	-	226
Treatment for Severe Acute Malnutrition	452	419	841	9,888	-		0%	9,600	10,441	841	-	3,206
Treatment for Severe Acute Malnutrition	452	419	841	9,888	-		-%	9,600	10,441	841	-	3,206
Water Treatment Tablets	-	336,053	648,160	1,862,250	923,400		(30)%	4,513,480	75,359,102	10,655	-	198
Aquatab	-	85,333	256,000	864,000	-		-%	334,000	36,164,790	4,208	-	78
Biyosifeeye	-	250,720	392,160	998,250	923,400		(58)%	4,179,480	39,194,312	6,446	-	120
Zinc Provided	2,294	2,305	6,670	12,189	-		0%	11,834	18,504	6,670	-	175
Non-PSI Zinc Provided	2,294	2,305	6,670	12,189	-		-%	11,834	18,504	6,670	-	175
South Sudan											-	88,531
Acute Malnutrition Screening_CU5	-	-	-	-	-		0%	619,055	619,055	-	-	-
Acute Malnutrition Screening_CU5	-	-	-	-	-		-%	619,055	619,055	-	-	-
LLIN	19,399	208,612	61,899	4,947,768	31,793		95%	755,027	14,517,333	100,276	-	20,494
Free Permanet Mesh	19,399	208,612	61,899	4,947,768	1,500		4,027%	724,734	8,632,626	100,276	-	20,494
Mass LLIN - WES	-	-	-	-	30,293	6/14	(100)%	30,293	5,884,707	-	-	-
Malaria PPT (ACT)	113,364	128,116	215,848	4,650,120	420,341		(49)%	3,022,439	14,283,329	194,263	-	68,037
ACTs for Adult (14+ years)	44,883	83,842	90,583	1,257,791	49,130		84%	641,055	3,141,678	81,525	-	28,552
ACTs for Child (6-14 years)	27,053	24,300	61,253	918,479	3,500		1,650%	479,609	1,837,923	55,128	-	19,307
ACTs for Infant (2-12 months)	7,809	4,740	11,319	882,296	232,438		(95)%	692,193	3,498,703	10,187	-	3,568
ACTs for Toddler (1-5 years)	9,895	9,300	21,295	1,232,271	135,273		(84)%	1,139,058	5,703,103	19,166	-	6,712
Artemether Tabs – Adult	21,300	2,920	25,350	139,755	-		-%	36,350	61,700	22,815	-	7,990
Artemether Tabs - Child	2,424	2,058	5,124	102,053	-		-%	26,276	31,400	4,612	-	1,615

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Artemether Tabs - Infant	-	386	264	49,016	-		-%	2,022	2,286	238	-	83
Artemether Tabs - Toddler	-	570	660	68,459	-		-%	5,876	6,536	594	-	208
Malaria RDK	29,650	48,475	80,950	1,275,396	109,000		(26)%	3,256,042	8,572,845	72,855	-	-
Malaria Rapid Diagnostic Kit	29,650	48,475	80,950	1,275,396	109,000		(26)%	3,256,042	8,572,845	72,855	-	-
ORS	-	-	-	-	386,761		(100)%	1,210,375	5,520,636	-	-	-
ORS	-	-	-	-	386,761	9/08	(100)%	1,210,375	5,520,636	-	-	-
Pneumonia PPT	-	-	-	-	31,101		(100)%	565,947	1,994,485	-	-	-
Amoxicillin for Children (1-5 years)	-	-	-	-	26,363	10/12	(100)%	361,615	1,358,695	-	-	-
Amoxicillin for Infant (2-12 months)	-	-	-	-	4,738	10/12	(100)%	204,332	635,790	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	-	-		0%	3,106	44,752	-	-	-
Treatment for Severe Acute Malnutrition	-	-	-	-	-		-%	3,106	44,752	-	-	-
Zinc	-	-	-	-	146,999		(100)%	499,704	1,893,104	-	-	-
Zinc	-	-	-	-	146,999	1/08	(100)%	499,704	1,893,104	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

Social Enterprise Market Group

POPULATION SERVICES INTERNATIONAL
CYPs, Cases, and Deaths by Country
1/2019 - 3/2019

	<u>New HIV Infections</u>	<u>STI Deaths</u>	<u>PWID Deaths</u>	<u>TB Deaths</u>	<u>CYP*</u>	<u>Maternal Deaths</u>	<u>Unintended Pregnancies</u>	<u>Malaria Deaths</u>	<u>Diarrhea Deaths</u>	<u>Pneumonia Deaths</u>	<u>Cervical Cancer Death</u>	<u>Sum of All Deaths</u>
Social Enterprise	6,168	-	-	-	315,673	297	101,401	-	180	-	-	1,012
India LLC	1,015	-	-	-	225,102	277	75,029	-	180	-	-	839
Paraguay	80	-	-	-	19,221	4	6,278	-	-	-	-	21
PSI South Africa	5,073	-	-	-	71,350	16	20,095	-	-	-	-	151
Total	42,359	12	-	1,567	3,565,395	3,497	1,416,121	8,207	477	80	4	32,969

* Using USAID CYP conversion factors

POPULATION SERVICES INTERNATIONAL
 Monthly Distribution by Market Group and Product
 Period: 3
 Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE SALES	YTD USERS REACHED ^(a) 2019	YTD CYP 2019	YTD DALY 2019
Social Enterprise										315,673	316,480
Condom	19,699,731	15,609,881	31,931,785	202,585,322	28,914,697	10%	159,709,190	740,743,884	239,488	239,488	272,974
Emergency Contraception	38,534	35,315	102,332	1,240,030	97,066	5%	553,951	3,168,435	4,605	4,605	388
Injectable 3-IM	3,469	7,462	10,754	20,736	16,619	(35)%	129,729	209,564	2,420	2,420	405
IUD 10	-	11,634	35	-	15,000	(100)%	65,510	65,545	32	145	31
IUD 3	188	(50)	(62)	-	2,213	(103)%	6,953	6,891	(56)	(140)	(30)
IUD 5	3,092	7,324	19,204	111,600	19,380	(1)%	79,621	199,539	17,284	57,036	12,930
IUS 5	23	88	287	5,184	-	-%	-	287	258	852	193
Lubricant	4,296	2,580	7,884	-	4,464	77%	37,944	132,252	-	-	-
Male Vasodilator	366,400	58,300	541,300	-	-	-%	-	541,300	4,060	-	-
Medical Abortion	49,410	93,247	137,691	1,656,000	180,570	(24)%	1,139,134	1,791,761	123,922	-	12,798
Misoprostol for Safe Abortion	-	-	-	250,000	-	-%	-	-	-	-	-
Multivitamin	130,560	104,160	346,170	2,232,000	514,020	(33)%	1,974,210	37,355,730	1,731	-	59
OCs	51,063	330,579	187,779	7,097,180	544,843	(66)%	4,758,355	16,271,179	11,267	11,267	1,162
ORS	377,947	141,223	775,966	1,320,000	432,975	79%	1,144,506	2,246,900	349,185	-	15,570
Pregnancy Test	14,220	68,449	72,936	1,188,000	-	-%	575,675	648,611	-	-	-
Vaginal Wash	6,048	640	7,968	-	-	-%	-	7,968	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Social Enterprise											315,673	316,480
India LLC											225,102	106,184
Condom	15,878,104	12,173,296	21,716,182	160,842,000	19,628,880		11%	121,087,377	283,015,411	162,871	162,871	64,003
Masti Cherry 2's	156,600	61,200	340,200	-	-		-%	-	340,200	2,551	2,551	1,003
Masti Chocolate 4's	2,003,760	-	2,003,760	-	-		-%	-	2,003,760	15,028	15,028	5,906
Masti Classic 10's	-	925,200	-	-	2,437,440	10/17	(100)%	12,641,730	17,074,530	-	-	-
Masti Classic 10's (Flavoured)	7,616,590	1,929,140	7,616,410	-	1,555,200	6/17	390%	12,638,400	29,464,450	57,123	57,123	22,447
Masti Classic 2's Orange	3,430	1,100,477	972,902	-	-	4/18	-%	7,334,310	8,307,212	7,297	7,297	2,867
Masti Classic 3's Cool Mint	-	(143)	(429)	-	-	4/18	-%	1,000,080	999,651	(3)	(3)	(1)
Masti Classic 3's	49,935	3,885,579	3,843,552	-	11,340,240	12/16	(66)%	43,947,594	112,956,973	28,827	28,827	11,328
Masti Classic 3's (Flavoured)	4,586,909	2,717,292	5,483,105	-	2,516,400		118%	22,653,043	42,222,508	41,123	41,123	16,160
Masti Classic 6's	-	-	-	-	-	12/16	-%	960	27,094,440	-	-	-
Masti Green Apple 2's	-	710,230	-	-	-		-%	4,018,980	4,018,980	-	-	-
Masti Long Innings 2's	-	40	120	-	-		-%	-	120	1	1	-
Masti Mix 10's Chocolate & Strawberry	1,458,000	-	1,458,000	-	-		-%	-	1,458,000	10,935	10,935	4,297
Masti Premium 10's (Flavoured)	5,040	842,647	4,700	-	486,000		(99)%	6,531,960	10,786,580	35	35	14
Masti Premium 2's Chocolate	-	-	-	-	-		-%	134,910	134,910	-	-	-
Masti Premium 2's Strawberry	-	-	-	-	-		-%	134,824	134,824	-	-	-
Masti Premium 3's	-	-	-	-	-	12/16	-%	23,656	8,984,681	-	-	-
Masti Premium 3's Cool Mint	-	-	-	-	-	4/18	-%	913,200	913,200	-	-	-
Masti Premium 3's (Flavoured)	(2,160)	1,634	(6,138)	-	1,293,600		(100)%	9,113,730	16,120,392	(46)	(46)	(18)
Masti Standard 10's	-	-	-	85,536,000	-		-%	-	-	-	-	-
Masti Standard 3's	-	-	-	49,896,000	-		-%	-	-	-	-	-
Premium Condom (ONE)	-	-	-	25,410,000	-		-%	-	-	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Emergency Contraception	11,116	10,150	24,776	594,000	18,500		34%	212,227	237,003	1,115	1,115	142
Pronta	-	-	-	-	18,500		(100)%	18,500	18,500	-	-	-
Pronta1	60	6,496	2,857	-	-	4/18	-%	178,469	181,326	129	129	16
Pronta-72	11,056	3,654	21,919	594,000	-		-%	15,258	37,177	986	986	126
Injectable 3-IM	3,469	7,462	10,754	20,736	16,619		(35)%	129,729	209,564	2,420	2,420	405
Freedom Inject (3-month)	3,469	7,462	10,754	20,736	16,619		(35)%	129,729	209,564	2,420	2,420	405
IUD 10	-	11,634	35	-	15,000		(100)%	65,510	65,545	32	145	31
Freedom 10	-	11,634	35	-	15,000	12/16	(100)%	65,510	65,545	32	145	31
IUD 3	188	(50)	(62)	-	2,213		(103)%	6,953	6,891	(56)	(140)	(30)
Freedom 3	188	(50)	(62)	-	2,213	1/18	(103)%	6,953	6,891	(56)	(140)	(30)
IUD 5	3,092	7,324	19,204	111,600	19,380		(1)%	79,621	199,539	17,284	57,036	12,930
Freedom 5	2,713	7,290	18,933	64,800	17,170		10%	70,638	190,285	17,040	56,231	12,748
Freedom 5 – Sleek	178	17	128	-	2,210	1/18	(94)%	6,909	7,037	115	380	86
Freedom 5 (PPIUCD) Cu 375	201	17	143	46,800	-		-%	2,074	2,217	129	425	96
IUS 5	23	88	287	5,184	-		0%	-	287	258	852	193
Freedom LNG-IUS	-	-	-	5,184	-		-%	-	-	-	-	-
Sabatica – LNG IUS	23	88	287	-	-		-%	-	287	258	852	193
Male Vasodilator	366,400	58,300	541,300	-	-		0%	-	541,300	4,060	-	-
Masti Super 100 - 100 mg Tab	366,400	58,300	541,300	-	-		-%	-	541,300	4,060	-	-
Medical Abortion	49,410	93,247	137,691	1,656,000	180,570		(24)%	1,139,134	1,791,761	123,922	-	12,798
Mifeso	-	-	-	72,000	-		-%	-	-	-	-	-
Safe Abort kit	49,410	93,247	137,691	1,584,000	180,570		(24)%	1,139,134	1,791,761	123,922	-	12,798
Misoprostol for Safe Abortion	-	-	-	250,000	-		0%	-	-	-	-	-
Avertiso	-	-	-	250,000	-		-%	-	-	-	-	-
OCs	5,930	267,533	13,378	6,376,560	363,815		(96)%	4,052,619	7,735,957	803	803	142

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
Freedom 28	798	(40)	(582)	1,134,000	-		-%	42,146	41,564	(35)	(35)	(6)
MEURI	4,482	1,813	6,200	216,000	35		17,614%	37,645	43,845	372	372	66
Pearl	650	265,760	7,760	5,026,560	363,780		(98)%	3,972,828	7,650,548	466	466	82
ORS	377,947	141,223	775,966	1,320,000	432,975		79%	1,144,506	2,246,900	349,185	-	15,570
Neotral Orange 1000ml	377,947	141,223	775,966	1,320,000	432,975		79%	1,144,506	2,246,900	349,185	-	15,570
Pregnancy Test	14,220	68,449	72,936	1,188,000	-		0%	575,675	648,611	-	-	-
Pronta (PTK)	14,220	68,449	72,936	1,188,000	-		-%	575,675	648,611	-	-	-
Vaginal Wash	6,048	640	7,968	-	-		0%	-	7,968	-	-	-
Pronta Intimate Wash – 100 ml bottle	6,048	640	7,968	-	-		-%	-	7,968	-	-	-
Paraguay											19,221	5,358
Condom	227,243	210,841	702,243	3,317,080	640,737		10%	3,450,963	44,090,270	5,267	5,267	4,033
Pantera	97,092	105,775	346,940	1,628,902	311,751	8/98	11%	1,641,868	37,128,095	2,602	2,602	1,992
Pantera Banana	9,846	10,494	30,947	154,498	33,585	9/16	(8)%	168,808	432,747	232	232	178
Pantera Chocolate	12,301	11,584	35,736	219,757	38,424	2/14	(7)%	231,222	1,059,658	268	268	205
Pantera Retardant	52,021	29,316	114,034	536,632	100,559	2/14	13%	562,869	2,375,703	855	855	655
Pantera Ribbed	7,744	11,073	29,968	136,806	35,610	2/14	(16)%	165,502	826,674	225	225	172
Pantera Strawberry	22,339	19,471	65,293	293,511	54,996	2/14	19%	313,950	1,345,814	490	490	375
Pantera Tachas	10,929	9,544	32,934	130,508	26,200	9/16	26%	147,059	389,574	247	247	189
Pantera Tutti Frutti	14,971	13,585	46,391	216,466	39,612	9/16	17%	219,685	532,005	348	348	266
Emergency Contraception	27,418	25,165	77,556	358,605	78,566		(1)%	338,724	2,928,432	3,490	3,490	246
Pronta	25,003	24,707	73,767	241,605	78,566		(6)%	338,634	2,924,553	3,320	3,320	234
Pronta1	2,415	458	3,789	117,000	-		-%	90	3,879	171	171	12
Multivitamin	130,560	104,160	346,170	2,232,000	514,020		(33)%	1,974,210	37,355,730	1,731	-	59
VitalDia	130,560	104,160	346,170	2,232,000	514,020		(33)%	1,974,210	37,355,730	1,731	-	59

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.

POPULATION SERVICES INTERNATIONAL

Monthly Distribution by Country

Period: 3

Year: 2019

	DISTRIBUTION 3/2019	MONTHLY AVG PREV 3 MONTHS	YTD DISTRIBUTION 2019	DISTRIBUTION TARGET 2019	YTD DISTRIBUTION 2018	LAUNCH DATE	YTD % CHANGE	TOTAL DISTRIBUTION 2018	CUMULATIVE DISTRIBUTION	(a)YTD USERS REACHED 2019	YTD CYP 2019	YTD DALY 2019
OCs	45,133	63,047	174,401	720,620	181,028		(4)%	705,736	8,535,222	10,464	10,464	1,021
Segura	40,779	60,174	163,112	690,020	172,740		(6)%	667,753	8,280,484	9,787	9,787	955
Segura Plus	4,354	2,872	11,289	30,600	8,288		36%	37,983	254,738	677	677	66
PSI South Africa											71,350	204,938
Condom	3,594,384	3,225,744	9,513,360	38,426,242	8,645,080		10%	35,170,850	413,638,203	71,350	71,350	204,938
Lovers Plus	317,664	358,104	1,076,688	4,207,083	929,647	10/92	16%	3,350,719	48,810,448	8,075	8,075	23,072
Lovers Plus C&F	-	135,840	137,016	2,785,260	630,095	1/08	(78)%	3,238,511	38,586,190	1,028	1,028	2,938
Lovers Plus C&S	230,976	105,552	547,632	-	-		-%	-	547,632	4,107	4,107	11,741
Lovers Plus Climax Delay	47,232	27,456	129,600	-	-		-%	-	129,600	972	972	2,779
Lovers Plus Extra Play	-	40,512	63,072	831,317	122,300	3/16	(48)%	610,748	3,790,718	473	473	1,352
Lovers Plus R&S	195,480	187,920	533,520	2,282,405	465,732	11/12	15%	2,216,556	23,310,029	4,001	4,001	11,438
Lovers Plus UltraThin	26,856	45,312	122,616	429,981	-		-%	634,392	757,008	920	920	2,629
Trust	516,672	789,336	2,152,440	15,041,017	2,215,115	5/01	(3)%	9,253,073	142,516,272	16,143	16,143	46,191
Trust Extra C&S	72,144	75,648	185,400	865,152	-		-%	705,528	890,928	1,390	1,390	3,754
Trust Extra Thin	89,568	67,440	231,120	1,049,252	-		-%	692,496	923,616	1,733	1,733	4,871
Trust Studded	2,097,792	1,392,624	4,334,256	10,934,775	4,282,191	1/05	1%	14,468,827	153,375,762	32,507	32,507	94,175
Emergency Contraception	-	-	-	287,425	-		0%	3,000	3,000	-	-	-
Pronta1	-	-	-	287,425	-		-%	3,000	3,000	-	-	-
Lubricant	4,296	2,580	7,884	-	4,464		77%	37,944	132,252	-	-	-
Lovers Plus Lube Natural (100mL)	3,468	2,580	7,056	-	4,464	1/13	58%	37,944	131,424	-	-	-
Lovers Plus Lubricant 2-in-1, 100 ml tube	276	-	276	-	-		-%	-	276	-	-	-
Lovers Plus Lubricant Strawberry, 100 ml tube	276	-	276	-	-		-%	-	276	-	-	-
Lovers Plus Lubricant Warming, 100 ml tube	276	-	276	-	-		-%	-	276	-	-	-

(a)The grand total of users reached will inevitably double count individuals who receive more than one PSI product or service, and should be avoided. Users reached can be summed within product categories or as key interventions across health areas to represent scale.

(b) DALY credit is given separately for product distribution and product insertion. To avoid double-counting when a PSI product is both distributed AND inserted, this line subtracts DALYS for product distribution.